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Summary 
This study describes: 
• The development and validation of three ultra-performance convergence chromatography
tandem mass spectrometry (UPC2-MS/MS) analytical methods which were applied in the
detection and quantification of C19 and C21 steroids, including C11-oxy C19 and C11-oxy C21
steroids;
• The investigation into the contribution of adrenal 11β-hydroxyandrostenedione (11OHA4)
and 11β-hydroxytestosterone (11OHT) to the pool of active androgens in the prostate, by
following androgen metabolism in normal epithelial prostate PNT2, benign prostatic
hyperplasia (BPH-1) and prostate cancer LNCaP, C4-2B and VCaP cell models;
Steroid profiles revealed 11β-hydroxysteroid dehydrogenase type 2 (11βHSD2) activity in all
the cell models, confirmed in the conversion of 11OHA4 to 11keto-androstenedione
(11KA4), with reductive 17β-hydroxysteroid dehydrogenase (17βHSD) enzymes metabolising
11KA4, ultimately yielding 11keto-testosterone (11KT).
• The in vitro investigation into the inactivation, reactivation, glucuronidation and sulfation of
11OHA4, 11OHT and their downstream metabolites;
In prostate cancer (PCa) cell models, the conjugation of 11KT and 11keto-
dihydrotestosterone (11KDHT) were hampered compared to testosterone (T) and
dihydrotestosterone (DHT), while the inactivation and reactivation of the C11-oxy C19
steroids were less efficient than the C19 steroids in BPH-1 cells.
• The in vivo steroid profiles in PCa, BPH and castration-resistant prostate cancer (CRPC)
tissue and plasma of healthy and PCa patients;
Analyses of the C19 and C11-oxy C19 steroids, together with glucuronide and sulfate
conjugates, showed increased unconjugated levels of 11KT and 11KDHT in plasma of PCa
patients compared to a healthy subject, and 11OHA4, 11KT and 11KDHT levels were
prominent in PCa tissue, while downstream inactive C11-oxy 3α-reduced metabolites were
identified in BPH and CRPC tissue.
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Opsomming 
Hierdie studie beskryf die volgende: 
• Die ontwikkeling en validering van drie UPC2-MS/MS analitiese metodes wat vervolgens
toegepas is in die skeiding en kwantifisering van steroïedmetaboliete.
• Die ondersoek na 11OHA4 and 11OHT se bydrae tot die aktiewe androgeen poel in die
prostaat;
Androgeen metabolisme is in normale epiteel prostaat PNT2, BPH-1 en prostaat kanker
LNCaP, C4-2B en VCaP selmodelle ondersoek. Die steroïdprofiele bevestig die
teenwoordigheid van 11βHSD2 aktiwiteit in al die modelle in die omsetting van 11OHA4 na
11KA4, sowel as die aktiwiteit van 17βHSD wat vervolgens die omsetting van 11KA4 na 11KT
gekataliseer het.
• Die in vitro inaktivering, heraktivering en konjugering van 11OHA4 en 11OHT metaboliete;
In prostaatkanker selmodelle was 11KT en 11KDHT konjugering oneffektief in vergelyking
met T en DHT, en die inaktivering van die C11-oksie C19 steroïede was nie optimaal in
vergelyking met die C19 steroïede in BPH-1 selmodelle nie.
• Die in vivo steroïedprofiele in prostaatkankerweefsel, BPH weefsel en kastrasie-
weerstandige prostaatkankerweefsel en in plasma van gesonde normale individuë en
prostaatkanker pasïente, asook die teenwoordigheid van ongekonjugeerde en
gekonjugeerde steroïedmetaboliete in sirkulasie;
Analiese toon dat ongekonjugeerde 11KT en 11KDHT hoër was in die plasma van pasïente
met prostaatkanker; 11OHA4, 11KT en 11KDHT vlakke was abnormaal hoog in die
prostaatkankerweefsel, terwyl onaktiewe C11-oksie 3α-gereduseerde metaboliete
geïdentifiseer was in BPH weefsel en in kastrasie-weerstandige prostaatkankerweefsel.
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Chapter 1 
General introduction 
 
Steroids produced in the adrenals serve as precursors for the biosynthesis of steroid hormones in the 
prostate (Sharifi and Auchus 2012), and while the biosynthesis of active steroids is essential in the 
progression of prostate cancer (PCa), the inactivation and conjugation of steroids in the prostate 
microenvironment are also important. The production, inactivation and elimination of active steroids 
must be finely regulated within the prostate to maintain homeostasis, however, dysregulation of these 
pathways contributes to the initiation and development of PCa. Overproduction of active steroids and 
impeded inactivation pathways, in addition to promiscuous receptor binding, together all contribute to 
PCa progression.  
The adrenal steroids relevant to PCa which are the focus of this thesis are divided into two categories: 
the C19 and C21 steroids, which consists of either 19 or 21 carbon atoms in the steroid backbone 
structures, respectively. C19 steroids include the androgens, while C21 steroids include the 
mineralocorticoids and glucocorticoids. C19 and C21 steroids can be metabolised by adrenal 
steroidogenic enzymes that either hydroxylate the carbon 11 (C11) or convert the C11-hydroxy group 
to a keto group, resulting in the production of C11-oxy C19 and C11-oxy C21 steroids, respectively. These 
C11-oxy steroids are produced in the adrenals, released into circulation, where after they exert 
physiological effects once taken up by peripheral target tissue. An important adrenal C11-oxy C19 
steroid, 11β-hydroxyandrostenedione (11OHA4) is abundantly produced in the adrenals  
(Rege et al. 2013), and although this steroid is not androgenic, it is metabolised to potent downstream 
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androgens in the prostate (Storbeck et al. 2013; Swart et al. 2013; Bloem et al. 2015). 11OHA4, 
together with its metabolites, have been identified as role-players in the progression of PCa and are 
metabolised in a metabolic pathway termed, the 11OHA4-pathway. The pathway is particularly 
important in the context of castration-resistant prostate cancer (CRPC), in which gonadal androgens 
are negligible and adrenal steroids remain in abundance. To date, the metabolism of 11OHA4 and its 
metabolites have been shown in non-steroidogenic cells transfected with appropriate steroidogenic 
enzymes and in LNCaP cells, which endogenously express steroidogenic enzymes (Storbeck et al. 2013; 
Swart et al. 2013). In addition, the androgenic capability of downstream 11OHA4 metabolites towards 
the androgen receptor (AR) has been reported (Yazawa et al. 2008; Rege et al. 2013;  
Storbeck et al. 2013; Campana et al. 2016). These studies have shown that the relevance of the 
11OHA4-pathway lies within two C11-keto metabolites: 11keto-testosterone (11KT) and  
11keto-dihydrotestosterone (11KDHT). Both steroids bind and activate the AR, induces the expression 
of AR-regulated genes, while also increasing cell proliferation in PCa cell models (Pretorius et al. 2016). 
11KT and 11KDHT have been determined to be equipotent to testosterone (T) and dihydrotestosterone 
(DHT), respectively, with T and DHT historically established as potent androgens in the steroid arena. 
While in vitro studies have reported the contributory role of 11OHA4 and its metabolites to PCa, in vivo 
evidence of these steroids in PCa or benign prostatic hyperplasia (BPH) has not been established, in 
addition to the presence of these C11-oxy C19 steroids in normal physiology. Both BPH and PCa are 
androgen dependent prostate diseases, however, these are two different diseases in terms of their 
origin and aggressiveness, with BPH considered a precursor disease to the development of PCa 
(Penning 2010). Moreover, while the biosynthesis of the C11-oxy C19 steroids and their metabolism to 
active androgens are now well documented, the inactivation and conjugation of these steroids, to 
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date, have not been clarified. The presence of these C11-oxy C19 steroids in vivo, together with their 
inactivation being inefficient, will firmly establish these steroids as major role-players in PCa. Another 
important concept to consider is the role of adrenal C11-oxy C21 steroids in PCa. Recent in vitro studies 
have shown the contribution of adrenal C11-oxy C21 precursor steroids to the androgen pool –
producing 11KDHT via the backdoor pathway in non-steroidogenic cells transfected with the 
appropriate steroidogenic enzymes, and in LNCaP cells (Barnard et al. 2017), adding another layer of 
complexity to the role of C11-oxy steroids in the progression of PCa. 
The analyses and quantification of steroids in the research and clinical setting have been accomplished 
by gas chromatography mass spectrometry (GC-MS) and liquid chromatography tandem mass 
spectrometry (LC-MS/MS) for many years, however, progress in technologies regarding mass 
spectrometry, combining aspects of both GC-MS and LC-MS/MS, has led to the introduction of  
ultra-performance convergence chromatography tandem mass spectrometry (UPC2-MS/MS) enabling 
the separation of chemically similar steroid structures, within minutes, as well as the accurate 
quantification of steroids present at very low concentrations (Quanson et al. 2016). Using the  
state-of-the-art UPC2-MS/MS in the analyses of these C11-oxy steroids has allowed not only the 
evaluation of the influence of these steroids on PCa progression, but has also showed that 
comprehensive steroid profiles can be applied in the analyses of steroidogenic pathways.  
The PhD study conducted will be presented as follows: 
Chapter 2 provides an overview of adrenal steroidogenesis and highlights steroid metabolic pathways 
and the enzymes involved in the biosynthesis and inactivation of steroid hormones in the prostate. This 
chapter furthermore reviews the C11-oxy C19 steroids and their contribution to disease, highlighting 
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their receptor action. The chapter concludes with a discussion on the progression of PCa to CRPC and 
current clinical treatment regimens. 
The aims of this thesis, which have been addressed in Chapters 3, 4, 5 and 6, can be summarised as 
follows: 
• to develop and validate UPC2-MS/MS analytical methods for the separation and quantification 
of C19, C11-oxy C19, C21 and C11-oxy C21 steroids; 
• to investigate the metabolism of 11OHA4 and 11β-hydroxytestosterone (11OHT) and their 
downstream metabolites in normal epithelial PNT2 cells, epithelial BPH cells and in cancer cell 
models, LNCaP, VCaP and C4-2B cells;  
• to evaluate the inactivation by 3α-hydroxysteroid dehydrogenases (3αHSDs) and reactivation 
by retinol-like hydroxysteroid dehydrogenase (RL-HSD) of the C11-oxy C19 and C19 steroids in 
BPH-1, LNCaP, VCaP and C4-2B cells, which are cells that endogenously express 3αHSDs and  
RL-HSD; 
• to compare the glucuronidation of C11-oxy C19 and C19 steroids by endogenously expressed 
uridine-diphosphate glucuronosyltransferases (UGTs) in LNCaP, C4-2B and VCaP cells and to 
evaluate the sulfation of C11-oxy C19 and C19 steroids by endogenously expressed 
sulfotransferases (SULTs) in LNCaP cells; 
• to determine circulating C11-oxy C19 and C19 steroid glucuronide and sulfate levels; 
• to evaluate to presence of the C11-oxy C19 steroids in BPH, PCa and CRPC tissue, together with 
determining steroid profiles in plasma of healthy subjects and in PCa patients. 
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Chapter 3 is presented in the form of three published manuscripts. The first manuscript  
(Du Toit and Swart 2016) provides a review on prostate steroidogenesis with the focus on the 
conjugating enzymes, UGT2Bs, in regulating steroid action. A perspective is furthermore given on the 
role of the specific UGT2B type 28 (UGT2B28) isoform in PCa, while also discussing aspects still 
unknown in terms of the regulation of the UGT2B enzymes. In the second manuscript  
(Du Toit et al. 2017), C11-oxy C19 steroids are profiled in PNT2 and LNCaP cells and the glucuronidation 
of the C19 steroids, T, DHT, androsterone (AST) and 5α-androstane-3α, 17β-diol (3αDIOL) are analysed 
and compared to the glucuronidation of 11KT and 11KDHT in LNCaP cells. Furthermore, in vivo levels of 
the C11-oxy C19 are shown in steroid panels determined in PCa tissue and in plasma of PCa patients. 
The third manuscript (Du Toit and Swart 2018) describes the inefficient UGT-conjugation of the  
C11-oxy C19 steroids in LNCaP, C4-2B and VCaP cell models. In addition, the metabolism of the  
C11-oxy C19 and C19 steroids are described in the aforementioned cell models, while the inactivation 
and reactivation of DHT and 11KDHT by enzymes endogenously expressed in the cell models are also 
described. Comprehensive steroid panels of the C11-oxy C19 and C19 steroids in CRPC tissue are also 
presented, and C11-oxy C19 and C19 steroid glucuronides in plasma of a healthy subject and in PCa 
patients are shown. 
Chapter 4 describes a preliminary investigation into the SULT-conjugation of the C11-oxy C19 steroids in 
LNCaP cells. Firstly, the development of an in-laboratory dual deconjugating protocol, which 
deconjugates steroid glucuronides and steroid sulfates, is discussed. This protocol was subsequently 
applied to deconjugate steroid glucuronides and sulfates present in aliquots collected after in vitro 
enzymatic conversion assays were conducted, and in plasma samples. The conjugation of T- and  
DHT-metabolites are discussed, comparing the C11-oxy C19 steroids to the C19 steroids. In addition, the 
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SULT-conjugation of ketosteroids (androstenedione [A4] and 11OHA4) are shown in LNCaP cells, 
together with in vivo steroid sulfate levels determined in plasma of healthy subjects and in a PCa 
patient. 
In Chapter 5 the metabolism of 11OHA4 and its downstream metabolites in BPH-1 cells are presented, 
together with a comparison of the inactivation by 3αHSD and reactivation by RL-HSD of the C11-oxy C19 
and C19 steroids. In addition, in vivo evidence establishing the presence of the C11-oxy C19 steroids in 
BPH tissue is presented and depicted as steroid panels. 
Chapter 6 describes a novel UPC2-MS/MS method that was developed and validated for the separation 
and quantification of C19 and C21 steroids, including their C11-hydroxy and C11-keto derivatives. This 
chapter discusses the application of the method in the evaluation of augmented steroid metabolic 
pathways and steroid levels in adrenal-linked endocrine diseases. In addition, preliminary unpublished 
results concerning the application of this method in the analysis of C11-oxy steroids in vivo is 
summarised. 
Chapter 7 presents a general discussion of the results described in this thesis, highlights the main 
conclusions that were drawn from these findings and concludes with recommendations for future 
studies. 
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Chapter 2 
The biosynthesis of the C11-oxy C19 steroids and their contribution to prostate cancer 
 
2.1 Introduction 
Steroid hormones are involved in normal physiological development, including cellular growth and 
sexual maturation. However, these same hormones are implicated in steroid-dependent diseases with 
for example, steroid hormones having been linked to PCa since 1946 (Huggins 1946; Huggins and 
Bergenstal 1952). In addition, the clinical diseases and disorders known today that result from 
androgen excess or androgen deficiency include congenital adrenal hyperplasia (CAH), polycystic ovary 
syndrome (PCOS), 21-hydroxylase deficiency (21OHD), as well as the excess or deficit production of 
steroid hormones which presents as disorders of sex development (DSD) in newborns (Rauh 2009; 
Auchus and Miller 2012; Auchus 2015; Turcu and Auchus 2015). During childhood, adrenarche is linked 
to androgen imbalances (Auchus and Rainey 2004), while in maturing females, PCOS present with 
androgen excess (Azziz et al. 1998). The development of breast cancer, as with PCa, is androgen 
dependent, wherein androgens are converted to estrogens, which in turns drives hormone-dependent 
tumour growth (Risbridger et al. 2010). In addition, insufficient production of the stress hormone, 
cortisol, in Addison’s disease or excess cortisol production in Cushing’s syndrome are both 
consequences of hormonal imbalances (Ten et al. 2001; Rang et al. 2003; Løvås et al. 2009; Couchman 
et al. 2011). Other conditions, including male pattern baldness, pre- and post-menopause, 
premenstrual syndrome, metabolic syndrome and skin conditions, all of which have been linked to 
steroid hormones (Anagnostis et al. 2009; Couchman et al. 2011; Slominski et al. 2013). 
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The inactivation and conjugation of steroid hormones, which interrupts steroid signalling and 
terminates physiological effects, contribute to the development of steroid-dependent diseases when 
not proceeding efficiently. In addition, steroid receptor interactions causing downstream effects also 
contribute to disease, with active steroid hormones binding receptors and while non-androgenic 
steroids may not bind receptors, these steroids may be channelled to downstream potent steroids as 
in the case of the adrenal C11-oxy C19 steroid, 11OHA4. 
This chapter will summarize the biosynthesis of androgens in the adrenals, focusing on the production 
of the C11-oxy C19 steroids. Peripheral steroid metabolic pathways and the respective enzymes 
involved in these pathways will be highlighted, together with the implication of the C11-oxy steroids in 
disease states. Lastly, androgen receptor action will be reviewed, as well as the progression of PCa to 
CRPC, together with treatment regimens currently employed in the clinical setting. 
2.2 Adrenal steroidogenesis 
The adrenal glands are found atop the kidneys in the human body, comprising of three layers: the 
outer capsule, the adrenal cortex, and the inner medulla. The adrenal cortex, in turn, also consists of 
three layers wherein adrenal steroidogenesis takes place: the zona glomerulosa (ZG), the zona 
fasciculata (ZF) and the zona reticularis (ZR) (Messiano and Jaffe 1997). The steroid hormone output of 
the adrenal cortex is controlled by corticotropin-releasing hormone (CRH) from the hypothalamus, 
which stimulates the release of adrenocorticotropic hormone (ACTH) from the pituitary corticotropes, 
with ACTH in turn stimulating the ZF and the ZR to produce their respective steroid hormones. This 
signalling pathway, termed the HPA-axis, representing the hypothalamus-pituitary-adrenal pathway 
that regulates steroid hormone production. The ZG is, however, under the regulation of angiotensin II, 
which forms part of the renin-angiotensin system, with the extracellular potassium concentration also 
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involved in this regulation (Hammer et al. 2005). The zones of the adrenal cortex are not only defined 
by their physiological compartmentalization, but also by their differential enzyme expression. As the 
layers are divided into three sections, so also is adrenal steroidogenesis divided into three pathways: 
the mineralocorticoid pathway within the ZG, the glucocorticoid pathway within the ZF and the 
androgen pathway within the ZR (Fig. 2.1). While the steroid hormones produced in the first two 
pathways are termed C21 steroids, the androgen pathway represents the production of C19 steroids. 
The C21 steroids produced in the mineralocorticoid pathway represents steroid hormones that are 
involved in regulating the electrolyte and water balance of the human body, including the regulation of 
blood pressure, denoted by the production of aldosterone. The C21 steroids produced in the 
glucocorticoid pathway represent steroid hormones that are involved in the stress response of the 
human body, denoted by the production of cortisol (and cortisone). Moreover, these steroids are also 
involved in carbohydrate-, protein- and lipid metabolism, as well as in immune and inflammatory 
responses. Although the mineralocorticoids and glucocorticoids are involved in steroid-dependent 
diseases, these steroids will not be the primary focus of this thesis.  
The C19 steroids produced in the androgen pathway of adrenal steroidogenesis are involved in sexual 
development and growth, and will be the focus of this thesis. C19 androgens are produced from the 
universal precursor of all steroid hormones, the 27-carbon cholesterol. Cholesterol is transported from 
the outer to the inner mitochondrial membrane by steroidogenic acute regulatory protein (StAR)  
(Clark et al. 1994; Ghayee and Auchus 2007), and subsequently oxidized by cytochrome P450  
side-chain cleavage (CYP11A1) to produce the C21 steroid, pregnenolone (PREG) (Fig. 2.1). This reaction 
occurs in all three zones of the adrenal cortex, however, the subsequent production of androgens 
occurs only in the ZR. The hydroxylase catalytic activity of 17α-hydroxylase/17,20-lyase (CYP17A1), a 
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microsomal cytochrome P450 enzyme, subsequently converts PREG to  
17-hydroxypregnenolone (17OHPREG), followed by the conversion of 17OHPREG, catalysed by the 
lyase activity of CYP17A1, to the C19 androgen precursor, dehydroepiandrosterone (DHEA) (Fig. 2.2). 
3β-hydroxysteroid dehydrogenase type 2 (3βHSD2) catalyses the conversion of ∆5 to ∆4 steroids and 
biosynthesizes two androgens namely, A4 from DHEA, and T from androstenediol, the  
17β-hydroxysteroid dehydrogenase (17βHSD) product of DHEA (Miller and Auchus 2011). DHEA, if not 
channelled to androstenediol or A4, can be inactivated by SULTs, specifically SULT2A1, to DHEA-sulfate 
(DHEA-S), while androstenediol is also sulfated (Rege et al. 2016). Although the sulfation pathway is 
dominant in the adrenals, steroid sulfation is reversible as steroid sulfatase (STS) removes the sulfate 
group, and is expressed in the adrenal cortex (Dalla Valle et al. 2007; Mueller et al. 2015). 
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Figure 2.1 Adrenal steroidogenesis representing the three pathways of steroid hormone production; the 
mineralocorticoid-, the glucocorticoid- and the androgen pathways. 
The lyase activity of CYP17A1 is therefore a key enzyme required for the production of androgens, as 
the absence of the lyase activity of CYP17A1 will channel steroids into the glucocorticoid pathway. 
Indeed, in the absence of the 17,20-lyase activity in the ZF, 3βHSD2 converts 17OHPREG to  
17-hydroxyprogesterone (17OHPROG), followed by the sequential conversion of 17OHPROG by 
cytochrome P450 steroid 21-hydroxylase (CYP21A2) producing 11-deoxycortisol which is converted by 
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cytochrome P450 11β-hydroxylase (CYP11B1), to produce cortisol in the glucocorticoid pathway. In the 
ZG, CYP17A1 is absent, hence 3βHSD2 converts PREG to progesterone (PROG), followed by the 
conversion of PROG to deoxycorticosterone (DOC) by CYP21A2, where after cytochrome P450 
aldosterone synthase (CYP11B2) sequentially converts DOC to corticosterone (CORT), 18-hydroxy-CORT 
(18OH-CORT) and finally aldosterone, in the mineralocorticoid pathway. Of note, while CYP17A1 
hydroxylates PROG at C17, the enzyme also hydroxylates PROG at C16, producing  
16-hydroxyprogesterone (16OHPROG) (Swart et al. 1993).  
Adrenal steroid production is divided between the endoplasmic reticulum, for the 3βHSD2, CYP17A1 
and CYP21A2 catalysed reactions, while the CYP11A1, CYP11B1 and CYP11B2 catalysed reactions occur 
in the mitochondria. The latter reactions require an electron shuttle system, adrenodoxin/adrenodoxin 
reductase for their hydroxylase or oxidase activity, while the endoplasmic reticulum localized 
enzymatic reactions require electrons from nicotinamide adenine dinucleotide phosphate (NADPH) 
using the enzymatic action of P450 oxidoreductase (POR) (Miller and Auchus 2011). Moreover, the 
lyase activity of CYP17A1 requires the co-factor cytochrome b5 (cyt b5), a flavoprotein which facilitates 
both CYP17A1 and POR (Storbeck et al. 2013). 
While cholesterol can be biosynthesized de novo from acetate in the endoplasmic reticulum, recruited 
from intracellular sources, such as cytosolic vacuoles, or recruited from outer cellular circulatory 
lipoproteins, free cholesterol (C27H460) is derived from cholesterol esters (low-density lipoprotein and 
high-density lipoprotein) and possess a chemical structure based on the common 
cyclopentanoperhydrophenanthrene ring structure (You 2004), which is the chemical backbone for all 
steroid hormones (Fig. 2.2). 
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Figure 2.2 Common cyclopentanoperhydrophenanthrene ring structures, representing the carbons whereupon 
steroidogenic enzymes act. The addition of the hydroxyl group at C11 by CYP11B1/2, the interconversion of the 
C11-hydroxy and C11-keto group by 11βHSDs, and the conversion of C21 to C19 steroids catalysed by CYP17A1 are 
shown. 
2.2.1 The production of C11-oxy steroids by cytochrome P450 11β-hydroxylase and aldosterone 
synthase 
While CYP11B1 and CYP11B2 are crucial in the production of cortisol and aldosterone, respectively, 
these enzymes both biosynthesise C11-oxy C19 steroids in vitro. However, in the androgen pathway of 
adrenal steroidogenesis (Fig. 2.1) CYP11B1 would be the enzyme catalysing the hydroxylation at C11. 
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The production of C11-hydroxy C19 steroids catalysed by CYP11B has been reported using recombinant 
bovine CYP11B (Mathew et al. 1990), guinea pig CYP11B1 and B2 (Bülow et al. 1996; Bülow and 
Bernhardt 2002) and by human CYP11B1 and B2 (Schloms et al. 2012; Swart et al. 2013). CYP11B1 and 
B2 are mitochondrial enzymes, which utilize NADPH as an electron donor and transfer an electron via 
the flavoprotein, adrenodoxin reductase, and subsequently via adrenodoxin, a nonheme iron-sulfur 
protein, ultimately transferring the electron to the substrate via the P450 heme group, producing the 
hydroxylated steroid product. Both CYP11B1 and CYP11B2 are able to catalyse the biosynthesis of 
11OHA4 and 11OHT from A4 and T, respectively (Fig. 2.1, 2.2). While CYP11B2 is expressed in the ZG 
only, CYP11B1 has been shown to be expressed in the ZF and the ZR (Gomez-Sanchez et al. 2014). This 
suggests that CYP11B1 catalyses the C11 hydroxylation of A4 and T in the ZR. Interestingly, CYP11B2 
has been shown to convert T to 11OHT more efficiently compared to the hydroxylation of A4 in vitro 
(Swart et al. 2013).  
The first report of 11OHA4 was in 1953, when Jeanloz et al. (1953), showed the production of 11OHA4 
in bovine adrenal glands following perfusion with A4, while 11OHA4 was also identified as a 
downstream metabolite of DHEA and A4 by Dorfman (1954), and in human adrenals (Touchstone et al. 
1955). Adrenal steroidogenesis in guinea pigs also showed the production of 11OHA4, with its 
production being increased following ACTH stimulation (Bélanger et al. 1993), suggesting the 
involvement of the ZF and ZR and the enzymes expressed in these zones. The ACTH dependent 
increase in 11OHA4 has been shown repeatedly (Bloch et al. 1957; Dyrenfurth et al. 1960; Cohn and 
Mulrow 1963; Rege et al. 2013), and ACTH has been linked to increased 11β-hydroxylation activity 
(Kowal 1969; Kowal et al. 1970; Ganguly et al. 1977). While the side-chain cleavage of cortisol by 
CYP17A1 producing 11OHA4 is plausible, this conversion has not been proven without a doubt and A4 
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remains the main precursor in the production of 11OHA4 in the adrenals. In addition, while the 
gonadal contribution to the production of 11OHA4 cannot be ruled out, as CYP11B has been shown in 
the testes, ovaries (Imamichi et al. 2016) and in testicular tumours (Savard et al. 1960;  
Lipsett et al. 1966), the adrenal remains the primary steroid producing organ in the production of 
11OHA4.  
Moreover, the hydroxylation of A4 by CYP11B has been shown in H295R adrenocarcinoma cells  
(Xing et al. 2011; Schloms et al. 2012; Swart et al. 2013) –in the presence of a 3βHSD2 inhibitor, 
trilostane, 11OHA4 was produced when A4 was assayed and in the presence of a CYP11B1 inhibitor, 
etomidate, 11OHA4 could not be recovered when A4 was assayed (Schloms et al. 2012). Clearly, 
11OHA4 is produced from the CYP11B hydroxylation of A4. The hydroxylation of T has also been 
reported (Swart et al. 2013), and 11OHT has been detected in vivo in adrenal vein samples  
(Rege et al. 2013), but 11OHT levels were ~300-fold lower than 11OHA4, under stimulated and 
unstimulated conditions (Rege et al. 2013). Although the expression of 17βHSD type 5 (AKR1C3) has 
been reported in the adrenals (Rege et al. 2013), the AKR1C3 and 17βHSD type 3 (17βHSD3) catalysed 
conversion of 11OHA4 to 11OHT does not occur (Storbeck et al. 2013). Furthermore, following the 
addition of 14[C]T, 11OHT was recovered in adrenal tissue homogenates (Chang et al. 1963), 
establishing that 11OHT is predominantly produced from T by CYP11B enzymes in the adrenals. 
Once 11OHA4 and 11OHT are biosynthesised in the adrenal, 11β-hydroxysteroid dehydrogenase type 2 
(11βHSD2) can catalyse the conversion of these C11-hydroxy metabolites to 11keto-androstenedione 
(11KA4) and 11KT, respectively (Fig. 2.1, 2.2). Indeed, these conversions have been shown in vitro in 
non-steroidogenic cells transfected with 11βHSD2 (Swart et al. 2013) and 11KA4 has been identified in 
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normal subjects and in patients with diseased adrenals (Goldzieher and Beering 1969). Furthermore, 
11KA4 and 11KT were also identified in vivo in adrenal vein samples, and although comparable to 
11OHT levels, the C11-oxy steroids were much lower than 11OHA4 (Rege et al. 2013). 11βHSD1, which 
catalyses the reverse reaction of 11βHSD2 (Fig. 2.2), has also been shown to convert 11KA4 and 11KT 
to 11OHA4 and 11OHT, respectively (Swart et al. 2013). Moreover, 11OHA4, 11OHT, 11KA4 and 11KT 
were shown to be better substrates for the 11βHSD enzymes than the glucocorticoids, cortisol and 
cortisone. Once 11KA4 and 11KT are produced in the adrenals, 17βHSDs expressed in the ZR (Rege and 
Rainey 2012; Rege et al. 2013), interconvert these metabolites, while oxidative 17βHSDs also convert 
11OHT to 11OHA4 (Storbeck et al. 2013; Swart et al. 2013) (Fig. 2.1). However, as the adrenals express 
low levels of 11βHSD2 and 17βHSDs, the adrenal output of 11OHA4 surpasses that of 11OHT, 11KA4 
and 11KT, and also that of A4 (Bloch et al. 1957; Rege et al. 2013). 
Up until this point the CYP11B enzymes has been discussed in terms of C19 steroid substrates (A4 and 
T), producing C11-oxy C19 and C21 steroids (DOC, CORT, 18OHCORT and deoxycortisol). These enzymes 
are, however, also critical in the production of 11-hydroxyprogesterone (11OHPROG) from PROG and 
21-deoxycortisol (21-dF) from 17OHPROG (Barnard et al. 2017; Van Rooyen et al. 2017), steroid 
hormones detected in 21OHD patients which are important in the initial reactions in the backdoor 
pathway (section 2.3), together with the production of 11,16-diOHPROG from 16OHPROG by CYP11B2 
(Van Rooyen et al. 2017).   
In circulation, steroids are bound to carrier plasma proteins (>95%), with free unbound steroids being 
taken up by target tissue, such as the prostate, signifying them biologically active upon binding to 
receptors (Barahona et al. 1980; Fernlund et al. 1990). In a recent review, Turcu and Auchus (2017), 
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highlighted that the binding of the C11-oxy C19 steroids to plasma proteins, such as sex-hormone 
binding globulin and albumin, in circulation has, to date, not been elucidated. While it has not been 
reported how these steroids are transported in circulation, their biosynthesis in and secretion from the 
adrenals as well as their contribution to the androgen pool through steroid metabolic pathways in the 
prostate, has been the subject of a number of recent reports. 
2.3 Steroid metabolic pathways in the prostate 
The testes predominantly contribute to circulatory T under normal condition, however, under castrate 
conditions, it is the adrenals that provide the C19 androgen precursors. Once these androgen 
precursors are taken up by the prostate, they are efficiently metabolised in the classic-, alternative- 
and 11OHA4-pathways. Moreover, adrenal C21 steroid precursors may also be metabolised in the 
prostate via the backdoor pathway, given the required enzymes are abundantly expressed. These 
metabolic pathways will be discussed below. 
2.3.1 The classic and alternative pathway to DHT production 
Adrenal C19 steroid precursors, T (negligible), DHEA and A4 contribute to the production of the potent 
steroid, DHT, in the classic and alternative pathways in the prostate (Mostaghel 2013). In the classic 
pathway, once A4 is converted to T by reductive 17βHSDs, 5α-reductase type 1 (SRD5A1) and  
5α-reductase type 2 (SRD5A2) converts T to DHT (Russell and Wilson 1994) (Fig. 2.3). A4 either 
contributes directly to T, or is firstly metabolised from adrenal DHEA, by 3βHSD type 1 (3βHSD1) or 
3βHSD2 (Chang et al. 2011). Again, it is worth mentioning that under normal physiological condition, 
the testes provide T in abundance, which is directly converted to DHT by SRD5As in the prostate. While 
the classic pathway to DHT production has been recognized as the dominant pathway for decades, the 
alternative ‘5α-androstanedione (5αDIONE)’ pathway is taking center stage (Auchus 2004;  
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Luu-The et al. 2008; Miller and Auchus 2011; Chang and Sharifi 2012). In this pathway, DHT is 
predominantly produced from A4 via 5αDIONE as an intermediate metabolite, and SRD5A1 has been 
shown to preferentially convert A4 to 5αDIONE rather than T to DHT in CRPC models and in tissue 
(Thigpen et al. 1993; Chang et al. 2011). Moreover, SRD5A1 silencing hampered the conversion of A4 to 
5αDIONE and the ultimate production of DHT in CRPC, suggesting the upregulation of SRD5A1 reported 
in CRPC would surely increase the flux via the alternative pathway (Chang et al. 2011; Sharifi 2012). 
 
Figure 2.3 The classic- (blue arrow) and alternative (red arrows) pathways leading to the production of DHT from 
adrenal C19 steroid precursors in the prostate (Boxed steroid; potent steroid). 
Following its production, DHT can be inactivated to 3αDIOL by 3αHSD enzymes present in the prostate, 
and while reactivation by RL-HSD enzymes are also possible, DHT may also be conjugated by UGTs and 
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SULTs. Furthermore, AST, produced from 5αDIONE by 3αHSDs may also be conjugated, together with T 
and 3αDIOL. 
2.3.2 The 11OHA4-pathway to 11KT and 11KDHT production 
Adrenal 11OHA4 is metabolised to the potent C11-oxy C19 steroids, 11KT and 11KDHT, in the  
11OHA4-pathway in the prostate (Fig. 2.4). In addition, as trace amounts of 11OHT, 11KA4 and 11KT 
are produced in the adrenals, these steroid hormones are also capable of contributing to prostate 
steroids and 11KT and 11KDHT levels, however, it is generally accepted that 11KA4 and 11KT only 
contribute to the 11OHA4-pathway once 11OHA4 and 11OHT are metabolised in the prostate  
(Turcu and Auchus 2017). The following section will describe and summarize the production of the 
C11-oxy C19 steroids from 11OHA4 in the 11OHA4-pathway as has been reported by  
Bloem et al. (2013), Storbeck et al. (2013) and Swart et al. (2013). 
In the prostate, 11βHSD2 is a key enzyme metabolising adrenal 11OHA4 to 11KA4, which initiates the 
11OHA4-pathway. The subsequent conversions by reductive 17βHSDs and SRD5As ultimately yields 
11KT and 11KDHT, respectively. In transfected non-steroidogenic cells, reductive 17βHSD3 and 
AKR1C3, have been shown to catalyse the conversion of C11-keto A4-metabolites to C11-keto  
T-metabolites, while SRD5A1 and SRD5A2 catalyse the production of 11β-hydroxy-5α-androstanedione 
(11OH-5αDIONE), 11keto-5α-androstanedione (11K-5αDIONE), 11β-hydroxydihydrotestosterone 
(11OHDHT) and 11KDHT. Furthermore, oxidative 17βHSD type 2 (17βHSD2) catalyses the conversion of 
11OHT, 11KT, 11OHDHT, 11KDHT and 11keto-5α-androstane-3α, 17β-diol (11K-3αDIOL) to their 
respective C11-oxy A4-metabolites, while both 11β-hydroxysteroid dehydrogenase type 1 (11βHSD1) 
and 11βHSD2 have been revealed to be involved in the interconversions between C11-hydroxy and 
C11-keto metabolites (Swart and Storbeck 2015). In addition, 11βHSD2 has been shown to be 
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expressed in LNCaP prostate cells (Page at al. 1994; Dovio et al. 2009), and therefore reported to 
catalyse the metabolism of 11OHA4 in these cells, while 11βHSD2 has also been shown in prostate 
tissue (Albiston et al. 1994; Pelletier et al. 2004) Clearly, 11βHSDs, 17βHSDs and SRD5As are essential 
in the metabolism of adrenal 11OHA4 in the prostate. Furthermore, SRD5A conversions assays have 
shown that 11OHA4 and 11KA4 are preferentially converted to their 5α-reduced products compared to 
the T-metabolites, 11KT and 11OHT, comparable to the alternative pathway in DHT production 
described above. In addition, AKR1C3 has been shown to preferentially convert 11KA4 and  
11K-5αDIONE to their T-derivatives, compared to the conversion of A4 to T (Swart and Storbeck, 2015) 
and, to date, 11OHDHT and 11K-3αDIOL have not been shown to be substrates for 3αHSDs and 
11βHSD1, respectively. 
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Figure 2.4 11OHA4-pathway leading to the production of 11KT and 11KDHT from adrenal 11OHA4 in the 
prostate (Boxed steroids; potent steroids). 
Following its production, 11KDHT can be inactivated to 11K-3αDIOL by 3αHSD enzymes present in the 
prostate, and while reactivation by RL-HSD enzymes are also possible, 11KDHT may also be conjugated 
by UGTs and SULTs. Furthermore, 11β-hydroxyandrosterone (11OHAST) and 11keto-androsterone 
(11KAST), produced by 3αHSDs from 11OH-5αDIONE and 11K-5αDIONE, respectively, may also be 
conjugated, together with 11OHT, 11KT, 11OHDHT and 11K-3αDIOL. While the adrenals have been 
described as the primary source of 11OHA4 in circulation, CYP11B1 and CYP11B2 have been shown to 
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be expressed in human primary prostate and metastatic primary prostate carcinomas  
(Biancolella et al. 2007; Mitsiades et al. 2012). Therefore, it is possible that within the prostate 
microenvironment, adrenal A4 and T, together with gonadal T, may be converted to 11OHA4 and 
11OHT, respectively. 
2.3.3 The backdoor pathway to DHT and 11KDHT production 
The backdoor pathway, also termed ‘the alternative backdoor pathway’, was initially described as the 
conversion of 3αDIOL to DHT, thereby bypassing T and A4 as precursors and was reported in testes of 
tammar wallaby pouch young and immature mouse testis by Auchus (2004). In human physiology, the 
backdoor pathway has been described in 21OHD patients, in which the accumulation of adrenal PROG 
and 17OHPROG levels leads to androgen excess and specifically to the production of DHT  
(Kamrath et al. 2012). Since hampered CYP21A2 activity in these patients results in an accumulation in 
PROG and 17OHPROG levels in vivo, SRD5A enzymes are able to convert PROG and 17OHPROG to 
dihydroprogesterone (DHPROG) and 5α-pregnan-17α-ol-3,20-dione (Pdione), respectively. DHPROG 
and Pdione are subsequently substrates for 3αHSDs, producing allopregnanolone and  
5α-pregnan-3α,17α-diol-20-one (Pdiol), respectively, followed by the lyase activity of CYP17A1 yielding 
AST (Fig. 2.5). Indeed, Pdiol has been reported to be an excellent substrate for CYP17A1  
(Gupta et al. 2003). Ultimately, AST can be converted to DHT, following 3αHSD (RL-HSD) and reductive 
17βHSD catalysed reactions (Fig. 2.3 and 2.5). In addition to 21OHD patients, the backdoor pathway 
may also be active in diseases and adrenal disorders clinically characterized by androgen excess, 
including PCOS, 3βHSD deficiency and Antley-Bixler syndrome (POR deficiency)  
(Ghayee and Auchus 2007; Marti et al. 2017). 
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Figure 2.5 Backdoor pathway leading to the production of DHT from PROG and 17OHPROG, and 11KDHT from 
11OHPROG, 11KPROG, 21-dF and 21-deoxycortisone (21-dE). (Boxed steroids, potent steroids; boxed pathway, 
represents the ‘classical’ backdoor pathway).  
As previously mentioned, CYP11B enzymes convert PROG and 17OHPROG to 11OHPROG and 21-dF, 
respectively. These steroids, together with their 11βHSD2 products 11keto-progesterone (11KPROG) 
and 21-dE, are also substrates for the SRD5As and as such are able to contribute to the backdoor 
pathway, yielding 11KDHT (Barnard et al. 2017; Van Rooyen et al. 2017) (Fig. 2.5). Moreover, 
16OHPROG has also recently been shown to be a substrate for CYP11B2, with this product (11,16-
diOHRPOG) and 16OHPROG itself shown to be substrates for SRD5As in vitro. The SRD5A product of 
16OHPROG was also in turn a substrate for the catalytic activity of 3αHSD (Van Rooyen et al. 2017). 
While the backdoor pathway would be active in peripheral tissue that readily express SRD5As (the 
initial step in these pathways), 3αHSDs and 17βHSDs, the expression of CYP17A1 and 11βHSD2 may 
not be optimal in peripheral tissue. The adrenals do not express SRD5As (Auchus 2009), although 
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SRD5A activity has been reported in the fetal adrenal by Hanley and Arlt (2006). The testes and skin 
also express most of the enzymatic machinery; the testes express SRD5A2 (Flück et al. 2011), together 
with CYP17A1 and 17βHSD, while skin cells express CYP11B1, CYP17A1, 3βHSD, SDR5A1 and SRD5A2 
(Dumont et al. 1992; Thigpen et al. 1993; Slominski et al. 1996d; Thiboutot et al. 2003; Slominski et al. 
2004c). Clearly, some target tissue would produce some of the steroids in the backdoor pathways up 
until point, after which the steroids would be released into circulation, to be taken up by other 
peripheral target tissue and further metabolised dependent on the expression of enzymes required.  
Interestingly, the prostate expresses all the enzymes involved in the backdoor pathway, together with 
CYP17A1, with mRNA transcripts having been reported in PCa cell lines (Dillard et al. 2008;  
Locke et al. 2008). Moreover, while de novo steroid biosynthesis from cholesterol has been suggested 
to occur in CRPC (Cai et al. 2011), the topic is controversial as others have reported the negligible 
contribution of de novo biosynthesis compared to the contribution of adrenal precursors to the 
androgen pool in the prostate (Hofland et al. 2010; Kumagai et al. 2013). Clearly, all the above 
mentioned pathways are able to metabolise a wide-array of precursor steroids, incorporating these to 
produce potent androgens within the prostate microenvironment. 
2.4 Steroidogenic enzymes involved in steroid metabolic pathways in the prostate 
While steroid metabolic pathways can utilize multiple adrenal precursor steroids, including C19 and C21 
adrenal steroids, this thesis will focus mainly on the contribution of 11OHA4 and its metabolites to PCa, 
which is dependent on the expression of 11βHSDs, 17βHSDs and SRD5As as pre-receptor regulatory 
enzymes, together with 3αHSDs, RL-HSDs, UGTs and SULTs as post-receptor regulatory enzymes. 
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The epithelium lining the tube alveoli of the prostate consists of two steroidogenic cell layers 
adjacently located, namely basal (adjacent to the bloodstream) and luminal cells (above the basal 
cells). Steroids in circulation are taken up into the basal cells, where after androgen receptor action 
occurs in the luminal cells. 3βHSDs, 3αHSDs, 17βHSDs, SRD5As and UGTs are expressed in the basal 
cells, while SRD5As and UGTs are also expressed in the luminal cells, together with the AR  
(Labrie et al. 2001; Bélanger et al. 2003; Pelletier 2008). Basal cells are, therefore, actively involved in 
steroid metabolic pathways, while also supplying luminal cells with steroid precursors, and both cells 
are secretory cells, contributing to steroid conjugates in circulation. 
2.4.1 11β-hydroxysteroid dehydrogenases 
Traditionally, the role of 11βHSDs have been linked solely to the interconversion of the glucocorticoids, 
namely cortisol and cortisone, however, their role in the interconversion between C11-hydroxy and 
C11-keto androgens has recently come under the spotlight (Fig. 2.2). While the keto-metabolite, 
cortisone, is considered an inactive metabolite in the glucocorticoid pathway, the C11-keto metabolites 
in the androgen pathway are active steroid hormones, specifically considering 11KT and 11KDHT 
(section 2.5). The microsomal oxo-reductase, 11βHSD1, is a NADPH-dependent enzyme which converts 
the C11-keto moiety to a C11-hydroxy moiety (Cooper and Stewart 2009). The required NADPH is 
supplied by the microsomal NADPH regenerating enzyme, hexose-6-phosphate dehydrogenase 
(H6PDH), which favours the reductive activity of this enzyme, however, this enzyme also possesses 
dehydrogenase activity, which catalyses the reverse reaction, converting C11-hydroxy moieties to their 
C11-keto moieties. In vivo conditions, however, favour the oxo-reductase activity of 11βHSD1 and 
therefore the production of C11-hydroxy metabolites. Conversely, 11βHSD2 possesses only 
dehydrogenase activity, efficiently converting C11-hydroxy to C11-keto metabolites. Moreover, while 
Stellenbosch University  https://scholar.sun.ac.za
26 
 
11βHSD2 has been reported to be involved in the production of C11-keto metabolites in the adrenals  
(Rege et al. 2013) (Fig. 2.1) and has been shown in vitro to produce C11-keto derivatives in the 
11OHA4-pathway (Swart et al. 2013) (Fig. 2.4), this enzyme is also involved in the biosynthesis of novel 
C21 steroids as precursors to be metabolised in the backdoor pathway (Barnard et al. 2017) (Fig. 2.5). 
While 11βHSD2 is expressed in prostate tissue, it is also expressed in the adrenals (ZG, ZF, ZR), in 
addition to the placenta, testis, ovary, skin and kidneys (Miller and Auchus 2011; Mostaghel 2014). 
2.4.2 17β-hydroxysteroid dehydrogenases 
17βHSDs catalyse the interconversion between C17-hydroxy and C17-keto metabolites, with specific 
isoforms catalysing the reductive activity, while other isoforms catalyse the dehydrogenase reactions 
(Fig. 2.2). The isoforms catalysing the reductive activity utilize NADPH/NADP+ as a cofactor, converting 
C17-keto to C17-hydroxy metabolites, while the dehydrogenases utilize NAD+/NADH to convert the 
C17-hydroxy to C17-keto metabolites (Luu-The 2001). The most well characterised reductive 17βHSDs 
are 17βHSD3 and AKR1C3, whereas 17βHSD2 is a commonly reported oxidative 17βHSD. 17βHSDs are 
intricately involved in the interconversion between A4 and T (Fig. 2.1, 2.3), as well as 11KA4 and 11KT 
(Fig. 2.4), with the reductive 17βHSDs catalysing the activation of androgens –both 17βHSD3 and 
AKR1C3 biosynthesize T and 11KT, with these transcripts, together with 17βHSD2 present in prostate 
tissue (Dumont et al. 1992; Martel et al. 1992; Akinola et al. 1996). Furthermore, 17βHSD isoforms are 
also expressed in other peripheral tissue, including the adrenals (in the ZR) and the testis  
(Dufort et al. 1999; Luu-The 2001; Mostaghel 2014). 
2.4.3 5α-reductases 
SRD5As reduces the C4-C5 double bond on the steroid backbone structure (Fig. 2.2). This reaction is 
irreversible and produces potent steroids, such as DHT and 11KDHT, and as such these steroids are 
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involved in the classic-, alternative-, 11OHA4-, and backdoor pathway (Fig. 2.3, 2.4, 2.5). SRD5As are 
NADPH-dependent enzymes (Russell and Wilson 1994; Soronen et al. 2004), with three isoforms 
isolated to date. SRD5A2 is known as the predominant isoform active in normal prostatic physiology, 
while SRD5A1 has been reported to be increased in PCa (Stanbrough et al. 2006; Chang et al. 2011). 
Both SRD5A1 and SRD5A2 has been identified to catalyse the production of 5α-reduced metabolites in 
the 11OHA4-pathway (Storbeck et al. 2013; Swart et al. 2013), however, the ability of the third SRD5A 
isoform, 5α-reductase type 3 (SRD5A3) (Uemura et al. 2008), to catalyse the production of 5α-reduced 
C11-oxy C19 steroids has, to date, not been clarified. SRD5As are expressed in multiple steroidogenic 
tissue, including the prostate, ovary, skin, liver and testes (Russell and Wilson 1994;  
Uemura et al. 2008) 
2.4.4 3α-hydroxysteroid dehydrogenases 
3αHSDs catalyse the reversible reduction of the C3-keto moiety to a C3-hydroxy moiety, thereby 
converting active 5α-reduced steroids to inactive 3α-reduced metabolites (Fig. 2.2), utilizing NADP(H) 
as cofactors (Miller and Auchus 2011). This reduction is considered an inactivation step in prostate 
steroidogenesis, as these reduced products are less androgenic and serve as potential substrates for 
elimination from the prostate microenvironment by conjugation. The specific isoform,  
3α-hydroxysteroid dehydrogenase type 3 (AKR1C2), has been shown to mediate the inactivation of C19 
steroids (Penning and Byrns 2009) and is therefore involved in the classic-, alternative- and  
11OHA4-pathway (Fig. 2.3, 2.4). In the backdoor pathway (Fig. 2.5), however, AKR1C2 is essential in the 
conversion of 5α-reduced metabolites to their 3α-reduced products, which demonstrates that in this 
pathway 3αHSD catalyses an important step that is required for the conversion of adrenal C21 steroid 
precursors to active steroids (DHT and 11KDHT).  
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Interestingly, 3α-hydroxysteroid dehydrogenase type 4 (AKR1C1), a 20α(3β)-hydroxysteroid 
dehydrogenase, results in the formation of a β-hydroxyl moiety at C3 of C19 steroids, including  
5α-androstane-3β-17β-diol (3βDIOL) and epiandrosterone (epiAST). AKR1C1 also has marginal 3αHSD 
activity and may therefore function as a 3α/β- and 20α-HSD (Steckelbroeck et al. 2003; Penning and 
Byrns 2009). However, in the prostate microenvironment, AKR1C2 would predominantly produce  
3α-conformational steroids and AKR1C1 would produce 3β-conformational steroids  
(Penning et al. 2000). Moreover, although AKR1C3 has been discussed as a 17βHSD enzyme, AKR1C3 
may also function as a 3α/3β-HSD, producing 3αDIOL (2.7 nmoles product/min/mg protein) and 
3βDIOL (2.0 nmoles product/min/mg protein) (Penning and Byrns 2009). Clearly, HSD enzymes possess 
dual activities, and the preferred activity will depend on co-factor and steroid substrate availability, in 
addition to the stage of PCa development. While the role of C3β-hydroxy steroids in PCa still needs to 
be clarified, these metabolites may contribute to downstream physiological effects, such as AR or 
estrogen receptor (ER) binding. For instance, 3βDIOL has been shown to bind the ERβ, and was 
identified as a proapoptotic ligand which regulates growth in the prostate (Muthusamy et al. 2011). 
2.4.5 Retinol-like hydroxysteroid dehydrogenases 
RL-HSD enzymes catalyse the oxidation of the 3α-reduced steroids (Fig. 2.2), utilizing NAD(H) as 
cofactors (Miller and Auchus 2011). These enzymes are sometimes referred to as 3αHSDs, however, 
literature does distinguish between the reductive and dehydrogenase activities, while certain enzyme 
isoforms also possess dual activities. For this thesis, RL-HSDs functions by converting a C3-hydroxy 
moiety to a C3-keto moiety, thereby once again providing potent steroids to the androgen pool, in the 
classic-, alternative-, 11OHA4-, and backdoor pathways (Fig. 2.3, 2.4, 2.5).  
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Importantly, 17βHSD type 6 (17βHSD6) functions as a 3α/β-HSD (moderate activity), but more 
predominantly as a RL-HSD, converting 3αDIOL to DHT (Miller and Auchus 2011). 17βHSD6, also known 
as retinol dehydrogenase-like 3α-hydroxysteroid dehydrogenase, has also been shown to convert DHT 
to 3βDIOL (3-ketoreductase/3β-hydroxysteroid dehydrogenase activity), which activates the ERβ. 
Interestingly, in BPH 17βHSD6 and ERβ were co-expressed, while expression of both proteins was lost 
in PCa (Muthusamy et al. 2011). Moreover, in the presence of both DHT and 3αDIOL and 17βHSD6, ERβ 
activation was increased, suggesting 17βHSD6 has dual activity whereby both DHT (3βHSD activity) and 
3αDIOL (3α→β epimerization activity) are converted to 3βDIOL (Muthusamy et al. 2011). This has also 
been shown for 5αDIONE, whereby a 3(α→β) hydroxysteroid epimerase (HSE) converted 5αDIONE to 
epiAST, while also metabolising AST to epiAST, however, this enzyme also converts epiAST to AST 
(<20% activity) (Huang et al. 2000). In addition, the conversion of 3αDIOL to DHT by 17βHSD6  
(RL-HSD activity) has been reported (Biswas 1997; Bauman et al. 2006), as well as the RL-HSD 
conversion of AST to 5αDIONE (Belyaeva et al. 2007), further contributing to the complexities of 
steroidogenesis in the prostate. This enzyme may be a regulatory enzyme, especially in the context of 
C11-oxy C19 and C11-oxy C21 steroids, that requires further investigation. The C11-oxy C19 steroids with 
3β-conformations, such as 5α-androstan-3β,11β-diol-17-one (11OH-epiAST),  
5α-androstan-3β-ol-11,17-dione (11K-epiAST) and 11keto-5α-androstane-3β, 17β-diol (11K-3βDIOL) 
have not been shown to be produced in vitro by enzymatic conversions, neither have their levels been 
reported in vivo or their AR and ERβ activation been described. Furthermore, literature reports 3βDIOL 
levels to be increased 5-fold compared to 3αDIOL in the prostate (Bélanger et al. 1990;  
Matthews et al. 2006), and epiT (17α-epimer of T) has been shown in plasma (Starka et al. 1997) and to 
be increased in PCa tissue compared to BPH tissue (Heracek et al. 2007), while epiAST is not a 
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preferred substrate for UGT-conjugation (Beaulieu et al. 1996) –clearly indicating a role for epi-steroids 
in PCa.  
2.4.6 Uridine-diphosphate glucuronosyltransferases 
Once C19 steroids are reduced by 17βHSDs and 3αHSDs, UGT enzymes conjugate the C17 β- and  
C3 α-hydroxy groups by glucuronidation and thereby terminates the steroid signal (Fig. 2.2) These 
conversions are irreversible and requires the regenerating system which converts uridine diphosphate 
(UDP) glucose to UDP glucuronic acid by UDP glucose-6-dehydrogenase (Fig. 2.6). This system provides 
UDP glucuronic acid to the UGT enzymes, which subsequently adds the glucuronide group to the 
oxygen moiety on the steroid chemical backbone, and releases a hydrogen atom and UDP as products, 
together with the steroid glucuronide. While two superfamilies of UGTs exist, UGT1 and UGT2, this 
thesis focusses on the UGT2 family, which in turn is subdivided into UGT2A and UGT2B families. UGT2A 
enzymes are linked to the olfactory epithelium (Lazard et al. 1991), while UGT2Bs are expressed in the 
prostate and conjugate C19 steroids, phenols and fatty acids (Beaulieu et al. 1996). The UGT2B enzymes 
are expressed in the basal and luminal cells of the prostate, thereby regulating the potency of active 
steroids in both cell layers and, following glucuronidation, increases the water-solubility of the 
steroids, thereby facilitating their secretion from the cells (Tukey and Strassburg 2000). UGT steroid 
substrates in the classic- and alternative pathways include T, DHT, AST and 3αDIOL (Fig. 2.3)  
(Bélanger et al. 2003; Chouinard et al. 2007; Byrns et al. 2012), while potential substrates in the 
11OHA4-pathway include; 11OHT, 11KT, 11OHDHT, 11KDHT, 11OHAST, 11KAST and 11K-3αDIOL  
(Fig. 2.4). In the backdoor pathway DHT, 11K-3αDIOL, 11KDHT, in addition to their 3αHSD products 
AST, 3αDIOL, 11KAST and 11OHAST are potential substrates for UGT2B enzymes (Fig. 2.5). Three 
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isoforms of UGT2B enzymes are present in the prostate: UGT2B type 15 (UGT2B15), UGT2B type 17 
(UGT2B17) and UGT2B type 28 (UGT2B28), and are discussed in detail in chapter 3.  
 
Figure 2.6 Regeneration system for the UGT2B catalysed reaction of DHT to DHT-glucuronide (DHT-G). 
While literature has extensively explored the glucuronidation of C19 steroids, the glucuronidation of 
C11-oxy C19 has not been described. It has, however, been suggested that UGT2B17 is able to 
glucuronidate 11OHAST and AST, but that the presence of the C11α/β hydroxy group may interfere 
with the conjugation of these C19 steroids (Beaulieu et al. 1996), with impeded glucuronidation of the 
C11-oxy C19 steroids contributing to the potency of these steroids. 
2.4.7 Sulfotransferases and sulfatases 
It was previously discussed that SULT and STS enzymes are involved in adrenal steroidogenesis, 
regulating the conjugation of DHEA (Fig. 2.1). These enzymes are, however, also present in the prostate 
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and conjugate other C19 steroids. Cytosolic SULTs that conjugate steroids include, SULT2A1 and 
SULT2B1a and SULT2B1b, and while SULT2A1 is the predominant form in the adrenals, the expression 
of SULT2B1b is greater than SULT2B1a in the prostate (Geese and Raftogianis 2011). PREG, 17OHPREG, 
AST, DHEA and androstenediol are substrates for SULT2A1, PREG for SUL2B1a and cholesterol for 
SULT2B1b (Mueller et al. 2015). These SULT enzymes requires a sulfate supplied by  
3’-phosphoadenosine-5’-phosphosulfate (PAPS), which is biosynthesized from ATP by PAPS synthase 1 
and 2 (PAPSS1, PAPSS2) (Strott 2002), to conjugate hydrophobic steroids (Fig. 2.7). Notably, the 
sulfation of steroids is a reversible reaction, with the back reaction catalysed by membrane-bound 
microsomal STS, thereby providing androgens to the steroid pool in peripheral tissue. STS catalyses the 
hydrolysis of steroid sulfates, such as DHEA-S, PREG-sulfate (PREG-S) and cholesterol-sulfate  
(Mueller et al 2015) and is expressed in normal (Farnsworth 1973) and cancerous prostate tissue 
(Nakamura et al. 2006), while also being expressed in LNCaP cells (Day et al. 2009). 
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Figure 2.7 Sulfation cycle representing the transfer of sulfate through sulfate channels, enzyme activity of PAPSS 
and the ultimate sulfation of the steroid backbone structure. Reproduced from Hemmerich et al. 2004. 
Interestingly, upregulation and downregulation of sulfation has been linked to diseases: in 21OHD, 
DHEA and DHEA-S levels have been shown to be reduced, while PREG-S levels were reported to be 
higher (Turcu et al. 2016); in PCOS, high DHEA and DHEA-S levels have been reported, while impaired 
DHEA sulfation due to PAPSS2 deficiency has been shown in a PCOS patient (Noordam et al. 2009); in 
adrenarche, DHEA-S levels have been shown to be elevated and is therefore considered a biomarker 
for this occurrence. In the latter scenario circulatory 11OHA4 has also been shown to be involved, 
increasing from 2.5 to 6.4 nM during childhood in boys and girls (Holownia et al. 1992). Clearly,  
C11-oxy C19 steroids and their sulfation and desulfation may be important in adrenarche, in addition to 
their potential influence in clinical conditions such as 21OHD, PCOS and PCa. 
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The steroid metabolic pathways and steroidogenic enzymes involved in these pathways, as discussed 
above, are active in prostate cell models, such as PNT2, BPH-1, LNCaP, C4-2B and VCaP, which were cell 
models used to conduct the studies presented in this thesis. These cell models are excellent for 
studying prostate enzymatic conversions involved in the metabolism of C19 and C11-oxy C19 steroids, as 
these cells express both pre-receptor and post-receptor regulatory enzymes. Chapters 3 and 4 will 
include data relating to LNCaP metabolic pathways, while Chapter 3 will also discuss metabolic 
pathways in PNT2, VCaP and C4-2B cells and Chapter 5 will discuss metabolic pathways in BPH-1 cells. 
PNT2 prostate epithelial cells are derived from normal human prostatic epithelium and have been 
immortalized (Cussenot 1991), however, while they have retained most of the characteristics of normal 
epithelial cells and are non-tumorigenic, PCa related genetic alterations are also present in these cells 
(Berthon 1995; Blanchere et al 1998).  The BPH-1 prostate epithelial cells are androgen-independent 
and non-tumorigenic, originating from human prostate tissue obtained by transurethral resection and 
subsequently primary cell cultures from a male which displayed a BPH phenotype (Hayward 1995). 
LNCaP prostate cancer epithelial cells are hormone-dependent, show low tumorgenicity and originated 
from a supraclavicular lymph node metastasis (Horoszewicz et al. 1983), while VCaP prostate cancer 
cells are androgen dependent, non-tumorigenic and derived from a vertebral metastasis in a patient 
representing an advanced PCa and a castrate resistant phenotype (Korenchuk et al. 2001). C4-2B 
prostate cancer cells are androgen-independent, represented as ‘androgen ablation resistance’ and 
highly tumorigenic with CRPC characteristics. Interestingly, C4-2B cells are derived from bone 
metastatic tumours maintained in intact athymic male mice, which originated from LNCaP cells 
(Thalmann et al. 2000). 
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2.5 C11-oxy C19 steroids and their implications in disease 
Adrenal C11-oxy C19 steroids, once secreted, would have implications in peripheral target tissue, while 
C11-oxy C19 steroids produced within peripheral tissue will also have downstream effects. In this 
regard, the androgenicity of steroid hormones are important, as most physiological effects are 
mediated through receptors, and intraprostatic androgenicity are specifically mediated through the 
AR. As pre-receptor and post-receptor regulations are in place in the prostate microenvironment, there 
is a balance maintained between these two mechanisms, regulating the availability of AR agonists. 
When this balance is, however, perturbed, AR agonists are produced in abundance causing cellular 
effects implicated in the initiation and development of PCa, and the progression to CRPC. 
2.5.1 Androgen receptor action 
The AR protein is expressed in the nuclei of luminal cells of the prostate epithelium and is a member of 
the steroid hormone receptor family of ligand-activated nuclear transcription factors  
(Labrie et al. 2001; Pelletier 2008). In the cytoplasm of the luminal cells, the AR is inactive and 
unliganded, although attached to heat shock proteins (HSPs) which stabilize their tertiary structure 
(Smith and Toft 1993). Once the AR binds its ligand, it disassociates from the HSPs, dimerizes with 
other ARs, undergoes phosphorylation and translocates into the nucleus (McEwan 2000; Prins 2000). 
Thereafter, the AR-ligand complex binds DNA, followed by the recruitment of transcriptional- and  
co-factors, in order to activate genetic pathways (Habib 2004). The androgenicity of steroid hormones 
are, therefore, determined by the binding and activation of the AR, the induction of AR regulated gene 
expression, and cell proliferative effects, with DHT deemed the most potent AR ligand and, 
preferentially to T, binds the AR. 
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To date, the transactivation of the AR by the C11-oxy C19 steroids has been shown (Yazawa et al. 2008; 
Rege et al. 2013; Storbeck et al. 2013; Campana et al. 2016), in addition to the binding of the  
C11-oxy C19 steroids to the human AR (Pretorius et al. 2016) (Table 2.1). While the androgenicity of 
11OHA4 was determined to be negligible since the 1960s already (Rosemberg et al. 1958; Dorfman et 
al. 1966), other authors have also confirmed that 11OHA4 is non-androgenic (Rege et al. 2013; 
Storbeck et al. 2013; Campana et al. 2016), however, the C11 keto metabolite, 11KA4, has been shown 
to have similar, albeit low, androgenicity compared to A4 (Rege et al. 2013; Campana et al. 2016). 
Considering the T-metabolites, 11KT and T exhibit comparable androgenicity, while the androgenicity 
of 11OHT was 2-fold lower than that of T and 11KT. Furthermore, 11KDHT showed androgenicity 
comparable to DHT, at 1 nM, while 11OHDHT was not as potent as DHT (Storbeck et al. 2013). It was, 
however, shown at 10 nM that 11OHT, 11OHDHT, 11KT and 11KDHT activate the AR comparable to 
DHT (Bloem et al. 2015). Furthermore, the induction of AR regulated gene expression in LNCaP cells, 
which express a mutated AR (Veldscholte et al. 1990), was shown, suggesting the C11-oxy C19 steroids 
also bind this mutant, while the induction of AR regulated genes by C11-oxy C19 steroids were also 
shown in VCaP cells, which express the wild-type AR. Importantly, the authors concluded that 11KT and 
11KDHT are equipotent steroids compared to T and DHT, respectively (Pretorius et al. 2016). 
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Table 2.1 Androgenicity of C11-oxy C19 steroids indicated by AR binding, AR activation, induction of AR-regulated 
genes and cell proliferative effects. Comparing 11KDHT and 11OHDHT to DHT, and 11KT and 11OHT to T. 
  11KDHT 11OHDHT 11KT 11OHT 
Whole cell binding assays wild-type hARa √ = - √ = - 
Transactivation assays (hAR) at 1 nMb 
at 10 nMc 
at 100 nMd 
√ = 
√ = 
- 
√ < 
√ = 
- 
√ = 
√ = 
√ = 
√ < 
√ = 
√ < 
Cell proliferation assays (at 1 nM) In LNCaP cellsa 
In VCaP cellsa 
√ > 
√ = 
- 
- 
√ > 
√ = 
- 
- 
Induction of AR-regulated gene 
expression (In LNCaP cells at 1 nM) 
KLK3a 
TMPRSS2a 
FKBP5a 
√ 
√ 
√ 
- 
- 
- 
√ 
√ > (p=0.052) 
√ > (p<0.05) 
- 
- 
- 
aData from (Pretorius et al. 2016); bData from (Storbeck et al. 2013); cData from (Bloem et al. 2015); dData from (Rege et al. 
2013); -, steroid not included in the assay; =, equal comparison; > compared more efficient; < compared less efficient 
The intraprostatic androgenicity of the C11-oxy C19 steroids is evident, clearly showing that the  
C11-oxy C19 steroids, 11KT and 11KDHT, are potent steroids and their androgenic activity comparable 
to that of C19 steroids. In PCa, the activation of the AR is integral to disease progression, positioning 
11KT and 11KDHT as role players in PCa and CRPC. 
2.5.2 Castration-resistant prostate cancer 
While PCa is driven by gonadal T, with the contribution of adrenal steroid hormones to the uncastrated 
prostate microenvironment being minimal, CRPC is driven by adrenal androgens, including the C19, 
C11-oxy C19, C21 and C11-oxy C21 steroids. The difference between PCa and CRPC is not only the 
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different origins of precursor steroids and the aggressiveness of the disease, but also the expression of 
steroidogenic enzymes which is altered, in addition to the presence of mutated ARs. In terms of the AR, 
mutations in the ligand binding domain produces mutated AR variants that bind promiscuously or 
which are constitutively active (Mohler et al. 2004), in addition to reduced AR specificity and AR gene 
amplifications, with the latter reported in one third of the cases (Taplin et al. 1995;  
Holzbeierlein et al. 2004). Furthermore, ligand-independent activation of AR signalling pathways may 
also occur. In terms of steroidogenic enzymes, subcellular localization may change, in addition to  
post-translational changes, while the availability of cofactors may impede activity, leading to a 
preference for the binding of alternative steroid substrates (Mizrachi and Auchus 2009; Sharifi 2012; 
Sharifi and Auchus 2012).  
While both 3βHSD1 and 3βHSD2 expression is increased in CRPC, 3βHSD1 is also 10-fold more efficient 
than 3βHSD2 in the production of ∆4 androgens (Miller and Auchus 2011). In addition, SRD5A1 has 
been shown to be increased in PCa and CRPC (Titus et al. 2005; Stanbrough et al. 2006; Montgomery et 
al. 2008), together with SRD5A3 (Uemura et al. 2008; Titus and Mohler 2009; Godoy et al. 2011; 
Azzouni et al. 2012; Mitsiades et al 2012). Up-regulation of AKR1C3 has also been shown in PCa and 
CRPC (Lin et al. 2004; Fung et al. 2006; Penning et al. 2006; Stanbrough et al. 2006; Luu-The et al. 2008; 
Montgomery et al. 2008; Mitsiades et al. 2012), while increased 17βHSD3 and decreased 17βHSD2 
expression has also been reported (Koh et al. 2002). While the above mentioned enzymes would 
biosynthesize active androgens, the expression of UGT2B17 is increased in PCa, compared to BPH 
(Paquet et al. 2012), while UGT2B15 is also increased in androgen-independent PCa  
(Stanbrough et al. 2006), and in CRPC (Mostaghel 2013), suggesting alterations also occur to counter 
the increase in steroid production. The aforementioned AR mutations and enzymatic changes, 
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however, represents the adaptations prostate cells undergo to survive, producing a cancerous growth, 
and in the case of CRPC, shows high fatality with an average survival of only 1-2 years in these patients 
(Ross et al. 2008). 
2.5.3 Treatments regimens in PCa and CRPC 
Prior to discussing treatment options with patients, PCa needs to be accurately diagnosed. Diagnosis is 
based upon clinical and histological parameters. While histological data will accurately diagnose PCa, 
this is an invasive biopsy which has a high morbidity and mortality rate, showing minor and major 
complications, in 69.7 % and 1-3% in patients, respectively. Clinical data instead includes a digital rectal 
examination supported by imaging evidence of cancerous growth, in addition to determining  
prostate-specific antigen (PSA) circulatory levels. Clinical evidence is less invasive with lower risk of 
infections, and while it has its own pitfalls, as PSA determination results in false positives, PSA is still 
correlated to PCa risk and diagnosis of PCa based on clinical data is still considered the better option, 
as well as being cost effective. Following diagnosis, surgery and radiation is suggested as treatment 
options. If, however, prognosis shows the continued increase in PCa risk, denoted by Gleason scoring, 
tumour stage and PSA levels, bilateral orchiectomy (BO) is suggested as the first line of  
androgen-deprivation therapy (ADT) treatment, reported in 56.2% cases as the treatment option 
employed (Heyns et al. 2014). While physical castration through BO is a once-off treatment and is the 
more cost-effective option, chemical castration requires medication to be taken regularly, together 
with monthly payments, with patient compliances adding to the complications of this form of ADT 
(Mariani et al. 2001; Heyns et al. 2014). It is worth mentioning that the  
hypothalamus-pituitary-gonadal axis is involved in testicular steroidogenesis, and works through pulses 
of gonadotropin-releasing hormone (GnRH) released by the hypothalamus, which in turn stimulates 
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the pituitary gland to release luteinizing hormones (LH), which ultimately stimulate the testis to 
produce T. T in turn has a negative feedback mechanism on the hypothalamus and the pituitary to 
suppress T production. Chemical castration, therefore, involves the intake of GnRH antagonists such as 
degarelix, which blocks the GnRH receptor and the release of LH or long-acting GnRH/LH-releasing 
hormones (LHRH) agonists, such as leuprolide acetate and goserelin, which continues the stimulation 
of GnRH, and over time desensitization occurs, and as such less LH is released and T produced  
(Tolis et al. 1982). Interestingly, physical and chemical castration have been shown to be equally 
effective, with relapse also being similar. The measurement of PSA levels is routinely employed to 
assess the relapse, which is expected within 48 months up until 16 years (Heyns et al. 2014). 
 Biochemically CRPC has adapted to survive, even after ADT treatment, and therefore necessitates the 
need for targeted enzymatic treatments. Indeed, steroidogenic enzymes involved in prostate metabolic 
pathways are currently being targeted. CYP17A1 inhibition, by abiraterone acetate, has been shown to 
be effective in PCa patients (Attard et al. 2009). As CYP17A1 is a branch point in adrenal 
steroidogenesis, in the production of mineralocorticoids, glucocorticoids and androgens (Fig. 2.1), this 
treatment is, however, not without its disadvantages. With CYP17 inhibition, less C21 steroids are 
shunted into the androgen pathway, which in turn leads to the accumulation of precursor steroids, 
metabolised to mineralocorticoids and glucocorticoids. Patients on abiraterone treatment therefore 
need to be monitored for mineralocorticoid excess and a potential increase in cardiovascular risk  
(Pia et al. 2013). Other enzymes for targeted inhibition are SRD5As, with dutasteride and finasteride 
shown to be successful pharmaceutical compounds, and while dutasteride inhibits both SRD5A1 and 
SRD5A2, finasteride only inhibits SRD5A2 (Luo et al. 2003; Shah et al. 2009). The inhibition of SRD5A is 
a more specific target than the inhibition of CYP17A1, as SRD5A is directly involved in the production of 
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DHT, however, dutasteride and finasteride do not block SRD5A3, suggesting this isoform is a potential 
target to be explored. The inhibition of CYP17A1 and SRD5As as monotherapies, or in combination, 
would decrease the influence of adrenal steroids in CRPC, as SRD5As are involved in the classic-, 
alternative-, 11OHA4- and backdoor pathways, while CYP17A1 is also required for the backdoor 
pathway. Furthermore, the inhibition of AKR1C3 may also be a potential target. Inhibiting this enzyme 
would reduce the adrenal and peripheral production of active androgens, such as T and 11KT, together 
with depriving the AR of a co-activator (Yepuru et al. 2013). AKR1C3 inhibition would, however, only 
limit the alternative-, 11OHA4- and backdoor pathways, but the classic pathway would still contribute 
to intraprostatic DHT levels from T as a precursor steroid. Under castrated conditions, however, 
minimal T is produced by the adrenal which highlights AKR1C3 as a viable enzymatic target specifically 
in CRPC. Two additional enzymatic targets are 3βHSD1 and STS. While the inhibition of 3βHSD1 would 
limit the contribution of DHEA to the intraprostatic androgen pool as the conversion of DHEA to A4 is 
inhibited, this treatment should be specific to this isoform as the inhibition of 3βHSD2 would also 
influence the mineralocorticoid and glucocorticoid pathways (Fig. 2.1). Inhibition of STS would limit the 
contribution of DHEA-S, together with other steroid sulfates, to the androgen pool, however, inhibiting 
STS would limit the production of cholesterol from cholesterol sulfate, ultimately obstructing 
steroidogenesis (Penning 2014). 
While the addition of hormones seems an unlikely treatment option, the use of exogenous steroid 
hormones has been employed in PCa patients, notably, estrogens (diethyl stilbestrol) and progestins 
(synthetic progesterones). Both these compounds activate the negative feedback of the hypothalamus 
thereby reducing GnRH and LH pulses. These compounds have the advantage of not activating the AR, 
however, side effects have been reported, including gynecomastia and thromboembolism. Clinically, 
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the use of GnRH/LHRH analogues are, therefore, favoured above the use of these exogenous 
hormones (Sharifi and Auchus 2012). 
Another treatment regime in PCa patients is the use of AR antagonists, which are compounds that bind 
the AR and renders the AR non-functional. These compounds include; flutamide, bicalutamide, 
nilutamide and enzalutamide (Tran et al. 2009). This form of treatment, however, has a high 
occurrence of resistance, as the AR mutates or binds ligands promiscuously, while the AR may also be 
constitutively active without ligand binding. In addition, bicalutamide has been reported to act as an 
antagonist of the AR, while over time, under androgen ablation, bicalutamide becomes a AR agonist 
(Culig et al. 1999). 
While the above mentioned treatment regimens have advantages and disadvantages as individual 
treatments, the combination of these treatments may be the most advantageous in PCa and CRPC 
patients. For instance, abiraterone treatment in combination with prednisone, a synthetic 
glucocorticoid receptor agonist which suppresses CRH and ACTH release, has shown potential in CRPC 
treatment approaches (Ryan et al. 2013; Rathkopf et al. 2014). The combination of abiraterone and 
enzalutamide has also been employed, however, the combination treatment did not deter relapse of 
the cancer, and requires further investigation (Loriot et al. 2013; Noonan et al. 2013;  
Bianchini et al. 2014; Schrader et al. 2014). 
2.6 Summary 
From this chapter it is clear that adrenal steroidogenesis contributes an important adrenal androgen to 
the androgen pool, namely 11OHA4. Adrenal 11OHA4 is a key precursor steroid which is metabolised 
in the 11OHA4-pathway, producing potent steroids, 11KT and 11KDHT, that bind and activate the AR, 
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while also upregulating AR regulated genes –pinpointing these C11-oxy steroids as crucial role-players 
in CRPC. In the clinical setting, however, the C11-oxy C19 steroids have not, to date, been considered in 
the diagnosis of PCa or prognostic scoring of PCa patients, nor are these steroid levels determined in 
vivo to assess treatment efficacy. The aim of this thesis is to establish the metabolism of the  
C11-oxy C19 steroids in PCa in the research setting, with potential implications in the clinical setting. 
While the pre-receptor metabolism and receptor action of C11-oxy C19 steroids have been investigated, 
the inactivation and glucuronidation of these steroids have not been described. Of particular interest 
for this PhD study is to ascertain whether the glucuronidation of the C11-oxy C19 steroids is hampered 
when compared to the C19 steroids. Furthermore, the presence of the C11-oxy C19 steroid in vivo have 
also not been described nor has the metabolism of these steroids been investigated in normal prostate 
cells. In the next chapter, presented in the form of three published manuscripts, the investigation into 
the inactivation and glucuronidation of the C11-oxy C19 steroids, and their presence in plasma and 
tissue, together with their metabolism in different prostate cell models, will be discussed. 
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Chapter 3 
Published Manuscripts 
 
3.1 Introduction 
Adrenal C19 steroids serve as precursors to active androgens once metabolized in peripheral tissue, 
such as the prostate. One such is 11OHA4 which was discovered in the 1950’s (Jeanloz et al. 1953; 
Dorfman 1954; Touchstone et al. 1955; Masuda 1957; Goldzieher and Beering 1969), but considered an 
inactive androgen with no specific physiological role (Dorfman et al. 1966). Our group has shown that 
adrenal 11OHA4 and 11OHT are metabolized to potent AR agonists, 11KT and 11KDHT, the latter as 
potent as DHT at 1 nM (Bloem et al. 2013; Storbeck et al. 2013; Swart et al. 2013). The rediscovery of 
11OHA4 and the identification of androgenic downstream metabolites has brought about a new 
perspective on adrenal C11-oxy C19 steroids and their contribution to PCa. In this regard our laboratory 
has identified novel enzymatic pathways in the metabolism of 11OHA4 and 11OHT and their 
metabolites, with these C11 hydroxy- and C11 keto C19 steroids also being produced in prostate cells  
(Bloem et al. 2013; Storbeck et al. 2013; Swart et al. 2013). Although many advances have been made 
in elucidating the downstream metabolism of 11OHA4 and its metabolites in PCa, further research was 
undertaken regarding this adrenal steroid. The aim of this section of the thesis was therefore to 
present recent reports undertaken in the PhD study identifying and quantifying C19 steroids and their 
C11-oxy derivatives in vitro, in prostate cell models and in vivo, in prostate tissue and plasma using the  
state-of-the-art UPC2-MS/MS technology. Firstly, a review is presented on UGT2B enzymes which 
regulate active androgen levels by conjugating androgens and terminating their physiological signal.  
A specific perspective is given on the UGT2B28 isoform which has been attributed a role in the 
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progression of PCa, as its expression in tissue has been correlated with conjugated steroid levels, PSA 
levels, Gleason scoring and PCa risk. The glucuronidation of C19 and C11-oxy C19 steroids was 
subsequently investigated in PCa cell models that endogenously express UGT isoforms –in LNCaP cells, 
together with C4-2B and VCaP cells. In addition, the metabolism of C11-oxy C19 steroids in normal PNT2 
prostate cells are shown, as well as their metabolism in LNCaP, C4-2B and VCaP cells. Furthermore, the 
inactivation and reactivation of the C19 steroid, DHT, and the C11-oxy C19 steroid, 11KDHT, are 
highlighted. UPC2-MS/MS analysis also allowed for the quantification, at nM level, of C11 hydroxy- and 
C11 keto C19 steroids in PCa tissue and human plasma obtained from PCa patients. In vivo circulating 
glucuronide levels were also determined in PCa patients and compared to normal levels.  
These studies are presented in the three manuscripts included in this chapter.1 
 
                                                          
1Author contributions to the manuscript entitled Profiling adrenal 11β-hydroxyandrostenedione metabolites in prostate 
cancer cells, tissue and plasma: UPC2-MS/MS quantification of 11β-hydroxytestosterone, 11keto-testosterone and  
11keto-dihydrotestosterone: LMB generated and supplied the data presented in Fig. 6A and B and added minor corrections 
to the final draft of the manuscript; JLQ advised with UPC2-MS/MS method development and validation; RE contributed 
towards the data presented in Fig.8 in the analysis of 11KDHT only; AMS supplied tissue and plasma samples. 
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active ligand levels and in so doing, the activation of the androgen receptor (AR). The glucuronidation of 
potent ligands renders them unable to bind the AR, allowing the secretion of conjugated steroids. Uridine 
diphosphate glucuronosyltransferase 2B type 28 (UGT2B28), one of the UGT enzymes catalyzing the 
glucuronidation of androgens, has recently been given a prominent role in the regulation of prostate 
steroidogenesis—one which stands in contrast to the accepted dogma that lower androgen levels resulting 
from increased conjugation are associated with decreased prostate cancer (PCa) risk and disease progression. 
Increased DHT and its precursors, T and androstenediol, were reported to be associated with increased 
UGT2B28 tumor expression levels, linked to lower PSA levels but higher Gleason scores and increased 
PCa risk. In addition, the complete deletion of UGT2B28, was associated with decreased T, DHT and 
glucuronide derivatives when compared to patients carrying both alleles. UGT2B28 is encoded by a single 
gene giving rise to UGT2B28 type I which catalyses androgen glucuronidation and, due to alternative 
splicing, also produces two distinct transcripts, UGT2B28 type II and III. Type II with its premature stop 
codon, is devoid of the cofactor binding domain while type III is devoid of the substrate binding domain, 
both catalytically inactive, truncated proteins. Increased UGT2B28 mRNA expression was reported in 
primary tumours, and while variable nuclear and strong cytoplasmic staining were distinctive of tumour cells, 
the expression levels and compartmentalization of the specific protein isoforms remain unknown. While 
increased expression of type I would contribute towards lowering androgen levels, increased expression of 
types II and III would not. The abundance of type III transcripts in multiple tissues may provide insight into 
a regulatory role with truncated isoforms possibly affecting androgen levels by regulating substrate and/or 
co-factor availability, dimerization or the formation of protein complexes with other UGTs, while protein-
protein interaction may also impact cascade signaling pathways in PCa development and disease progression. 
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In their article “The UGT2B28 sex-steroid inactivation 
pathway is a regulator of steroidogenesis and modifies the 
risk of prostate cancer progression” published in Eur Urol 
in April 2016, Belledant et al. report a regulatory role to 
the enzyme uridine diphosphate glucuronosyltransferase 
2B type 28 (UGT2B28), modulating prostate cancer (PCa) 
progression. This role is separate from that of UGT2B28’s 
function as a conjugative inactivating enzyme, with 
UGT2B28 influencing circulating androgen levels in PCa 
patients as well as clinical and pathologic factors associated 
with the disease (1).
Placing the work in context, we will discuss the 
contribution of steroidogenic enzymes towards the 
production and maintenance of active androgens which 
interact with the androgen receptor (AR) and the crucial 
role that these enzymes play—not only in normal prostate 
homeostasis but also in PCa. We will also briefly discuss 
genetic variability within UGT2B enzymes, focusing on 
B28, after which we will review the concepts highlighted by 
Belledant et al. and provide a perspective on the role of this 
conjugating enzyme in PCa.
Active androgen levels  are maintained by both 
metabolic and catabolic enzymes with 5α-reductase 
type 1 (SRD5A1) and type 2 (SRD5A2) catalyzing 
the biosynthesis of dihydrotestosterone (DHT) from 
testosterone (T) or alternatively from androstenedione 
(A4) and the 5α-androstane-3,17-dione (5αDIONE) 
intermediate. The interconversion of A4 and T and their 
5α-reduced metabolites by the reductive or oxidative 
17β-hydroxysteroid dehydrogenase (17βHSD) enzymes 
further adds to the complexity of steroidogenesis in the 
prostate. The equilibrium is however perturbed in PCa and 
tumour development is associated with the modulation of 
enzyme expression. Increased expression of the reductive 
enzyme 17βHSD3 (31-fold) has been reported in the 
prostate tumour microenvironment (2) as well as increases 
in 17βHSD5 (AKR1C3) expression ranging 2–5-fold, 
favouring T biosynthesis. In conjunction with the increased 
expression of the reductive enzymes, a 7-fold decrease in 
the expression of the oxidative enzyme 17βHSD2 which 
catalyzes the reverse conversion of T to A4, has been 
reported which again diverts the flux towards T production. 
In addition, while SRD5A2, which is expressed in normal 
prostate tissue, is decreased (2–4-fold), the expression 
of SRD5A1 has been shown to be increased (2-fold) in 
castration-resistant prostate tumours thus maintaining 
DHT levels in the prostate [(3) and the references therein)]. 
Contributing to the active androgen levels in the prostate 
microenvironment are the inactivating and conjugating 
enzymes. Only androgens with a hydroxyl group at C17 or 
C3 are potential substrates for conjugation by UGTs and as 
such both T and DHT can be converted to their glucuronide 
derivatives, rendering them inactive to be secreted into 
circulation. DHT together with 5αDIONE are, however, 
also inactivated by 3α-hydroxysteroid dehydrogenase type 3 
(AKR1C2), which catalyzes the reduction of the keto group 
at C3, forming 5α-androstane-3α,17β-diol (3αDIOL) and 
androsterone (AST), respectively, allowing the subsequent 
addition of the glucuronide moiety at C3. While AKR1C2 
also exhibits oxidative activity, this reverse reaction is 
primarily catalyzed by 17βHSD6, 17βHSD10 and retinol 
dehydrogenase 5 expressed in the prostate (4-7). In primary 
PCa, AKR1C2 expression levels have been reported to be 
significantly decreased compared to benign tissues (7-9), 
which contributes to significantly higher DHT levels in 
primary PCa tumours (10). In malignant epithelial cells, 
increased expression (3-fold) of 17βHSD10, which mediates 
the conversion of 3αDIOL to DHT, increased DHT tumour 
production (11). Furthermore, androgen deprivation therapy 
led to a 2-fold increase in 17βHSD6 expression levels, also 
associated with the biochemical progression of PCa (11). It 
is therefore apparent that the intricate homeostasis in the 
prostate is modulated by the perturbed expression of the 
steroidogenic enzymes catalyzing DHT production and 
those catalyzing the inactivation of androgens. 
The expression of the UGT2B enzymes are tissue 
and substrate specific. UGT2B7, B15 and B17 are the 
three major UGT2Bs primarily responsible for androgen 
conjugation in humans and of these only B15 and B17 
are actively expressed in the prostate (12). The UGT2B 
enzymes conjugate androgens in a regiospecific manner, 
either catalyzing the addition of the glucuronide moiety at 
C17 and/or at C3. UGT2B7 conjugates 3αDIOL and AST 
at C3 and T, DHT and 3αDIOL at C17; UGT2B15 only at 
C17 of T and 5α-reduced androgens, DHT and 3αDIOL; 
UGT2B17 at C3 and C17 of T, DHT, 3αDIOL and AST 
and UGT2B28 conjugates 3αDIOL at both C3 and C17 
(low efficiency), as well as AST and T. Although UGT2B28 
conjugates 3αDIOL, its capacity to conjugate 3αDIOL is 
much lower than that of B15 and B17 (12,13). In addition, 
UGT2B28 also conjugates estradiol (E2), etiocholanolone 
and 5β-androstane-3α,17β-diol. The latter is the product of 
androstenediol (5-diol) catalyzed by AKR1C2 and SRD5A 
(13,14). Interestingly, 5-diol was shown by Belledant et al. 
to be increased and associated with increased UGT2B28 
levels in prostate tumour tissue.
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In contrast to the steroidogenic enzymes catalyzing 
biosynthesis pathways, the genes encoding the UGT enzymes 
are characterized by substantial genetic variability brought 
about by polymorphisms, the production of alternative 
transcripts through alternative splicing/last exon/internal 
exon use and exon skipping, together with copy number 
variation (CNV) and alternative promoters. These factors all 
contribute to the complexity of the role of the UGT enzymes 
in steroid inactivation, impacting protein expression levels 
and enzymatic activities which in turn impact circulating 
androgen levels and PCa outcomes (15). 
While comparative studies relating to circulating 
hormone levels are complicated by interindividual 
variations, biochemical studies inevitably yield tangible data 
regarding enzyme kinetics as, for example, in the case of 
the Asp85Tyr polymorphism of UGT2B15. This functional 
polymorphism encodes a protein with the Asp85Tyr 
mutation and has been shown to be expressed either 
homozygously for one or the other as well as heterozygously 
in patients with both alleles. Similar Km values for DHT 
and 3αDIOL are reported but the enzyme containing Tyr 
residue catalyzes the inactivation more efficiently with a 
2-fold higher Vmax value (16,17). UGT2B15, B17 and B28 
are encoded by a single gene (15), with polymorphisms in 
the former two genes having been shown to significantly 
impact circulating levels of free unconjugated T and AST 
(18-20), and the intra-prostatic levels of 3αDIOL-3G and 
3αDIOL-17G (21). Whole gene deletions were reported for 
UGT2B28 in this paper and previously by Nadeau et al. (18), 
in which they also showed that in UGT2B17 (−/−) PCa 
patients circulating 3αDIOL-17G levels were significantly 
reduced. Although T and DHT levels were not significantly 
lower, AST levels were increased, indicative of increased 
flux in these metabolic pathways and if unconjugated, would 
allow the reactivation of AST and a concomitant increase 
in AR signaling. This study also showed that in UGT2B28 
(+/−) patients, circulating androgen levels were not affected. 
However, patients with a single copy in conjunction with 
the UGT2B17 (−/−) deletion not only had significantly 
increased AST levels but also significantly decreased AST-G 
and 3αDIOL-17G levels (15,18). 
Investigations into complete UGT2B28 deficiency 
by Belledant et al. (1) reported significantly decreased 
circulating T, DHT AST-G, and 3αDIOL (both C3 and 
C17 derivatives) in patients when compared to UGT2B28 
(+/+) patients. In addition, their study also reported that 
high tumour expression levels of UGT2B28 were associated 
with lower protein specific antigen (PSA), smaller tumour 
volume, but with higher Gleason score and positive nodal 
status. Patients with increased nuclear and cytosolic 
UGT2B28 expression in tumours together with significantly 
increased circulating T and DHT levels suggested an 
association with progression to a more aggressive disease. 
It should be noted that three UGT2B28 isoforms are 
expressed in humans—type I, II and III characterized in 2001 
by Lévesque et al. (13). RT-PCR data identified the three 
transcripts in mammary gland tissue and in LNCaP prostate 
cancer cells with only type III expressed in prostate and 
benign prostatic hyperplasia tissue. The active UGT2B28 
type I was shown to catalyze the conjugation of E2, T, AST 
and 3αDIOL efficiently. UGT2B28 type II contained a 308 
bp deletion, amino acid residues 335 to 437 in the cofactor 
binding domain and contained a premature stop codon, and 
UGT2B28 type III lacked residues 105 to 221 in the putative 
substrate binding domain. Both truncated isoforms yielded 
a non-functional protein. Western blot analyses, using the 
polyclonal EL-93 anti-UGT2B17 antiserum, specific to 
the UGT2B enzymes, showed the three isoforms to have 
apparent molecular masses of 52, 35 and 42 kDa, respectively. 
While UGT2B protein was also shown to be present in 
liver preparations together with RT-PCR identifying 
UGT2B28 type II and III transcripts (13), the present study 
by Belledant et al. showed the polyclonal EL-93 antibody 
yielding a positive signal for all the UGT2B proteins. In 
contrast, the UGT2B28 antibody was shown to specifically 
bind UGT2B28 protein only and since it was raised against 
a peptide sequence spanning residues 113–124 the antibody 
only recognizes the type I and type II isoforms. Since only 
type III mRNA transcripts were shown in normal prostate (a 
single prostate tissue sample purchased from Clontech) (13), 
it is therefore interesting that immunohistochemistry (IHC) 
analyses showed the presence of UGT2B28 in normal 
prostate tissue, in the nucleus of basal and some secretory 
cells, pointing to the presence of both the type I and II 
isoforms. Cancer tumour cells from UGT2B28 (+/+), on 
the other hand, showed strong nuclear and cytoplasmic 
staining (1) and while it is very possible that type III is also 
present, the data cannot distinguish between type I and II. 
Interestingly comparative analyses of UGT2B28 expression 
and gene copy number showed, in both the nuclei and 
cytoplasm, that expression levels were similar between +/+ 
and +/− patients. Strong nuclear staining was associated 
with significantly lower PSA levels and patients presented 
with smaller tumours, while strong cytoplasmic staining was 
associated with higher Gleason scores and positive nodal 
status. Considering circulating androgens, significantly 
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increased T and DHT levels were also associated with 
increased nuclear UGT2B28 expression. Although these 
androgens also increased with increased cytosolic expression, 
their levels were not significant. 5-diol, the product of 
dehydroepiandrosterone catalyzed by AKR1C3/17βHSD3, 
also increased with increased nuclear (P=0.079) and 
cytoplasmic (P=0.026) expression of UGT2B28 (1), and 
would as such contribute towards T levels due to the presence 
of 3β-hydroxysteroid dehydrogenase type 2 catalyzing the 
conversion of 5-diol to T.
Analyses of circulating androgens in UGT2B28 (−/−) 
PCa patients showed significantly reduced T, DHT as 
well as downstream conjugated metabolites, AST-G and 
3αDIOL-3G and 3αDIOL-17G levels in comparison to 
UGT2B28 (+/+) patients. Circulating A4 was significantly 
increased in the UGT2B28 (−/−) cohort (1) which would 
contribute to the production of DHT via the 5αDIONE 
pathway in prostate steroidogenesis (22). Although all 
downstream intermediate steroid metabolites were not 
reported in this study, analyses of the ratio of A4, T and 
DHT to their conjugated metabolites, 8.59 [UGT2B28 
(+/+)] and 8.97 [UGT2B28 (−/−)] offers some perspective 
into the metabolic flux. However, these steroids cannot 
be regarded in isolation as we have also shown the 
hydroxylation of A4 by cytochrome P450 11β-hydroxylase 
leads to the production of 11β-hydroxyandrostenedione 
(11OHA4) in the adrenal, which would also be increased in 
UGT2B28 (−/−) patients with higher A4 levels, and would 
certainly contribute to the androgen pool via the 11OHA4-
derived pathway (23,24).
The data presented is certainly open to interpretation 
and the manner in which the enzyme isoforms would 
impact PCa complex. Inactive androgens in circulation are 
also products of other UGT enzymes. When considering 
increased circulating T, DHT and 5-diol being associated 
with increased tumour expression of UGT2B28, it is 
prudent to note that androgens in the prostate and in 
circulation would be conjugated by UGT enzymes 
expressed either in the prostate itself or in other target 
tissue and therefore circulating levels cannot be regarded 
in isolation. In addition, the expression levels of UGT2B28 
isoforms in the prostate and prostate tumours are unclear, 
since the expression can be that of type I or type II. It is 
furthermore possible that type III is also present. In the 
translation of UGT2B28 transcripts encoding type II, 
the deletion of exon 4 and 5 excises the UDPGA binding 
site and disrupts the open reading frame with the ensuing 
premature stop codon yielding a protein fold different 
to that of type I. Despite not having a transmembrane 
domain, the truncated type II was reported to nevertheless 
be present in the endoplasmic reticulum and in the 
perinuclear membrane as in the case of type I. Type III on 
the other hand contains all the relevant structural domains 
but not the substrate binding domain. Although the data 
was not shown Lévesque et al. also reported that type III 
was capable of homodimerization (13). It is interesting to 
note that in their study in which the three isoforms were 
expressed in HEK293 cells, Western blotting showed type 
I and III to be represented by single bands while only type 
II showed additional bands of greater apparent masses 
indicting possible protein aggregation, either type II with 
itself or with the other two isoforms. Although one would 
normally not expect protein aggregation under denaturing 
electrophoretic conditions, it is fairly common that proteins 
form stable aggregates as for example in the case of 
cytochrome b5, which electrophoreses as dimer and tetramer 
aggregates even under stringent denaturing conditions (25). 
Besides the IHC data not distinguishing between type 
I and II, it is unclear if isoform expression would be 
compartmentalized as in the case of UGT2B15 and 17 with 
the former being expressed in the luminal cells and the 
latter in the basal cells (26), further contributing towards 
the fine regulation brought about by compartmentalized 
conjugation and ligand availability to the AR. An interesting 
aspect brought to the fore by the Belledant et al. study is 
indeed a novel tier of regulation other than that of the 
inactivation of androgens. Increased T and DHT levels 
associated with increased UGT2B28 protein expression and 
more aggressive PCa could perhaps also be indicative of 
decreased UGT2B15 and B17 expression since androgens 
have been shown to negatively regulate their conjugation by 
these enzymes (27).
While an increase in the active isoform may contribute 
towards high levels of circulating conjugated androgens, 
the expression of the inactive forms would not contribute 
towards conjugated androgen levels. Linking UGT2B28 
(+/+) to an increase in biochemical recurrence (BCR) and 
overexpression to increased PCa risk and potent androgens, 
would possibly implicate the expression of the inactive 
isoforms and an impaired ability to conjugate androgens. 
On the other hand, the isoforms may aggregate as has been 
shown for the UGT1 and UGT2 enzymes (28,29)—not 
only forming dimer-dimer complexes but also aggregates 
with other UGT2B enzymes thus rendering them unable to 
catalyze the conjugation of androgens. 
Whether UGT2B28 is the active androgen-inactivating 
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UGT isoform under high-androgen exposure as the authors 
suggested is unclear as the expression of UGT2B28 in the 
prostate remains to be fully characterized. While type I 
would certainly contribute towards androgen inactivation 
in the prostate, the expression of the isoform types in 
normal and PCa tissue and the expression level of the 
three isoforms as well as possible compartmentalization 
remain unknown. Since data thus far indicate tissue-
specific processing of mRNA transcripts, investigations 
into the regulation of post-transcriptional activities in the 
expression of UGT enzymes will shed light on the role of 
the UGT2B28 isoforms. It is possible that type III may 
be involved in regulating co-factor availability while type 
II may sequester androgens, rendering them unavailable 
for AR activation, depending on the level of expression. In 
addition, the role of UGT2B28 type I in the inactivation of 
estrogens rendering these steroids incapable of activating 
the estrogen receptor, AR or mutated AR may be one of 
critical importance. Furthermore, UGT2B28 has been 
considered only in terms of T and DHT—C18, C21 and 
C11-oxy steroids would certainly also impact PCa and 
possibly find associations with BCR. Previously published 
data suggests a regulatory role for UGT2B28 in terms 
of estrogen conjugation as AST and E2 were efficiently 
conjugated while more than 50% estrone (E1) remained in 
the free form in breast cyst fluid (13). Lévesque et al. (13) 
showed the presence of all three isoforms of UGT2B28 
in mammary gland tissue, however, when transiently 
expressed, E1 was not conjugated by UGT2B28 type I—
suggesting that other UGT2B enzymes are involved in 
the conjugation of E1. However, since the conjugation of 
E2 has been shown, a role for UGT2B28 in breast cancer 
is highlighted. Furthermore, with perturbed UGT2B28 
expression and E2 conjugation decreased, promiscuous 
binding of E2 to the mutated AR in PCa may also occur (30). 
Interestingly while the three UGT2B28 transcripts were 
detected in breast tissue none were detected in the ovary or 
placenta and thus the presence of UGT2B28 type III in the 
testis, prostate and BPH tissue (13) suggests a prominent 
role for UGT2B28 in male steroid homeostasis. It was 
previously reported that the C11-oxy C19 steroids were 
poor substrates for conjugation and that UGT2B17 exhibits 
lower catalytic activity towards C19 steroids containing a 
C11-hydroxyl group, even though it has been shown that 
5α-androstane-3α,11α/β-17β triol and T are conjugated at 
similar rates (15,31). We recently reported that 11OHA4 
is metabolized to 11keto-dihydrotestosterone in PCa cells 
and have shown that it is as potent as DHT in activating 
the AR (32). We have since shown that 11keto-testosterone 
is not glucuronidated efficiently in LNCaP cells and as 
such would readily activate the AR as T and DHT are fully 
conjugated. Furthermore, we reported that the C11-oxy C19 
steroids are present at significantly higher levels than the 
C19 steroids in circulation, in PCa tissue (33) and in BPH 
tissue (unpublished data), drawing attention to C11-oxy 
metabolites in PCa. 
In summary, the contribution of UGT2B enzymes to 
active ligand availability can only be fully assessed in the 
context of all steroids which may contribute to PCa and 
its aggressive progression. This will certainly lead to a 
better understanding of the complex regulation by these 
inactivating enzymes, modulating receptor signaling, not 
only in terms of C19 steroids but also in terms of the C18 
and C21 steroids as well as the C11-oxy steroids.  As has 
been demonstrated by this study, genetic variations together 
with tissue-specific mRNA processing and the biosynthesis 
of different isoforms, as well as CNVs, contribute to the 
complexities of the UGT enzymes and their impact on PCa 
development and disease progression. Both UGT2B15 and 
B17 have also been reported to conjugate pharmacological 
compounds while the contribution of UGT2B28 to drug 
inactivation remains unknown. UGT2B17 and B28 are also 
among the UGT genes of the human genome which are the 
most commonly deleted genes and as such may impact drug 
metabolism and therapeutic strategies. While the usage of 
an alternative promoter may modulate the expression and/
or activity of UGTs, it may also contribute to variability 
in the glucuronidation pathway and steroid hormone 
levels observed in patients. In the case of UGT2B17, gene 
deletions and CNVs have been shown to affect steroid 
inactivation, altering tissue and circulating androgen levels, 
supporting the general hypothesis of reduced inactivation 
by UGT enzymes resulting in increased active ligands, 
risk of PCa and its recurrence (34). The current report by 
Belledant et al. (1) showing increased UGT2B28 expression 
linked with increased T, DHT and 5-diol and a more 
aggressive disease, together with CNV associating gene 
deletion with decreased active AR ligands and conjugated 
downstream derivatives, points to other mechanisms at play 
involving pathways other than steroid inactivation.
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A B S T R A C T
Adrenal C19 steroids serve as precursors to active androgens in the prostate. Androstenedione (A4), 11b-
hydroxyandrostenedione (11OHA4) and 11b-hydroxytestosterone (11OHT) are metabolised to potent
androgen receptor (AR) agonists, dihydrotestosterone (DHT), 11-ketotestosterone (11KT) and 11-
ketodihydrotestosterone (11KDHT). The identiﬁcation of 11OHA4 metabolites, 11KT and 11KDHT, as active
androgens has placed a new perspective on adrenal C11-oxy C19 steroids and their contribution to prostate
cancer (PCa).
We investigated adrenalandrogenmetabolism in normal epithelial prostate (PNT2)cellsandin androgen-
dependent prostate cancer (LNCaP) cells. We also analysed steroid proﬁles in PCa tissue and plasma,
determining the presence of the C19 steroids and their derivatives using ultra-performance liquid
chromatography (UHPLC)- and ultra-performance convergence chromatography tandem mass spectrome-
try (UPC2-MS/MS).
In PNT2 cells, sixty percent A4 (60%) was primarily metabolised to 5a-androstanedione (5aDIONE) (40%),
testosterone (T) (10%), and androsterone (AST) (10%). T (30%) was primarily metabolised to DHT (10%) while
low levels of A4, 5aDIONE and 3aADIOL (20%) were detected. Conjugated steroids were not detected and
downstream products were present at <0.05 mM. Only 20% of 11OHA4 and 11OHT were metabolised with
the former yielding 11keto-androstenedione (11KA4), 11KDHT and 11b-hydroxy-5a-androstanedione
(11OH-5aDIONE) and the latter yielding 11OHA4,11KTand 11KDHT with downstream products <0.03 mM.
In LNCaP cells, A4 (90%) was metabolised to AST-glucuronide via the alternative pathway while T was
detected as T-glucuronide with negligible conversion to downstream products. 11OHA4 (80%) and 11OHT
(60%) were predominantly metabolised to 11KA4 and 11KT and in both assays more than 50% of 11KT was
detected in the unconjugated form. In tissue, we detected C11-oxy C19 metabolites at signiﬁcantly higher
levels than the C19 steroids, with unconjugated 11KDHT, 11KT and 11OHA4 levels ranging between 13 and
37.5 ng/g. Analyses of total steroid levels in plasma showed signiﬁcant levels of 11OHA4 (230–440 nM),
11KT (250–390 nM) and 11KDHT (19 nM). DHT levels (<0.14 nM) were signiﬁcantly lower.
In summary,11b-hydroxysteroid dehydrogenasetype 2 activity in PNT2cellswassubstantially lower than
in LNCaP cells, reﬂected in the conversion of 11OHA4 and 11OHT. Enzyme substrate preferences suggest that
the alternate pathway is dominant in normal prostate cells. Glucuronidation activity was not detected in
PNT2 cells and while all T derivatives were efﬁciently conjugated in LNCaP cells, 11KT was not. Substantial
11KT levels were also detected in both PCa tissue and plasma. 11OHA4 therefore presents a signiﬁcant
androgenprecursorand itsdownstream metabolism to 11KTand11KDHTaswell as itspresencein PCa tissue
and plasma substantiate the importance of this adrenal androgen.
ã 2016 Elsevier Ltd. All rights reserved.
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1. Introduction
Most prostate cancers (PCa) are androgen driven and as such
androgen deprivation therapy (ADT) is currently the primary
clinical approach in the treatment of the disease. Reducing
circulating testosterone (T) levels is initially effective in lowering
the production of the potent androgen, dihydrotestosterone (DHT),
however, most cases progress to castration-resistant prostate
cancer (CRPC). CRPC is androgen-dependent and in the absence of
testicular T, adrenal C19 steroids serve as substrates for the
intratumoral biosynthesis of androgen receptor (AR) agonists in
the prostate [1–4]. Following castration and the elimination of
testicular androgens, DHT is nevertheless still detected in the
prostate, denoting the importance of the adrenal’s contribution to
the prostate androgen tumor micro-environment and cell prolif-
eration [5,6].
The production of active androgens, their subsequent activation
of the AR and transcription of AR-regulated genes, are prerequisites
in the development and differentiation of the normal prostate, as
well as in the development and progression of PCa [7]. The
androgen signalling pathway is closely linked to tumor initiation
and invasion, and the subsequent development of metastatic
disease. Following ADT, the biosynthesis of active androgens in
prostate cells are initiated by the uptake of circulating dehydro-
epiandrosterone (DHEA), androstenedione (A4), 11b-hydroxyan-
drostenedione (11OHA4) and T produced in the adrenal gland. In
the adrenal, basal and adrenocorticotropic hormone (ACTH)-
stimulated A4 levels, 79 and 585 nM respectively, are 100-fold
greater than T levels, while 11OHA4 levels are even higher, 157 and
811 nM, respectively. 11-ketoandrostenedione (11KA4), 11b-
hydroxytestosterone (11OHT) and 11-ketotestosterone (11KT) are
also produced in the adrenal albeit at negligible levels, similar to
that of T [8]. These aforementioned adrenal C19 steroids contribute
to androgen production in the prostate with A4 and T being
converted to DHT via the conventional and ‘alternative’ 5a-
androstanedione (5aDIONE) pathways (Fig. 1) while the C11
hydroxy- and keto- A4 and T metabolites contribute to the
production of 11keto-dihydrotestosterone (11KDHT) and 11b-
hydroxy-dihydrotestosterone (11OHDHT) through much the same
pathways, also known as the 11OHA4-derived pathway (Fig. 2)
[9,10].11KDHT exhibits agonist activity towards the AR comparable
to that of DHT, thereby implicating it as a role player in CRPC. In
contrast, 11OHA4 exhibited negligible androgenic activity at 1 nM
while the androgenic activity of 11OHT increased upon its
reduction to 11OHDHT. Even at 10 nM the androgenic activity of
11OHA4 remained weak, however, the androgenicity of the other
metabolites in the pathway increased with both 11b-hydroxy-5a-
androstanedione (11OH-5aDIONE) and 11KA4 exhibiting partial
agonist activity and the remaining metabolites in the pathway
showing full agonist activity [9,11,12].
The peripheral metabolism of adrenal androgens rely on the
activity of 17b-hydroxysteroid dehydrogenase (17bHSD) and 5a-
reductase (SRD5A) [7,13–17], while the activation of 11OHA4 relies
on the presence of 11b-hydroxysteroid dehydrogenase type 2
(11bHSD2) [9–12,18]. The subsequent inactivation and conjugation
relies on the expression of 3a-hydroxysteroid dehydrogenase
(3aHSD) type 1 (AKR1C1) and type 3 (AKR1C2) and uridine
diphosphate glucuronosytransferases (UGT2B15, UGT2B17 and
UGT2B28) [19–23]. In the conventional C19 pathway, which
primarily refers to the production of T by the testes and the
subsequent biosynthesis of DHT from T in the prostate, it is the
adrenal androgens, DHEA, A4 and to a lesser degree T, metabolised
by the same enzymes that contribute towards the androgen pool in
the recurrence of PCa. The uptake of A4 and T by prostate cells
results in their interconversion by 17bHSD, followed by the
conversion to 5a-reduced steroids (Fig. 1). Both 17bHSD3 and
17bHSD type 5 (also known as AKR1C3) are present in prostate
Fig. 1. C19 steroid metabolism in the conventional and alternate pathways. A4,
androstenedione; T, testosterone; 5aDIONE, 5a-androstenedione; DHT, dihydro-
testosterone; AST, androsterone; 3aADIOL, 5a-androstane-3a, 17b-diol; 17bHSD,
17b-hydroxysteroid dehydrogenase (downward reaction by 17bHSD3 and/or
AKR1C3; upward reaction by 17bHSD2); SRD5A1/2, 5a-reductase type 1 and/or
2; 3aHSD, 3a-hydroxysteroid dehydrogenase (forward reaction by AKR1C1 or
AKR1C2; reverse reaction by 17bHSD6). Steroids shaded in grey depict UGT2B
substrates. Steroid metabolites in white text; human AR agonists at 1 nM.
T. du Toit et al. / Journal of Steroid Biochemistry & Molecular Biology 166 (2017) 54–67 55
Stellenbosch University  https://scholar.sun.ac.za
tissue and play a dominant role in converting A4, 5aDIONE and
androsterone (AST) to T, DHT and 5a-androstane-3a, 17b-diol
(3aADIOL), respectively. However, 17bHSD2 is also expressed and
catalyses the reverse reaction to produce A4, 5aDIONE and AST
[24]. In the conventional pathway the production of DHT is
reported to be via A4 being converted to T which is subsequently
reduced by SRD5A1 and SRD5A2. In CRPC, however, the preferred
route of DHT biosynthesis is the conversion of adrenal derived A4
to 5aDIONE by SRD5A1, followed by the reduction of this
intermediate by 17bHSD in the ‘alternative’ 5aDIONE pathway
[17,25].
The metabolism of 11OHA4 follows a similar route in that it is
readily metabolised by the SRD5As while not being reduced to
11OHT by 17bHSD3 and/or AKR1C3. However, in the presence of
11bHSD2, both 11OHA4 and 11OHT are reduced to their C11 keto
form (Fig. 2). In the 11OHA4-derived pathway, the conversion of
11OHA4 to produce 11KA4 is catalysed by 11bHSD2, which in turn
is utilized by AKR1C3 and/or 17bHSD3 to produce 11KT with the
latter subsequently being reduced to its dihydro-form, 11KDHT, by
SRD5A1/2. However, 11OHA4 is also metabolised by SRD5A
yielding 11OH-5aDIONE which is also not reduced by 17bHSDs.
In the presence of 11bHSD2, 11OH-5aDIONE is converted to its
keto derivative, 11-keto-5a-androstanedione (11K-5aDIONE) and
upon reduction by 17bHSD, also yields 11KDHT. In addition, 11KA4
and 11OHT produced in the adrenal may also be metabolised in the
prostate by SRD5A1 and SRD5A2 to their 5a-reduced forms, viz.
11K-5aDIONE and 11OHDHT, respectively [9–12,18].
As previously mentioned the subsequent inactivation and
glucuronidation of androgens in the prostate are catalysed by
3aHSD and UGT2Bs (Figs. 1 and 2), with the reversible reduction of
DHT and 5aDIONE to 3aADIOL and AST, respectively, which exhibit
only weak androgenic activity, being catalysed by AKR1C2. AKR1C2
is also capable of converting 11OH-5aDIONE, 11K-5aDIONE and
11KDHT to 11OHAST,11KAST and 11K-3aADIOL, respectively, while
11OHDHT is not a substrate for AKR1C2 (unpublished data). The
presence of 3(a/b)-hydroxysteroid epimerase in the prostate
results in the b-conformations of these steroids also being
produced, 3bADIOL [26] and epiAST [27,28] from DHT and
5aDIONE, respectively. It is also possible for this enzyme to
catalyse the production of 11OH-epiAST, 11K-epiAST and 11K-
3bADIOL. The enzyme mediating the reverse oxidoreduction of
3aADIOL and AST has been shown to be attributed to the retinol
dehydrogenase (RoDH) like 3aHSDs (RL-HSD/17bHSD6 and
17bHSD10) [29], with 17bHSD6 having both oxidoreductase and
epimerase activities. The reverse reaction for epiAST to 5aDIONE
has also been shown [27]. The potential for 11OHAST, 11KAST, 11K-
3aADIOL and their respective b-conformations to be oxidore-
duced by 3aHSD is therefore also possible. Although the
aforementioned reactions have been investigated regarding T,
the inactivation and conjugation of the C11- hydroxy and keto C19
adrenal steroids and their derivatives remain unknown. Earlier
studies in which 11OHAST and 11KAST were detected in urine,
concluded that these were the products of the metabolism of
11OHA4 and 11KA4–the ﬁrst evidence of the inactivation of the
C11-oxy C19 steroids [30]. More recently, we reported these
steroids, 11OHAST and 11KAST, in the LNCaP androgen-dependent
PCa cell model [9,10]. It has also been reported that b-con-
formations of steroids, such as epiAST, are not readily glucur-
onidated, but rather sulfonated, compared to their a-counterparts
which are more readily conjugated [31–33].
Our characterization of the metabolism of 11OHA4, using ultra
high performance liquid chromatography tandem mass spectrom-
etry (UHPLC–MS/MS), has identiﬁed novel steroid metabolites
capable of activating the AR [9,10]. Although the inactivation and
conjugation of these metabolites have not been elucidated, our
studies clearly implicated 11OHA4’s role in PCa with its
metabolites contributing to the intratumoral androgen pool in
CRPC. Further advancements in LC–MS led to the introduction of
ultra performance convergence chromatography tandem mass
spectrometry (UPC2-MS/MS) bringing about improved
Fig. 2. C11 hydroxy- and keto- C19 steroids metabolism in the 11OHA4-derived pathway. 11OHA4, 11b-hydroxyandrostenedione; 11OHT, 11b-hydroxytestosterone; 11KA4,
11-ketoandrostenedione; 11KT, 11-ketotestosterone; 11OH-5aDIONE, 11b-hydroxy-5a-androstenedione; 11K-5aDIONE, 11-keto-5a-androstenedione; 11KDHT, 11-
ketodihydrotestosterone; 11OHDHT, 11b-hydroxy-dihydrotestosterone; 11OHAST, 11b-hydroxyandrosterone; 11KAST, 11-ketoandrosterone; 11K-3aADIOL, 11-keto-5a-
androstane-3a, 17b-diol; 17bHSD,17b-hydroxysteroid dehydrogenase; 17bHSD2, 17b-hydroxysteroid dehydrogenase type 2; SRD5A1/2, 5a-reductase type 1 and 2; 3aHSD,
3a-hydroxysteroid dehydrogenase; 11bHSD2, 11b-hydroxysteroid dehydrogenase type 2. Steroids shaded in grey depict potential UGT2B substrates. Dashed arrows;
conversions catalysed by 11bHSD2. Steroid metabolites in white text; human AR agonists at 1 nM.
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chromatographic resolution, reduced run times and increased
sensitivity resulting in more accurate analyses of androgen
metabolites and steroid proﬁles in the prostate.
The aim of this study was to ﬁrstly analyse the metabolism of C
19 and C11-oxy C19 steroids in vitro, in a normal prostate epithelial
cell model (PNT2) and in an androgen-dependent cancer cell
model (LNCaP), in order to establish steroid proﬁles which would
also allow downstream analyses of inactivation. Our previous
studies focused primarily on characterising the activation of
adrenal derived C11-oxy C19 steroids in the 11OHA4-derived
pathway in LNCaP cells while the metabolism of C19 steroids have
also not been fully described in a normal prostate cell model. We
therefore analysed the metabolism of these steroids in PNT2 and
LNCaP cells using UPC2-MS/MS and in order to demonstrate the
relevance of these steroid hormones in the physiological milieu, we
investigated these C19 metabolites in PCa tissue as well as in PCa
plasma. Our ﬁndings show for the ﬁrst time 11OHA4 and 11OHT
and their hydroxyl- and keto-metabolites to be present in human
PCa tissue and plasma, with levels far exceeding those of A4, T and
their metabolites.
2. Materials and methods
2.1. Tissue and plasma
Human PCa tissue and blood samples were collected in a study
investigating clinical markers of PCa (reference no. N09/11/330;
Faculty of Medicine and Health Sciences, Stellenbosch University
and Tygerberg Hospital, South Africa). PCa tissue samples were
obtained from patients (A) aged 71, untreated, prostate-speciﬁc
antigen (PSA) 351 and (B) aged 67, 4 years after anti-androgen
treatment commenced, PSA 60.8, and blood was obtained from
patients (A) aged 74, who underwent bilateral orchiectomy, PSA
37.3 and (B) aged 66, luteinising hormone-releasing hormone
analogue (LHRHa) treatment, PSA 7.1, 4.4 months and 1 year,
respectively, after treatment commenced. Tissue samples, imme-
diately snap-frozen in liquid nitrogen upon resection, and plasma
samples were stored at 80 C until further use.
2.2. Materials
Steroids (A4, T, 5aDIONE, DHT, AST, and 3aADIOL), b-glucu-
ronidase (Type VII-A from E. coli, 5,292,000 units/g), RPMI-1640
medium, D-(+)-Glucose, dichloromethane (DCM) and methyl tert-
butyl ether (MTBE) were purchased from Sigma-Aldrich (St. Louis,
MO, USA). 11OHA4, 11OHT, 11KA4, 11KT, 11KDHT, 11OHAST, 11OH-
epiAST, 11KAST, 11K-epiAST and DHT-glucuronide (DHT-G) were
purchased from Steraloids (Wilton, USA). Corning1 CellBIND1
Surface 10-cm dishes, 6-well and 24-well plates were purchased
from Corning1 Life Sciences (NY, USA). PNT2 and LNCaP cells were
obtained from the Sigma’s European Collection of Cell Cultures (St.
Louis, USA). Penicillin-streptomycin (penstrep), fetal bovine serum
(FBS), trypsin-EDTA and phosphate buffered saline were obtained
from Oxoid limited (Hampshire, England). Deuterated cortisol (9,
11, 12, 12-D4-cortisol), deuterated testosterone (Testosterone 1, 2-
D2, 98%), deuterated progesterone (Progesterone
2,2,4,6,6,17A,21,21,21-D9, 98%) and deuterated 11b-hydroxyan-
drostenedione (4-androsten-11b-OL-3,17-DIONE 2,2,4,6,6,16,16-
D7, 98%) were purchased from Cambridge isotopes (Andover,
MA, USA). HEPES buffer (1 M) and sodium pyruvate (100 mM) were
purchased from Biochrom (Berlin, Germany). The UPC2 BEH and
BEH 2-Ethylpyridine columns were purchased from Waters and the
Kinetex PFP column was purchased from Phenomenex. All other
chemicals were of analytical grade and supplied by reliable
scientiﬁc houses.
2.3. Steroid metabolism in PNT2 and LNCaP cells
PNT2 cells were cultured in RPMI-1640 medium supplemented
with 10% FBS, 1.5 g NaHCO3/L (pH 7), 1% penstrep at 37 C, in an
atmosphere of 90% humidity and 5% CO2. After 3–4 passages
conﬂuent cells were plated into 24-well plates (1 105 cells/mL,
0.5 mL/well) and incubated for 48 h. The medium was removed and
replaced with 0.5 mL RPMI-1640 medium containing individual
steroid substrates: A4, T, 11OHA4, 11OHT, 11KA4 and 11KT (1 mM).
The cells were incubated for 48 h after which 0.5 mL aliquots were
removed for analysis of free steroids.
LNCaP cells were cultured in RPMI-1640 growth medium,
supplemented with 2.5 g D-(+)-Glucose, 1% HEPES and 1% sodium
pyruvate and once conﬂuent replated into 24 well Corning1
CellBIND1 surface plates (2  105 cells/mL, 0.5 mL/well). The same
experimental protocols were followed as above and the metabo-
lism of A4, T, 5aDIONE, DHT, AST, 3aADIOL, 11KT and 11KDHT
(1 mM) assayed. Aliquots, 0.5 mL were removed after 48 h for
analyses of free steroids. A second experiment was conducted to
determine downstream metabolism of 11OHA4 and 11OHT (1 mM)
in LNCaP cells, plated at 4 104 cells/mL. Cells were incubated with
steroid substrates for a longer period (96 h) in phenol-free media,
without serum supplementation, after which 0.5 mL aliquots were
removed for analysis of free steroids.
Analysis of total steroids (free + conjugated) was carried out
after treating duplicate 0.5 mL aliquots with 400 units (76 mL) of
b-glucuronidase (E. coli Type VII-A; Sigma-Aldrich) at 37 C, pH 6.5,
for 24 h to deconjugate steroids. DHT-G (1 mM; in 0.5 mL media)
was deconjugated and extracted, and used as a control for
deconjugation efﬁciency, determined by the amount of DHT
recovered using UHPLC-MS/MS (Supplemental Fig. 1).
2.4. Steroid extraction
In vitro assays were analysed after liquid/liquid steroid
extractions were carried out with either DCM or MTBE. Cortisol-
D4 (15 ng) and testosterone-D2 (15 ng), were added to each sample
as internal standards prior to steroid extraction. A 10:1 vol of DCM
was added to medium aliquots from A4, T, 5aDIONE, DHT, AST,
3aADIOL and 11KT assays in LNCaP cells and 11OHA4, 11KA4,
11OHT, 11KT, A4 and T assays in PNT2 cells, the samples vortexed at
1000 RPM for 15 min, and centrifuged for 5 min. Extracted media
was aspirated, the DCM phase dried under nitrogen and the dried
residues dissolved in 0.15 mL 50% methanol in water. A 3:1 vol of
MTBE was added to medium aliquots from 11OHA4, 11OHT and
11KDHT assays in LNCaP cells, the samples vortexed at 1000 RPM
for 15 min, and frozen at 80 C. Thereafter the organic phase was
removed, dried under nitrogen, and the dried residues dissolved in
0.15 mL 50% methanol in water.
Frozen PCa tissue samples, 100 mg, were lyophilised overnight
and homogenised in 5 mL MTBE after addition of internal standard
containing testosterone-D2 (1.5 ng) and cortisol-D4 (15 ng), after
which samples were sonicated for 10 min. Samples were trans-
ferred to screw cap tubes, shaken at 1000 RPM for 60 min, and
centrifuged for 10 min. The supernatant was transferred and dried
under nitrogen. Dried steroid residues were resuspended in
0.15 mL 50% methanol in water.
Plasma samples (1 mL) were thawed on ice and vortexed after
which one 0.5 mL aliquot was deconjugated prior to extraction as
described above. Internal standards testosterone-D2 and cortisol-
D4, were prepared in MTBE and added to samples to a ﬁnal
concentration of 1.5 ng and 15 ng, respectively. The samples were
vortexed in 5 mL MTBE for 15 min at 1000 RPM, and subsequently
centrifuged for 5 min. The organic layer was removed and dried
under nitrogen after which the dried steroid residue was dissolved
in 0.15 mL 50% methanol in water.
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All samples were stored at 20 C prior to UHPLC- and UPC2-
MS/MS analysis.
2.5. Separation and quantiﬁcation of steroid metabolites
Stock solutions of A4, T, 5aDIONE, DHT, AST, 3aADIOL, 11OHA4,
11KA4, 11OHT, 11KT, 11KDHT, 11OHAST, 11OH-epiAST, 11KAST, 11K-
epiAST and DHT-G were dissolved in absolute ethanol (2 mg/mL)
and stored at 20 C. Two sets of standards ranging from 0.001 to
1 ng/mL were prepared – one in 50% methanol and another series
extracted from the appropriate cell culture media using the
protocol described in 2.4.
Steroids analysed by UHPLC–MS/MS (ACQUITY UHPLC, Waters,
Milford, USA) were separated using a Phenomenex UHPLC Kinetex
PFP column (2.1 mm  100 mm, 2.6 mm) (Torrance, CA, USA) as
previously described [34], with modiﬁcations to the applied
gradient (supplemental Tables 1 and 2). Brieﬂy, the mobile phases
consisted of 1% formic acid in water (A) and 49%: 49%: 2%
methanol: acetonitrile: isopropanol (B). Steroids, in an injection
volume of 5 mL, were eluted at a ﬂow rate of 0.4 mL/min in a total
run time of 5 min per sample. A Xevo triple quadrupole mass
spectrometer (Waters, Milford, USA) was used for quantitative
mass spectrometric detection and steroids were analysed in
multiple reaction monitoring (MRM) mode. Electrospray in the
positive ionization mode (ESI+) was utilized in the MRM mode. The
capillary voltage of 3.5 kV, cone voltage of 15–35 V and collision
energy of 4–36 eV was set during this quantiﬁcation. The following
settings were used: source temperature 120 C, desolvation
temperature 400 C, desolvation gas 900 L/h and cone gas 50 L/h.
Retention times (RT), parent and daughter ions, cone (V) and
collision (eV) voltages, limit of detection (LOD) and limit of
quantiﬁcation (LOQ) are shown in supplemental Table 3.
The C19 steroids analysed by ACQUITY UPC2–MS/MS (Waters
Corporation, Milford, USA) were separated as previously described
using an ACQUITY UPC2 BEH column (3 mm  100 mm, 1.7 mm
particle size) for the A4 and T metabolites and an ACQUITY UPC2
BEH 2-Ethylpyridine (EP) column (3 mm  100 mm,1.7 mm particle
size) for the C11-oxy C19 metabolites [9,35], shown in Fig. 3a and b,
with modiﬁcations to the applied gradient (supplemental Tables 4
and 5).
The mobile phase consisted of CO2 modiﬁed with methanol in
which steroids, in an injection volume of 2 mL, were eluted at a
ﬂow rate of 2 mL/min in a total run time of 5 min per sample. The
column temperature was set to 60 C and the automated back
pressure regulator (ABPR) was set to 2000 psi. A Xevo TQ-S triple
quadrupole mass spectrometer (Waters, Milford, USA) was used
for quantitative mass spectrometric detection and all steroids were
analysed in MRM mode, using the ESI+mode. A make-up pump was
utilized in the system, which fed 1% formic acid in methanol into
the mixer preceding the MS line at a constant ﬂow rate of 0.2 mL/
min. The capillary voltage of 3.8 kV, cone voltage of 15–35 V and
collision energy of 8–30 eV was set during this quantiﬁcation. The
following settings were used: source temperature 120 C, des-
olvation temperature 500 C, desolvation gas 1000 L/h and cone
gas 150 L/h. The mass transitions, RT, LOD and LOQ and additional
relevant data is shown in Table 1. Data was collected and analysed
with the MassLynx 4.1 (Waters Corporation) software program.
2.6. Method validation
Method validation regarding the extraction of steroid metab-
olites from RPMI-1640 cell culture media (0.5 mL) and subsequent
separation and analyses of steroid metabolites using the UHPLC–
MS/MS system has been reported previously by Swart et al. [18].
Biological repeats and instrumental repeats were completed and
absolute recoveries of steroid metabolites (T, 11OHT, 11KT, A4,
11OHA4 and 11KA4) were reported to be 97.57  14.64% [18]. The
chromatographic separation of the steroid metabolites using
UHPLC–MS/MS is shown in supplemental Fig. 2 (for separating
C19 steroids) and Supplemental Fig. 3 shows the chromatogram for
11KT. Method validation regarding the separation and analysis of
steroid metabolites using UPC2-MS/MS was carried out by replicate
analysis (n = 3) of cell culture media RPMI-1640 and FBS, spiked
with each steroid at low (0.0002 ng/mL), middle (0.02 ng/mL) and
high concentrations (0.1 ng/mL), as well as cortisol-D4 (15 ng),
progesterone-D9 (15 ng) and testosterone-D2 (1.5 ng) as internal
standards. Steroids were extracted and samples prepared as
described in 2.4; spiked cell culture media was extracted using
DCM and MTBE and spiked FBS was extracted using MTBE.
Absolute recoveries and matrix effects, calculated as reported in
Taylor et al. [36], are summarized in Supplemental Tables 6a and b.
Method validation regarding the UPC2-MS/MS separation and
analysis of steroid metabolites in human prostate tissue were
carried out by replicate analysis (n = 3) of baboon prostatic tissue
(100 mg), spiked with testosterone-D2 (1.5 ng), progesterone-D9
(15 ng), cortisol-D4 (15 ng) and 11b-hydroxyandrostenedione-D7
(15 ng), and steroids extracted as described in 2.4. Process
efﬁciencies are summarized in supplemental Table 7.
Fig. 3. UPC2-MS/MS separation of C19 reference standards. (a) C19 steroids, 2 mL each of a 0.1 ng/mL standard solution, are depicted in the elution order of (1) 5aDIONE,
1.66 min, (2) A4, 2.35 min, (3) DHT, 2.79 min, (4) AST, 2.86 min, (5) T, 3.53 min and (6) 3aADIOL, 3.93 min; (b) C11-oxy C19 steroids, 2 mL each of a 0.1 ng/mL standard solution,
are depicted in the elution order of (1) 11KA4, 1.16 min, (2) 11KAST, 1.91 min, (3) 11OHA4, 1.99 min, (4, 5) 11K-epiAST/11KDHT (clear peak), 2.04 min, (6) 11KT (clear peak),
2.47 min, (7) 11OHAST, 2.49 min, (8) 11OH-epiAST, 2.76 min and (9) 11OHT, 3.48 min.
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2.7. Statistical analysis
Experiments were performed in triplicate, representative of at
least duplicate experiments and the results are given as means
 SEM. Data were processed using GraphPad Prism (version 5)
software (GraphPad Software, San Diego, California). Steroids that
were not commercially available were quantiﬁed by UPC2-MS/MS,
following peak integrations, using response factors, previously
determined by Quanson (2015, p. 39) [37], as follows: for 11OH-
5aDIONE relative to 11OHA4, 4.147  0.640; for 11K-5aDIONE
relative to 11KA4, 4.501 0.549; for 11OHDHT relative to 11OHT,
3.812  0.243 and for 11KDHT relative to 11KT, 2.973  0.179.
Standard curves were generated by integrating respective sub-
strates to quantify aforementioned C11-oxy 5a-reduced steroids.
3. Results and discussion
The role of adrenal androgens in CRPC has been widely reported
and with the emphasis on A4, the contribution of 11OHA4 to the
intratumoral environment has been sorely neglected. The study
into the metabolism of the C11 hydroxy- and keto- C19 steroid
metabolites in PNT2 and LNCaP cells, in conjunction with UPC2-
MS/MS, provides analysis of both free unconjugated and conju-
gated androgen levels, with steroid proﬁles highlighting the roles
of the steroidogenic enzymes. Steroid proﬁles also allow for
comparative analyses of C19 and C11-oxy C19 steroids in PCa tissue
and in plasma, demonstrating the relevance of adrenal C19
precursor steroids in PCa.
3.1. Androgen metabolism in PNT2 cells
The metabolism of the C11 hydroxy- and keto-metabolites of
both A4 and T was ﬁrstly investigated in a normal prostate cell
model. We assayed these steroids at 1 mM even though their
production in the adrenal was reported to be lower, with the
exception of 11OHA4 [8], as this allowed detection of their
downstream metabolites. Analyses of 11OHA4 (Fig. 4a) and 11OHT
(Fig. 4b) showed the conversion of these substrates to their C11-
keto products, 11KA4 and 11KT, suggesting the presence of
11bHSD2 in these cells, albeit at very low levels. Only twenty
percent 11OHA4 (20%) was converted to 11KDHT via 11KT, and to
11OH-5aDIONE by SRD5A with 80% 11OHA4 remaining after 48 h.
The metabolism of 11OHT was similar  20% was metabolised,
yielding the same amount of 11KT. The metabolism of 11KA4
(Fig. 4c) and 11KT (Fig. 4d) was somewhat more efﬁcient than the
C11-hydroxy androgens 40% was metabolised to downstream
products. The conversion of 11KA4 yielded mainly 11KT due to
catalysis by endogenous reductive 17bHSD activity, and also
11KDHT catalysed by SRD5A. Similarly, 11KT was oxidised to 11KA4
by 17bHSD2 and subsequently inactivated, evident from the levels
of C11 keto-AST derivatives, while 10% of the 11KT was reduced by
SRD5A yielding 0.1 mM 11KDHT.
While the inactivation of 11KDHT via the formation of 11K-
3aADIOL was not evident, the C11-oxy AST derivatives were
detected. In addition, glucuronidated steroids were negligibly low
with most of the steroids detected at 48 h present in the free form.
In contrast, the metabolism of A4 was far more efﬁcient than
that of 11OHA4. More than 50% (0.6 mM) of the A4 substrate was
converted to downstream products (Fig. 5a) compared to the
signiﬁcantly lower conversion of 11OHA4 (20%). Analysis of the
Table 1
UPC2-MS/MS detection and quantiﬁcation of C19 steroid standards. Parent molecular ion species and mass transitions of daughter ions; retention time (RT, min); limit of
detection (LOD) and limit of quantiﬁcation (LOQ) of steroids; mass spectrometer settings, cone voltages (CV), collision energy (CE); and internal deuterated standards,
testosterone-D2, cortisol-D4 and progesterone-D9.
Steroid metabolite RT (min) Mass transitions CV (V) CE (eV) LODa (ng/mL) LOQb (ng/mL) Calibration range (ng/mL) Linearity (r2)
Quantiﬁer Qualiﬁer
A4 2.35 287.2 > 96.9 287.2 > 108.8 30 30 15 15 <0.00001c 0.001 0.0011 0.9968
T 3.53 289.2 > 97.2 289.2 > 109.0 30 30 22 22 <0.00001c 0.001 0.0011 0.9940
5aDIONE 1.66 289.2 > 253.1 289.2 > 97.2 22 30 16 22 0.00025c 0.001 0.0011 0.9993
DHT 2.79 291.2 > 255.0 291.2 > 273.0 25 25 15 20 0.00025c 0.001 0.0011 0.9990
AST 2.86 273.2 > 105.3 291.3 > 273.3 30 18 30 8 0.00025c 0.001 0.0011 0.9962
3aADIOL 3.93 275.2 > 257.0 275.2 > 175.0 15 15 15 15 0.0001c 0.001 0.0011 0.9999
Testosterone-D2 3.53 291.0 > 99.1 291.0 > 111.2 30 30 20 30 – – – –
Cortisol-D4 4.69 367.0 > 121.0 35 25 – – – –
Progesterone-D9 2.18 324.2 > 100.0 324.2 > 113.0 30 30 20 25 – – – –
11OHA4 1.99 303.2 > 267.2 303.2 > 121.0 30 30 30 15 0.00001c 0.001 0.0011 0.9855
11OHT 3.48 305.3 > 121.0 305.3 > 269.0 35 35 20 15 0.00001c 0.001 0.0011 0.9970
11KA4 1.16 301.2 > 257.0 301.2 > 265.2 35 35 25 25 0.00001c 0.001 0.0011 0.9806
11KT 2.47 303.2 > 121.0 303.2 > 267.0 30 30 20 20 0.00001c 0.001 0.0011 0.9955
11OH-5aDIONE 1.52 305.0 > 269.2 305.0 > 287.2 35 35 15 15 – – – –
11K-5aDIONE 0.87 303.2 > 241.0 303.2 > 267.0 35 35 30 25 – – – –
11OHDHT 3.59 307.0 > 253.0 307.0 > 271.0 35 35 20 20 – – – –
11KDHT 2.04 305.2 > 243.0 305.2 > 269.0 30 30 20 20 0.00025c 0.001 0.0011 0.9882
11OHAST 2.49 289.0 > 271.0 289.0 > 213.0 15 15 15 15 0.005c 0.01 0.011 0.9740
11OH-epiAST 2.76 289.0 > 271.0 289.0 > 213.0 15 15 15 15 0.005c 0.01 0.011 0.9935
11KAST 1.91 305.0 > 147.2 305.0 > 173.1 30 30 30 30 0.005c 0.01 0.011 0.9976
11K-epiAST 2.04 305.0 > 147.2 305.0 > 173.1 30 30 30 30 0.01c 0.01 0.011 0.9993
11K-3aADIOL 3.32 307.0 > 271.0 307.0 > 253.0 15 15 10 10 – – – –
Testosterone-D2 1.71 291.0 > 99.1 291.0 > 111.2 30 30 20 30 – – – –
Cortisol-D4 4.15 367.0 > 121.0 35 25
Progesterone-D9 0.80 324.2 > 100.0 324.2 > 113.0 30 30 20 25
a Limit of detection was deﬁned as S/N ratio >3.
b Limit of quantiﬁcation was deﬁned as a S/N ratio >10.
c [35].
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Fig. 4. C11-oxy androgen metabolism in PNT2 cells: (a) 11OHA4; (b) 11OHT; (c) 11KA4 and (d) 11KT. Steroid (1 mM; patterned bars) was assayed after 48 h and free
unconjugated steroids depicted as clear bars and total steroids as shaded bars. The experiment was performed in triplicate, analysed by UPC2-MS/MS and the results
expressed as the mean SEM (n = 3). Steroid levels below the dashed grey line represent steroids detected below the level of accurate quantiﬁcation.
Fig. 5. Steroid (1 mM; patterned bars) metabolism in PNT2 cells: (a) A4 and (b) T was assayed after 48 h and free unconjugated steroids depicted as clear bars and total steroids
as shaded bars. The experiment was performed in triplicate, analysed by UPC2-MS/MS, representative of two independent experiments. Results are expressed as the
mean  SEM (n = 6).
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steroid proﬁles showed that the catalytic activity of SRD5A towards
A4 was more efﬁcient than that of the reductive 17bHSD activity
was in catalysing T’s biosynthesis, reﬂected in the signiﬁcantly
lower levels of T produced relative to 5aDIONE after 48 h. Although
17bHSD3 and AKR1C3 mRNA expression levels are similar to
SRD5A1 and SRD5A2 in normal prostate tissue [2], A4 is
nevertheless preferentially converted to 5aDIONE suggesting that
the ‘alternative’ 5aDIONE pathway also takes precedence in
normal cells. 5aDIONE, in turn, is further metabolised to DHT and
AST. While DHT is formed from both 5aDIONE and T, DHT levels
detected in the conversion of A4 are much lower than in the
conversion of T, 0.05 mM and 0.1 mM, respectively. In addition, the
conversion of T (Fig. 5b) to downstream metabolites appears to be
less efﬁcient with 70% of the substrate remaining after 48 h.
Data also suggests that the reductive 17bHSD activity is
predominant compared to the oxidative activity since A4 was more
readily converted to T ( 0.1 mM T; Fig. 5a) while the conversion of
T to A4 ( 0.05 mM A4; Fig. 5b) was markedly lower. These ﬁndings
are supported by data reported by Berthaut et al. [38] showing
predominant 5a-reductase activity converting T to DHT with
negligible conversion of T to A4 in isolated epithelial cells. Our data
showed that the conversion of T and 11KT yielded similar levels of
DHT and 11KDHT ( 0.1 mM), respectively suggesting an equal
contribution to the AR agonist pool provided by adrenal C19
precursors T and 11KT.
Interestingly, glucuronide derivatives of T, DHT and their
inactive metabolites were not detected. UGT2B15 and 17 have
however been shown in normal prostate tissue with UGT2B17
expressed only in basal epithelial cells of the alveoli where it
catalyses the conjugation of T, DHT, ADT and 3aADIOL. UGT2B15 is
expressed in luminal epithelial cells and since the inactivating
enzymes are not expressed in these cells the enzyme modulates AR
interaction by conjugating T and DHT [20,39]. Reports regarding
steroid metabolism in PNT2 cells are limited and with our analyses
showing no detectable glucuronides in the metabolism of A4 and T,
together with negligible levels of conjugated downstream 11OHA4
and 11OHT metabolites (detected below the limit of accurate
quantiﬁcation), suggest that these UGT isoforms are not active. It
has furthermore been reported that PNT2 cells, although derived
from normal human prostatic epithelium tissue, exhibit some
characteristics of prostatic tumours, and present with genetic
alterations found in prostatic tumours [40].
Androgen metabolism has, to date, not been characterized in
the PNT2 cell model. Our data shows no catalytic activity of UGTs
towards T and its downstream metabolites, indicating that this cell
line presents itself as an ideal cell model to study androgen
metabolism in the absence of glucuronidation.
3.2. Androgen metabolism in LNCaP cells
Since LNCaP cells metabolise the C11-oxy C19 steroids to yield
active androgens [12] and exhibit high glucuronidation activity
[19,41–43], this cell model was used to investigate the downstream
inactivation and conjugation of the C11-oxy steroids. In LNCaP
cells, 11OHA4 is metabolised by 11bHSD2 and SRD5A to yield
11KA4 and 11OH-5aDIONE, respectively [44,45]. Analysis of
steroid proﬁles showed that 11OHA4’s metabolism (Fig. 6a)
yielded predominantly 11KA4, together with the inactive C11-
oxy AST derivatives. 11KT was the only C11-oxy T derivative
detected with negligible 11OHT forming due to 11OHA4 not being
reduced by 17bHSD. In addition, 50% of 11KT (0.06 mM) was in the
free form after 96 h, while unconjugated 11KAST and 11OHAST
were also detected, albeit at low levels, these steroids could recycle
to active androgens. In contrast,11OHTcan be metabolised (Fig. 6b)
by 17bHSD2, 11bHSD2 and SRD5A to yield 11OHA4, 11KT and
11OHDHT, respectively. Analysis showed that while 0.672 mM
11OHT had been conjugated with no free steroid present after 96 h,
the steroid was also converted to 11OHA4 (0.164 mM), 11KA4
(0.121 mM) and 11KT (0.266 mM). 11KT was, however, also present
in the free form at 0.078 mM (30%). We did not detect 11KDHT or
11OHDHT in either of the assays. We also did not detect these
metabolites in the metabolism of 11OHA4 and 11OHT in our
previous study even though independent duplicate samples
aliquots were pooled 11KDHT was detected only when 1 mM
11OH-5aDIONE and 11OHDHT were assayed as substrates [9].
These data suggest that in the metabolism of 11OHA4 and 11OHT in
LNCaP cells, the major C11-oxy T derivative to be produced is 11KT.
Considering the output of the adrenal in terms of 11OHA4 it
would seem that 11KT, given the inefﬁciency of its conjugation,
would contribute markedly to AR activation and downstream
physiological effects. The expression of 11bHSD2 is central to the
production of active androgens as is evident in the analysis of the
conversion of 11OHA4 and 11OHT in LNCaP cells. However, in both
cell lines, the presence of 11bHSD2 led to the production of 11KT.
Fig. 6. Steroid (1 mM; patterned bars) metabolism in LNCaP cells: (a) 11OHA4 and (b) 11OHT was assayed after 96 h and free steroids depicted as clear bars and total steroids
as shaded bars. The experiment was performed in triplicate, analysed by UPC2-MS/MS, the results are expressed as the mean  SEM (n = 3).
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The conversion of 11OHT to 11KT by 11bHSD2, converts a partial
agonist to a full agonist [11], placing 11bHSD2 central to the
potency of these metabolites.
Analysis of A4 metabolism in LNCaP cells clearly demonstrated
the preferred conversion of A4 to 5aDIONE, followed by the
conversion of 5aDIONE to DHT by reductive 17bHSD data
supporting the predominant ‘alternative’ 5aDIONE pathway in the
biosynthesis of DHT in these cells (Fig. 7a). Data showed that the
catalytic activity of endogenously expressed SRD5A towards A4 in
producing 5aDIONE was more efﬁcient, compared to T in the
biosynthesis of DHT (Supplemental Fig. 4a). In the conversion of
A4, the major ﬂux was towards AST ( 0.6 mM) via 5aDIONE
( 0.07 mM), with no free AST detected after 48 h. Analyses
detected T, indicating conversion of A4 to T by reductive 17bHSD,
however, at low levels and in the glucuronidated form only, with
50% ( 0.02 mM) of the detected DHT being unconjugated.
Negligible conversion of T to DHT by SRD5A was further evident
from the low DHT levels detected when T was assayed as substrate,
again showing more efﬁcient glucuronidation of T with 0.9 mM of
the steroid present in the conjugated form. These steroid proﬁles
also suggests that reductive 17bHSD activity, catalysing the
conversion of the A4 derivatives to T derivatives, takes precedence
over the oxidative 17bHSD activity catalysing the reverse reactions
in these cells. It is, however, possible that the UGT2B isoforms,
catalysing the conjugation were simply more efﬁcient than
17bHSD. UGT2B15 and UGT2B17 are both expressed in LNCaP
cells with the latter conjugating glucuronide formation at both C15
and C17 hydroxyl groups [42,46]. It was shown that UGT2B17,
when transiently expressed in HEK293 cells, conjugated DHT most
efﬁciently followed by AST, and 3aADIOL, while conjugation of T
was 5-fold less efﬁcient than that of DHT [46]. Our analyses,
however, indicate downstream conversion of DHT with 0.74 mM
being conjugated, while very little downstream conversion of T
was detected with most of the steroid being conjugated
(Supplemental Fig. 4a and b).
Effective inactivation and glucuronidation is further demon-
strated in Fig. 7b in which 5aDIONE and DHT were converted to
AST and 3aADIOL in reactions catalysed by AKR1C2. The
conjugation of AST was highly efﬁcient with no free AST being
detected (also conﬁrmed in Supplemental Fig. 4c). Most of the
3aADIOL was detected in the conjugated form when assayed as
substrate (Supplemental Fig. 7d) with low levels of the free form
present possibly accounting for the DHT detected. It is interesting
to note that when DHT was assayed only conjugated DHT was
detected after 48 h (Supplemental Fig. 4b). In contrast, when
produced as an intermediate, the free form of DHT was always
detected together with conjugated DHT, albeit at low levels.
We also assayed 11KT and 11KDHT in LNCaP cells after 48 h to
determine free and conjugated steroid levels in order to compare
the conjugation of the C19 and C11-oxy C19 steroids (Fig. 8). As
discussed in the aforementioned text, AST and 3aADIOL, the
inactive derivatives of 5aDIONE and DHT, may either be
conjugated or may undergo reactivation by RL-HSDs (17bHSD6)
or 17bHSD10 [15,20,47]. Although AST is conjugated at C3 only and
3aADIOL at both C3 and C17, the former was detected in the
conjugated form (0.97 mM) only, indicating that the steroid had not
been converted to 5aDIONE (Supplemental Fig. 4c). Negligibly
lower levels of conjugated 3aADIOL (0.87 mM) was detected,
together with free 3aADIOL (0.018 mM) which was also channelled
to DHT (Supplemental Fig. 4d). When assayed, DHT was converted
to downstream products evident from the 0.74 mM present in the
conjugated form after 48 h, of which free DHT was negligible and
3aADIOL contributed 0.097 mM (Supplemental Fig. 4b). T was
conjugated efﬁciently with minimal conversion to downstream
Fig. 7. Steroid (1 mM; patterned bars) metabolism in LNCaP cells: (a) A4 and (b) 5aDIONE was assayed after 48 h and free unconjugated steroids depicted as clear bars and
total steroids as shaded bars. The experiment was performed in triplicate, representative of two independent experiments analysed by UHPLC–MS/MS. Results are expressed
as the mean  SEM (n = 6).
Fig. 8. Analyses of conjugated steroid products in LNCaP cells. Individual steroid
substrates (1 mM) were incubated for 48 h and metabolites analysed. Free
unconjugated steroids depicted as clear bars and total steroids as shaded bars.
The experiment was performed in triplicate, analysed by UHPLC–MS/MS (T, DHT,
AST, 3aADIOL and 11KT) and UPC2-MS/MS (11KDHT), representative of two
independent experiments. Results are expressed as the mean  SEM (n = 6).
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products (Supplemental Fig. 4a), 0.93 mM being present in the
conjugated form with no free T present. In assaying 11KDHT as
substrate our data showed that only 20% of the steroid was
metabolised after 48 h, comparable to DHT, with 11KDHT-
glucuronide levels detected at 0.78 mM. The level of free 11KDHT
(0.017 mM) were signiﬁcantly higher (10-fold) than the levels of
free DHT.
It is interesting to note that the levels of the other C19
glucuronide metabolites were all greater than 0.75 mM. Glucur-
onidation is, however, not the only form of conjugation that occurs
in vitro and in vivo, as androgens may also undergo sulphonation.
Our assays and UHPLC- and UPC2-MS/MS analyses did not include
sulphonated conjugates or other steroid products that may have
formed by endogenous CYP enzymes catalysing hydroxylation or
methylations [48–56]. It is therefore possible that additional
products may have formed during the long incubation periods.
11KT was predominantly present in the free form (70%) when
11KT was assayed as substrate, reﬂecting the inefﬁcient glucur-
onidation of 11KT also observed for the metabolism of 11OHA4 and
11OHT in LNCaP cells  inefﬁcient glucuronidation of 11KT
possibly affecting elimination, together with subsequent reactiva-
tion would have implications in PCa. We previously showed that
11KT is able to bind the AR as a partial agonist at 1 nM and as a full
agonist at 10 nM [9,11]. Since 11KT may thus remain available, the
steroid may inﬂuence transcription levels of AR regulated genes,
more so than T, DHT and 11KDHT in PCa. DHT has been shown to
induce the upregulation of a number of androgen responsive genes
in LNCaP cells in which the expression of UGT2B15 and UGT2B17
were silenced [20]. In addition, AR activation by 11KT could be
exaggerated due to AR mutations in the ligand binding domain,
reducing AR-ligand speciﬁcity with an ensuing increase in AR gene
ampliﬁcation and expression of mutated AR variants that are
constitutively active in PCa [57,58]. Since 11KT may also bind
mutant receptors more readily than other androgens the presence
of this active androgen may lead to increased transcription and cell
proliferation despite ADT, which targets only T in the biosynthesis
of DHT.
3.3. In vivo C19 steroid proﬁles
We have shown that 11OHA4, in the presence of 11bHSD2, is
metabolised in normal and PCa cell models in much the same
manner as A4, with our data suggesting differential inactivation
and conjugation of the 5a-reduced C11-oxy C19 steroids. It is
possible that the hampering of the inactivation and conjugation, by
the presence of either the functional hydroxyl or keto group at C11,
may affect cellular processes via the AR. The relevance of these
steroids in PCa and their contribution to the diseased state can only
be assessed by establishing their presence in PCa tissue as well as
in circulation. We thus analysed C19 steroid levels in prostate tissue
as well as in plasma obtained from PCa patients using UPC2-MS/
MS, which allows a more sensitive and robust means of analysing
and quantifying metabolites in the nM range.
3.3.1. PCa tissue
In this investigation we aimed at identifying the intratumoral
C11-oxy C19 steroids, which have, to date, not been shown, and to
quantitate these steroids relative to the known C19 androgens and
their metabolites. Proﬁles of free, unconjugated steroid metabo-
lites in PCa tissue from both patient tissue specimens (A and B)
showed that 11OHA4 and its downstream metabolites were
present at far higher levels that A4, T and their metabolites
(Fig. 9). Comparative analyses of individual metabolites are
hampered due to the variability of steroid levels reported to date,
possibly due to sample collection strategies, steroid extraction and
analytical techniques. For example, in both patient samples T
levels, 2.56 and 6.3 ng/g, were detected to be far higher than those
in normal tissue (0.2–1.8 ng/g) which is expected, but normal
ranges for DHT (0.7–9.3 ng/g) [59], placed both patients at the
lower end with their DHT levels, 1.06 and 1.77 ng/g. On the other
hand, in PCa tissue DHT levels were reported between 0.66 and
6.98 ng/g with T levels 0.4–1.34 ng/g [59]. The data obtained in the
case of patient A can however be compared to levels reported in a
study by Heracek et al. [60], which included 121 untreated
patients, with A4, T and DHT levels of 1.4, 1.3 and 2.5 ng/g,
Fig. 9. UPC2-MS/MS analysis of C19 steroid levels in PCa tissue. Steroids represented as free unconjugated steroids; clear bars, patient A, no prior treatment; shaded bars,
patient B, treatment with an androgen antagonist. Steroids below the dashed line represent steroids detected below the level of accurate quantiﬁcation.
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respectively. However, the SEM values were high indicating
possible inter-patient variability also contributing to the wide
ranges that have been reported for normal and disease values. In
both patients the downstream metabolites of A4 and T followed a
similar proﬁle, with the exception of 5aDIONE. Regardless of the
higher A4 levels in patient B, 5aDIONE levels were comparable
which indicate that patient B formed less of the intermediate than
patient A, suggesting differences in SRD5A activity. Also suggestive
of a greater SRD5A activity in patient A, are the comparable levels
of 11KDHT (9.9 and 12.6 ng/g) despite the 11KT precursor being 9-
fold lower in patient A’s tissue.
In the steroid proﬁles only two SRD5A products, namely
11KDHT and 11K-5aDIONE (a 11KDHT precursor steroid) were
detected whilst 11OHDHT and 11OH-5aDIONE were not. It is
possible that 11OHDHT may be present in the conjugated form and
that 11OH-5aDIONE together with 11K-5aDIONE may have been
inactivated by AKR1C2 and subsequently conjugated. No other 5a-
or 3a-reduced metabolites were detected in the free form, other
than 11KDHT and 11K-5aDIONE  which suggests either the
predominant production of these keto-dihydro derivatives or
alternatively, the inactivation and conjugation of the other 5a-
reduced metabolites.
Although the presence of 11OHA4, 11KA4, 11OHT and 11KT in
the tissue samples was not an unexpected ﬁnding since these are
produced by the adrenal, the levels at which the latter three
metabolites were detected was surprising. The expression of
11bHSD2 in peripheral tissue, as well as in PCa tissue [44,45] will
yield 11KA4 and 11KT from their respective C11-hydroxy
precursors [18] and while the adrenal produces high levels of
11OHA4, which can account for the high levels thereof in PCa, the
high 11OHT levels cannot be attributed solely to adrenal
production. Although CYP11B1 and CYP11B2 have been reported
to be expressed in human primary prostate carcinomas and
metastatic primary prostate carcinomas [48,49], we have not
detected hydroxylation of A4 or T at C11 in LNCaP cells. T has been
shown to be hydroxylated at C11 in liver microsomal preparations
[61–63] and by CYP3A4 [48,50] and CYP3A5 [51] which are
expressed in PCa tissue and may thus produce 11OHT, and may as
such contribute towards the pool of C11 hydroxy- and keto C19
metabolites observed in prostate tissue [52–56]. 11OHT can
furthermore be converted by the oxidative activity of 17bHSD2
to 11OHA4 and subsequently to 11KA4. Both 11KA4 as well as
11OHT can be converted to 11KT, further accounting for the high
11KT levels (23 ng/g).
Although DHT levels were signiﬁcantly lower than 11KDHT in
both patient samples cases (7- and 9-fold), the DHT levels were
comparable with other studies [3,59,64,65] and still fell within the
physiological relevant range able to activate the AR. It is apparent
that the presence of 11OHA4 in both patients suggests a major
inﬂux from adrenal origin, and together with the downstream
metabolites, present a pool of intratumoral C19 steroids of which
11KDHT and 11KT are the most prominent in the tissue.
3.3.2. Plasma
Since androgens play an important role in the progression of
PCa, ADT, the mainstay in metastatic PCa treatment, strives to
eliminate the source of DHT by decreasing circulating T levels.
Circulating C19 steroids are indicators of ADT efﬁcacy and are
generally accepted to be <0.69 nM (20 ng/dL) [66]. This is,
however, not always achieved in all PCa patients and the variations
reported are likely due to the contribution of adrenal C19 steroids
[67,68]. We therefore proﬁled the adrenal C19 steroids in plasma
samples obtained from PCa patients and showed that the levels of
11OHA4 and its downstream metabolites far exceed those of A4, T
and their downstream metabolites. In Fig. 10 we show C19 steroid
levels in two patients after treatment, one who had undergone
physical and the other chemical castration. Although the C19
steroid levels A4, 0.77 and 0.306 nM; T, 3.5 and 2.38 nM and DHT,
0.138 and 0.114 nM were low and T speciﬁcally well below the
normal circulating T levels (15.4  5.6 nmol/L) [69], collectively the
C19 steroids were above the cut-off for ADT efﬁcacy. However,
while T levels were higher than the generally accepted castrate
levels, DHT levels were similar to the reported DHT castrate levels
(0.5–0.18 nM) [66–68]. It is interesting to note that the down-
stream inactive products of DHT and 5aDIONE ranged from 22 to
170 nM. The levels of AST and 3aADIOL may also be of signiﬁcance
as, when in circulation, these steroids can be taken up by the
prostate and oxidised by RL-HSDs to DHT. Analysing the complete
Fig. 10. UPC2-MS/MS analysis of plasma C19 steroid levels of PCa patients. Steroids represented as total steroids; clear bars, patient treatment BO, shaded bars, patient
treatment LHRH analogue. Steroids below the dashed line represent steroids detected below the level of accurate quantiﬁcation.
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C19 panel and not only T and DHT, indicates a shunt of C19 steroids
in the alternate or conventional pathways and also highlights the
fact that these are downstream products of A4 and T in peripheral
tissue.
In targeting T only in order to circumvent DHT in treatment
regimes, the C11-oxy androgens are overlooked. These steroids
could certainly be considered in combination therapies which
would include, in addition to chemical/surgical castration,
CYP17A1 or CYP11B1 inhibitors to either inhibit the biosynthesis
of A4 and T by CYP17A1, for instance by abiraterone acetate, which
has been proven to be effective in survival of CRPC patients [70,71]
or the biosynthesis of 11OHA4 and 11OHT by CYP11B1 in the
adrenal. Our analysis show 11OHA4 and 11KT, C11-oxy derivatives
of A4 and T, to be present at levels signiﬁcantly higher than the C19
steroids, 850-fold and 115-fold, respectively (Fig. 10). 11KDHT
was detected at levels 136- and 170-fold more than DHT and
while no other C11-oxy 5a- or 3a-reduced metabolites were
detected, 11KT was present at signiﬁcantly higher levels than
11KDHT, 13- and 19-fold. Our data obtained in LNCaP cells which
suggest that 11KT is poorly conjugated by the UGT enzymes
together with the high levels of 11KT detected in plasma samples,
certainly implicate 11KT as a role player in PCa. This is the ﬁrst
analyses of the C11-oxy C19 steroids in plasma obtained from PCa
patients and serve only to demonstrate the presence of these
steroids in circulation. Although 11OHA4, 11KA4, 11OHT and 11KT
have been shown in iliac vein samples in women diagnosed with
adrenal aldosterone-producing adenoma, these were reported to
be very low (<3.5 nM) both pre- and post ACTH stimulation [8]. It is
interesting to note that, although the analysis of tissue and plasma
represents four different PCa patients, 11KDHT levels were high in
all cases and at these levels in prostatic tissue 11KDHT would
certainly activate the AR, suggesting that circulating adrenal
androgens contribute to post-castration tissue androgen levels.
In our analyses we also investigated the glucuronidation of
these C11-oxy steroids in plasma and found the glucuronide
conjugates to be negligible. Our data therefore presents unconju-
gated steroid levels only. It is possible that these steroids may have
been sulphonated, which may also be the case in the PCa tissue
analysed. Although sulphonation of steroids by SULT2B has been
reported in prostate tissue, glucuronidation is a major route of C19
steroid catabolism, with reports showing urinary T predominantly
present as T-glucuronide compared to its sulfonated conjugated
form [33]. In addition, the reduced expression of SULT2B has been
reported in PCa specimens [72]. It should be noted that
b-conformations of steroids, such as T (C17 hydroxyl group) and
AST (C3 hydroxyl group) have been shown to be predominantly
sulphonated and not glucuronidated [31,33,46], however, the
production of these epi(3b)-steroids were minimal in steroid
conversion assays in prostate cell models, and none of these
steroids were detected in PCa tissue or plasma (data not shown).
Conjugation of the C11-oxy C19 steroids in tissue still remains to be
investigated.
4. Conclusion
Taken together, these studies show that while C11-oxy C19
steroids are metabolised in the androgen-dependent cancer cell
model and in the normal cell model, albeit to a lesser degree,
11bHSD2 has an integral role in driving the 11OHA4-derived
pathway, most prominent in the LNCaP cells. On the other hand,
SRD5A was more efﬁcient than the reductive 17bHSDs expressed
endogenously in PNT2 and LNCaP cells regarding the metabolism
of A4 suggesting that the alternative pathway is the preferred
pathway in PNT2 cells as is the case in LNCaP cells. Although
glucuronidation activity in PNT2 cells was negligible, steroid
conjugation was efﬁcient in LNCaP cells (T-glucuronide > DHT-
glucuronide > 11KDHT-glucuronide)  with the exception of 11KT.
Inefﬁcient conjugation of 11KT and activation of the AR would
further impact PCa progression in ADT regimes targeting T only.
11KT is inevitably shunted to downstream metabolites since it is
only marginally glucuronidated, with free 11KT and its down-
stream metabolites able to exert physiological effects via the AR.
The relevance of these C11-oxy C19 steroids came to the fore in
our steroid proﬁle analysis of PCa tissue and plasma. This is the ﬁrst
report of C11-oxy C19 steroids in vivo, and our data show that these
steroid levels are signiﬁcantly higher compared to the C19 steroids,
both in circulation and in tissue of PCa patients. In addition, 11KT
and 11KDHT were signiﬁcantly higher than DHT in plasma which
was also the case in tissue, together with high 11OHT levels. Since
the data represent four case studies only, no deductions other than
comparing C11-oxy C19 steroid levels to the C19 steroid levels and
analysing the respective pathways, can be made. However, steroid
proﬁles generated using UPC2-MS/MS, highlight subtle differences
that would otherwise have been overlooked in the analyses of only
single steroids  for example; low A4, T and DHT plasma levels
present no indication of inactive products formed from these
precursor steroids in the tumor microenvironment.
The steroid proﬁles presented in this study substantiate the
importance of adrenal 11OHA4 as a signiﬁcant androgen precursor
underscoring its role in PCa. Although 11OHA4 exhibits no
androgenic activity, our ﬁndings clearly show that this much
neglected adrenal androgen can no longer be excluded when
assessing the progression of PCa and the efﬁcacy of treatment
regimes.
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Supplementary Fig. 1: UHPLC-MS/MS analyses of deconjugation efficiency of DHT-G. Free steroida 
in experimental samples before β-glucuronidase treatment, clear bars; and total steroidb (free + 
conjugated) after β-glucuronidase treatment, grey bars. The experiment was performed in triplicate 
and results are depicted as the mean ±SEM (ns=not significant). 
Supplementary table 1: Gradient specifications of the UHPLC separation of C19 steroid metabolites. 
Step Time (min) Solvent A (%) Solvent B (%) Curve 
1 0 85 15 Initial 
2 1.00 60 40 6 
3 3.50 45 55 6 
4 3.60 0 100 6 
5 4.00 0 100 6 
6 4.01 85 15 6 
7 5.00 85 15 6 
Supplementary table 2: Gradient specifications of the UHPLC separation of C11-oxy C19 steroid 
metabolites. 
Step Time (min) Solvent A (%) Solvent B (%) Curve 
1 0 85 15 Initial 
2 3.50 61.5 38.5 4 
3 3.60 0 100 6 
4 4.00 0 100 6 
5 4.01 85 15 6 
6 5.00 85 15 6 
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Supplementary table 3: UHPLC-MS/MS detection and quantification of C19 steroid standards. Parent molecular ion species and mass transitions of 
daughter ions; retention time (RT, min); limit of detection (LOD) and limit of quantification (LOQ) of steroids; mass spectrometer settings, cone voltages 
(CV), collision energy (CE); and internal deuterated standards, testosterone-D2 (T-D2) and cortisol-D4. 
Steroid 
metabolite 
RT 
(min) 
Precursor 
ion 
CV 
Product 
ion A 
CE 
Product 
ion B 
CE 
Product 
ion C 
CE 
Internal 
standard 
LODa 
(ng/µL) 
LOQb 
(ng/µL)
Calibration 
range 
(ng/µL) 
Linearity 
(r2) 
C
1
9
 s
te
ro
id
s 
A4 3.13 287.2 30 96.9 15 108.8 15 T-D2 0.002c 0.02 0.02-2 0.9996 
T 2.98 289.2 30 97.2 22 109.0 22 T-D2 0.002c 0.02 0.02-2 0.9989 
5αDIONE 3.57 289.2 30 119.2 35 171.2 35 T-D2 <0.02 0.02 0.02-2 0.9995 
DHT 3.35 291.2 25 255.0 15 273.0 20 T-D2 <0.02 0.02 0.02-2 0.9998 
AST 3.60 273.2 30 105.3 30 147.0 25 T-D2 <0.02 0.02 0.02-2 0.9997 
3αADIOL 3.26 275.2 15 161.0 15 175.0 15 257 15 T-D2 <0.02 0.02 0.02-2 0.9993 
Testosterone-
D2 
2.98 291.0 30 99.1 20 111.25 20 
- 
Cortisol-D4 1.95 367.0 35 121.0 25 - 
C
1
1
 o
xy
 C
1
9
 
st
er
o
id
s 
11KT 3.16 303.2 30 121.0 20 267.0 20 T-D2 0.0007d 0.02 0.02-2 0.9999 
Testosterone-
D2 
4.21 291.0 30 99.1 20 111.25 20 
- 
Cortisol-D4 2.51 367.0 35 121.0 25 - 
aLimit of detection was defined as S/N ratio >3 
bLimit of quantification was defined as a S/N ratio >10 
c[34] 
d[18] 
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Supplementary table 4: Gradient specifications of the UPC2 separation of C19 steroid metabolites. 
Step Time (min) Solvent A (%) Solvent B (%) Curve 
1 0 99 1 Initial 
2 4.0 91 9 7 
3 4.1 75 25 6 
4 5.0 99 1 6 
Supplementary table 5: Gradient specifications of the UPC2 separation of C11-oxy C19 steroid 
metabolites. 
Step Time (min) Solvent A (%) Solvent B (%) Curve 
1 0 98 2 Initial 
2 4.0 90.5 9.5 6 
3 4.1 75 25 6 
4 5.0 98 2 6 
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Supplementary Fig. 2: UHPLC-MS/MS separation of 6 C19 steroids. Standards, 5 µL each of a 2 ng/µL 
standard solution, are depicted in the elution order of (1) T, 2.97 min; (2) A4, 3.12 min; (3) 3αADIOL, 
3.24 min; (4) DHT, 3.33 min; (5) 5αDIONE (clear peak), 3.55 min and (6) AST, 3.57 min. 
Supplementary Fig. 3: UHPLC-MS/MS analysis of 11KT.  A Standard (shaded peak), 5 µL of 2 ng/µL 
standard solution, is depicted at 2.97 min (peak at 3.15 min represent 11OHA4 cross-talk). 
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Supplementary table 6a: UPC2-MS/MS method validation for the extraction of steroids from cell culture media using DCM and MTBE, organic 
solvents for steroid extractions. Three steroid concentrations were analysed to determine recovery (%, n=3) and matrix effect (%, n=3)*. 
Organic solvent 
extraction Steroid metabolite 
Recovery (%) 
ng/µL 
Matrix effect (%) 
ng/µL 
0.002 0.02 0.1 0.002 0.02 0.1 
M
TB
E
11OHA4 279 111 99 21 3 -4 
11OHT 284 106 100 7 1 -2 
11KA4 249 108 100 38 10 -2 
11KT 297 107 100 4 8 -6 
11KDHT 259 89 100 -33 17 -4 
11OHAST <LOQ 132 99 <LOQ 16 0 
11OH-epiAST <LOQ 95 100 <LOQ -2 -2 
11KAST <LOQ 133 93 <LOQ 4 -3 
11K-epiAST <LOQ 87 100 <LOQ 8 -10 
D
C
M
 
C
1
9
 s
te
ro
id
s 
A4 196 94 100 31 -3 5 
T 217 98 100 37 1 1 
5αDIONE 202 93 100 21 -3 9 
DHT 193 100 100 20 -8 3 
AST 195 94 100 -14 -1 -2 
3αADIOL 197 84 101 16 4 -3 
C
1
1
 o
xy
 C
1
9
 s
te
ro
id
s 
11OHA4 332 143 98 43 -2 -7 
11OHT 329 143 98 27 3 -2 
11KA4 326 157 98 63 11 -6 
11KT 333 143 104 42 3 -6 
11KDHT 285 143 101 -48 -9 -10 
11OHAST <LOQ 148 98 <LOQ 3 -2 
11OH-epiAST <LOQ 149 98 <LOQ 4 0 
11KAST <LOQ 130 99 <LOQ 35 10 
11K-epiAST <LOQ 133 99 <LOQ 9 -13 
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Supplementary table 6b: UPC2-MS/MS method validation for the extraction of steroids from FBS. Three steroid concentrations were analysed to 
determine recovery (%, n=3) and matrix effect (%, n=3)*. 
Steroid metabolite 
Recovery (%) 
ng/µL 
Matrix effect (%) 
ng/µL 
0.002 0.02 0.1 0.002 0.02 0.1 
C
1
9
 s
te
ro
id
s 
A4 183.1 111.1 99.5 206 -18 -0.5 
T 177 122 99 216 -59 -46 
5αDIONE 145 78 101 123 -31 -7 
DHT 128 83 101 160 -23 -4 
AST 94 74 101 256 -25 -18 
3αADIOL 330 114 99 128 -12 -5 
C
1
1
 o
xy
 C
1
9
 s
te
ro
id
s 
11OHA4 275 120 99 184 1 -7 
11OHT 268 139 98 162 8 7 
11KA4 237 127 99 169 5 -2 
11KT 251 137 98 148 4 -5 
11KDHT 209 130 99 -30 -17 -14 
11OHAST <LOQ 174 97 <LOQ 7 8 
11OH-epiAST <LOQ 92 100 <LOQ -12 -16 
11KAST <LOQ 136 98 <LOQ -3 6 
11K-epiAST <LOQ 120 99 <LOQ 5 -12 
*Absolute recoveries were calculated by generating standard curves and comparing the concentration of the standards extracted from cell culture
media and FBS to that of the expected concentrations. Matrix effects were determined by comparing the area of the steroid standards after post-
extraction addition to that of steroid standards in 50% methanol. The difference in the responses of the steroids added post-extraction and those of 
the standards in 50% methanol was divided by the response of the latter. 
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Supplementary table 7: UPC2-MS/MS method validation for the extraction of deuterated steroids from baboon prostatic tissue, recovery (%, n=3); 
matrix effect (%, n=3) and process efficiency (%, n=3)*. 
Deuterated steroid Recovery (%) Matrix effect (%) Process efficiency (%) 
C19 steroids 
Testosterone-D2a 109 -48 56 
Progesterone-D9b 78 -68 25 
Cortisol-D4b 99 -23 77 
C11 oxy C19 steroids 
Testosterone-D2a 75 -60 30 
Progesterone-D9b 52 -63 19 
Cortisol-D4b 55 -14 47 
11β-hydroxy-
androstenedione-D7b 
46 -56 20 
aDetermined at the concentration of 0.01 ng/µL 
bDetermined at the concentration of 0.1 ng/µL 
*Deuterated steroid recovery was calculated by comparing the area of the spiked deuterated steroid, added before the extraction of baboon prostatic
tissue (representative of human prostatic tissue) described in 2.4, to that of post-extraction addition of deuterated steroids. Matrix effects were 
determined by comparing the area of the deuterated steroids recovered after post-extraction addition to that of steroid standards in 50% methanol 
(not extracted). The difference in area between samples added post-extraction and the standards in methanol was divided by the response of the 
latter. According to Taylor et al. [36] the overall process efficiency may subsequently be calculated by comparing the area of spiked steroids extracted 
from tissue to that of standards in 50% methanol.  
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Supplementary Fig. 4: C19 Steroid metabolism in LNCaP cells. Steroid substrates (1 µM; patterned 
bars) were incubated and after 48 h free and total steroid metabolites analysed.  Metabolism of (a) 
T, (b) DHT, (c) AST and (d) 3αADIOL with free steroids depicted as clear bars and total steroids as 
shaded bars. The experiment was performed in triplicate, representative of two independent 
experiments analysed by UHPLC-MS/MS. Results are expressed as the mean ±SEM (n=6). 
a b 
c d 
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a b s t r a c t
Although the adrenal C19 steroids, androstenedione and testosterone, contribute to prostate cancer (PCa)
progression the full complement of adrenal androgens, including the C11-oxy C19 steroids, 11b-
hydroxyandrostenedione (11OHA4) and 11b-hydroxytestosterone (11OHT) and their androgenic me-
tabolites, 11keto-testosterone (11KT) and 11keto-dihydrotestosterone (11KDHT) have, to date, not been
considered. This study investigated the contribution of 11OHA4 and 11OHT to the pool of active an-
drogens in the prostate. Steroid proﬁles were determined in LNCaP, C4-2B and VCaP cell models, in PCa
tissue, and in plasma focussing on the inactivation, reactivation and glucuronidation of 11OHA4, 11OHT
and their downstream products using ultra-performance convergence chromatography tandem mass
spectrometry (UPC2-MS/MS). The C11-oxy C19 steroids were the predominant steroids with the pro-
duction of 11KT and 11KDHT in prostate cell models identifying 11b-hydroxysteroid dehydrogenase type
2 activity. Active:inactive steroid ratios indicated efﬁcient inactivation of dihydrotestosterone (DHT) and
11KDHT by 3a-hydroxysteroid dehydrogenases, while the reactivation of DHT by retinol-like de-
hydrogenases was greater than the reactivation of 11KDHT. In PCa tissue, inactive C11-oxy C19 steroids
ranged from 27 to 30 ng/g, whereas inactive C19 steroids were below 1 ng/g. Steroid glucuronidation was
impeded: in VCaP cells, the C11-oxy C19 steroids were unconjugated and the C19 steroids fully conju-
gated; in C4-2B cells, all steroids were unconjugated, except for DHT of which 50% was conjugated; in
LNCaP cells only androsterone, 11KT and 11b-hydroxyandrosterone were unconjugated. In PCa patients’
plasma 11KDHT was present only in the unconjugated form, with 11KT also predominantly unconjugated
(90e95%). Even though plasma and tissue sample numbers were limited, this study serves to demon-
strate the abundance of C11-oxy C19 steroids, with notable differences in their metabolism, dictated by
steroidogenic enzymes and hampered conjugation, affecting active androgen levels. Larger cohorts are
required to analyse proﬁles in modulated metabolic pathways, in order to shed light on treatment
outcomes. The C11-oxy C19 steroids are involved in PCa, with impeded glucuronidation in PCa ascribing a
dominant role to these steroids in disease progression.
© 2017 Elsevier B.V. All rights reserved.
Abbreviations: UDP, uridine diphosphate; UGT, UDP-glucuronosyltransferases; 17bHSD, 17b-hydroxysteroid dehydrogenase; AKR1C3, 17b-hydroxysteroid dehydrogenase
type 5; 11bHSD2, 11b-hydroxysteroid dehydrogenase type 2; SRD5A, 5a-reductase; SRD5A1, 5a-reductase type 1; SRD5A2, 5a-reductase type 2; 3aHSD, 3a-hydroxysteroid
dehydrogenase; UGT2B, UDP-glycosyltransferase 2 family polypeptide B; RL-HSD, retinol-like hydroxysteroid dehydrogenase; DHEA, dehydroepiandrosterone; A4, andro-
stenedione; T, testosterone; 5aDIONE, 5a-androstanedione; DHT, dihydrotestosterone; AST, androsterone; 3aDIOL, 5a-androstane-3a 17b-diol; 11OHA4, 11b-hydroxyan-
drostenedione; 11OHT, 11b-hydroxytestosterone; 11KA4, 11keto-androstenedione; 11KT, 11keto-testosterone; 11KDHT, 5a-dihydro-11-keto-testosterone; 11OH-5aDIONE,
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1. Introduction
It is widely accepted that although the adrenal C19 steroids,
commonly referred to as androgens, do not exhibit androgenic
activity, they serve as precursors to more potent androgens bio-
synthesized in peripheral tissue. This holds true when considering
dehydroepiandrostenedione (DHEA), androstenedione (A4) and
11b-hydroxyandrostenedione (11OHA4) (Bloem et al., 2015; Chang
et al., 2011; Du Toit et al., 2017; Mizokami et al., 2009; Mohler et al.,
2011; Mostaghel, 2014; Storbeck et al., 2013; Swart et al., 2013). In
addition, the adrenal also produces 11b-hydroxytestosterone
(11OHT) and 11keto-testosterone (11KT) (Rege et al., 2013) which,
at 10 nM, have been shown to be capable of activating the androgen
receptor (AR), comparable to dihydrotestosterone (DHT) (Bloem
et al., 2015). Testosterone (T) is targeted in androgen deprivation
therapy (ADT) aimed at reducing DHT, and has been the primary
approach in the treatment of metastatic prostate cancer (PCa) for
decades. The disease, which is dependent on active androgens,
nevertheless progresses to castration-resistant prostate cancer
(CRPC) with intratumoral DHT levels still capable of activating the
AR (Chang et al., 2011; Mohler et al., 2011; Mostaghel, 2014). Ad-
renal A4 has been implicated in driving PCa in the absence of
testicular T as it is converted to DHT in the prostate via 5a-
androstanedione (5aDIONE) in the alternative pathway. The con-
version of A4 to 5aDIONE, catalysed by 5a-reductase (SRD5A) is
more efﬁcient than that of T, with the upregulation of SRD5A type 1
(SRD5A1) and the concomitant down-regulation of SRD5A type 2
(SRD5A2) conﬁrmed in the progression to CRPC (Chang et al., 2011;
Montgomery et al., 2008; Stanbrough et al., 2006; Thomas et al.,
2008; Titus et al., 2005).
A4 is however not the only adrenal androgen precursor
contributing to CRPC with 11OHA4 also in circulation with levels
having been reported to be ~2 fold higher than A4 (Rege et al.,
2013). We have shown that 11OHA4 is converted to potent an-
drogens, 11KT and 11-ketodihydrotestosterone (11KDHT) by the
same steroidogenic enzymes catalysing the production of DHTwith
11b-hydroxysteroid dehydrogenase type 2 (11bHSD2) and SRD5A
playing pivotal roles (Bloem et al., 2015; Storbeck et al., 2013; Swart
et al., 2013). The adrenal also produces 11-ketoandrostenedione
(11KA4), 11OHT and 11KT, albeit at levels considerably lower than
11OHA4 (~0.99, 0.48, 0.39 and 157 nM, respectively) measured in
female adrenal vein samples (Rege et al., 2013). These C11-oxy
steroids are readily reduced by SRD5A, with 11KT and 11KDHT
capable of activating the AR to the same degree as DHT, and of
inducing androgen dependent gene expression (Bloem et al., 2015;
Pretorius et al., 2016; Storbeck et al., 2013). Due to the improved
capabilities of analytical technologies in the ﬁeld of liquid chro-
matography tandem mass spectrometry (LC-MS/MS), we have also
shown that these steroids are present in serum and tissue of PCa
patients (Du Toit et al., 2017), which therefore begs the question as
to the exclusivity of DHT being the sole potent androgen in terms of
contributing to the progression of PCa. Furthermore, it is evident
that the steroid proﬁle in PCa remains incomplete and skewed since
neither the C11-oxy androgens nor their conjugation are taken into
account.
The biosynthesis of active androgens from their adrenal pre-
cursor C19 steroids and their subsequent inactivation are dependent
on the expression levels of the relevant steroidogenic enzymes in
peripheral tissue. Furthermore, the conjugation by the uridine
diphosphate (UDP)-glucuronosyltransferase (UGT) isoforms adds
another level of complexity with the expression of these enzymes
characterized by copy number variation, the use of alternative
promoters, polymorphisms, alternative splicing and exon skipping
(Guillemette et al., 2010; Du Toit and Swart, 2016). We have shown
11KT is not conjugated as readily as T, DHT or 11KDHT by the UGT
enzymes (Du Toit et al., 2017). The irreversible conjugation by the
UGT enzymes contributing to the inactivation and reactivation
equilibrium directly impact active androgen levels, not only in the
prostate affecting PCa treatment strategies, but also in other clinical
conditions which are characterized by adrenal-derived androgen
excess. Increased C11-oxy C19 steroid levels have been detected in
classic 21-hydroxylase deﬁciency patients and it has been sug-
gested that these steroids could act as speciﬁc biomarkers of ad-
renal androgen excess (Turcu et al., 2016).
In the C19 steroid metabolic pathway, T, DHT, androsterone (AST)
and 5a-androstane-3a,17b-diol (3aDIOL) are substrates for the
conjugation by the UDP-glycosyltransferase 2 family, polypeptide B
(UGT2B) enzymes (Fig. 1). DHT is inactivated by the 3a-hydrox-
ysteroid dehydrogenase (3aHSD) enzymes to 3aDIOL, and, if not
conjugated and secreted, 3aDIOL may be reactivated to DHT by the
retinol-like hydroxysteroid dehydrogenase (RL-HSD) enzymes. AST
can undergo the same conversion by the RL-HSD enzymes to
5aDIONE, followed by the 17b-hydroxysteroid dehydrogenase
(17bHSD) reduction producing DHT (Supplemental Fig. 1).
In the C11-oxy C19 steroid metabolic pathway, 11OHT, 11KT, 11b-
hydroxydihydrotestosterone (11OHDHT), 11KDHT, 11b-hydroxyan-
drosterone (11OHAST), 11-ketoandrosterone (11KAST) and 11-keto-
5a-androstane-3a,17b-diol (11K-3aDIOL) are potential substrates
for glucuronidation enzymes (Fig. 1). 11KDHTmay be inactivated by
the 3aHSD enzymes to 11K-3aDIOL, which may be reactivated to
11KDHT by the RL-HSD enzymes if unconjugated. 11OHAST and
11KAST may undergo the same conversion by RL-HSD enzymes to
11b-hydroxy-5a-androstenedione (11OH-5aDIONE) and 11-keto-
5a-androstenedione (11K-5aDIONE), respectively. The subsequent
conversion of 11OH-5aDIONE by 11bHSD2 to 11K-5aDIONE, fol-
lowed by the 17bHSD reduction of the latter leads to the production
of 11KDHT. 11OHDHT is not converted by the 3aHSD enzymes
(Supplemental Fig. 1).
The aim of this study was to investigate the inactivation, reac-
tivation and UGT-conjugation in the metabolism of the C19 and the
C11-oxy C19 steroids in PCa cell models, plasma and tissue. The
metabolism of 11OHA4 and 11OHT was ﬁrstly assayed in C4-2B and
VCaP cell models together with that of T and 11OHDHT. Steroid
proﬁles were established which allowed the analyses of active and
inactive androgen levels. The reversible inactivation and reac-
tivation of DHT and 11KDHT by 3aHSD and RL-HSD enzymes were
subsequently assayed in LNCaP, VCaP and C4-2B prostate models
expressing these enzymes endogenously. Analyses of the uncon-
jugated steroids in prostate tissue of a CRPC patient produced
proﬁles for comparative analyses of the full spectrum of active and
inactive androgens. In addition, PCa cell models were used to assess
glucuronidation in terms of unconjugated and conjugated metab-
olites. The C19 and the C11-oxy C19 glucuronide metabolites were
subsequently identiﬁed in normal and in PCa plasma.
2. Material and methods
2.1. Tissue and plasma
Human PCa tissue and plasma samples were collected in a study
investigating clinical markers of PCa (reference no. N09/11/330;
Faculty of Medicine and Health Sciences, Stellenbosch University
and Tygerberg Hospital, South Africa). The PCa tissue sample was
obtained from a patient aged 83, classiﬁed as having CRPC, who
underwent a bilateral orchiectomy (BO). Plasmawas obtained from
a normal subject, aged 59 and PCa patients, aged 74 who under-
went BO and aged 66 who received luteinising hormone-releasing
hormone analogue treatment (LHRHa). The tissue sample was
snap-frozen in liquid nitrogen upon resection and stored with
plasma samples at 80 C.
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2.2. Materials
Dulbecco's Modiﬁed Eagle medium (DMEM), Roswell Park Me-
morial Institute (RPMI)-1640 medium, D-(þ)-Glucose, b-glucu-
ronidase (Type VII-A from E. coli, 5,292,000 units/g; G7646), D-
(þ)-Glucose, dichloromethane (DCM), methyl tert-butyl ether
(MTBE) and steroids (A4, T and DHT) were purchased from Sigma-
Aldrich (St. Louis, MO, USA). All other steroids were from Steraloids
(Wilton, USA). All cell culture plates were purchased from Corning®
Life Sciences (NY, USA). LNCaP: C4-2B cell line (C4-2B cells) was
donated by Prof DE Neal (Nufﬁeld Department of Surgery, Oxford,
United Kingdom). HEK293 (CRL-1573) and VCaP (CRL-2876) cells
were bought from American Type Culture Collection (Johannes-
burg, South Africa) and LNCaP cells (Cat no. 89110211) were ob-
tained from the Sigma's European Collection of Authenticated Cell
Cultures (St. Louis, USA). Penicillin-streptomycin (penstrep), fetal
bovine serum (FBS), trypsin-ethylenediaminetetraacetic acid
(EDTA) and phosphate buffered saline (PBS) were obtained from
Oxoid limited (Hampshire, England). Pierce™ BCA Protein deter-
mination kit was purchased from Thermo Fischer Scientiﬁc (South
Africa). All deuterated steroids were purchased from Cambridge
isotopes (Andover, MA, USA), and all other chemicals were of
analytical grade and supplied by reliable scientiﬁc houses.
2.3. Steroid metabolism in LNCaP, C4-2B and VCaP cells
LNCaP cells were cultured in RPMI-1640 growth medium sup-
plemented with 10% FBS, 1.5 g NaHCO3/L (pH 7), 1% penstrep, 2.5 g
D-(þ)-Glucose, 1% HEPES and 1% sodium pyruvate at 37 C, in an
atmosphere of 90% humidity and 5% CO2, and once conﬂuent
replated into 12-well Corning® CellBIND® surface plates at
2  105 cells/mL. C4-2B cells were cultured in RPMI-1640 medium,
supplemented with 2.5 g D-(þ)-Glucose as described above and
conﬂuent cells replated at 1  105 cells/mL. VCaP cells were
cultured in DMEM medium as described above and conﬂuent cells
replated at 2  105 cells/mL. After 48 h, the medium was replaced
with 1 mL cell-culture medium containing steroid substrates
(1 mM): A4, T, 5aDIONE, DHT, AST, 3aDIOL, 11OHA4, 11OHT, 11KA4,
11KT, 11KDHT, 11KAST, 11OHAST, 11OHDHT and 11K-3aDIOL.
11OHDHT and 11K-3aDIOL were prepared (supplemental ﬁle) as
these are not available commercially. Duplicate aliquots were
removed for analysis of unconjugated steroids (0.5 mL) and of total
(unconjugated þ conjugated) steroids (0.5 mL), following decon-
jugation with b-glucuronidase (supplemental ﬁle), as previously
described (Du Toit et al., 2017). Protein concentrations were
determined to normalise data. Brieﬂy, cells were lysed and
collected with 0.5 mL trypsin-EDTA, washed with 0.5 mL 1 PBS,
after which 50 mL passive cell lysis buffer was added to the cells. The
cells were vortexed, sonicated for 20 min, subjected to 2 freeze-
thaw-cycles and incubated overnight at 20 C, after which a
Pierce® BCA protein determination was carried out.
In vitro assays were analysed after liquid/liquid steroid extrac-
tions using DCM (supplemental ﬁle). Cortisol-D4 (15 ng),
testosterone-D2 (D2T, 1.5 ng), progesterone-D9 (D9PROG, 15 ng),
androstenedione-D7 (D7A4, 15 ng) and 11b-hydroxyan-
drostenedione-D7 (D711OHA4, 15 ng) were added as internal
standards. Frozen prostate tissue samples (100 mg) were analysed
after steroids were extracted using MTBE after addition of internal
standard, D2T (1.5 ng), cortisol-D4 (15 ng), D7A4 (15 ng) and
D711OHA4 (15 ng). Steroids were extracted from plasma samples
using MTBE with 0.5 mL extracted for the analyses of unconjugated
steroids and 0.5 mL subjected to deconjugation prior to extraction
for the analyses of total steroids. Internal standards D2T (1.5 ng)
and cortisol-D4 (15 ng) were added to samples prior to extraction.
Extracted steroids were dissolved in 0.15 mL 50% methanol in wa-
ter. All samples were stored at 20 C prior to ultra-performance
convergence chromatography tandem mass spectrometry (UPC2-
MS/MS) analysis.
2.4. Separation and quantiﬁcation of steroid metabolites
The C19 and C11-oxy C19 steroids were analysed by ACQUITY
UPC2eMS/MS (Waters Corporation, Milford, USA) as previously
described, with method validation, including recovery and matrix
effect as published (Du Toit et al., 2017), with modiﬁcations to the
gradient (Supplemental Tables 1 and 2). Further method validation,
including accuracy and precision, is shown in Supplemental
Tables 3 and 4. UPC2-MS/MS separation of the C19 and C11-oxy
C19 steroids are shown in Supplemental Fig. 1a and b, respec-
tively. The mass transitions, limit of detection (LOD) and limit of
quantiﬁcation (LOQ) are shown in Supplemental Table 5. Data were
collected and analysed with the MassLynx 4.1 (Waters Corporation)
software program.
Fig. 1. C19 and C11 hydroxy and keto C19 steroids metabolism. Boxed steroid pathways depict C19 steroid metabolism; boxed steroid pathways (dashed line) depict activation of
steroid androgens and boxed steroids (dashed line) depict human AR agonists at 1 nM.
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2.5. Statistical analysis
Experiments were performed in triplicate and representative of
at least duplicate experiments. Statistics were calculated by an
unpaired t-test using GraphPad Prism (version 5) software
(GraphPad Software, San Diego, California). Differences were
considered statistically signiﬁcant at P < 0.05.
3. Results
3.1. 11OHA4, 11OHT, T and 11OHDHT metabolism in C4-2B and
VCaP cells
The metabolism of 11OHA4 and 11OHT was ﬁrstly investigated
in PCa cells. It should be noted that both 11bHSD2 and SRD5A
catalysed reactions are irreversible with 11bHSD2 converting the
C11 hydroxyl group to a keto group, while SRD5A reduces the C4/C5
double bond. The 17bHSD enzymes exhibit either a reductive or
oxidative activity. The reductive activity converts the C17 keto
group of A4 and its derivatives to the hydroxyl group characteristic
of T and its derivatives, and the oxidative activity catalyses the
conversion of the hydroxyl group back to a keto group. 11OHA4 is
converted either by 11bHSD2 or SRD5A as it is not a substrate for
the 17bHSDs (Supplemental Fig. 1). 11bHSD2's conversion of
11OHA4 to 11KA4, 0.73 mM, was conﬁrmed in C4-2B cells (Fig. 2a)
with the 5a-reduction by SRD5A yielding 11OH-5aDIONE
(~0.007 mM) and the subsequent 3a-reduction by 3aHSD yielding
11OHAST (~0.013 mM)e both at low levels. Although 11KDHT levels
were negligible, the precursor steroid 11KT (0.05 mM), produced in
the conversion of 11KA4 by the 17bHSDs, was detected. 11OHA4's
metabolism in VCaP cells, although minimal, shows the production
of 11KA4 (0.03 mM) by 11bHSD2 and 11OH-5aDIONE (~0.003 mM;
below the LOQ) by SRD5As (Fig. 2b). Only low conjugated levels of
11KDHT (~0.006 mM), via 11KT (0.012 mM), was produced from
11OHA4 in this cell line, showing the pathway of 11OHA4 to 11KA4
(11bHSD2 activity), and subsequently to 11KT (17bHSD activity)
followed by the 5a-reduction to 11KDHT (SRD5A activity). In
contrast, 11OHT is a substrate for 11bHSD2 and SRD5A as well as
17bHSD2 (Supplemental Fig. 1). The metabolism of 11OHT in C4-2B
cells showed the conversion by 17bHSD2 to 11OHA4 (0.016 mM) and
by 11bHSD2 to 11KT, 0.49 mM (Fig. 2c). However, 11KT can also be
biosynthesized from 11OHT via 11OHA4 and 11KA4 and subse-
quently to 11KT. Although no 5a-reduction of 11OHT could be
detected, minimal 5a-reduction of 11KT to 11KDHT was detected
(~0.0013 mM, below the LOQ). No other downstream 3a-reduced
metabolites were detected. 11OHT's metabolism in VCaP cells
showed the production of 11OHA4 (0.16 mM) and 11KT (0.1 mM)
catalysed by 17bHSDs and 11bHSD2, respectively (Fig. 2d). The 5a-
reduction of 11OHT to 11OHDHT (~0.0016 mM; below the LOQ) was
also detected, however, no other 5a- or 3a-reduced metabolites
were detected. Although 11OHTappears to be conjugated after 48 h
in VCaP cells, following normalisation to protein, steroid levels
were not signiﬁcantly different (see Fig. 5c).
T's metabolism in C4-2B cells showed the predominant 5a-
reduction to DHT (0.1 mM) by SRD5As, while lower A4 levels were
detected, 0.044 mM (Fig. 2e). Downstream metabolism showed the
3aHSD reduction of DHT and 5aDIONE, to 3aDIOL (0.078 mM) and
AST (0.057 mM), respectively. No conjugation of T derivatives was
detected in this cell line following the addition of T after 48 h. In
VCaP cells, unconjugated T levels were low, 0.05 mM, after 48 h
(92.4% present in the conjugated form) (Fig. 2f). The endogenous
SRD5As catalysed the conversion of T, producing DHT (0.019 mM
unconjugated, 72.9% present in the conjugated form), while T was
also converted to A4 (0.11 mM) by endogenous 17bHSDs. 3aHSD
subsequently converted both 5aDIONE and DHT to AST (0.03 mM
unconjugated; 50.2% present in the conjugated form) and 3aDIOL
(0.025 mM unconjugated), respectively. A substantial level of
5aDIONE (0.14 mM) was also produced from T via A4.
In both cell models 11OHDHTwasmetabolised efﬁciently (92.9%
in C4-2B cells and 52.6% in VCaP cells) with only the unconjugated
form being detected in C4-2B (0.07 mM) (Fig. 2g) and in VCaP cells
(0.45 mM) (Fig. 2h). The steroid is predominantly converted to
11KDHT by 11bHSD2 in the cell models with the subsequent inac-
tivation resulting in the production of 11K-3aDIOL,15-fold higher in
C4-2B cells, with 11KDHT and 11K-3aDIOL present at comparable
levels in C4-2B cells. 11OHDHT was also converted to 11OH-
5aDIONE (0.23 mM) in VCaP cells at levels comparable to 11KDHT
(0.16 mM). 11OH-5aDIONE's subsequent metabolism is two direc-
tional e either inactivated to 11OHAST or converted to 11K-
5aDIONE with its subsequent inactivation yielding 11KAST. Only
11KAST (0.012 mM) was detected in C4-2B cells and only 11OHAST
(0.054 mM) was detected in VCaP cells.
3.2. Androgen inactivation and reactivation in prostate cell models
T and its derivatives are either conjugated at C17 or, upon
reduction, at C3 by the 3aHSD enzymes. In the case of the A4 de-
rivatives, conjugation occurs once the steroid is reduced at C3, with
subsequent conjugation preventing conversion back to active an-
drogens. As androgen inactivation and reactivation by the 3aHSD
and RL-HSD enzymes would impact the levels of active androgens,
we assayed the inactivation and reactivation by these enzymes
with the relevant steroids in LNCaP, VCaP and C4-2B cells. In LNCaP
cells, DHT and 11KDHT were more readily inactivated to 3aDIOL
and 11K-3aDIOL, 2- and 15-fold greater, than the respective active
forms (Fig. 3). In addition, 0.12 mM11K-3aDIOL was produced in the
metabolism of 11KDHT in these cells, 2-fold higher than 3aDIOL
produced in DHT's metabolism, highlighting a more efﬁcient
inactivation of 11KDHT in LNCaP cells. In contrast, in VCaP and C4-
2B cells, the inactivation and reactivation of DHT was similar, re-
ﬂected in the 1:1 ratio. Interestingly, the inactivation and reac-
tivation of 11KDHT is markedly different in both thesemodelse the
inactivation of 11KDHT was more efﬁcient than the activation of
11K-3aDIOL back to 11KDHT, 11-fold in VCaP and 17-fold in C4-2B
cells, with the metabolism of 11KDHT yielding 0.21 mM 11K-
3aDIOL in VCaP cells and 0.40 mM in C4-2B cells.
3.3. C19 and C11-oxy C19 steroid proﬁles in prostate tissue
Analyses of unconjugated intratumoral androgens and down-
stream inactive metabolites in CRPC prostate tissue showed that
the C11-oxy C19 steroids were present at considerably higher levels
than the C19 steroids, comprising of the inactive 11OHAST
(27.34 ng/g) and 11KAST (29.60 ng/g) steroids (Fig. 4). These inac-
tive C11-oxy C19 steroids were present at levels higher than AST.
The level of A4 (7.99 ng/g) was the highest C19 steroid present while
the T level was detected at levels generally reported for normal
tissue (0.2e1.8 ng/g). All other C19 steroidswere below the LOQ, and
no 3aDIOL was detected. Interestingly, 11KDHT was detected at
~0.97 ng/g, signiﬁcantly higher than DHT, detected at ~0.23 ng/g.
3.4. Androgen conjugation in prostate cell models
Since the conjugation of C19 steroidswould remove T derivatives
and inactive androgens from the active androgen pool, we inves-
tigated the activity of the UGT enzymes towards the relevant an-
drogens in prostate cell models. We previously reported that the
conjugation of 11KT was inefﬁcient in LNCaP cells (Du Toit et al.,
2017), with present data again showing inefﬁcient conjugation
(Fig. 5a) with 0.027 mM 11KT (~15%) present in the unconjugated
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form. No other steroids were present in the unconjugated form at
48 h, except for AST (0.016 mM) and 11OHAST (0.014 mM).
UGT-conjugation in androgen-independent C4-2B and VCaP cell
models was markedly different. In C4-2B cells all C19 and C11-oxy
C19 steroids remained unconjugated after 48 h. However, low
levels of unconjugated DHT, 0.012 mM, were detected with ~50%
Fig. 2. C19 and C11-oxy C19 steroid metabolism in C4-2B and VCaP cells. 11OHA4 metabolism in (a) C4-2B and (b) VCaP cells; 11OHT metabolism in (c) C4-2B and (d) VCaP cells; T
metabolism in (e) C4-2B and (f) VCaP cells and 11OHDHT metabolism in (g) C4-2B and (h) VCaP cells. 11OHA4, 11OHT, T and 11OHDHT (1 mM; patterned bars) metabolism was
assayed after 48 h. Clear bars, unconjugated steroids; shaded bars; total steroids. Experiments were performed in triplicate, analysed by UPC2-MS/MS and the results expressed as
the mean ± STD DEV (11OHA4 n ¼ 3, for all other substrates n ¼ 6, **P < 0.01, ***P < 0.001).
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being present in the glucuronidated form (Fig. 5b). In contrast, in
VCaP cells (Fig. 5c) the C19 steroids were predominantly present in
the glucuronidated form with negligible unconjugated T and DHT
(<1 nM) and low levels of unconjugated inactive AST, 0.026 mM, and
3aDIOL, ~0.011 mM. All the C11-oxy C19 steroids were predomi-
nantly present in the unconjugated form.
3.5. Conjugated androgen plasma levels
Glucuronidated C11-oxy C19 steroids levels in circulation have,
to date, not been reported. Since glucuronide C11-oxy C19 steroid
standards are unavailable, we chose to deconjugate plasma steroid
metabolites to assess the C19 and C11-oxy C19 steroid glucuronide
proﬁles showing total steroids as unconjugated and glucuronidated
(Table 1). Comparative analyses (Fig. 6a, b and c) showed that the
C11-oxy C19 steroid levels were higher than the C19 levels in all
samples. Although data depicts a single sample, we have found that
unconjugated C11-oxy C19 steroids are present at signiﬁcantly
higher levels than the unconjugated C19 steroids (~1.4-fold) in
plasma of nineteen healthy subjects (unpublished results). While
DHTwas below the LOQ in all samples, in the healthy subject, T was
detected in its unconjugated form only, while only 11KDHT-
glucuronide was present (Fig. 6a). 11KT was the most abundant
steroid with a greater portion present as unconjugated steroid, as
only 26% was glucuronidated. Glucuronidated AST and 11OHAST
comprised ~14% of the total steroids detected with 11KAST present
in its glucuronidated form only. The two conjugated glucuronide
derivatives of 3aDIOL viz. 3aDIOL-17G and 3aDIOL-3G, could not be
resolved chromatographically, and are shown as unconjugated and
total 3aDIOL (17G and 3G). Although the data obtained in the an-
alyses of the PCa plasma samples does not represent a cohort of
patients, the analyses clearly demonstrate different UGT activities
towards the steroids. The androgens detected in the PCa patient
(Fig. 6b), although markedly lower than in the healthy subject,
showed only 11KT in the glucuronidated form, albeit at only 3%,
signiﬁcantly lower than in the healthy subject. In the PCa sample, in
which the patient had progressed to CRPC (Fig. 6c), T levels were
negligible, 3aDIOL of which ~50% was glucuronidated was, how-
ever, higher than in the healthy and the other PCa sample (Fig. 6b).
In both PCa samples, AST was detected only as unconjugated while
11OHAST levels were considerably higher in the CRPC sample. Of
the active C11-oxy C19 steroids, 11KT was present predominantly in
the unconjugated form in all the samples, with markedly lower
levels of the glucuronidated form being detected in the PCa samples
(10- to 20-fold). In both PCa patient plasma samples 11KDHT was
present at comparable levels, however, only in the unconjugated
form (Fig. 6b and c).
4. Discussion
Our present study shows that the C11-oxy C19 steroids are the
predominant androgens in PCa cell models, PCa tissue and in cir-
culation. The metabolism of adrenal 11OHA4 and 11OHT yielded
active androgens in VCaP and C4-2B cells e predominantly 11KT
and very low levels of 11KDHT and 11OHDHT. The conversion of
11OHA4 and 11OHT (Fig. 2a, b, c and d) to 11KA4 and 11KT
respectively, in both models indicates the presence of 11bHSD2. In
addition, in 11OHA4's metabolism, 11KA4 and 11KT levels are
markedly higher in the C4-2B cells compared to VCaP cells, 25- and
4.5-fold respectively, suggesting higher expression levels of
11bHSD2 in C4-2B cells. The more efﬁcient reduction of the C11-
hydroxy moiety in C4-2B cells is substantiated in the conversion
of 11OHDHT to 11KDHT (Fig. 2g) in which negligible 11OH-
5aDIONE was detected, while this intermediate was detected in
VCaP cells (Fig. 2h) at levels slightly higher than 11KDHT, which, in
turn was 2.8-fold lower than in C4-2B cells.
Considering the metabolism of T, in which the presence of
11bHSD2 would not inﬂuence the conversion by steroidogenic
enzymes, the data (Fig. 2e and f) depicts similar levels of A4 and
DHT in both cell models, however, efﬁcient conjugation of T and
DHT occurred in VCaP cells only. Even though 5aDIONE levels were
~2.3-fold higher in VCaP cells together with 3aDIOL present only in
the unconjugated form, with both these metabolites able to
contribute to DHT, the level of unconjugated DHT remained
markedly lower in VCaP cells, even though all the steroids were
unconjugated in C4-2B cells. While only the inactive downstream
3aHSD metabolites, 3aDIOL and AST, were detected in C4-2B and
VCaP cells, 11OHAST was formed in the metabolism of 11OHA4 in
the former with the downstream 5a-reduced 11OHA4 and 11OHT
metabolites, mid-tier of the pathway, remaining low (<20 nM).
These data show that 11OHA4 and 11OHT metabolites remain
predominantly in the top tier of the metabolic pathway
(Supplemental Fig.1b) in C4-2B and VCaP cells, at levels higher than
previously reported in LNCaP cells (Bloem et al., 2015). However,
Fig. 2. (continued).
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Fig. 3. Ratios of inactive androgens catalysed by 3aHSD enzymes and active androgens catalysed by RL-HSD enzymes in LNCaP, VCaP and C4-2B cells. Cells were incubated with
DHT, 11KDHT, 3aDIOL and 11K-3aDIOL (1 mM) for 48 h. Bars show product formation with inactive androgens (white bars) representing the 3aHSD conversion of DHT to 3aDIOL and
11KDHT to 11K-3aDIOL and active androgens (grey bars) representing the RL-HSD conversion of 3aDIOL to DHT and 11K-3aDIOL to 11KDHT. Experiments were performed in
triplicate, total steroids were analysed by UPC2-MS/MS and the results expressed as the mean ± STD DEV (n ¼ 3).
Fig. 4. UPC2-MS/MS analysis of free, unconjugated C19 steroid proﬁles in prostate tissue. Steroids below the dashed line represent steroids detected below the LOQ. ND: not
detected. Insert; relative contribution of the active and inactive (a) C19 and (b) C11-oxy C19 steroids to the patient's steroid proﬁle.
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Fig. 5. Analyses of steroid glucuronidation. Substrate (mM normalised to mg protein), unconjugated (clear bars) and total (shaded bars), remaining after conversion of 1 mM in (a)
LNCaP; (b) C4-2B and (c) VCaP cells after 48 h. Experiments were performed in triplicate, analysed by UPC2eMS/MS and the results are expressed as the mean ± STD DEV (n ¼ 6,
ns ¼ not signiﬁcant, *P < 0.05, **P < 0.01, ***P < 0.001, #P ¼ 0.0593).
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when assaying 11OHDHT, signiﬁcantly higher levels of 11KDHT and
11K-3aDIOL were detected in C4-2B and VCaP cells than in LNCaP
cells, suggesting a greater shunt of androgens in the metabolic
pathways in the former two PCa models, which may be ascribed to
the endogenous enzyme expression levels 17bHSD types 3, 5 and
6 and SRD5A1 in VCaP cells (Cai et al., 2011; Mitsiades et al., 2012;
Sakai et al., 2016; Yepuru et al., 2013) and SRD5A1 and 3 in C4-2B
cells (Uemura et al., 2008). We previously reported that it was
only in the conversion of 11OHDHT in LNCaP cells (and not when
11OHA4 was assayed as substrate), that we were able to detect
11KDHT in the unconjugated form, showing 11KDHT to be the
predominant active androgen formed with low levels of 11KAST
(Bloem et al., 2015). In the present study both 11OHA4 and 11OHT
yielded active SRD5A reduced androgens 11KDHT and 11OHDHT,
Table 1
Unconjugated, glucuronidated and total plasma steroid levels detected by UPC2-MS/MS (Shaded steroids detected below the LOQ).
Steroid metabolite Concentration (nM)
Healthy patient (Fig. 6a) PCa patient (Fig. 6b) PCa patient (Fig. 6c)
Unconjugated Conjugated Total Unconjugated Conjugated Total Unconjugated Conjugated Total
T 18.93 0.00 18.93 0.79 0.21 1 0.86 0 0.86
DHT 0.59 0.00 0.59 0.27 0.00 0.27 0.07 0.05 0.11
AST 6.93 12.41 19.34 8.84 0.00 8.84 10.75 0 10.75
3aDIOL 1.52 25.38 26.90 13.39 1.87 15.26 44.44 38.62 83.05
11OHT 0.28 1.92 2.20 0.35 0.91 1.26 1.67 0 1.67
11KT 203.63 71.60 275.23 237.74 11.75 249.49 351.05 35.40 386.44
11KDHT 0.00 49.11 49.11 24.70 0.00 24.70 26.42 0 26.42
11OHAST 26.00 54.76 80.76 75.19 1.51 76.70 17.90 318.74 336.64
11KAST 0.59 10.12 10.71 7.72 0.00 7.72 6.52 0 6.52
Fig. 6. Relative contribution of unconjugated and conjugated androgens to C19 and C11-oxy C19 plasma steroid proﬁles. (a) Healthy subject; (b) PCa patient (BO treatment) and (c)
PCa patient (LHRHa treatment, progressed to CRPC). Clear wedges, C19 steroids; shaded wedges, C11-oxy C19 steroids and patterned wedges, conjugated steroids.
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albeit at low levels. The proﬁle obtained in VCaP cells furthermore
clearly indicate competition for 11OHDHT between the oxidative
17bHSDs and 11bHSD2, with the formation of 11OH-5aDIONE and
11KDHT respectively e higher 11OH-5aDIONE levels in VCaP cells
than in C4-2B cells reﬂect higher levels of the oxidative 17bHSDs in
VCaP cells than in C4-2B cells. This may be due to the expression of
17bHSD2 in VCaP cells, reported by Sakai et al. (2016). However, the
formation of 11OH-5aDIONE would also lead to 11K-5aDIONE
production and subsequently 11KDHT (Supplemental Fig. 1).
Interestingly the expression of SRD5A2 has, to date, not been re-
ported in these two PCa cell models, possibly due to low expression
levels, accrediting the conversion of the C19 and C11-oxy C19 pre-
receptor steroids to their 5a-reduced forms to SRD5A1 (VCaP and
C4-2B cells) and SRD5A3 (C4-2B cells). It is therefore clear that
steroid proﬁles would be dictated by the expression levels of
endogenous steroidogenic enzymes in the tumour microenviron-
ment. However, the complete steroid proﬁle can only be generated
once all steroids in the pathway can be accurately identiﬁed and
quantitated, currently dependent on the availability of the full
cohort of steroid standards.
The levels of pre-receptor androgens produced from adrenal
11OHA4 and 11OHT would be inﬂuenced by inactivation and
conjugation as well as the conversion of the inactive steroids back
to their active forms. Both T and DHT were conjugated efﬁciently in
VCaP cells in which negligible levels of unconjugated steroids were
detected, while conjugation was negligible in C4-2B cells. No
studies have, to date, reported on C19 steroid conjugation in this cell
model. In both cell models, the active C11-oxy steroids were pre-
sent in the unconjugated form, however, low levels of conjugated
11KDHT were detected in VCaP cells. We therefore determined the
glucuronidation of the C19 and the C11-oxy C19 steroids in these
models as well as in LNCaP cells (Fig. 5a, b, c). The prostate ex-
presses UGT2B type 15, 17 and 28 with these enzymes conjugating
androgens by adding a glucuronide group either at C17 and/or C3:
UGT2B15 conjugates androgens (T, DHT, 3aDIOL) at C17 only;
UGT2B17 conjugates androgens (T, DHT, 3aDIOL, AST) at C3 and
C17; and UGT2B28 conjugates androgens (T, 3aDIOL, AST) at both
C3 and C17. It should be noted that UGT2B28 does not conjugate
DHT, while also conjugating 3aDIOL with a lower efﬁciency
compared to the other two enzymes (Belanger et al., 2003; Du Toit
et al., 2017; Levesque et al., 2001).
In LNCaP cells which express all the aforementioned UGTs
(Beaulieu et al., 1996; Belanger et al., 1995; Guillemette et al., 1995;
Levesque et al., 2001), 11KT was detected in the unconjugated form,
while none of the C11-oxy C19 steroids were conjugated in the C4-
2B cells. It is possible that the speciﬁc UGT isozymes in C4-2B cells,
are expressed at very low levels thus accounting for the detected of
DHT conjugation only, or it may perhaps be that the non-functional
UGT isoforms are being expressed. Conjugation of C19 steroids in
VCaP cells has not been characterized. An investigation by Bao et al.
(2008), into AR mediated expression of the UGT isoforms, showed
that UGT2B15 gene transcripts were expressed in VCaP cells while
UGT2B17 was not detected. In a more recent study, UGT2B28 was
detected by RT-qPCR in VCaP cells, however, primers, common to
three UGT2B28 isoforms, spanned exon one and it cannot therefore
be concluded that these transcripts would reﬂect the expression of
a functional protein (Malinen et al., 2015). UGT2B28 type Ⅰ isoform
actively conjugates androgens, with type Ⅱ possessing a 308 bp
deletion, amino acid residues 335e437 in the co-factor binding
domain, producing an inactive isoform and type Ⅲ lacking residues
in the substrate binding domain also producing an inactive isoform
(Du Toit and Swart, 2016; Levesque et al., 2001). Having shown that
UGT2B15 is present in VCaP cells, our data allows perhaps a
tentative speculation that UGT2B15 does not catalyse the conju-
gation of the C11-oxy C19 steroids and since the enzyme acts
speciﬁcally at C17 of the C19 steroids, it is possible that the inability
to conjugate the C11-oxy derivatives suggests that the C11-oxy
moiety hampers substrate binding to and/or positioning in the
active pocket which readily accommodates the C19 steroids (Du Toit
et al., 2017; Guillemette et al., 1995). In contrast, it appears that the
C11moiety does not affect inactivation by 3aHSD and in the PCa cell
models, 11KDHT was predominantly present in the inactive form
while DHT and 3aDIOL were present at equimolar concentrations,
however, at markedly higher concentrations than 11KDHT and 11K-
3aDIOL.
Our study thus far has investigated the metabolism of the C11-
oxy C19 steroids depicting their inactivation, reactivation and
conjugation in prostate cell models, which is dependent on the
expression of steroidogenic enzymes. The resulting steroid proﬁles
permits the postulation and identiﬁcation of physiologically rele-
vant enzymatic conversions. However, it was reported by Sakai
et al. (2016), that in vitro ﬁndings may perhaps not be reﬂected
in vivo and using prostate cell models to study steroid metabolism
may be an inaccurate way of investigating steroid biosynthesis.
Human prostate samples may contain different transcripts encod-
ing for enzymes and proteins not necessarily detected in prostate
cell models (Sakai et al., 2016). Interpreting steroid panels in
prostate tissue is therefore fundamental in understanding C11-oxy
C19 steroid metabolism in vivo.
Analyses of tissue clearly demonstrate the different manner in
which the C19 and the C11-oxy C19 steroids are metabolised in vivo
and the levels at which they are present in their active, inactivated
and unconjugated forms. Although our data only includes a single
patient's proﬁle, these steroid panels serve to show, not only the
abundance of the C11-oxy C19 steroids in vivo, but also that these
steroids are present at signiﬁcantly higher levels than the C19 ste-
roids. These ﬁndings corroborate our previous ﬁndings (Du Toit
et al., 2017), showing too that proﬁles vary markedly between pa-
tients. In addition, the C19 steroids are present primarily as DHT and
pre-receptor derivatives with inactivated steroids, AST (3aDIOL not
detected) comprising only 7%. In contrast, the inactivated C11-oxy
C19 steroids 11OHAST and 11KAST (11K-3aDIOL not detected)
comprised 92%. The high levels of inactivated steroids suggest that
while inactivation of the C11-oxy C19 steroids appear efﬁcient,
conjugation may be less efﬁcient, hampering elimination. 11OHAST
and 11KAST in their unconjugated form may be reactivated to
11KDHT, however, neither 3aDIOL nor 11K-3aDIOL were detected
suggesting that these were either reactivated or eliminated
following conjugation. The reactivation pathway of 11KAST and
11OHAST has been observed in preliminary studies conducted in
prostate cells (unpublished results), however, this is dependent on
the endogenous expression of the RL-HSD enzymes. We previously
reported unconjugated androgen proﬁles in PCa tissue of patients
prior to castration and on LHRH treatment in which the steroids
were present at far higher levels than those of the CRPC patient
proﬁled in this study, with the exception of A4. In the previous
study 11KAST and 11OHAST were below the LOD with AST and
3aDIOL at 2e5 ng/g, while DHT and 11KDHT were also markedly
higher than in the CRPC patient. The signiﬁcantly higher levels of
unconjugated 11KAST and 11OHAST detected in this study indicate
an increased shunt in the C11-oxy C19 steroid pathway.
Plasma analyses showed, in the healthy subject, that the inac-
tivated C11-oxy C19 steroids were ~2-fold higher than the inacti-
vated C19 steroids, however, in both PCa patients the inactive C11-
oxy C19 steroids were ~3.4-fold higher, also indicating a higher
throughput of steroids in the 11OHA4 pathway. The contribution of
adrenal DHEA to the pool of inactive C19 steroids in plasma was,
however, not measured. Furthermore, even though T and DHT
levels were negligible in treated patients, 11KT and 11KDHT present
in their unconjugated form together ranged between 261 and
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377 nM (8e11.5 mg/dL). While 11KDHT levels were 2-fold higher in
normal plasma compared to treated patients, the steroid was fully
glucuronidated. Analyses of circulating steroids also showed that
the level of total androgens analysed were similar when comparing
the normal subject and the patient who had undergone BO. In the
patient who had progressed to CRPC total steroid levels were
~850 nM, 2-fold greater than the BO patient. It should be noted that
the contribution of glucuronides detected in circulation are due to
UGT2B15, UGT2B17, and UGT2B28 which are expressed in the liver
(UGT2B28 Ⅰ and Ⅱ), kidney (UGT2B28 type Ⅲ) and prostate
(UGT2B28 type Ⅲ), with UGT2B15 also expressed in adipose tissue
(Beaulieu et al., 1996; Belanger et al., 2003; Levesque et al., 1997,
2001). In addition, UGT2B7, which is also capable of conjugating
androgens (T, 3aDIOL and AST), is not expressed in the prostate, but
is expressed in the liver and kidney, and as such would also
contribute to conjugated steroid levels in circulation (Turgeon et al.,
2001).
It is clear from our data that larger cohorts are required for
conclusions to be drawn regarding active, inactive and glucur-
onidated androgen levels in PCa. For more accurate quantiﬁcation,
it is important to note that deuterated internal steroids are required
for all the steroids which are being measured, however, most of the
relevant deuterated steroids are currently commercially unavai-
lable. Although it is possible that C11-oxy C19 steroids are conju-
gated by sulfation, their presence in the unconjugated form already
suggests that the downstream metabolism of C19 and C11-oxy C19
steroids are very different. If unconjugated, these metabolites will
remain available, shunted in the metabolic pathway towards 11KT
and 11KDHT, activating the AR, possibly exacerbated by enzyme
inhibitors. Androgen proﬁles, both in tissue and in circulation,
indicating the necessity of the inclusion of C11-oxy C19 steroids in
the assessment of not only PCa but also clinical conditions associ-
ated with androgen excess.
5. Conclusions
Our data show the C11-oxy C19 steroids are the predominant
androgens in PCa tissue and in circulation, thereby corroborating
our previous reports. Also in contrast to C19 steroids, a higher ﬂux is
observed in the metabolic pathway of the C11-oxy C19 steroids,
reﬂected in higher levels of inactive 11OHAST and 11KAST
compared to AST. Data also shows the efﬁcient inactivation of the
C11-oxy C19 steroids in PCa cell models, with the C19 ratio of
DHT:3aDIOL being 1:1, compared to the C11-oxy C19 ratio of
11KDHT:11K-3aDIOL being >10:1, in all models. Furthermore,
in vitro and in vivo data indicates the C11-oxy C19 steroids are not
glucuronidated efﬁciently, with both 11KT and 11KDHT predomi-
nantly present in their unconjugated form, while T and DHT were
predominantly in the glucuronidated form. In summary, the
investigation identiﬁes the presence of the C11-oxy C19 steroids and
for the ﬁrst time not only their abundance but, also their inacti-
vation in tissue and glucuronide levels in plasma. These data war-
rant further in vivo studies to provide details regarding the
contribution of inactivation and conjugation to the regulation of
active androgen levels.
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1 
Supplemental Fig. 1 – (a) C19 and (b) C11-oxy C19 metabolic pathways. Boxed steroids (dashed line) 
depict human AR agonists at 1 nM; a11OHDHT has not been shown to be a substrate for AKR1C2 
nor 11OHAST for 17βHSD3 and AKR1C3, and neither 11K-3αDIOL for 11βHSD1 co-transfected 
with hexose 6-phosphate dehydrogenase. 
a b
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Supplemental table 1: Gradient specifications of the UPC2 separation of C19 steroid metabolites. 
Step Time (min) Solvent A (%) Solvent B (%) Curve 
1 0 99 1 Initial 
2 4.0 85 15 7 
3 4.1 75 25 6 
4 4.2 99 1 6 
5 5.0 99 1 6 
Supplemental table 2: Gradient specifications of the UPC2 separation of C11-oxy C19 steroid 
metabolites. 
Step Time (min) Solvent A (%) Solvent B (%) Curve 
1 0 98 2 Initial 
2 4 85 15 6 
3 4.1 75 25 6 
4 4.2 98 2 6 
5 5 98 2 6 
Supplemental Fig. 2 - UPC2-MS/MS separation of C19 reference standards. (a) C19 steroids, 2 µL 
each of a 1 ng/µL standard solution, are depicted in the elution order of (1) 5αDIONE, 1.91 min, (2) 
A4, 2.44 min, (3) DHT, 2.83 min, (4) AST, 2.88 min, (5) T, 3.43 min and (6) 3αDIOL, 3.75 min; and 
(b) C11-oxy C19 steroids, 2 µL each of a 1 ng/µL standard solution, are depicted in the elution order 
of (1) 11KA4, 1.59 min, (2) 11KAST, 2.19 min, (3) 11OHA4, 2.24 min, (4) 11KDHT, 2.40 min, (5) 
11KT (clear peak), 2.76 min, (6) 11OHAST, 2.76 min and (7) 11OHT, 3.47 min. 
a b
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Supplemental table 3: UPC2-MS/MS method validation for the extraction of steroids from cell culture 
media using DCM. Three steroid concentrations were analysed to determine accuracya (%RSD, n=8) 
and precisionb with inter day variability (%RSD, n=8). 
Steroid metabolite 
Accuracy (%RSD) 
ng/µL 
Precision (%RSD) 
ng/µL 
Day 1 Day 2 
0.002 0.02 0.1 0.002 0.02 0.1 0.002 0.02 0.1 
C
19
 s
te
ro
id
s 
A4 2.99 2.12 4.49 5.35 7.78 3.57 7.16 10.10 3.78 
T 4.24 1.98 2.26 4.97 10.60 5.05 9.28 9.03 10.93 
5αDIONE 12.92 3.27 4.20 9.49 9.17 4.44 8.76 7.25 2.50 
DHT 7.96 3.44 6.67 14.67 14.46 4.94 8.19 8.78 7.21 
AST 17.76 3.32 6.11 9.21 11.61 5.93 12.50 17.39 10.00 
3αDIOL 14.51 13.25 4.59 19.70 18.26 9.87 18.50 8.64 3.07 
C
1
1
-o
xy
 C
1
9 
st
e
ro
id
s 
11OHA4 15.36 7.51 5.78 14.89 9.19 9.64 9.85 12.74 6.21 
11OHT 11.47 8.70 2.98 18.07 8.51 8.13 19.60 14.79 13.42 
11KA4 17.35 6.70 8.50 18.59 14.87 10.81 6.48 13.23 19.30 
11KT 18.67 5.46 12.70 19.95 18.94 9.34 9.55 9.56 4.37 
11KDHT <LOQ 17.38 15.80 <LOQ 18.22 10.44 <LOQ 15.74 13.81 
11OHAST <LOQ 18.50 12.83 <LOQ 19.69 12.37 <LOQ 18.63 13.35 
11KAST <LOQ 18.83 15.63 <LOQ 16.09 10.69 <LOQ 10.50 7.76 
aAccuracy: %RSD from the average calculated response following repeated injection; bPrecision: %RSD from the average calculated 
response following independent replicates and was repeated over two days to assess inter day variability.
Supplemental table 4: UPC2-MS/MS method validation for the extraction of steroids from FBS using 
MTBE. Three steroid concentrations were analysed to determine accuracya (%RSD, n=8) and 
precisionb with inter day variability (%RSD, n=8). 
Steroid metabolite 
Accuracy (%RSD) 
ng/µl 
Precision (%RSD) 
ng/µL 
Day 1 Day 2 
0.002 0.02 0.1 0.002 0.02 0.1 0.002 0.02 0.1 
C
19
 s
te
ro
id
s 
A4 1.78 3.58 1.94 4.20 6.62 2.62 3.84 5.40 3.81 
T 1.27 2.10 1.86 2.16 8.25 1.50 10.11 7.28 4.21 
5αDIONE 3.52 5.09 2.49 5.55 9.10 5.08 6.69 9.56 3.70 
DHT 3.21 6.78 4.19 5.41 9.26 7.05 10.32 7.08 4.59 
AST 9.44 4.94 2.57 8.37 6.90 5.84 11.53 9.71 5.96 
3αDIOL 11.76 2.89 4.41 12.33 4.84 7.87 15.09 5.88 6.77 
C
1
1
-o
xy
 C
1
9
 
st
e
ro
id
s 
11OHA4 5.50 4.87 3.64 5.32 5.35 5.30 8.00 4.29 8.82 
11OHT 9.61 7.96 8.34 10.72 3.62 6.68 9.81 4.70 18.92 
11KA4 9.15 5.45 13.63 7.86 7.35 6.86 8.36 9.46 9.14 
11KT 8.92 5.02 3.37 8.74 4.19 6.89 10.60 5.15 7.72 
11KDHT <LOQ 8.88 6.46 <LOQ 13.76 6.69 <LOQ 8.32 7.27 
11OHAST <LOQ 13.38 8.70 <LOQ 13.42 8.90 <LOQ 3.05 3.67 
11KAST <LOQ 10.03 5.40 <LOQ 11.45 6.85 <LOQ 9.23 8.81 
aAccuracy: %RSD from the average calculated response following repeated injection; bPrecision: %RSD from the average calculated 
response following independent replicates and was repeated over two days to assess inter day variability.
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Supplemental table 5: UPC2-MS/MS detection and quantification of C19 steroid standards. Molecular ion species and mass transitions; retention time 
(RT, min); limit of detection (LOD) and limit of quantification (LOQ) of steroids; mass spectrometer settings, cone voltages (CV), collision energy (CE); 
and internal deuterated standards, testosterone-D2, cortisol-D4, progesterone-D9, androstenedione-D7 and 11β-hydroxyandrostenedione-D7. 
Steroid metabolite 
RT 
(min) 
Mass transitions 
CV (V) CE (eV) 
LODa 
(ng/µL)1 
LOQb 
(ng/µL) 
Quantifier Qualifier 
A4 2.44 287.2>96.9 287.2>108.8 30 30 15 15 <0.00001 0.0001 
T 3.43 289.2>97.2 289.2>109.0 30 30 22 22 <0.00001 0.0001 
5αDIONE 1.91 289.2>253.1 289.2>97.2 22 30 16 22 0.00025 0.001 
DHT 2.83 291.2>255.0 291.2>273.0 25 25 15 20 0.00025 0.001 
AST 2.88 273.2>105.3 291.3>273.3 30 18 30 8 0.00025 0.001 
3αDIOL 3.75 275.2>257.0 275.2>175.0 15 15 15 15 0.0001 0.001 
          
Testosterone-D2 3.43 291.0>99.1 291.0>111.2 30 30 20 30 - - 
Cortisol-D4 4.51 367.0>121.0  35  25  - - 
Progesterone-D9 2.28 324.2>100.0 324.2>113.0 30 30 20 25 - - 
Androstenedione-D7 2.43 294.3>100.0 294.3>113.0 25 25 25 25 - - 
11β-hydroxyandrostenedione-D7 3.56 310.2>99.8 310.2>147.2 25 25 30 25 - - 
11OHA4 2.24 303.2>267.2 303.2>121.0 30 30 30 15 0.00001 0.0001 
11OHT 3.47 305.3>121.0 305.3>269.0 35 35 20 15 0.00001 0.0001 
11KA4 1.59 301.2>257.0 301.2>265.2 35 35 25 25 0.00001 0.0001 
11KT 2.76 303.2>121.0 303.2>267.0 30 30 20 20 0.00001 0.0001 
11OH-5αDIONE 1.81 305.0>269.2 305.0>287.2 35 35 15 15 - - 
11K-5αDIONE 1.28 303.2>241.0 303.2>267.0 35 35 30 25 - - 
11OHDHT 3.06 307.0>253.0 307.0>271.0 35 35 20 20 - - 
11KDHT 2.40 305.2>243.0 305.2>269.0 30 30 20 20 0.00025 0.01 
11OHAST 2.76 289.0>271.0 289.0>213.0 15 15 15 15 0.005 0.01 
11KAST 2.19 305.0>147.2 305.0>173.1 30 30 30 30 0.005 0.01 
11K-3αDIOL 3.37 307.2>271.0 307.2>253.0 15 15 10 10 - - 
          
Testosterone-D2 2.14 291.0>99.1 291.0>111.2 30 30 20 30 - - 
Cortisol-D4 3.74 367.0>121.0  35  25  - - 
Progesterone-D9 1.14 324.2>100.0 324.2>113.0 30 30 20 25 - - 
Androstenedione-D7 1.17 294.3>100.0 294.3>113.0 25 25 25 25 - - 
11β-hydroxyandrostenedione-D7 2.22 310.2>99.8 310.2>147.2 25 25 30 25 - - 
aLimit of detection was defined as S/N ratio >3 for the quantifier ion; bLimit of quantification was defined as a S/N ratio >10 for the quantifier ion and >3 for the qualifier ion; 1Quanson et al., 2016.
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Preparation of commercially unavailable steroids 
11OHDHT and 11K-3αDIOL were prepared as follows: HEK293 cells were transfected with SRD5A1 
(0.5 µg) and SRD5A2 (0.5 µg) and with AKR1C3 (1 µg). After 72 hrs, 11OHT (2 μM) was added to 
HEK293 cells expressing SRD5A1/2 and incubated for 24 hrs to produce 11OHDHT. 11KAST (2 
μM) was converted to 11K-3αDIOL in HEK293 cells expressing AKR1C3 following the same 
protocol. Media were collected from HEK293 cells, diluted (1:1) with prostate cell-specific culture 
media and added at 1 µM to LNCaP, C4-2B and VCaP cells. 
Steroid extraction 
A 10:1 volume of dichloromethane (DCM) was added to sampled aliquots for assays in prostate 
cells, vortexed at 1000 RPM for 15 min, and centrifuged for 5 min. Extracted media was aspirated, 
the DCM phase dried under nitrogen and the dried residues dissolved in 0.15 mL 50% methanol in 
water.  
Frozen prostate tissue samples were homogenised with 3 mL deionized water and the 
samples lyophilised overnight. Dried samples were homogenised in 5 mL methyl tert-butyl ether 
(MTBE), after which samples were sonicated for 10 min. Samples were transferred to screw cap 
tubes, shaken at 1000 RPM for 60 min, and centrifuged for 10 min. The supernatant was transferred 
and dried under nitrogen. Dried steroid residues were resuspended in 0.15 mL 50% methanol in 
water.  
Plasma samples (1 mL) were thawed on ice and vortexed after which one 0.5 mL was 
extracted, and the other 0.5 mL subjected to deconjugation (see below), prior to extraction. Internal 
standards testosterone-D2 and cortisol-D4 were prepared in MTBE and added to samples prior to 
extraction. The samples were vortexed in 5 mL MTBE for 15 min at 1000 RPM, the organic layer 
was removed and dried under nitrogen. The dried steroid residue was dissolved in 0.15 mL 50% 
methanol in water.  
 
Deconjugation of steroids 
 
Aliquots (0.5 mL) were treated with 400 units (76 µL) of β-glucuronidase (Type VII-A from E.coli, 
5,292,000 units/g; G7646 from Sigma-Aldrich; St.Louis, MO, USA) at 37 °C, pH 6.5, for 24 hrs to 
deconjugate steroids. DHT-G (1 µM; in 0.5 mL media) was deconjugated and extracted, and used 
as a control for deconjugation efficiency, confirmed by the amount of DHT recovered using UPC2-
MS/MS.  
 
Separation and quantification of steroid metabolites 
Stock solutions of steroids were dissolved in absolute ethanol (2 mg/mL) and stored at -20°C. 
Standards were prepared as follows: a standard range, 0.00025 – 0.5 ng/µL prepared in deionized 
water applied in tissue sample analysis, a standard range, 0.0001 to 1 ng/µL, prepared (i) in RPMI-
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1640 cell culture media applied in analysis of cell model assays and (ii) in FBS for plasma sample 
analysis. The prepared steroid standards were extracted using the protocol described above. 
Steroids that were not commercially available were quantified by UPC2-MS/MS, following peak 
integrations, using response factors, previously determined by Quanson (2015), as follows: for 
11OH-5αDIONE relative to 11OHA4, 4.147±0.640; for 11K-5αDIONE relative to 11KA4, 
4.501±0.549; and for 11OHDHT relative to 11OHT, 3.812±0.243 (tissue samples only). Standard 
curves were generated by integrating respective substrates to quantify C11-oxy 5α-reduced steroids. 
For enzymatic assays completed in prostate cells, 11OHDHT and 11K-3αDIOL concentrations were 
calculated relative to the ionisation when only the product is present, representing 100% conversion 
of substrate to product (1 µM of 11OHT converted to 1 µM 11OHDHT after 24 hrs in transiently 
SRD5A1/2 transfected HEK293 cells and 1 µM of 11KAST converted to 1 µM 11K-3αDIOL after 24 
hrs in transiently AKR1C3 transfected HEK293 cells). Standard curves were generated by 
integrating respective substrates to quantify C11-oxy 5α-reduced steroids. 
The C19 steroids were analysed by ACQUITY UPC2–MS/MS (Waters Corporation, Milford, USA), 
separated using ACQUITY UPC2 BEH column (3 mm x 100 mm, 1.7 µm particle size) for the A4 and 
T metabolites and an ACQUITY UPC2 BEH 2-EP column (3 mm x 100 mm, 1.7 µm particle size) for 
the C11-oxy C19 metabolites. Briefly, the mobile phase consisted of CO2 modified with methanol in 
which steroids, injection volume, 2 µL, were eluted at a flow rate of 2 mL/min in a total run time of 5 
min per sample. The column temperature was set to 60°C and the automated back pressure 
regulator (ABPR) was set to 2000 psi. A Xevo TQ-S triple quadrupole mass spectrometer (Waters, 
Milford, USA) was used for quantitative mass spectrometric detection and all steroids were analysed 
in MRM mode, using the ESI+ mode. A make-up pump was utilized in the system, which fed 1% 
formic acid in methanol into the mixer preceding the MS line at a constant flow rate of 0.2 mL/min. 
The capillary voltage of 3.8 kV, cone voltage of 15-35 V and collision energy of 8-30 eV was set 
during this quantification. The following settings were used: source temperature 120 °C, desolvation 
temperature 500 °C, desolvation gas 1000 L/h and cone gas 150 L/h. 
 
References:  
Quanson, J.L. 2015. The characterisation of the catalytic activity of human steroid 5α-reductase 
towards novel C19 substrates, MSc thesis, Stellenbosch University, 
http://scholar.sun.ac.za/handle/10019.1/97057. 
Quanson, J.L., Stander M., Pretorius E., Taylor, A., Storbeck, K.-H., 2016. High-throughput analysis 
of 19 endogenous androgenic steroids by ultraperformance convergence chromatography tandem 
mass spectrometry. J. Chromatogr. B 1031, 131–138. 
https://doi.org/10.1016/j.jchromb.2016.07.024. 
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3.2 Summary 
The in vitro and in vivo data clearly show that the C11-oxy C19 steroids are not glucuronidated as 
efficiently as the C19 steroids. In LNCaP and C4-2B cells, 11KT-G and 11KDHT-G formation was inefficient 
compared to T-G and DHT-G formation, and while C19 steroids were glucuronidated in VCaP cells, the 
C11-oxy C19 steroids remained unconjugated. Furthermore, in PCa patients, circulatory 11KT and 11KDHT 
were present in their unconjugated forms, while 11KDHT-G was the predominant form present in the 
healthy subject. In addition, T and DHT levels were negligible in the PCa patients, with high levels of 
unconjugated T detected only in the healthy subject. Clearly, glucuronidation of 11KT and 11KDHT was 
impeded and the levels of these steroids detected as unconjugated metabolites in plasma and tissue, 
highlight the relevance of these steroids in PCa and their potential role in PCa progression. 
Unique steroid profiles, which revealed enzyme activities and substrate preferences, were also 
established in prostate cell models. In both PNT2 and LNCaP cells DHT was predominantly produced from 
the precursor steroid, A4, highlighting SRD5A catalysing the alternative pathway as the preferred route 
to DHT in these cells. Interestingly, PNT2, C4-2B and VCaP cells produced equal amounts of DHT, 
although in VCaP cells, DHT was primarily present in the glucuronidated form. Considering the 17βHSD 
isoform, reductive 17βHSD activity was also more active compared to the oxidative 17βHSD isoform, 
thus promoting the biosynthesis of active androgens in both PNT2 and LNCaP cells. All cell models 
showed 11βHSD2 activity, able to convert C11-hydroxy to C11-keto metabolites, however, different 
preferences were evident. PNT2 cells exhibited the least 11βHSD2 activity when compared to VCaP cells, 
which in turn was lower than that in C4-2B cells when considering the conversions of 11OHA4 and 11OHT 
to 11KA4 and 11KT, respectively, suggesting C4-2B cells has the highest 11βHSD2 expression levels.  
C4-2B cells also metabolized 11OHDHT more readily compared to VCaP and LNCaP cells, while exhibiting 
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no conjugating activity towards the C11-oxy metabolites compared to the glucuronidation of DHT. 
Furthermore, both C4-2B and VCaP cells showed equal inactivation and reactivation activity towards 
DHT, while the inactivation of 11KDHT was very different. 11KDHT’s inactivation by 3αHSDs 
endogenously expressed in LNCaP, VCaP and C4-2B cells was efficient, being greater than that of the 
inactivation of DHT, suggesting that the C11 keto-moiety did not affect the binding of the steroid to the 
enzyme. Conversely, the reactivation of 11KDHT when compared to DHT was hampered in all the cell 
models, suggesting the C11-keto moiety may affect steroid-enzyme binding. 
Taking together, our in vitro metabolic assays, suggest that the C11-oxy C19 steroids  
(11OHA4, 11OHT, 11KA4 and 11KT) remained mainly in the top tier of the 11OHA4-pathway regarding 
the C4-2B and VCaP cells, more so than in LNCaP cells, which in turn was also higher than in the normal 
PNT2 cell model. This highlights a greater metabolic shunt of these C11-oxy steroids in the PCa cells, 
suggesting a more prominent role for these metabolites in PCa. 11KT, produced at high levels in these 
PCa cell models in the metabolism of 11OHA4 and 11OHT, and together with its hampered 
glucuronidation, places this steroid in the spotlight as the most prominent androgen in the  
11OHA4-pathway. 
In terms of UGT2B enzymes, while UGT2B15 and B17 are intricately involved in the inactivation of 
steroids and decreased UGT2B17 expression has been associated with reduced steroid glucuronide 
production, UGT2B28 has been shown to have a more prominent regulatory role in PCa rather than 
steroid inactivation. Moreover, whether the C11-oxy C19 are glucuronidated by specific isoforms still 
remains to be clarified. While LNCaP cells, which endogenously express all three isoforms, conjugated 
the C19 and the C11-oxy C19 steroids suggesting the involvement of all three UGT isoforms, VCaP cells 
which express UGT2B15 did not conjugate the C11-oxy C19 steroids –suggesting UGT2B17 is the isoform 
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involved in the glucuronidation of the C11-oxy C19 steroids. Although, in terms of these C11-oxy steroids, 
UGT2B28 cannot be disregarded as a conjugating enzyme, UGT2B28 has been shown to be a weaker 
UGT enzyme compared to UGT2B15 and B17 in the glucuronidation of the C19 steroids. UGT2B17 
enzymatic conversion assays conducted with single steroid substrates, may provide insight into the 
conjugation at C17 and C3 of the C11-oxy C19 steroids, in addition to the possible glucuronidation of the 
C11-hydroxy group. It would also be interesting to determine whether increased conjugated C11-oxy C19 
steroids are detected in vivo, together with the increased expression of UGT transcripts, as has been 
reported regarding the UGT2B28 isoform. If it is assumed that increased UGT2B28 expression allows 
isoform aggregation, leading to inactive UGT enzymes, decreased steroid glucuronidation and therefore 
increased C19 androgens in circulation –which may further contribute to increased active C11-oxy C19 
steroids in circulation. 
Collectively, our in vivo data show for the first time, that the C11-oxy C19 steroids are present at levels 
higher than the C19 steroids. Although our in vivo data did not include the analysis of DHEA as a 
contributing C19 steroid, this steroid is considered a precursor steroid to C19 steroids, which include the 
C11-oxy C19 steroids. This study, furthermore, quantified high levels of 11OHA4, 11KT and 11KDHT in PCa 
tissue and plasma of PCa patients; and in tissue samples 11KDHT, and 11OHAST and 11KAST were 
present at levels higher than DHT and AST, respectively –underscoring these C11-oxy metabolites as  
role-players in PCa.  
Taken together, it is clear that targeting T alone cannot be justified in treatment regimes, nor can T and 
DHT be the only steroid metabolites measured for prognostic scoring and in ascertaining treatment 
efficacy in PCa patients. Adrenal 11OHA4 presents a significant androgen precursor and its downstream 
metabolism to 11KT and 11KDHT substantiates the important role of this adrenal androgen in PCa. 
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Chapter 4 
A preliminary investigation into the conjugation of C11-oxy C19 steroids by sulfation in LNCaP prostate 
cells and in plasma 
4.1 Introduction 
The sulfation of steroids is another form of conjugation, besides glucuronidation, that occurs in target 
tissue such as, the adrenals, kidneys, liver and prostate (Javitt et al. 2001; Rainey and Nakamura 2008; 
Riches et al. 2009; Rege et al. 2014). Sulfation proceeds with the addition of a sulfate group to the steroid 
backbone structure, either at C3 or C17 with a hydroxy moiety and is catalysed by SULTs. In contrast to 
glucuronidation, however, steroid sulfation is reversible whereby the sulfate group is hydrolysed, 
catalysed by arylsulfatase C also known as STS, which restores the hydroxy group and provides once 
again an androgen precursor to the pool of active androgens (Mueller et al. 2015). STS mRNA expression 
and enzyme activity has been shown in the testis, ovary, adrenals, kidney and prostate (Reed et al. 2005; 
Dalla Valle et al. 2007; Nardi et al. 2009). Although, steroid sulfation contributes to the inactivation of 
the steroids, it is not a termination of the physiological signal since reactivation by desulfation is possible.  
Steroid sulfation is possible only once sulfate is taken up into the target cell by sulfate transporters, the 
subsequent conversion of the sulfate to PAPS by PAPSS1 and PAPSS2, and finally the transfer of the 
sulfate group to the oxygen moiety by cytoplasmic SULTs (Hemmerich et al. 2004). SULTs that are 
involved in steroid sulfation include SULT1A1 (also known as phenol sulfotransferase), SULT1E1 (also 
known as estrogen sulfotransferase), SULT2A1 (also known as DHEA sulfotransferase) and SULT2B1a and 
SULT2B1b (Strott 2002; Mueller et al. 2015). SULT2A1 has been shown to catalyse the sulfation of DHEA, 
PREG and AST (Falany et al. 1989; Chang et al. 2001; Meloche and Falany 2001;  
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Fuda et al. 2002; Chang et al. 2004; Ekuase et al. 2011; Gulcan and Duffel 2011), with SULT2B1a catalysing 
the sulfation of PREG and SULT2B1b the sulfation of cholesterol (Fuda et al. 2002). In addition to 
SULT2A1, SULT1E1 and SULT2Bs would also catalyse the sulfation of DHEA (Hempel et al. 2000; Mueller 
et al. 2015) (Fig. 4.1). 
 
Figure 4.1 Adrenal and peripheral steroid metabolism. Shaded steroids, sulfated derivatives detected in 
circulation; Dashed boxed steroid, A4 and PROG, novel SULT2A1 ketosteroid substrates; 11OHA4, not a SULT2A1 
substrate.  
The most commonly reported adrenal steroids involved in sulfation and in desulfation are DHEA and 
DHEA-S, respectively. DHEA, once produced from 17OHPREG by the CYP17A1 catalysed reaction, is the 
first precursor in the androgen arm of adrenal steroidogenesis, and can either be converted to A4 by 
11βHSD                                                                                               
PREG
PROG
17OHPREG
17OHPROG
DHEA
A4
CYP21A2                          CYP21A2
3βHSD2                             3βHSD2                                                  3βHSD2                            3βHSD2                                                                                                
CYP11B1                         CYP11B1
C
Y
P
1
7
A
1
  
  
C
Y
P
1
7
A
1
C
Y
P
1
7
A
1
11OHA4
Downstream 
metabolism to 
cortisol and 
cortisone
S
U
L
T
2
A
1
S
U
L
T
1
E
1
S
U
L
T
2
B
s
T
DHEA-S
1
7
β
H
S
D
  
  
  
  
 1
7
β
H
S
D
  
  
  
  
  
  
  
  
  
  
  
  
  
 1
7
β
H
S
D
11OHT
11KT
Androstenediol
Cholesterol
CYP11A1   
S
R
D
5
A
1
/2
  
  
  
 S
R
D
5
A
1
/2
  
  
  
S
R
D
5
A
1
/2
S
T
S
Downstream 
metabolism 
to 
aldosterone
Mineralocorticoids Glucocorticoids
DHT
11OHDHT
11KDHT
S
R
D
5
A
1
/2
  
5αDIONE
17βHSD
AST
Androgens
Stellenbosch University  https://scholar.sun.ac.za
98 
 
3βHSD2 or inactivated to DHEA-S, specifically DHEA-3-sulfate, as the C3-hydroxy group of DHEA is 
sulfated by SULTs. Circulating DHEA-S levels range from 2000-1000 nmol/L in males, in premenopausal 
females from 1000-8000 nmol/L and in postmenopausal females from 1000-6000 nmol/L, with the 
DHEA:DHEA-S ratio shown to be 1:400, 1:200 and 1:300, respectively (Mueller et al. 2015). Although the 
sulfated C19 androgens are not as abundant, both AST-sulfate (AST-S, sulfate moiety at C3) and  
DHT-sulfate (DHT-S, sulfate moiety at C17) have been detected in circulation. Compared to DHEA-S, 
however, DHT-S levels are low, ranging between 50-100 nmol/L, with AST-S present at higher levels 
ranging from 0-5000 nmol/L in males (Mueller et al. 2015). Of note, both AST-S and DHT-S act as 
reservoirs to be reactivated to DHT by STS (Fig. 4.2) and steroidogenic enzymes (as is the case of AST-S). 
The sulfation of other C19 steroids, including T and 3αDIOL has not been widely reported, with both 
steroids possessing a C17-hydroxy group and 3αDIOL also possessing a C3-hydroxy group. It has been 
reported that SULTs prefer the C3-hydroxy group, therefore the sulfation of 3αDIOL would be expected, 
however, with the sulfation of DHT occurring at C17, the sulfation of T should also be possible. 
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Figure 4.2 Sulfation and desulfation of DHT and 11KDHT at C17. 11KDHT-S, 11keto-dihydrotestosterone-sulfate. 
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presence of DHEA (He and Falany 2007; Seo et al. 2013). STS activity has also been confirmed in PCa 
tissue, while STS activity has also been shown in LNCaP prostate cancer cells (Nakamura et al. 2006;  
Day et al. 2009). Therefore, a fine equilibrium between sulfation and desulfation is important in the 
regulation of steroid action.  
SULT2B1b is present in the cytosol of normal prostate, BPH and prostate adenocarcinoma tissue  
(He et al. 2004; He and Falany 2007). In LNCaP cells, SULT2B1b is also expressed in the cytosol  
(Vickman et al. 2016) and its expression has been shown to be regulated by the presence of DHT, while 
expression levels of SULT2B1a, SULT2A1 and SULT1E1 were not detected (He and Falany 2007). 
SULT2B1a and SULT2B1b isoforms are produced due to an alternative splicing on exon-1, and differ at 
the N-terminus (a 23-residue sequence in SULT2B1b and an 8-residue sequence in SULT2B1a)  
(Her et al. 1998; Fuda et al. 2002; Lee et al. 2003), and while the SULT2B1 antibody cannot discern 
between the two isoforms, their difference in weight, denoted as 39,6 kDa for SULT2B1a and  
41,3 kDa for SULT2B1b (Meloche and Falany 2001), allows sodium dodecyl sulfate polyacrylamide gel 
electrophoresis to resolve these proteins, to distinguish between which isoform is present. 
Of note, SULT2B1b shows selectivity for steroid sulfation at C3 with a β-hydroxy group (Fuda et al. 2002; 
Falany et al. 2006; He and Falany 2006; He and Falany 2007), while AST, T and DHT have been shown not 
to be ideal substrates (Meloche and Falany 2001). However, promiscuity and broad substrate specificity 
of the SULTs have been reported (Lewbart and Schneider 1956; Mueller et al. 2015), suggesting many 
different steroid substrates may be sulfated at C3 or C17, including those with a α-hydroxy group at C3 
and perhaps even those such as 11KDHT with a hydroxy group at C17 (Fig. 4.2). Although, DHT is indeed 
a substrate for SULT2B1a and SULT2B1b, the latter exhibits a high Km (~15.14 µM) and low  
Vmax (~0.32 pmol/min/µg) towards DHT (Vmax/Km value of 0.02) compared to DHEA (Vmax/Km value of 
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0.37), with the SULT2B1b catalysed sulfation of DHT being 18.5-fold less efficient than DHEA  
(Geese and Raftogianis 2001). The sulfation of C11-oxy C19 steroids has, to date, not been reported. 
These steroids possess a α-hydroxy group at C3, as is the case for 11OHAST, 11KAST and 11K-3αDIOL, or 
a β-hydroxy group at C17, as is the case for 11OHT, 11KT, 11OHDHT, 11KDHT and 11K-3αDIOL. In 
addition, 11OHT, 11OHDHT and 11OHAST also possess a β-hydroxy group at C11, therefore, all the above 
mentioned steroids may serve as potential substrates for SULTs. It is interesting to note that SULT2A1 
catalyses the sulfation of metabolites with a C3-hydroxy group in either the α or β conformation as well 
as at C17 of T (Falany et al. 1989; Falany et al. 1994). This isoform has, however, not been detected in 
LNCaP cells and is not readily expressed in prostate tissue, although it is prominent in the adrenals and 
liver (Falany et al. 1989; Falany 1997a; Javitt et al. 2001). 
Recent reports have identified ketosteroids as a new class of substrates for cytosolic SULTs.  
Hashiguchi et al. (2017), showed that the C19 steroid, A4, and the C21 steroid, PROG, are substrates for 
the human SULT2A1 enzyme, reporting Vmax values of ~170.5 and 5.5 pmol/min/mg enzyme, 
respectively. A4 possesses a keto-group at C3 and C17, and PROG at C3 and C20. Comparing A4 sulfation 
to DHEA sulfation, however, DHEA-S formation was more efficient with the catalytic efficiency (Vmax/Km) 
being ~360-fold higher than A4-sulfate formation. In addition, SULT2B1b exhibited weak activity towards 
A4 (Vmax of 7.1 pmol/min/mg enzyme), while PROG was not sulphated by this isoform. The authors 
concluded that further in vivo data are needed to show the sulfation of ketosteroids. Interestingly, the 
authors showed that human SULT2A1 exhibited no activity towards 11OHA4 (Hashiguchi et al. 2017).  
Since sulfation is a key step in regulating the cellular effects of steroids, conjugation by SULTs is important 
when we consider the C11-oxy C19 steroids, as the inactivation and conjugation of these steroids have 
not been fully investigated. Although immunoassays are generally used in the detection of sulfated and 
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non-sulfated steroids in the routine clinical setting, LC-MS/MS is currently gaining popularity  
(Rege et al. 2017). Most sulfated steroid reference standards, however, are not commercially available, 
thereby hampering quantification of in vitro and in vivo sulfated steroids. The aim of this study was 
therefore to investigate and compare the sulfation of the C11-oxy C19 and C19 steroids in LNCaP cells and 
to determine the levels of the sulfated steroid derivatives in plasma, by deconjugating steroids prior to 
extraction, enabling the quantification of all steroid metabolites using UPC2-MS/MS. 
4.2 Materials and methods 
4.2.1 Materials 
RPMI-1640 medium, D-(+)-Glucose, β-Glucuronidase (Type VII-A from E.coli, 5,292,000 units/g), 
Sulfatase (Type H-1 from Helix Pomatia, 53570 units/g), dichloromethane (DCM) and steroids  
(A4, DHEA, T and DHT) were purchased from Sigma-Aldrich (St. Louis, MO, USA). All other steroids were 
from Steraloids (Wilton, USA) and cell culture plates from Corning® Life Sciences (NY, USA). HEK293 cells 
were bought from American Type Culture Collection (Johannesburg, South Africa) and LNCaP cells from 
the Sigma’s European Collection of Authenticated Cell Cultures (St.  Louis, USA). The AKR1C3 pcDNA3 
plasmid construct were obtained from Prof J. Adamski (Helmholtz Zentrum München, Institute of 
Experimental Genetics, Neuherberg, Germany) and the SRD5A1 and SRD5A2 pCMV7 plasmid constructs 
were a gift from Prof DW. Russell (Southwestern Medical Center, University of Texas, Dallas, USA). 
Penicillin-streptomycin (penstrep) were obtained from Oxoid limited (Hampshire, England) and fetal 
bovine serum (FBS) from Biochrom GmbH (Berlin, Germany). All deuterated steroids were purchased 
from Cambridge isotopes (Andover, MA, USA) and all other chemicals were of analytical grade and 
supplied by reliable scientific houses. 
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Male human blood samples were collected in a study investigating clinical markers of PCa  
(reference no. N09/11/330; Faculty of Medicine and Health Sciences, Stellenbosch University and 
Tygerberg Hospital, South Africa) from a normal subject, aged 59 and a PCa patient, aged 74 who 
underwent physical castration through BO. The female human blood left-over sample was collected 
under the clinical protocol 11-CH-0119 (Clinical Trials Number: NCT01313455) that was approved by the 
Eunice Kennedy Shriver National Institute of Child Health and Human Development Institutional Review 
Board (IRB), and kindly donated by Prof C.A. Stratakis (NICHD, Bethesda, MD, USA). All samples were 
stored at -80°C until further use. 
4.2.2 Steroid conversion assays in LNCaP cells 
LNCaP cells were cultured in RPMI-1640 growth medium supplemented with 10% FBS, 1.5 g NaHCO3/L 
(pH 7), 1% penstrep, 2.5 g D-(+)-Glucose, 1% HEPES and 1% sodium pyruvate at 37°C, in 90% humidity 
and 5% CO2, and once confluent replated into 12-well Corning® CellBIND® surface plates at  
2 x 105 cells/mL. After 48 hrs, the medium was replaced with 1 mL culture medium containing steroid 
substrates (1 µM): T, DHT, AST, 3αDIOL, 11OHA4, 11OHT, 11KT, 11KDHT, 11KAST, 11OHAST, 11OHDHT, 
11K-3αDIOL and DHEA for 12, 24 and 48 hrs. Commercially unavailable steroids, 11OHDHT and  
11K-3αDIOL, were prepared as previously described (Du Toit and Swart 2018). Briefly, 11OHDHT and 
11K-3αDIOL were prepared by transiently transfecting HEK293 cells, using XtremeGene HP® DNA 
transfection reagents, according to the manufacturer’s instructions (Sigma-Aldrich, St. Louis, MO, USA), 
and adding the appropriate substrates ―11OHT (2 μM) was added to cells transfected with SRD5A1  
(0.5 µg) and SRD5A2 (0.5 µg) and converted to 11OHDHT. 11KAST (2 μM) was added to cells transfected 
with AKR1C3 (1 µg) and converted to 11K-3αDIOL. Media were collected, diluted (1:1) with culture media 
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and added to LNCaP cells. Steroid conversion was assayed by collecting aliquots (0.5 mL) at specific time 
intervals and stored at 4°C until extraction and UPC2-MS/MS analyses. 
Plasmid preparations for enzymatic assays in transiently transfected HEK293 cells 
Luria-Bertani medium, 100 mL, containing ampicillin (100μg/mL), was inoculated with freezer stocks of 
plasmid-containing E.coli cells, 100 μL, overnight at 37°C at 230 rpm (Innova shaking incubator, New 
Brunswick) to prepare plasmids. The plasmid DNA was isolated using the Nucleobond® Midiprep DNA 
isolation kit, according to the manufacturer’s instructions (Machery-Nagal). After precipitation, the DNA 
pellet was redissolved in nuclease free water, 200 μL, and the plasmid yield was calculated by UV 
spectrophotometry (Cary 60 UV-VIS; Agilent technologies), 260/280 nm. The average yield ranged from 
100 μg - 200 μg per 100 mL. 
4.2.3 β-glucuronidase and sulfatase deconjugation reactions 
Three aliquots were collected at each time interval for the analysis of unconjugated steroids (A), total 
(unconjugated + glucuronidated) steroids (B) and total (unconjugated + glucuronidated + sulfated) 
steroids (C), after deconjugation with either β-glucuronidase for B or with sulfatase for C. Aliquots B were 
treated with 400 units (76 µL) β-glucuronidase at 37 °C, pH 6.5, for 24 hrs to deconjugate glucuronidated 
steroids (Du Toit et al. 2017; Du Toit and Swart 2018). Aliquots C were treated with 66 units (617 µL) 
sulfatase at 55°C, pH 5 (+ 110 µL sodium acetate buffer), for 3 hrs to deconjugate glucuronidated and 
sulfated steroids. DHT-G (1 µM) in 0.5 mL media was deconjugated and extracted, serving as a control 
for deglucuronidation efficiency, confirmed by DHT recovery from those samples, compared to DHT  
(1 µM) in 0.5 mL media extracted without prior treatment. DHEA-S (1 µM) in 0.5 mL media was 
desulfated and extracted, serving as a control for desulfation efficiency, confirmed by DHEA recovery 
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from those samples, compared to DHEA (1 µM) in 0.5 mL media extracted without prior treatment. 
Plasma aliquots (0.5 mL) underwent the same protocol as described above to deconjugate steroids. 
4.2.4 Steroid extraction 
Prior to steroid extractions, testosterone-D2 (D2T), 1.5 ng, progesterone-D9 (D9PROG), 15 ng, 
androstenedione-D7 (D7A4), 15 ng, and 11β-hydroxyandrostenedione (D711OHA4), 15 ng, were added 
as internal standards (100 µL) to cell model and plasma aliquots. In vitro and in vivo samples were 
analysed after a liquid/liquid steroid extraction using 5 mL DCM (10:1) was conducted  
(Du Toit et al. 2017). The samples in DCM were vortexed at 1000 rpm for 7 min, and centrifuged for  
2 min, after which the extracted media was aspirated and the DCM phase dried under nitrogen. Dried 
residue was dissolved in 0.15 mL 50% methanol in water and all samples stored at −20°C until  
UPC2-MS/MS analysis. 
4.2.5 Separation and quantification of steroid metabolites 
Stock solutions of steroids were dissolved in absolute ethanol (2 mg/mL) and stored at -20°C. A standard 
range, 0.0001 to 1 ng/µL, prepared in RPMI-1640 cell culture media and extracted as described above. 
11OHDHT and 11K-3αDIOL concentrations were calculated relative to the ionisation signal when only 
the product is present, which represents 100% substrate conversion (1 µM 11OHT converted to 1 µM 
11OHDHT and 1 µM of 11KAST converted to 1 µM 11K-3αDIOL after 48 hrs). 
The C19 steroids were analysed by ACQUITY UPC2®–MS/MS (Waters Corporation, Milford, USA), 
separated using an ACQUITY UPC2 BEH column (3 mm x 100 mm, 1.7 µm particle size) for the A4 and T 
metabolites and DHEA, and an ACQUITY UPC2 BEH 2-EP column (3 mm x 100 mm, 1.7 µm particle size) 
for the C11-oxy C19 metabolites. The mobile phase consisted of CO2 modified with methanol in which 
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steroids, injection volume, 2 µL, were eluted at a flow rate of 2 mL/min in a total run time of 5 min per 
sample. The column temperature was set to 60°C and the automated back pressure regulator (ABPR) 
was set to 2000 psi. A Xevo TQ-S triple quadrupole mass spectrometer (Waters, Milford, USA) was used 
for quantitative mass spectrometric detection and all steroids were analysed in multiple reaction 
monitoring mode (ESI+). Preceding the MS line, a make-up pump mixed 1% formic acid in methanol at a 
constant flow rate of 0.2 mL/min. The following settings were used: capillary voltage of 3.8 kV, source 
temperature 120 °C, desolvation temperature 500 °C, desolvation gas 1000 L/h and cone gas 150 L/h. 
Data was collected and analysed with the MassLynx 4.1 (Waters Corporation) software program. The 
mass transitions of the steroids, limit of detection (LOD) and limit of quantification (LOQ) and method 
validation, including recovery, accuracy and precision has been previously published (Du Toit et al. 2017; 
Du Toit and Swart 2018; DHEA data reported in chapter 6). The cell model assay was performed in 
triplicate and representative of a single experiment, while plasma aliquots represent patient specific 
steroid profiling. Statistics were calculated by an unpaired t-test using GraphPad Prism (version 5) 
software (GraphPad Software, San Diego, California). Differences were considered statistically significant 
at P<0.05. 
4.3 Results 
In vitro sulfation of C19 and C11-oxy C19 steroids was investigated in LNCaP cells which express SULT2B1b 
endogenously. This is a well-established PCa cell model, in which conjugation of C19 steroids by 
glucuronidation was also investigated and described (Chapter 3). LNCaP cells, therefore, represent a cell 
model system capable of adding a sulfate or glucuronide to the steroid backbone structure with 
appropriate hydroxy moieties. Our laboratory does not currently hold a cell model in which steroids are 
only sulfated without glucuronidation, while in-laboratory steroid extraction protocols do not retain 
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water soluble conjugates. Dual deconjugating protocols, carried out prior to extraction and UPC2-MS/MS 
quantification, were therefore developed with the aim of distinguishing conjugation by sulfation from 
conjugation by glucuronidation. 
In order to analyse conjugation by glucuronidation, β-glucuronidase was used to deconjugate samples 
(B; section 4.2.3). In order to analyse conjugation by sulfation, sulfatase was used to deconjugate 
sulfated steroids (C; section 4.2.3). The latter enzyme, also has dual enzyme activity as this enzyme 
deconjugates glucuronidated and sulfated steroids, in a 3:1 ratio. Utilizing both deconjugating systems, 
the amount of steroid sulfates were calculated as follows: steroid sulfates = C - B (Table 4.1). 
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Table 4.1 Deconjugating enzymes employed in the analysis of conjugated metabolites in LNCaP cells and in plasma 
samples. R1 = OH; R2 = O or OH; R3 = H, O or OH1. 
A B C 
0.5 mL aliquot 
Untreated 
Unconjugated steroids 
extracted 
0.5 mL aliquot 
β-glucuronidase treated 
Unconjugated + glucuronidated 
steroids extracted 
0.5 mL aliquot 
Sulfatase treated 
Unconjugated + glucuronidated + 
sulfated steroids extracted 
   
 
  
  
 
                                                          
1Sulfation and glucuronidation is also possible at C3, if R2=OH. 
O
CH3
CH3
H H
H
H
OH
O
R1
R2
R3 O
CH3
CH3
H H
H
H
OH
O
R1
R2
R3 O
CH3
CH3
H H
H
H
OH
O
R1
R2
R3
R2
R3
OH
O
OH
OH
OH
O
CH3
CH3
H H
H
H
O
O
O
R2
3
R2
R3
OH
O
OH
OH
OH
O
CH3
CH3
H H
H
H
O
O
O
R2
3
R2
R3
OH
OO
S
O
CH3
CH3
H H
H
H
O
O2
Stellenbosch University  https://scholar.sun.ac.za
109 
 
4.3.1 Analyses of β-glucuronidase and sulfatase control reactions 
Control reactions were conducted in parallel when in vitro and in vivo aliquots were deconjugated to 
determine the hydrolysis activity of β-glucuronidase and sulfatase. The complete hydrolysis of 
glucuronidated steroids by β-glucuronidase was monitored by deconjugating DHT-G (Fig. 4.3a). DHT-G 
was fully hydrolysed to DHT by β-glucuronidase, while DHEA-S was not desulfated following the same 
protocol (Fig. 4.3b). DHEA-S and DHT-G were used as controls, to analyse the dual hydrolysis activity of 
sulfatase. Sulfatase fully hydrolysed DHEA-S and DHT-G to DHEA and DHT, respectively (Fig.4.3c and d). 
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Figure 4.3 Control reactions determining the hydrolysis activity of β-glucuronidase and sulfatase. (a) Untreated 
DHT (1 µM) extracted from media and DHT recovery from DHT-G (1 µM) after 24 hrs incubation with  
β-glucuronidase; (b) UPC2-MS/MS chromatogram of DHEA (1 µM) (black chromatogram), with no DHEA peak 
detected after 24 hrs incubation of DHEA-S (1 µM) with β-glucuronidase (grey chromatogram); (c) untreated DHEA 
(1 µM) extracted from media and DHEA recovery from DHEA-S (1 µM) after 3 hrs incubation with sulfatase; and 
(d) untreated DHT (1 µM) extracted from media and DHT recovery from DHT-G (1 µM) after 3 hrs incubation with 
sulfatase. Experiments were performed in triplicate, analysed by UPC2-MS/MS and the results expressed as the 
mean ± STD DEV (n=3 for a and b; n=4 for c and d; ns, not significant). 
4.3.2 Analyses of steroid conjugation in LNCaP cells 
Conjugation of T- and DHT-metabolites in LNCaP cells 
The conjugation of T- and DHT-metabolites in LNCaP cells, would involve only the C17 β-hydroxy group 
of these steroids. Analysis of T levels (Fig. 4.4a) shows a rapid decrease in the free unconjugated steroid 
levels at 12 hrs, with negligible unconjugated T remaining at 24 and 48 hrs. T was predominantly in the 
glucuronide form after 12 hrs, with no sulfation of T being detected. In contrast to T, 11KT was not 
glucuronidated as efficiently as T (Fig. 4.4b), with 11KT predominantly present in its free, unconjugated 
form at 12, 24 and 48 hrs, corroborating our previous findings (Du Toit et al. 2017; Du Toit and Swart 
2018). Although 11KT-glucuronide (11KT-G) levels were detected, this steroid was not sulfated. Analysis 
of 11OHT levels (Fig. 4.4c) showed that this steroid was predominantly present in its free, unconjugated 
form at 12 and 24 hrs, however, at 48 hrs 11OHT-glucuronide (11OHT-G) formation was higher compared 
to free, unconjugated 11OHT levels. In addition, while 11OHT-sulfate (11OHT-S) formation was not 
detected at 12 and 24 hrs, at 48 hrs 11OHT appeared to be sulfated at 48 hrs, however, the difference 
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between 11OHT-G and 11OHT-S levels was not significant. The low 11OHT-G levels, together with 
negligible free steroid is indicative of substrate conversion to 11KT, 11OHDHT and 11KDHT.  
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Figure 4.4 Steroid (1 µM) conjugation in LNCaP cells after 12, 24 and 48 hrs. (a) T; (b) 11KT; (c) 11OHT; (d) DHT; (e) 11KDHT; and (f) 11OHDHT. Solid line, 
unconjugated steroid (A); black dashed line, glucuronidated steroid (B); grey solid line, glucuronidated + sulfated steroid (C). Experiments were performed 
in triplicate, analysed by UPC2-MS/MS and the results expressed as the mean ± STD DEV (n=3). 
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Analysis of DHT (Fig. 4.4d) also shows a rapid decrease in unconjugated steroid levels after 24 hrs, similar 
to T, and DHT was also predominantly glucuronidated after 24 and 48 hrs. Data shows that DHT is 
sulfated, with the difference between glucuronide and sulfated DHT levels being 2.9-fold (p=0.0998) at  
12 hrs, 1.4-fold at 24 hrs and 1.1-fold at 48 hrs. In contrast to DHT, conjugation of 11KDHT (Fig. 4.4e) and 
11OHDHT (Fig. 4.4f) was negligible with glucuronidated and sulfated levels below 0.1 µM at 48 hrs. These 
steroids were predominantly in the free, unconjugated form throughout the assay period with 11KDHT 
remaining at 0.06 µM and 11ODHT at 0.2 µM, indicating conversion to downstream products. 
Percentage conjugated T- and DHT-metabolites 
In the analysis of the C19 steroids and the C11-oxy C19 steroids, conjugated T levels, when compared to 
those of 11KT and 11OHT, were significant throughout the assay period. 11KT and 11OHT conjugated 
levels remained <40% (Fig. 4.5a) with T and 11KT in the conjugated form remaining constant, ~80% and 
~30%, respectively. In contrast, the % 11OHT in the conjugated form significantly increased, 6-fold, after 
12 hrs to ~30% at 48 hrs. Comparing the conjugation of the 5α-reduced metabolites (Fig. 4.5b), at 12 hrs, 
their levels were not significantly different, however, after 24 hrs, conjugated DHT levels were increased, 
~1.9-fold, with the conjugated form of DHT being significantly higher when compared to those of 11KDHT 
and 11OHDHT. 11KDHT and 11OHDHT conjugation levels, however, remained <30%, with the conjugated 
derivatives of 11KDHT significantly decreasing after 12 hrs. 
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Figure 4.5 Steroid conjugation in LNCaP cells. Steroid (1 µM) conversion analysed after 12, 24 and 48 hrs.  
(a) % T-metabolites conjugated (glucuronidated + sulfated) and (b) % DHT-metabolites conjugated 
(glucuronidated + sulfated). Experiments were performed in triplicate, analysed by UPC2-MS/MS and the results 
expressed as the mean ± STD DEV (n=3; ns, not significant; *P<0.05, **P<0.005, ***P<0.001). 
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Percentage conjugated 3α-reduced metabolites 
The 3α-reduced C19 metabolites, AST and 3αDIOL, and the C11-oxy C19 metabolites, 11OHAST, 11KAST 
and 11K-3αDIOL, possess a C3α-hydroxy group, which presents these steroids as potentially substrates 
for glucuronidation and sulfation by enzymes endogenously expressed in LNCaP cells. In addition, only 
3αDIOL and 11K-3αDIOL also possess a C17α-hydroxy group. Conjugated levels of 3αDIOL, which has a 
C3- and C17-hydroxy group, were significantly higher than the conjugated levels of AST (Fig. 4.6), which 
only has a C3-hydroxy group. Glucuronidated 3αDIOL levels were significantly higher than the levels of 
free, unconjugated 3αDIOL at 12 hrs (Fig. 4.6 insert). Conjugated 11OHAST and 11KAST levels (~20%) 
were also higher than those of conjugated AST levels, although not significantly so. While unconjugated 
11K-3αDIOL levels were similar to those of 3αDIOL, they were also higher than the conjugated C11-oxy 
AST metabolites. 
 
Figure 4.6 Percentage (%) conjugated (glucuronidated and sulfated) steroids. Steroid (1 µM) conversion in LNCaP 
cells was analysed after 12 hrs. Insert, unconjugated (A) and total, unconjugated + glucuronidated, (B) 3αDIOL 
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levels. Experiments were performed in triplicate, analysed by UPC2-MS/MS and the results expressed as the mean 
± STD DEV (n=3; *P<0.05; **P<0.005). 
DHEA and 11OHA4 assays in LNCaP cells 
Since the sulfation of ketosteroids have recently been described (Hashiguchi et al. 2017), the sulfation 
of A4 and 11OHA4 was also investigated. In the analysis of downstream metabolites, only A4 was 
produced when the metabolism of DHEA was assayed in LNCaP cells (Fig. 4.7a). DHEA was not 
glucuronidated, nor sulfated (data not shown), and after 24 and 48 hrs, free, unconjugated levels were  
~0.65 µM. Since only A4 levels were detected, this suggests DHEA was converted to androstenediol in 
by 17βHSDs LNCaP cells (Fig. 4.1), this steroid was, however, not quantified. Unconjugated levels of A4 
were similar to the total steroid (unconjugated + glucuronidated) levels, ~0.02 µM, indicating that A4 
was not glucuronidated. A4 was, however, significantly sulfated after 12 and 24 hrs, 2.81-fold (Fig. 4.7b) 
although levels remained low (<0.05 µM). We were unable to determine whether SULTs acted on the C3 
or C17 keto-groups on the steroid backbone of A4, while A4 was also not directly assayed. Interestingly, 
when 11OHA4 was assayed, neither glucuronides nor sulfates of 11OHA4 were detected after 12 hrs 
(Fig. 4.7c). 11OHA4 was, however, metabolized to downstream products with only ~0.4 µM remaining, 
present in the free, unconjugated form only.  
Stellenbosch University  https://scholar.sun.ac.za
117 
 
 
 
D
H
E
A A
4
A
nd
ro
st
en
ed
io
l T
D
IO
N
E

5
D
H
T
0.00
0.02
0.04
0.06
0.08
0.10
0.2
0.4
0.6
0.8
1.0
12 hrs
24 hrs
NA

M
 s
te
ro
id
12 hrs 24 hrs
0.00
0.01
0.02
0.03
0.04
0.05
0.2
0.4
0.6
0.8
1.0 A
B
C
***
***

M
 A
4
a 
b 
Stellenbosch University  https://scholar.sun.ac.za
118 
 
 
Figure 4.7 - Steroid (1 µM) metabolism in LNCaP cells. (a) Conversion of DHEA and (b) conversion of DHEA to A4 
in LNCaP cells after 12 and 24 hrs; and (c) conversion of 11OHA4 in LNCaP cells after 12 hrs. A, unconjugated 
steroid; B, unconjugated + glucuronidated; C, unconjugated + glucuronidated + sulfated. Experiments were 
performed in triplicate, analysed by UPC2-MS/MS and the results expressed as the mean ± STD DEV  
(n=3; ns, not significant; ***P<0.001; NA, not analysed). 
4.3.3 Analyses of steroid sulfates in circulation 
4.3.3.1 Male plasma samples 
As the sulfation of C11-oxy C19 steroids in vivo has, to date, not been determined, these steroids together 
with the C19 steroid sulfates were analysed and compared in a healthy male subject and in a patient 
diagnosed with PCa. In the healthy subject, 11KDHT (59.5 nM) and 11KAST (153.6 nM) sulfates were 
predominant (Fig. 4.8), while 38.3 nM 3αDIOL-sulfate (3αDIOL-S) was detected, together with low levels 
of DHT-S (5.8 nM), AST-S (6.5 nM) and 11OHAST-S (3.0 nM). In the PCa plasma, the 3α-reduced 
metabolites were the most abundant sulfated derivatives, 11OHAST (33.8 nM), 11KAST (222.9 nM) and 
AST (21.8 nM), while DHT-S (2.9 nM), 3αDIOL-S (11.4 nM) and 11KDHT-S (8.0 nM) levels were low. 
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Comparing the healthy subject and the PCa patient, DHT-S levels were similar, while AST, 11OHAST and 
11KAST sulfate levels were higher and 3αDIOL-S and 11KDHT-S levels were lower, 3.4-fold and 7.4-fold, 
respectively, in the PCa patient. Results show that steroids possessing either a C3 α-hydroxy group or a 
C17 β-hydroxy group were sulfated, and present in circulation as sulfate derivatives. Circulatory sulfates 
of the T-metabolites, 11K-3αDIOL and 11OHDHT were not detected. 
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Figure 4.8 UPC2-MS/MS analyses of circulatory steroid sulfates. Clear bars, healthy male subject; shaded bars, PCa 
patient. Insert, contribution (%) of sulfated steroids to each profile (11KAST-S, 11KAST-sulfate;  
11OHAST-S, 11OHAST-sulfate). 
4.3.3.2 Female plasma sample 
Profile analyses of conjugated steroid metabolites in circulation showed both glucuronidated and 
sulfated derivatives to be present (Fig. 4.9). Of the C19 steroids, only AST and 3αDIOL were conjugated. 
Unconjugated AST was not detected, while AST-glucuronide (AST-G) and AST-S were detected at 49 nM 
and 24.9 nM, respectively. Unconjugated 3αDIOL was negligible detected at ~1.8 nM (below LOQ), with 
3αDIOL-glucuronide and 3αDIOL-S detected at 33.8 nM and 19.5 nM, respectively, and analysis was 
unable to distinguish between conjugation at C3 and C17 or whether at both. DHT levels and T levels  
(< 1.5 nM) were negligible, as were their conjugated derivatives. Analysis of the C11-oxy C19 steroids 
showed 11OHT and 11KT and their conjugated derivatives also below 1 nM, while free 11KDHT, 11OHAST 
and 11KAST were not detected. As in the case of the C19 steroids, the conjugate levels of the C11-hydroxy 
3α-reduced metabolites were high -11OHAST-glucuronide and 11OHAST-S at 51.8 nM and 25.8 nM, 
respectively, and 11KAST-S was detected at 17.3 nM. 11KAST-G was below the LOQ (~4.6 nM). 
Interestingly, only 11KDHT-glucuronide was detected, ~2.6 nM (below LOQ), while 11KDHT-S levels were 
negligible (~0.2 nM). Although these levels were below the LOQ, the data show that 11KDHT conjugate 
levels are higher than DHT levels. The data also suggests that, in circulation, steroids with C3 α-hydroxy 
groups are predominantly sulfated, while the C17-hydroxy group of 3αDIOL may also be potentially 
sulfated. Circulatory sulfates of 11K-3αDIOL and 11OHDHT were not detected. 
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Figure 4.9 UPC2-MS/MS analysis of circulatory healthy female C19 and C11-oxy C19 steroid levels. Clear bars, 
unconjugated steroids (A); light grey bars, unconjugated + glucuronidated steroids (B); dark grey steroids, 
unconjugated + glucuronidated + sulfated steroids (C). ND, not detected. 
4.4 Discussion 
While C19 steroid conjugates have been detected in circulation, evidence of adrenal and peripheral 
glucuronidation and sulfation pathways, the conjugation of the C11-oxy C19 steroids have not been 
widely reported. Here, we show that the conjugation of the C11-oxy C19 steroids are inefficient compared 
to the C19 steroids in vitro, and the analysis shows, for the first time, the presence of C11-oxy C19 sulfates 
in circulation, in both males and females. 
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Of all the C17 α-hydroxy steroid substrates assayed, SULT2B1b appeared to sulfate DHT (Fig. 4.4d), which 
may be ascribed to the reported increased expression of SULT2B1b in the presence of DHT detected in 
LNCaP cells. DHT, at 1 and 10 nM, increased the expression of SULT2B1b at the mRNA and protein level, 
while DHEA and T had no effect on the expression levels of SULT2B1b. This suggests that SULT2B1b is AR 
mediated –once the AR binds DHT, transcriptional induction of SULT2B1b proceeds  
(He and Falany 2007), or at least that the AR is involved in the regulation of SULT2B1b, and that the 
increased expression of this enzyme occurs as a possible feedback mechanism to limit the physiological 
downstream effect of DHT. LNCaP cells expresses a mutated AR (Veldscholte et al. 1990), which suggests 
this mutant is involved in this mechanism. However, while 11KDHT has been shown to bind and 
transactivate the AR and induce AR regulated gene expression in LNCaP cells (Pretorius et al. 2016), 
neither 11KDHT nor 11OHDHT were sulfated (Fig. 4.4e and f). In addition to the expression of SULT2B1b 
in LNCaP cells, STS has also been reported to be expressed in LNCaP cells (Day et al. 2009), and while this 
activity was not assayed in the analyses presented in this chapter, potential STS activity towards 11KDHT 
may catalyse the steroid’s deconjugation and explain the decreased 11KDHT conjugate levels observed 
during our assay period (Fig. 4.5), and while endogenous β-glucuronidase activity cannot be ruled out, 
this activity has not been shown in LNCaP cells. 
Furthermore, T, 11KT and 11OHT were not significantly sulfated in LNCaP cells (Fig. 4.4), and sulfate 
derivatives of these steroids were low in circulation (Fig. 4.9). Moreover, the in vitro data show that the 
C11-hydroxy and C11-keto metabolites behave similarly (Fig.4.4) –11KT and 11KDHT were 
predominantly present in the unconjugated form during the assay period, showing negligible 
conjugation by sulfation, and while glucuronide derivatives of these steroids were detected, these levels 
were <40% for 11KT and even lower for 11KDHT (<20%). Although 11OHDHT was not conjugated, this 
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steroid was metabolized to downstream metabolites, as negligible unconjugated steroid levels were 
detected at the end of the assay period. Similarly, 11OHT was also metabolized to downstream 
metabolites denoted by the decrease in unconjugated steroid level detected, however, at the end of the 
assay period conjugated levels of 11OHT was detected. In both cases it is possible that 11βHSD2 
converted 11OHDHT and 11OHT to 11KDHT and 11KT, respectively, thus contributing to the pool of 
active androgens. 
The data presented in this chapter show that the active C11-oxy C19 steroids are not conjugated as 
efficiently as the C19 steroids (Fig. 4.5), which strongly suggests that the presence of the C11-hydroxy or 
C11-keto moiety interferes with the binding of the steroid to the conjugating enzymes, thereby allowing 
the persistence of these steroids in their active forms, especially 11KT and 11KDHT. In this regard, 
structural modelling of the steroid and the enzyme could potentially contribute to our understanding of 
the manner in which binding is impeded, thus modulating activity towards specific substrates. Clearly, 
both 11KT and 11KDHT are less efficiently conjugated than T and DHT, respectively, thus remaining in 
the free form while 11OHT and 11OHDHT are metabolized efficiently in the 11OHA4-pathway, further 
contributing to the androgen pool in LNCaP cells. The 3α-reduced C11-oxy steroid conjugate levels were 
similar to the 3α-reduced C19 steroid conjugate levels, however, 3αDIOL was significantly conjugated 
compared to AST (Fig. 4.6). In addition, while conjugated 11K-3αDIOL was also higher than conjugated 
C11-oxy AST metabolites, these data suggest that conjugation is favoured at C17. LNCaP cells express 
high levels of UGT enzymes (Guillemette et al. 1995; Lévesque et al. 2001) which are capable of 
conjugating at C3 and C17 of 3αDIOL, compared to AST which only possesses a C3-hydroxy group. 
Although the results discussed above serve to demonstrate conjugation in LNCaP cells, our data is based 
on a single experiment, and while the results corroborate our previous findings relating to 
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glucuronidation, additional in vitro investigations are required to establish the sulfation of the C11-oxy 
C19 steroids. 
We have reported that 11KDHT is inefficiently glucuronidated in PCa patients compared to a healthy 
subject (Du Toit and Swart 2018), and here we report that circulating 11KDHT levels indicate that the 
steroid was inefficiently sulfated in vivo, as shown in the PCa patient compared to a healthy subject  
(Fig. 4.8). This result suggests that defective SULT activities, leading to increased active steroids in 
circulation, may contribute to the progression of PCa. As decreased 3αDIOL-S levels were also detected 
in the plasma of the PCa patient, supporting altered sulfation of the C19 steroids in PCa. It is worth 
mentioning that adrenal and hepatic SULTs contribute to steroid sulfates in circulation, with SULT2A1 
being expressed in the adrenals and the liver (Javitt et al. 2001; Riches et al. 2009). SULT2A1 adds a 
sulfate group to the oxygen moiety at C3 (α- and β-hydroxy groups) of steroids, in addition to the 
 C17-hydroxy group of T (Falany et al. 1989), which suggests that the adrenal and liver are predominantly 
contributing to the steroid sulfate levels detected in the plasma samples. Sulfate derivatives of  
AST-metabolites were, however, increased in the plasma of the PCa patient compared to the healthy 
subject (Fig. 4.8), suggesting the possible upregulation of 3αHSD enzymes in PCa patients, increasing 
AST, 11OHAST and 11KAST levels, which in turn provided more substrates for prostatic and hepatic 
SULTs. Furthermore, the DHT-S levels detected in the male plasma samples falls below the range of  
50-100 nM reported for circulatory DHT-S (Mueller et al. 2015). In both samples 11KAST was higher than 
11OHA4, indicating 11βHSD2 conversions and thus a contribution to 11KAST levels would also feed back 
to 11KDHT together with 11K-3αDIOL which was not quantitated due to lack of a reference standard. 
In contrast, in the female circulatory steroid profile, although 11KDHT was glucuronidated no 11KDHT-S 
was detected and 11OHAST-S levels were comparable to AST and 3αDIOL, while 11KAST was far lower. 
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DHT levels were negligible, and comparable to the low levels reported for DHT in premenopausal females 
(0.08-1.3 nM) (Mueller et al. 2015), with comparable AST-S, 11OHAST-S, 11KAST-S, and 3αDIOL-S,  
~22 nM, being efficiently sulfated (Fig. 4.9). In females, the adrenals will contribute 11OHA4 to the 
circulation, however, its downstream metabolism would be catalysed by steroidogenic enzymes 
expressed in breast tissue, the ovaries and the uterus (Miller and Auchus 2011). Once 11OHAST and 
11KAST is released into circulation, hepatic SULTs would sulfate these metabolites, while the kidneys 
may also be involved. Interestingly, the C19 steroid sulfate levels were similar to the C11-oxy C19 steroid 
sulfate levels, although 11KAST-G and 11KAST-S levels were lower than AST conjugates. 
In the current study we also reported on the sulfation of A4 by SULT2B1b expressed in LNCaP cells, and 
showed that 11OHA4 was not sulfated (Fig. 4.7). Hashiguchi et al. (2017), also reported on the sulfation 
of these two ketosteroids, however, the authors showed SULT2A1 activity towards A4, while this isoform 
did not sulfate 11OHA4. Although the data shows that the ketosteroids are very poor substrates as 
indicated by substrate turnover (Hashiguchi et al. 2017), the data still permits one to suggest that the 
presence of the C11-hydroxy group may interfere with the binding of the ketosteroid to SULTs and thus 
the sulfation at C3 and C17 does not occur, with sulfation at C11 unlikely. In the CRPC scenario, both A4 
and 11OHA4 are major adrenal steroids which are converted to active androgens in the prostate. The 
inability of SULTs to sulfate 11OHA4, suggests this steroid is more readily available in its unconjugated 
form and able to contribute to downstream products in the 11OHA4-pathway, compared to A4. Sulfate 
derivatives of ketosteroids could not be identified in our in vivo analysis and further in vivo investigations 
are therefore needed to establish data regarding the sulfation of ketosteroids. It is worth mentioning 
that although 11OHA4, 11KA4 and 11OHAST have been detected in neonatal and adult urine samples, 
the samples had to undergo deconjugation with β-glucuronidase and sulfatase before these metabolites 
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could be extracted and quantified (Homma et al. 2003; Dhayat et al. 2015) –suggesting that these  
C11-oxy C19 steroids are biotransformed by glucuronidation and sulfation in the human body. 
Similarly to sulfation pathways, desulfation is an active pathway in the prostate, but in contrast, 
desulfation utilizes circulating DHEA-S. DHEA-S is transported into the cell by organic anion transporter 
proteins (OATPs), desulfated by STS, and then metabolized to downstream androgens such as T and DHT 
(Mueller et al. 2015). In our LNCaP cell model, however, DHEA-S was not significantly converted to 
downstream metabolites after 12 and 24 hrs, as negligible DHEA, A4, T and DHT were detected (data not 
shown). OATPs expression has been reported to be increased in CRPC (Wright et al. 2011) and androgen 
deprived LNCaP cells showed elevated OATP1A2 expression and increased cell proliferation in the 
presence of DHEA-S (0.05, 0.5 and 5 µM for 7 days) (Arakawa et al. 2012) -it is interesting that in our 
hands 1 µM DHEA-S was not metabolised, suggesting either that OATPs did not transport DHEA-S into 
the cells or the STS catalysed reaction requires more time. When DHEA (1 µM) was assayed in LNCaP 
cells, negligible downstream metabolites were produced after 12 and 24 hrs (only ~0.02 µM A4 was 
detected, Fig. 4.7a). Androstenediol was, however, not quantified in the analysis, which may account for 
the DHEA levels, ~0.65 µM, recovered after 12 and 24 hrs.  It has been reported that LNCaP cells should 
be co-cultured with prostate stromal cells for DHEA to have downstream effects  
(Arnold et al. 2008; Mizokami et al. 2009), and as such may explain why DHEA was not metabolized more 
efficiently. 
4.5 Summary 
This preliminary investigation into the sulfation of C11-oxy C19 steroids reports that although  
C11-oxy C19 steroid sulfates were identified in plasma, these steroids were not sulfated in our in vitro 
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assays. In the LNCaP cells, the C11-oxy steroids were not sulfated, which suggests that the adrenal and 
hepatic SULTs contribute to steroid sulfates in circulation. Only when DHT was assayed were sulfate 
levels produced in our enzymatic conversion assays, while 11KDHT was not sulfated. In the PCa patient, 
circulatory 11KDHT-S levels were present at lower levels compared to the healthy subject, while DHT-S 
levels were negligible. Furthermore, DHT was significantly conjugated compared to 11KDHT in LNCaP 
cells, thereby underscoring the importance of 11KDHT in PCa. Adrenal 11OHA4 contributes to the 
androgen pool in peripheral target issue, more so than A4, especially relevant in the ADT treatment by 
castration in PCa patients. Further investigations into adrenal sulfation may provide in vivo evidence of 
ketosteroid sulfation. Our in vivo results show that adrenal, hepatic and prostatic sulfation may be 
involved in the sulfation at C17 and/or C3 with a α-hydroxyl moiety, and while it has been reported that 
SULTs prefer substrates with the C3 β-hydroxy orientation, the sulfation of 11OH-epiAST, 11K-epiAST 
and 11K-3βDIOL, still needs to be determined, in addition to the presence of these 3β-reduced 
metabolites in circulation.  
Our current analysis reports the impeded conjugation of the C11-oxy C19 steroids resulting in inefficient 
inactivation of these C11-oxy steroids, once again highlighting the contribution of these androgens to 
the androgen pool, with anticipated adverse downstream effects in steroid-dependent diseases. 
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Chapter 5 
An investigation into the metabolism of 11OHA4 and 11OHT and their metabolites in benign prostatic 
hyperplasia 
5.1 Introduction 
In normal prostate growth and development, the biosynthesis of DHT, from its gonadal precursor T, 
catalysed by SRD5A is vital. DHT is termed a ‘potent’ androgen, as it binds the AR, translocates into the 
nucleus and subsequently elicits its physiological effects. Consequently, the production of DHT is also 
considered the main driving force in the development of prostate diseases, cancers and benign tumours, 
such as BPH. BPH is characterized by lower urinary tract symptoms, such as obstruction of the urinary 
bladder, due to stromal and epithelial cellular growth, which subsequently enlarges the prostate 
(Penning 2010; Kahokehr and Gilling 2014). The hormonal contribution in the development of BPH has 
been widely reported (Siiteri and Wilson 1970; Marcelli and Cunningham 1999; Carson and Rittmaster 
2003; Andriole et al. 2004), and has resulted in clinical treatments progressing to include SRD5A 
inhibitors (Roehrborn et al. 2010; Kahokehr and Gilling 2014). SRD5A inhibitors would block the 
production of DHT from T in the classic pathway and, indirectly, from A4 via 5αDIONE in the alternative 
pathway (Fig. 5.1). Both T and A4 are produced de novo in testicular Leydig cells, however, the adrenal 
also produces androgen precursors, including T (low levels), A4 and 11OHA4 (Schloms et al. 2012; Rege 
et al. 2013) (Fig. 5.1), with 11OHA4 being implicated in the development of CRPC (Swart et al. 2013; Du 
Toit et al. 2017; Du Toit and Swart 2018) and in clinical conditions (Turcu et al. 2016; O’Reilly et al. 2017). 
The 11OHA4-pathway yields 11KT and 11KDHT (Fig. 5.1) –androgens capable of binding and activating 
the AR, and of induces AR dependent gene expression (Rege et al. 2013; Storbeck et al. 2013;  
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Pretorius et al. 2016). In the case of these C11-oxy androgens, SRD5A inhibitors would shunt steroids 
away from 11KDHT, but towards the production of 11KT –an AR agonist, which is inefficiently conjugated 
in vivo and in vitro (Du Toit et al. 2017; Du Toit and Swart 2018). In this setting, the 17βHSDs and 11βHSD2 
are role players, regulating 11KT levels arising from adrenal 11OHA4 (Fig. 5.1). Of note, the adrenal also 
produces 11KT, although minimal, together with 11KA4 and 11OHT (Rege et al. 2013), also dependent 
on the expression of CYP11B1 and CYP11B2, as these enzyme catalyse the production of 11OHA4 from 
A4 (Fig. 5.1) and 11OHT from T (Swart et al. 2013). 11KT can, therefore, originate in the adrenals and in 
peripheral tissue given the necessary enzyme machinery is expressed, while no reports, to date, on the 
production of 11KT or 11KDHT in the testis has been shown. 
 
Figure 5.1 Steroidogenic pathways leading to the production and inactivation of potent androgens DHT, 11KT and 
11KDHT (boxed steroids). 
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In the prostate, the conversion of 11OHA4, 11OHT, 11KA4 and 11KT by SRD5A1 and SRD5A2 are 
irreversible. 11OHA4, 11OH-5αDIONE and 11OHAST are not substrates for the 17βHSDs, while 11OHT, 
11OHDHT, 11KT, 11KDHT and 11K-3αDIOL are substrates for 17βHSD2, and 11KA4, 11K-5αDIONE and 
11KAST for 17βHSD3 and AKR1C3. While the conversion of 11OHA4, 11OHT, 11OH-5αDIONE, 11OHDHT 
and 11OHAST by 11βHSD2 is irreversible, only the presence of 11βHSD1 in the prostate would reverse 
this reaction (Bloem et al. 2013; Storbeck et al. 2013; Swart et al. 2013). The reversible inactivation of 
steroids by 3αHSD are dependent on the presence of a keto moiety at C3. Both C19 steroids, DHT and 
5αDIONE and C11-oxy C19 steroids, 11KDHT, 11OH-5αDIONE and 11K-5αDIONE are substrates for 3αHSD, 
with their respective 3α-reduced products presented as substrates for the reverse reaction catalysed by 
RL-HSD (Fig. 5.1). These conversions have been reported for the C19 steroids, however, for the C11-oxy 
C19 steroids, only the inactivation of 11KDHT and reactivation from 11K-3αDIOL in prostate cell models 
have been reported (Du Toit and Swart 2018). In addition to inactivation, termination of active androgen 
signalling proceeds with the glucuronidation of hydroxyl moieties by UGTs either at C3 or C17 on the 
steroid backbone structure (McNamara et al. 2013). 
Although the general clinical approach to BPH is symptomatic relief of the disease affecting the patient’s 
quality of life, medical interventions are currently practised (Kahokehr and Gilling 2014), however, for 
these interventions to have the best outcome, steroid metabolism in BPH needs to be fully described, 
with the downstream metabolism of the C11-oxy C19 steroids in BPH not yet, to date, clarified. The 
current study investigated and compared the metabolism of the C11-oxy C19 steroids, 11OHA4, 11OHT, 
11KA4 and 11KT and the metabolism of A4 and T in BPH-1 cells. The inactivation by 3αHSD enzymes and 
the reactivation by RL-HSD enzymes which are both endogenously expressed in BPH-1 cells, were also 
assayed, in so doing generated C19 and C11-oxy C19 steroid profiles of active and inactive androgens. The 
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interconversion of C19 and C11-oxy C19 steroids by 17βHSDs in BPH-1 cells were also investigated and 
analyses of the unconjugated steroids in prostate tissue of BPH patients produced profiles for 
comparative analyses of active and inactive androgens. 
5.2 Materials and methods 
5.2.1 Materials 
Steroids (A4, T and DHT), RPMI-1640 medium, β-Glucuronidase (Type VII-A from E.coli, 
5,292,000 units/g), methyl tert-butyl ether (MTBE) and DCM were purchased from Sigma-Aldrich (St. 
Louis, MO, USA), and all other steroids from Steraloids (Wilton, USA). All deuterated steroids were 
purchased from Cambridge isotopes (Andover, MA, USA). BPH-1 cells were a gift from Prof SW Hayward 
(NorthShore University HealthSystem, Chicago, USA) and HEK293 cells were purchased from ATCC 
(Johannesburg, South Africa). AKR1C3 pcDNA3, and SRD5A1 pCMV7 and SRD5A2 pCMV7 plasmid 
constructs were obtained from Prof J. Adamski (Helmholtz Zentrum München, Institute of Experimental 
Genetics, Neuherberg, Germany) and from Prof DW. Russell (Southwestern Medical Center, University 
of Texas, Dallas, USA), respectively. Leftover human PCa tissue and samples were anonymously selected 
following a study investigating PCa clinical markers (reference no. NO9/11/330; Faculty of Medicine and 
Health Science, Stellenbosch University and Tygerberg Hospital, SA), and stored at -80°C until further 
use. Analytical grade chemicals and tissue culture requirements were supplied by reliable scientific 
houses. 
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5.2.2 Steroid metabolism in BPH-1 cells 
BPH-1 cells were cultured in RPMI-1640 medium supplemented with 10% FBS, 1.5 g NaHCO3/L (pH 7), 
1% penstrep at 37°C, in an atmosphere of 90% humidity and 5% CO2. After 3-4 passages, confluent cells 
were replated into 12-well plates at 1 x 105 cells/mL and following 48 hrs incubation, the medium was 
replaced with 1 mL culture medium containing steroid substrates (1 µM): A4, T, 5αDIONE, DHT, AST, 
3αDIOL, 11OHA4, 11OHT, 11KA4, 11KT, 11KDHT, 11KAST, 11OHAST, 11OHDHT, 11OH-5αDIONE,  
11K-5αDIONE and 11K-3αDIOL. 11OHDHT and 11K-3αDIOL are unavailable commercially, and were 
prepared as previously described (Du Toit and Swart 2018). Briefly, 11OHT (2 µM) was converted to 
11OHDHT in HEK293 cells transfected with SRD5A1/2 and 11KAST (2 µM) was converted to 11K-3αDIOL 
in cells transfected with AKR1C3 (also reported in Chapter 4, section 4.2.2). After 48 hrs, media was 
collected and diluted (1:1) with culture media and added at 1 µM to BPH-1 cells. Duplicate 0.5 mL 
aliquots of T, DHT, AST and 3αDIOL were collected after 48 hrs for analysis of unconjugated (free) 
steroids and total (unconjugated + glucuronidated) steroids following deconjugation with  
β-glucuronidase (Du Toit and Swart 2018).  
5.2.3 Steroid extraction 
Liquid/liquid extractions of steroids (0.5 mL aliquots) were carried out using DCM (10:1) 
(Storbeck et al. 2013; Swart et al. 2013; Du Toit et al. 2017) with D2T (1.5 ng), D9PROG (15 ng), D7A4 
(15 ng) and D711OHA4 (15 ng) added as deuterated internal standards to media aliquots collected from 
assays carried out in BPH-1 cells. Steroids were extracted from transurethral resection of the prostate 
(TURP) tissue samples obtained from treatment-naïve BPH patients, using 5 mL MTBE after addition of 
D2T (1.5 ng), cortisol-D4 (15 ng), D7A4 (15 ng) and D711OHA4 (15 ng) to prostate tissue (100 mg) 
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homogenate (Du Toit et al. 2017; Du Toit and Swart 2018). Extracted steroids were dried and the residue 
dissolved in 0.15 mL 50% methanol in water and stored at -20˚C prior to UPC2-MS/MS analysis.  
 
5.2.4 Separation and quantification of steroid metabolites 
Stock solutions of steroids were dissolved in absolute ethanol (2 mg/mL) and stored at -20°C. Standards 
were prepared as follows: a standard range, 0.00025 – 0.5 ng/µL prepared in deionized water was used 
in the analysis of tissue samples, a standard range, 0.0001 to 1 ng/µL, prepared in RPMI-1640 cell culture 
media was used in the analysis of BPH-1 assays. The prepared steroid standards were extracted using 
the appropriate protocols described above. 
The C19 and C11-oxy C19 steroids were analysed by ACQUITY UPC2®–MS/MS (Waters Corporation, 
Milford, USA), separated using an UPC2® BEH column (3 mm x 100 mm, 1.7 µm particle size) for the A4 
and T metabolites and an UPC2® BEH 2-EP column (3 mm x 100 mm, 1.7 µm particle size) for the C11-oxy 
C19 metabolites, as previously reported (Du Toit et al. 2017; Du Toit and Swart 2018). Modifications to 
the gradient and the UPC2 separation of the C19 and C11-oxy C19 steroids, mass transitions, retention 
times, LOD, LOQ and other relevant data have been previously published (Du Toit and Swart 2018). 
Method validation, including recovery and matrix effect (Du Toit et al. 2017) and accuracy and precision 
(Du Toit and Swart 2018), have been reported. Steroids that were not commercially available were 
quantified by UPC2-MS/MS, following peak integrations, using response factors, previously determined 
by Quanson (2015), and as previously reported (Du Toit and Swart 2018). Data was collected and 
analysed with the MassLynx 4.1 (Waters Corporation) software program. Experiments were performed 
in triplicate, representative of at least duplicate experiments and the results are given as means ±STD 
DEV. Statistics were calculated by an unpaired t-test using GraphPad Prism (version 5) software 
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(GraphPad Software, San Diego, California). Differences were considered statistically significant at 
P<0.05. 
5.3. Results 
5.3.1 Androgen metabolism in BPH-1 cells 
The in vitro metabolism of the C11-oxy C19 steroids was firstly determined in BPH-1 cells. 11OHA4 was 
converted by both 11βHSD2 and SRD5A (Fig. 5.2a) yielding low levels of 11KA4 (0.07 µM), and  
11OH-5αDIONE (0.017 µM), respectively. The downstream 3α-reduced metabolite, 11OHAST, was 
detected at 0.02 µM, which was further metabolised to 11KAST (0.05 µM) by 11βHSD2. Although 
11KDHT and 11K-3αDIOL levels were negligible, the precursor steroid 11KT (0.03 µM), produced in the 
conversion of 11KA4 by the 17βHSDs, was also detected. The profile, however, does indicate that 
11OHA4 was predominantly present in its unchanged form after 48 hrs with all metabolites below 
0.1 µM. Conversely, 11OHT’s conversion to downstream metabolites (Fig. 5.2b) was more efficient 
primarily yielding 11OHA4, 0.48 µM, attributed to the oxidative activity of 17βHSD2 together with 
11βHSD2 yielding 11KT, 0.082 µM. 11OHA4 was subsequently converted to 11OH-5αDIONE (0.01 µM), 
together with 11KA4 (0.013 µM), 11K-5αDIONE (0.015 µM) and 11KAST (0.022 µM), while negligible  
5α-reduction of 11OHT to 11OHDHT was observed. In the conversion of 11KA4 (Fig. 5.2c), the formation 
of 11KT (0.5 µM) indicated reductive 17βHSD activity, together with the SRD5A catalysed reaction 
converting 11KA4 to 11K-5αDIONE, 0.015 µM. The downstream production of 11OHAST (0.025 µM) 
suggests possible 11βHSD1 activity –first the conversion of 11K-5αDIONE to 11KAST (3αHSD activity) 
followed by the production of 11OHAST from 11KAST (11βHSD1 activity). In the conversion of 11KT  
(Fig. 5.2d) to 11KA4 (0.3 µM), the oxidative 17βHSD activity is most efficient, followed by its subsequent 
conversion by SRD5A to produce 11K-5αDIONE (0.03 µM). Negligible levels of 11KDHT  
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(~0.01 µM; below LOQ) were detected, indicative of the conversion of 11K-5αDIONE and/or 11KT by 
reductive 17βHSDs and/or SRD5As, with only the inactive metabolite detected being 11KAST. 
 
Figure 5.2 C11-oxy C19 androgen metabolism in BPH-1 cells. Substrate (1 µM; patterned bars) conversion  
(a) 11OHA4, (b) 11OHT, (c) 11KA4 and (d) 11KT after 48 hrs. Experiments were performed in triplicate, analysed 
by UPC2-MS/MS and the results expressed as the mean ±STD DEV (n=6). 
The metabolic profile of A4 (Fig. 5.3a) showed that A4 was converted to T (0.3 µM) by reductive 17βHSDs 
and to 5αDIONE (0.12 µM) by SRD5As. Similarly, in the conversion of T (Fig. 5.3b), the steroid was 
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predominantly converted to A4 (0.56 µM) by oxidative 17βHSDs, which was subsequently converted to 
5αDIONE (0.13 µM). Low levels of DHT (0.02 µM) were detected, formed from both 5αDIONE  
(17βHSD activity) and T (SRD5A activity). 3αHSD subsequently converted 5αDIONE and DHT to AST and 
3αDIOL (Fig. 5.3a and b), respectively. 
 
Figure 5.3 C19 androgen metabolism in BPH-1 cells. Substrate (1 µM; patterned bars) conversion (a) A4 and (b) T 
after 48 hrs. Experiments were performed in triplicate, analysed by UPC2-MS/MS and the results expressed as the 
mean ±STD DEV (n=6). 
5.3.2 3αHSD and RL-HSD activity in BPH-1 cells 
Prior to the investigation into the 3αHSD and RL-HSD activity in BPH-1 cells, glucuronidation activity was 
determined in these cells. Following conversion assays of C19 steroids, and deconjugation of duplicate 
aliquots, data indicated that the cell model did not exhibit UGT activity (Fig. 5.4). 
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Figure 5.4 Unconjugated and total (unconjugated + glucuronidated) C19 steroid levels in BPH-1 cells. T, DHT, AST 
and 3αDIOL (1 µM) conversion after 48 hrs; clear bars, unconjugated (free) steroids; shaded bars, total steroids. 
Insert; untreated DHT (1 µM) extracted from media and DHT recovery from DHT-G (1 µM) after 24 hrs incubation 
with β-glucuronidase served as the control for this experiment. Experiments were performed in triplicate, 
analysed by UPC2-MS/MS and the results expressed as the mean ± STD DEV  
(n=3 for AST; for all other substrates n=6; ns=not significant). 
Since no glucuronidation activity was detected the BPH-1 cell model, inactivation and reactivation of 
active androgens would play an important role in regulating receptor activity. The metabolism of 
5αDIONE, AST, DHT, 3αDIOL, 11OHAST, 11OH-5αDIONE, 11KAST, 11K-5αDIONE, 11KDHT and  
11K-3αDIOL was subsequently assayed at 1 µM in BPH- cells. Relevant steroids were subsequently 
analysed to assess the 3αHSD inactivation and RL-HSD reactivation and depicted as ratios (Fig. 5.5). 
5αDIONE and DHT were reduced to AST (0.15 µM) and 3αDIOL (0.09 µM) by 3αHSD, respectively, while 
only AST was efficiently converted back to 5αDIONE (0.07 µM) by RL-HSDs. The inactivation and 
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activation of the C19 steroids yielded products in a 2:1 and 7:1 ratio. 3αHSD catalysed the reduction of 
11OH-5αDIONE and 11K-5αDIONE producing 11OHAST (0.1 µM) and 11KAST (0.05 µM), respectively.  
RL-HSD catalysed the conversion of 11OHAST producing 0.03 µM 11OH-5αDIONE, with the conversion 
of 11KAST to 11K-5αDIONE being negligible, resulting in 4:1 and 15:1 ratios, respectively. 11KDHT was 
converted to 11K-3αDIOL (0.024 µM), while the reverse reaction proceeded less efficiently to 11KDHT 
(0.015 µM), resulting in the 2:1 ratio. 
 
Figure 5.5 Ratios of inactive and active androgens catalysed by 3αHSD and RL-HSD in BPH-1 cells. Cells were 
incubated with 5αDIONE, DHT, 11OH-5αDIONE, 11K-5αDIONE and 11KDHT (1 µM) to assess 3αHSD activity and 
with AST, 3αDIOL, 11OHAST, 11KAST and 11K-3αDIOL (1 µM) to assess RL-HSD activity. Bars show product 
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formation catalysed by 3αHSD (white bars) and by RL-HSD (shaded bars) after 48 hrs. Experiments were performed 
in triplicate, steroids were analysed by UPC2-MS/MS and the results expressed as the mean ±STD DEV (n=6). 
5.3.3 The metabolism of 5α-and 3α-reduced C11-oxy C19 steroid metabolites in BPH-1 cells 
The complete steroid profiles of the 5α- and 3α-reduced C11-oxy C19 and C19 steroid metabolites after 
48 hrs are shown in figures 5.6 and 5.7, respectively. The C11-oxy C19 steroid profiles include the products 
of the reductive and oxidative 17βHSDs and 11βHSDs. The metabolism of 11OH-5αDIONE (Fig. 5.6a) 
yielded the 5α-reduced product 11OHAST (0.075 µM), together with the 11βHSD2 product,  
11K-5αDIONE (0.02 µM). The subsequent conversion of 11K-5αDIONE by reductive 17βHSDs is evident 
in the production of 11KDHT (0.04 µM). It should be noted that 11OH-5αDIONE is not a substrate for 
reductive 17βHSDs and the high levels detected at 0.74 µM after the assay period may be due to 
11OHAST being shunted back to the substrate by RL-HSD (Fig. 5.1). The metabolic profile of 11K-5αDIONE 
(Fig. 5.6b), showed the production of 11KDHT (0.12 µM) catalysed by reductive 17βHSDs, with no 
conversion to 11OH-5αDIONE by 11βHSD1 being detected. The downstream 3α-reduced metabolites, 
11K-3αDIOL and 11KAST detected at ~0.044 µM, may be shunted back to 11K-5αDIONE which was 
detected at 0.76 µM after the assay period. 11OHDHT was converted (Fig. 5.6c) to 11OH-5αDIONE (0.49 
µM) efficiently by oxidative 17βHSD as well as to 11KDHT (0.09 µM) by 11βHSD2. 11OHAST (0.09 µM) 
was subsequently produced from 11OH-5αDIONE catalysed by 3αHSDs. Negligible levels of 11KAST,  
11K-5αDIONE and 11K-3αDIOL were also detected, with 11OHDHT, 0.34 µM, detected after the assay 
period. The metabolic profile of 11KDHT (Fig. 5.6d) showed no formation of 11OHDHT by 11βHSD1, while 
oxidative 17βHSD activity efficiently produced 11K-5αDIONE (0.3 µM). 11OH-5αDIONE levels were 
negligible, however, 11OHAST (0.08 µM) and 11KAST (0.03 µM), were detected, suggesting the 
conversion of 11K-5αDIONE to 11KAST, followed by the 11βHSD1 catalysed reaction to 11OHAST. 
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11KDHT levels were detected at 0.59 µM after the assay period, suggesting the shunt via 11K-3αDIOL, 
11KAST and 11K-5αDIONE possibly contributing to these levels (Fig 5.1). The 11βHSD2 catalysed 
conversion of 11OHAST to 11KAST (0.04 µM) was confirmed in the metabolic profile of 11OHAST  
(Fig. 5.6e), and 11OHAST is not a substrate for reductive 17βHSDs. Negligible 11K-5αDIONE (from 11KAST 
by RL-HSD), 11K-3αDIOL (from 11KAST by reductive 17βHSDs) and 11KDHT (from 11K-3αDIOL by RL-HSD) 
were also detected, however, 0.92 µM 11OHAST was detected after the assay period. In the conversion 
of 11KAST (Fig. 5.6f), efficient reductive 17βHSDs produced 11K-3αDIOL (0.3 µM), and the 11βHSD1 
catalysed reaction produced 0.02 µM 11OHAST. 11KAST was detected at high levels (0.73 µM) after the 
assay period, and with 11KDHT (from 11K-3αDIOL by RL-HSD) being detected at 0.01 µM, together with 
the presence of 11K-5αDIONE indicative of a shunt in these metabolites contributing towards 11KAST 
levels. The metabolic profile of 11K-3αDIOL (Fig. 5.6g) showed the production of 0.36 µM 11KAST by 
reductive 17βHSDs, as well as 11KDHT (~0.015 µM) catalysed by RL-HSD. The conversion of 11KAST by 
11βHSD1 produced 0.035 µM 11OHAST, while 0.66 µM 11K-3αDIOL was detected after the assay period. 
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Figure 5.6 C11-oxy C19 androgen metabolism in BPH-1 cells. Substrate (1 µM; patterned bars) conversion  
(a) 11OH-5αDIONE, (b) 11K-5αDIONE, (c) 11OHDHT, (d) 11KDHT, (e) 11OHAST, (f) 11KAST and (g) 11K-3αDIOL after 
48 hrs. Experiments were performed in triplicate, analysed by UPC2-MS/MS and the results expressed as the mean 
±STD DEV (n=6). 
The oxidative and reductive 17βHSD enzymatic activity was subsequently assessed in the conversion of 
the C19 steroid since the 11βHSD enzyme do not compete for these substrates (Fig. 5.1). The metabolic 
profile of DHT (Fig. 5.7a) showed that DHT was efficiently converted to 5αDIONE (0.42 µM) by oxidative 
17βHSDs, as well as to 3αDIOL (0.09 µM) catalysed by 3αHSD. Both products were subsequently 
converted to AST (0.11 µM). A similar profile was observed in the conversion of 5αDIONE (Fig. 5.7b) 
produced AST (0.15 µM) and low levels of DHT (0.05 µM) which were subsequently converted to 3αDIOL 
(0.06 µM), with 0.62 µM 5αDIONE being detected after the assay period. The metabolic profiles of AST 
(Fig. 5.7c) and 3αDIOL (Fig. 5.7 d) showed their efficient interconversion by the 17βHSDs, yielding a 1:1 
ratio, as 0.28 µM 3αDIOL was produced from AST (reductive 17βHSD activity) and 0.3 µM AST was 
produced from 3αDIOL (oxidative 17βHSD activity). Negligible DHT (0.01 µM) was produced when AST 
was assayed, while 0.04 µM 5αDIONE was also produced when 3αDIOL was assayed. 
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Figure 5.7 C19 androgen metabolism in BPH-1 cells. Substrate (1 µM; patterned bars) conversion (a) 5αDIONE,  
(b) DHT, (c) AST and (d) 3αDIOL after 48 hrs. Experiments were performed in triplicate, analysed by UPC2-MS/MS 
and the results expressed as the mean ±STD DEV (n=6). 
5.3.4 C19 and C11-oxy C19 steroid profiles in BPH prostate tissue 
Analyses of the C19 steroid profile in three BPH prostate tissue samples showed only unconjugated A4 
present at detectable levels, ~7.5 ng/g (6, 8 and 8 ng/g), of the total androgens analysed (Fig. 5.8). No 
other C19 steroids were detected above the LOQ. In the analyses of the C11-oxy C19 steroids, only the 
3αHSD inactivated metabolites 11OHAST (18%, 15% and 8% of the total steroids detected) and 11KAST 
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(55%, 35% and 86% of the total steroids detected) were detected at levels above the LOQ, average levels 
detected at ~8.8 ng/g and ~64.8 ng/g, respectively. Although both 11KDHT and DHT were below the 
LOQ, 11KDHT levels (1.5-2.5 ng/g) were, in all cases, higher than DHT levels (<1 ng/g). 
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Figure 5.8 UPC2-MS/MS analysis of unconjugated C19 steroid profiles in TURP tissue samples of BPH patients. Clear 
bars, A, age 69; light grey bars, B, age 55 and dark grey bars, C, age 61. Steroids below the dashed line represent 
steroids detected below the LOQ. ND: not detected. Insert; relative contribution of C19 and C11-oxy C19 steroids 
to the steroid profile for each patient. 
Although 3αDIOL was not detected in the analysis of the tissue samples, 11K-3αDIOL was. However, the 
steroid could not be accurately quantified as it is unavailable commercially. Integration of the ionisation 
signal/peak area of 11K-3αDIOL and that of a deuterated internal standard peak area, enabled the 
analyses of the response generated by 11K-3αDIOL (Fig. 5.9). The data suggests the in vivo inactivation 
of 11KDHT to 11K-3αDIOL, together with 11KAST also being converted to 11K-3αDIOL by reductive 
17βHSDs. 
 
Figure 5.9 UPC2-MS/MS analysis of unconjugated (free) 11KDHT (shaded bars) and 11K-3αDIOL (clear bars) in 
TURP tissue samples of BPH patients. A, patient aged 69; B, patient aged 55 and C, patient aged 61. ND: not 
detected. 
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5.4. Discussion 
This study set out to investigate the metabolism of the C19 and C11-oxy C19 steroids in BPH-1 cells, 
endogenously expressing enzymes resembling a near normal scenario and potentially that of early stage 
PCa development. This is the first study reporting on the presence of the C11-oxy C19 steroids in BPH 
tissue and shows the metabolism of the C11-oxy C19 steroids in BPH-1 cells yielding active androgens –
11KA4 and 11OHT yielded 11KT, while in tissue downstream inactive steroids, 11OHAST and 11KAST, 
were identified.  
The main contributor to the progression of prostate diseases, including benign tumours, is the 
intraprostatic production of the potent steroid, DHT, while the production of potent C11-oxy C19 steroids 
may also impact BPH. This study therefore investigated the metabolism of A4, T, 11OHA4 and 11OHT to 
analyse the production of DHT, 11KT and 11KDHT. Comprehensive profiles enabled the analysis of 
steroid metabolic pathways and end-products, and established steroid levels after a specific period, as 
these would be dependent on enzyme expression. SRD5A1 and 2 mRNA are expressed in BPH tissue 
(Habib et al. 1998; Andriole et al. 2004), together with positive immunostaining for SRD5A1 (Thomas et 
al. 2003) and a moderate signal for SRD5A3 (Godoy et al. 2011). Quantitative gene expression of 
oxidative 17βHSD2, 4, 8 and 10, and reductive 17βHSD3, 7 and AKR1C3 have also been shown in BPH 
tissue (Gianfrilli et al. 2014), while an increase in AKR1C3 mRNA transcript has also been reported in BPH 
epithelial cells compared to normal prostate epithelial cells (Bauman et al. 2006). However, compared 
to PCa, BPH expresses substantially more 17βHSD2, 4 and 8, which are primarily oxidative 17βHSDs 
(Gianfrilli et al. 2014). Interestingly, a 10-fold increase and a 3-fold increase in AKR1C2 and RL-HSD mRNA 
transcripts, respectively, have been shown in BPH stromal cells compared to normal prostate stromal 
cells, however, no RL-HSD activity was detected in BPH epithelial cells (Bauman et al. 2006). 
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Steroidogenic enzyme expression is, on the other hand also modulated depending on the stage of PCa 
progression, as evidenced in the upregulation of SRD5A1 and SRD5A3 and the downregulation of SRD5A2 
in CRPC (Titus et al. 2005; Stanbrough et al. 2006; Montgomery et al. 2008; Thomas et al. 2008; Godoy 
et al. 2011; Azzouni et al. 2012), together with the upregulation of AKR1C3 in PCa  
(Stanbrough et al. 2006; Luu-The et al. 2008; Mitsiades et al. 2012). In CRPC, 3βHSD1 and 3βHSD2 
expression are also increased (Miller and Auchus 2015), while UGT2B15 has also been shown to be 
upregulated (Stanbrough et al. 2006; Mostaghel 2013). 
In the metabolism of A4 and T, conversions catalysed by 17βHSD and 3αHSD, are reversible reactions 
with the profiles generated (Fig. 5.3a and b) showing equal levels of downstream steroid metabolites 
detected, suggesting that the equilibrium was reached at this time interval. Considering the downstream 
metabolites produced, both A4 and T produced the same levels of DHT, 5αDIONE, AST and 3αDIOL, 
however, our collective data suggest their metabolism is dictated by oxidative and reductive 17βHSD 
activity. Low 17βHSD activity towards T has been reported, with 7.3% A4 being produced following a  
16 hr incubation with [3H]T (Hayward et al. 1995). In addition to our data showing a far more efficient 
conversion of T to A4, when AST and 3αDIOL were assayed (Fig. 5.7c and d), these steroids were also 
metabolised efficiently, stabilizing at ~0.33 µM after 48 hrs, with the interconversion by RL-HSD and 
3αHSD yielding comparable DHT and 5αDIONE levels, respectively. Clearly, 17βHSDs are major role 
players in steroid metabolic pathways in BPH-1 cells –regulating potent androgen biosynthesis and 
inactivation of steroids. Furthermore, DHT production is similar, irrespective of whether A4 or T was 
assayed, while 3αDIOL and AST levels were also similar. Interestingly, Hayward et al. (1995) also reported 
the equal downstream production of AST and 3αDIOL from T, yielding 4.6% AST and 4.1% 3αDIOL. 
Although the data show no glucuronidation of the C19 steroids, sulfation of steroid metabolites may 
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contribute to differences in the detected levels, however, in all cases, our analysis of downstream 
metabolites accounts for the substrate addition at 1 µM. 
The steroid profiles determined for the C11-oxy C19 steroids are more complex due to 11βHSD activity 
metabolising these analytes. The adrenals produce, 0.99 nmol/L 11KA4, 0.48 nmol/L 11OHT and  
0.39 nmol/L 11KT, however, 11OHA4 levels were detected at 157 nmol/L, which was ~2-fold greater than 
A4 levels (Rege et al. 2013). Since these steroids also contribute to active androgens, the metabolism of 
11OHA4, 11OHT, 11KA4 and 11KT was assayed in BPH-1 cells to ascertain the production of C11-oxy 
downstream metabolites. Considering the metabolism of 11OHA4 (Fig. 5.2a) –interpreting the profile is 
facilitated due to 11OHA4 not being a substrate for reductive 17βHSD3 and AKR1C3, with only 11βHSD2 
and SRD5A able to convert this adrenal steroid. The conversion of 11OHA4 to 11KA4 by 11βHSD2 led to 
the subsequent production of 11KT (by reductive 17βHSD activity) and negligible 11KDHT, with the data 
suggesting that 11βHSD2 levels are higher than SRD5A levels. The metabolism of 11OHT (Fig. 5.2b) 
yielded high levels of 11OHA4 and 11KT which in turn led to the production of 11KDHT at levels 
comparable to those reached in the metabolism of 11KT (Fig. 5.2d), however, 11KT levels remained high, 
with oxidative 17βHSD activity leading to the production of 11KA4. This data suggests that the expression 
levels of the 17βHSD enzymes are greater than that of 11βHSDs which in turn is greater than the SRD5As. 
Interestingly, although SRD5A activity has been reported in this cell model (Hayward et al. 1995), our 
data showed the enzyme’s catalytic activity towards the C11-oxy C19 steroids to be very low, as the  
C11-oxy C19 top tier steroid metabolites, 11OHA4, 11OHT, 11KA4 and 11KT were not readily reduced 
(Fig. 5.2), and the middle and bottom tier metabolites ranged from ~0.04 µM to negligible. Compared to 
our previously published work, in which 11KDHT was produced, catalysed by SRD5A in VCaP and C4-2B 
cells (Du Toit and Swart 2018), the pre-cancerous BPH-1 cell model, catalysed the production of 11KDHT 
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inefficiently, as this steroid was detected <0.018 µM for all substrates assayed. In contrast to the low 
SRD5A activity detected towards the top tier steroids, oxidative 17βHSD activity, efficiently converted 
11OHT and 11KT to 11OHA4 and 11KA4, respectively (Fig. 5.2), which may be attributed to 17βHSD2, as 
the expression of 17βHSD2 has been reported to be higher in BPH tissue than in prostatic tissue  
(Gianfrilli et al. 2014). It is worth noting that the conversions by 17βHSDs are reversible, and the data 
presented capture steroid levels at the single time interval of 48 hrs. Therefore, although the data show 
that 11OHT and 11OHDHT are more readily oxidised by 17βHSDs compared to 11KT and 11KDHT, the 
steroid products 11OHA4 and 11OH-5αDIONE (formed from 11OHT and 11OHDHT) are not substrates 
for reductive 17βHSDs, and are therefore not converted back to 11OHT and 11OHDHT. The C11 keto 
metabolites are, however, converted in the forward and reverse reactions. 17βHSD3, AKR1C3 and 
17βHSD2 activities (Bauman et al. 2006; Gianfrilli et al. 2014), were confirmed in the reversible 
conversions between 11KA4 and 11KT (Fig. 5.3), with the downstream production of metabolites being 
low. Of note, 11βHSD1 catalyses the conversion of C11-keto metabolites to C11-hydroxy metabolites 
(Swart et al. 2013), with the oxo-reductase activity of this enzyme observed in this cell line (Fig. 5.6). 
Only when 11KAST was directly assayed (Fig. 5.6f), did the 11βHSD1 activity produce 11OHAST. In this 
scenario it might be that 11βHSD1 is able to metabolise other C11-hydroxy metabolites, however, 
competition with steroidogenic enzymes, such as SRD5A, 17βHSD and 3αHSD, minimise the activity of 
11βHSD1. 
Although we have reported on the glucuronidation of the C11-oxy C19 steroids, their inactivation by 
3αHSDs has not been clarified –our group has only reported on the inactivation and reactivation of 
11KDHT in LNCaP, C4-2B and VCaP cells (Du Toit and Swart 2018). Since glucuronidation of C19 steroids 
was not detected in BPH-1 cells, and sulfation questionable, inactivation by 3αHSD and reactivation by 
Stellenbosch University  https://scholar.sun.ac.za
150 
 
RL-HSD would regulate the levels of potent androgens. The analysis of the inactivation and reactivation 
of C11-oxy C19 steroids in BPH-1 cells (Fig. 5.5) showed that 11OH-5αDIONE was more readily reduced 
by 3αHSD, compared to the 11K-5αDIONE, which in turn was also more efficiently reduced by 3αHSD 
than 11KDHT. This suggests the presence of a keto group at C11 hampers inactivation. This is also 
reflected in the 2:1 ratio of 11K-3αDIOL:11KDHT compared to the 7:1 ratio of 3αDIOL:DHT, showing the 
inefficient inactivation of 11KDHT. We previously reported that the presence of a keto moiety at C11 
appears not to affect inactivation by 3αHSD, but rather hampers reactivation in PCa cell models  
(Du Toit and Swart 2018). In the present study, however, the presence of a C11-oxy moiety appeared to 
hamper the reduction of the keto group at C3, while the oxidation of the hydroxyl group at C3 was 
negligible, however, reactivation of 11KDHT was comparable to DHT. Interestingly, 5αDIONE was more 
readily reduced by 3αHSD than DHT, and the reduced product more readily reactivated by RL-HSD than 
that of DHT. This may indicate that a keto moiety at C17 may also influence the catalytic activity of 3αHSD 
and RL-HSD enzymes towards the substrates. Our analyses, furthermore, corroborates reports that  
RL-HSD activity is minimal in BPH epithelial cells, while 3αHSD (AKR1C2) is upregulated (Bauman et al. 
2006). 
Our BPH tissue analysis showed only A4 levels above the LOQ, representing the contribution of gonadal, 
adrenal and de novo biosynthesis to the in vivo levels of this C19 steroid in prostate tissue (Fig. 5.8). The 
presence of A4 suggests that this steroid can be converted downstream to DHT, however, unconjugated 
DHT levels were <0.55 ng/g. The present study detected T at ~0.5 ng/g, within range of previously 
reported levels in untreated BPH tissue, 0.092-2.0 ng/g, with the DHT in the analysis detected at the 
lower limit compared to previously reported levels of 1.0-8.15 ng/g (Van der Sluis et al. 2011). The C19 
steroid levels ranged from 0-7.5 ng/g, however, the C11-oxy C19 steroid levels ranged from  
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0.02-64.8 ng/g. The high levels of inactive 11OHAST and 11KAST detected, indicates that the inactivation 
of the C11-oxy C19 steroids appears to be efficient, with the presence of these steroids in their 
unconjugated forms serving as potential substrates to be reactivated to 11KDHT (as observed in Fig. 5.6e 
and f). Although, we could not accurately quantify 11K-3αDIOL, the presence of this steroid in tissue, 
suggest that 11KDHT is inactivated and/or 11KAST is reduced, verifying the contribution of the  
11OHA4-pathway to androgens in patients with BPH. Interestingly, these steroid profiles depicted in the 
current study are similar to the steroid profile of a CRPC patient that we previously published  
(Du Toit and Swart 2018). This suggest intraprostatic levels of the C11-oxy C19 steroids are similar in BPH 
and CRPC tissue, while the flux through the 11OHA4-pathway is also similar. Only 11OHAST levels were 
marginally higher in the CRPC tissue compared to the levels in BPH tissue, while 11KDHT levels  
(also below LOQ) were lower in the CRPC tissue. And while our previous analyses in prostate tissue of 
PCa patients (Du Toit et al. 2017) did not include the inactivated metabolites, high levels of 11OHA4, 
11KA4, 11KT, 11OHT and 11KDHT were detected. These studies were, however, limited by the small 
sample number. Perhaps, determining circulatory C11-oxy C19 steroids in BPH, PCa and CRPC patients, 
as well as intraprostatic levels, will add to our current understanding of the differences between these 
diseases and the contribution of the C11-oxy steroids to disease conditions. 
In the clinical setting, BPH patients are treated with SRD5A inhibitors as a first line treatment to inhibit 
the production of DHT. From our in vitro analysis, we show that DHT levels are negligible. And while this 
treatment would also inhibit the production of 11KDHT, the production of 11KT will not be decreased. 
In this scenario, the question is whether the progression of BPH to PCa is perhaps due to the use of 
SRD5A inhibitors, which increases the shunt of adrenal C11-oxy C19 steroids in the 11OHA4-pathway, 
subsequently producing the top tier steroids in abundance, and ultimately yielding 11KT. Analysis of 
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steroid conversions in BPH-1 cells in the presence of SRD5A inhibitors would likely, in the future, shed 
light on the flux in the pathways altering the levels of potent steroids. 
5.5 Summary 
Profiling steroids in BPH and at different stages of PCa development is critical to understanding prostate 
steroidogenesis and enzyme activity, which in turn regulate potent androgen levels. Here we show, for 
the first time, the 11OHA4-pathway in BPH-1 cells, and highlight the role of the 17βHSD catalysed 
reactions in this cell model. Furthermore, while the production of DHT and 11KDHT is comparable, 11KT 
was produced in abundance. Inactivation of DHT was, however, more efficient compared to the 
inactivation of 11KDHT –suggesting hampered 3αHSD activity due to the presence of the keto group at 
C11. Our in vivo data further establishes the presence of C11-oxy C19 steroids in prostate tissue –
highlighting the abundantly present downstream metabolites, 11OHAST and 11KAST, as possible role 
players, able to feed back into the pool of potent androgens. The present study underscores the 
contribution of adrenal 11OHA4 to the androgen pool in the BPH scenario –suggesting both gonadal and 
adrenal precursor steroids should be considered in the diagnosis of this disease. 
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Chapter 6 
Profiling steroid metabolic pathways in adrenal-linked endocrine diseases by UPC2-MS/MS 
6. 1 Introduction 
Steroid hormones are involved in growth and sexual development, playing pivotal roles in adrenarche, 
the onset of puberty and pregnancy and while adrenal steroid hormones maintain the electrolyte 
balance in the body and regulate the metabolism of carbohydrates, proteins and lipids, they also regulate 
human stress responses.  Adrenal steroids therefore play a crucial role in normal physiological 
homeostasis and human development, with dysregulated androgen production being associated with 
abnormal development. DSD in neonates and in children, androgen-dependent diseases, including 
cancers such as breast and PCa, as well as endocrine disorders such as PCOS and CAH, are all driven by 
abnormal steroid production. Circulatory and urinary steroid reference ranges are therefore necessary, 
allowing accurate diagnosis of diseases and disorders characterized by androgen deficiency or by 
androgen excess. Steroid levels have been determined by many analytical methods, including enzyme 
linked immunoassays (ELISA), radioimmunoassays (RIA) and LC-MS/MS. More recently, supercritical fluid 
chromatography (SFC), which allows for a more sensitive method for quantifying steroids present in 
complex matrices, is being applied. Utilizing both liquid and gas chromatographic properties, SFC ensures 
a faster, more efficient separation per unit time, together with a shorter  
turn-around time between injections compared to high-performance liquid chromatography (HPLC). 
Furthermore, coupling SFC with mass spectrometry (MS) greatly enhances steroid detection, with the 
introduction of the UPC2-MS/MS system, by the Waters cooperation, propelling steroid separation and 
quantification into the next era. In addition, this system pumps CO2 as the predominant mobile phase, 
Stellenbosch University  https://scholar.sun.ac.za
154 
 
thus labelling this analytical method as environmentally friendly. Utilizing this tool will not only aid in the 
diagnosis of androgen-dependent diseases, in which only small volumes of samples are often available, 
but may also assist in the tracking of adrenal disorders and diseases, determining prognosis by enabling 
the assessment of steroid levels at different phases. In addition, this system allows the separation of 
multiple, structurally closely related steroids in a single chromatographic step, permitting efficient 
analyses of complex mixtures of steroids in one sample, in minutes. In addition, steroidogenic pathways 
can be modelled in patients and steroid biomarkers analysed or identified, allowing clinicians to 
accurately diagnose and treat patients effectively. 
Steroids originate from the adrenals and gonads, with the adrenals able to produce mineralocorticoids, 
glucocorticoids and androgens, whereas the gonads only produce androgens de novo and from adrenal 
precursors. Adrenal steroids are all dependent on the conversion of cholesterol to PREG by CYP11A1, 
which is then channelled into the respective pathways of adrenal steroidogenesis (Fig. 6.1). Adrenal 
precursor steroids, including PROG, 17OHPROG, A4 and T subsequently contribute to the peripheral 
metabolism of these precursors to potent androgens.  
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Figure 6.1 Adrenal steroid metabolism leading to the production of steroid precursors for peripheral metabolism 
(Boxed steroid, potent androgen). 
Both A4 and T contribute to the peripheral production of DHT –through the classic and alternative 
pathways, with both T and DHT able to bind the AR, playing pivotal roles in PCa (Stanbrough et al. 2006; 
Luu-The et al. 2008; Montgomery et al. 2008; Stein et al. 2012). The adrenal precursor 17OHPROG also 
leads to the production of DHT in the backdoor pathway, producing intermediates pdione following the 
conversion by SRD5A, and pdiol following the conversion by 3αHSD (Auchus 2004) (Fig. 6.1).  
The backdoor pathway has been identified as a dominant pathway in 21OHD patients  
(Kamrath et al. 2012), where a dysfunction in CYP21A2 activity leads to the accumulation of 17OHPROG 
(Milewicz et al. 1984; Nahoul et al. 1989), leading to the production of androgens and ultimately DHT. 
In addition, the production of 11OHPROG, catalysed by CYP11B1 and CYP11B2 from PROG, subsequently 
leads to the production of 11KPROG catalysed by 11βHSD2. The peripheral metabolism of PROG and 
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11KPROG by the SRD5As yields DHPROG and 11KDHPROG, respectively. DHPROG has been shown to 
activate the progesterone receptors (Van Rooyen et al. 2017), and 11KDHPROG, once produced by 
SRD5A, has been shown to yield another potent androgen, 11KDHT in the backdoor pathway  
(Van Rooyen et al. 2017). 
The role of 11βHSD2 is further highlighted in the peripheral metabolism of 11OHA4, the CYP11B1 and 
B2 product of A4 (Schloms et al. 2012) (Fig. 6.2). The 11OHA4-pathway leads to the production of 
11KDHT, and, due to the conversion of adrenal 11OHA4 and 11OHT by 11βHSD2, produces 11KT, with 
both 11KDHT and 11KT being AR agonist at 10 nM (Bloem et al. 2015) –playing pivotal roles in CRPC  
(Swart et al. 2013; Swart and Storbeck 2015). It should be noted that the adrenal also has 11βHSD2 
activity and following the biosynthesis of 11OHA4 and 11OHT, produces 11KA4 and 11KT, however, at 
negligible levels (Rege et al. 2013). These C11-oxy C19 steroids impact the progression of CRPC, with our 
studies having reported high levels of 11OHA4, 11KT and 11KDHT in circulation and in prostate tissue of 
PCa patients, as well as the inefficient conjugation of 11KT and 11KDHT in vitro in cell models, which was 
also reflected in our analyses of circulatory steroid levels in PCa patients (Du Toit et al. 2017;  
Du Toit and Swart 2018). 
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Figure 6.2 Peripheral metabolism of adrenal 11OHA4 in the 11OHA4-pathway (Boxed steroids, potent androgens). 
Accurate analytical techniques are required in the diagnosis of androgen-dependent diseases. 
Traditionally only the quantification of circulatory DHEA, A4 and T are included in the diagnosis of 
androgen excess in PCOS patients. Other androgens may, however, also be of importance. Recently,  
C11-oxy C19 steroids, including 11OHA4, 11KA4, 11OHT and 11KT, with the increased urinary excretion 
of 11OHAST, 11OHA4 and 11KA4 were detected in PCOS patients (O’Reilly et al. 2017), using LC-MS/MS 
and GC-MS. The C11-oxy C19 steroids have also been shown to be increased 3-4-fold in 21OH patients, 
with 11KT levels being the most prominent (Turcu et al. 2016). Furthermore, deficient CYP21A2 activity 
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in 21OHD patients leads to the excess production of 17OHPROG, 16OHPROG, and 21-dF  
(Turcu et al. 2015), the latter produced by the hydroxylation of 17OHPROG catalysed by CYP11B1  
(Fig. 6.3). These patients have abnormally low cortisol levels, together with increased androgen 
production. In terms of androgens, our laboratory recently reported the downstream metabolism of 
 21-dF also leading to the production of novel steroid intermediates, and ultimately to the production of 
11KDHT and 11OHDHT in the backdoor pathway (Barnard et al. 2017). Although, the physiological role 
of these novel steroid intermediates is still unknown, these metabolites should be included in the 
steroids analysed in 21OHD patients which would only be possible once these steroids can be accurately 
detected and quantified. 
 
Figure 6.3 Deficient CYP21A2 activity leading to the production of 21-dF, pregnanetriol and 11KDHT. 
Another downstream C21 steroid of importance is pregnanetriol (5β-pregnan-3α,17α,20α-triol), a urinary 
steroid metabolite of 17OHPROG monitored in CAH patients (Kamrath et al. 2017), which may be 
biosynthesized via two routes. It can either be produced from the 5β-reduction of 17OHPROG, followed 
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by the 3α-reduction of the C3 keto moiety by AKR1C2 and finally the reduction at the C20 keto group. 
 A second route would follow the reduction at C20 of 17OHPROG, and the subsequent 5β-reduction of 
the C4-C5 double bond and finally the 3α-reduction by AKR1C2. Another 5β-reduced steroid of 
importance is etiocholanolone (5β-androstan-3α-ol-17-one), a urinary metabolite detected in 21OHD 
and PCOS patients (Tsilchorozidou et al. 2003; Kamrath et al. 2012). It is produced from the reduction of 
A4 by SRD5A, producing 5β-androstanedione (5βDIONE), predominantly in the liver by Δ4-3-oxosteroid 
5β-reductase D1 of the aldo-keto reductase family 1 (AKR1D1). The C3 keto group of 5βDIONE is 
subsequently reduced by AKR1C2, thereby producing the etiocholanolone metabolite. Furthermore, 
11OH-etiocholanolone (5β-androstan-3α,11β-diol-17-one) and 11K-etiocholanolone  
(5β-androstan-3α-ol-11,17-dione) are also produced as end-metabolites of 11OHA4 and 11KA4, 
respectively, following the 5β-reduction of the double bond between C4-C5 and the subsequent 
reduction by AKR1C2. Notably, these C11-oxy metabolites have been detected as urinary metabolites in 
CAH patients (Jailer et al. 1955) and in healthy neonatal urinary samples (Homma et al. 2003;  
Dhayat et al. 2015), with increased or decreased levels possibly reflecting hormonal imbalances and 
abnormal development. 
In the following article, the development and validation of a high-throughput UPC2-MS/MS method is 
reported, which can be applied in the separation and quantification of C19 and C21 steroids, and their 
respective C11-hydroxy and C11-keto metabolites, particularly relevant in adrenal disorders and  
steroid-related diseases allowing for the in vitro and in vivo evaluation of comprehensive steroid panels.2 
                                                          
2 Author contribution to the manuscript entitled A high-throughput UPC2-MS/MS method for the separation and 
quantification of C19 and C21 steroids and their C11-oxy steroid metabolites in the classical, alternative, backdoor and 
11OHA4 steroid pathways: MAS advised with UPC2-MS/MS method development and validation. 
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A B S T R A C T
In the present study an ultra-performance convergence chromatography tandem mass spectrometry (UPC2-MS/
MS) analytical method was developed and validated for the determination of 17 C19 and 14 C21 steroids, in-
cluding C11-oxy C19 and C11-oxy C21 steroids. The limit of detection and limit of quantiﬁcation ranged from
0.01 to 10 ng/mL and from 0.01 to 20 ng/mL, respectively, and the method shows the recovery, matrix eﬀect
and process eﬃciency of steroids isolated from a serum matrix to be within acceptable limits. Good accuracy,
repeatability and reproducibility were also shown and the method provided excellent sensitivity and selectivity
as stereoisomers and regioisomers were also resolved and quantiﬁed accurately.
Clinical conditions such as congenital adrenal hyperplasia, polycystic ovary syndrome in females and dis-
orders of sex development in neonates and in children, amongst others, are characterized by abnormal steroid
levels. Steroid proﬁling is essential to accurately diagnose steroid levels in the above settings as well as in
androgen excess or deﬁciency in adrenal-linked endocrine diseases. Our method, separating C19 and C21 steroids
in a single chromatographic step, oﬀers a reduced sample turnover rate in the clinical setting, while providing
comprehensive steroid proﬁles of in vivo steroids in the nmol/L range. This is, to our knowledge, the ﬁrst method
reported to simultaneously separate C19 and C21 steroids, together with their C11-hydroxy and C11-keto me-
tabolites –one which may hold promise in the identiﬁcation of new steroid markers in steroid-linked endocrine
diseases, in addition to proﬁling steroid metabolism and abnormal enzyme activity in patients.
1. Introduction
Steroid hormones are essential to growth and development, playing
important roles in the maintenance of normal physiological and en-
docrinological processes. Diseases and genetic disorders are often
characterized by abnormal hormone production, with high circulatory
steroid levels associated with clinical conditions. Abnormal androgen
production is implicated, amongst others, in breast and prostate cancer
(PCa), as well as in polycystic ovary syndrome (PCOS) in females and
congenital adrenal hyperplasia (CAH) as well as in disorders of sex
development (DSD) in neonates and in children. Diagnosis of these
diseases is dependent on reliable reference ranges either identifying
speciﬁc steroid biomarkers or identifying a number of steroids present
at abnormal levels in either plasma, serum or urine samples. Advances
in liquid chromatography (LC) and ultra performance LC (UPLC) or
ultra high performance LC (UHPLC), together with the coupling of these
systems to mass spectrometry (MS) have resulted in improved
chromatographic resolution and increased sensitivity allowing accurate
detection and quantiﬁcation [1–3]. The introduction of the ultra-per-
formance convergence chromatography tandem mass spectrometry
(UPC2-MS/MS) system has furthermore greatly enhanced steroid ana-
lysis with the use of supercritical ﬂuid chromatography (SFC) im-
proving detection allowing a more sensitive method for separating
steroid compounds even those structurally closely related [4] and
present in complex matrices.
In adrenal disorders and disease conditions, adrenal steroid hor-
mones can be either deﬁcient or produced in excess –insuﬃcient cor-
tisol production in Addison's disease, excess cortisol in Cushing's syn-
drome and increased androgen production in PCOS and in CAH. In
adrenal steroidogenesis cholesterol is converted to pregnenolone by
P450 side-chain cleavage (CYP11A1), leading to the production of
mineralocorticoids, glucocorticoids and androgens. In contrast, the
gonads produce androgens only, de novo and via the metabolism of
adrenal steroid metabolites which include progesterone (PROG), 17α-
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hydroxyprogesterone (17OHPROG), androstenedione (A4) and testos-
terone (T) (Fig. 1). Downstream metabolism of both A4 and T yield
dihydrotestosterone (DHT), which activates the androgen receptor
(AR), playing a pivotal role in PCa [5]. DHT is produced either in the
classical pathway in which 5α-reductase (SRD5A) converts T directly to
DHT or in the alternative pathway in which A4 is converted to DHT via
5α-androstanedione (5αDIONE) (Fig. 1). The metabolism of the adrenal
precursor, 17OHPROG, will also lead to the production of DHT in the
backdoor pathway [6]. The backdoor pathway was identiﬁed as a
dominant pathway in 21-hydroxylase deﬁcient (21OHD) patients [7],
where a dysfunction in cytochrome P450 21-hydroxylase (CYP21A2)
leads to the accumulation of 17OHPROG [8,9], and thus to the pro-
duction of DHT (Fig. 1).
Also contributing to the androgen pool are 11keto-testosterone
(11KT) and 11keto-dihydrotestosterone (11KDHT), downstream meta-
bolites of adrenal 11β-hydroxyandrostenedione (11OHA4), which we
recently showed to be potent androgens and which are associated with
clinical conditions. In the 11OHA4-pathway, the C11-oxy C19 steroids
lead to the production of 11KDHT [10], impacting on castration-re-
sistant prostate cancer (CRPC) [11–13]. While the adrenal also pro-
duces 11β-hydroxytestosterone (11OHT), 11keto-androstenedione
(11KA4) and 11KT [14], we recently reported that 11-hydro-
xyprogesterone (11OHPROG) and 21-deoxycortisol (21-dF), both pro-
duced in 21OHD are, together with 11keto-progesterone (11KPROG)
and 21-deoxycortisone, reduced by SRD5As channelling these steroids
into the backdoor pathway to produce 11KDHT via 11β-hydro-
xydihydroprogesterone, 11keto-dihydroprogesterone (11KDHPROG),
5α-pregnan-11β,17α-diol-3,20-dione (also known 11OHPdione) and
5α-pregnan-17α-ol-3,11,20-trione (also known as 11KPdione) [15,16].
Standard reference ranges spanning preterm to adult have neither
been established for these C11-oxy C19 and C11-oxy C21 steroids nor for
their downstream metabolites. Recently, circulating 11OHA4, 11KA4,
11OHT and 11KT, as well as urinary 11β-hydroxyandrosterone
(11OHAST) were detected in PCOS patients [17], and while androgen
levels were increased in 21OHD patients, C11-oxy C19 steroids were 3
to 4-fold higher than in healthy subjects [18]. In addition, deﬁcient
CYP21A2 activity in 21OHD also results in low cortisol levels, together
with a concomitant increase in 16α-hydroxyprogesterone (16OH-
PROG), 17OHPROG and 21-dF levels [19]. 21-dF and 17OHPROG are
routinely analysed in 21OHD, together with the 17OHPROG metabo-
lite, 5β-pregnan-3α,17α,20α-triol (pregnanetriol), with analysis often
including androsterone (AST) and 5β-androstan-3α-ol-17-one (etio-
cholanolone), downstream A4 metabolites. The inclusion of the C11-
oxy C19 and C11-oxy C21 steroids and their downstream metabolites
together with 5β-androstan-3α,11β-diol-17-one (11OH-etiocholano-
lone), 5β-androstan-3β,11β-diol-17-one (11OH-epietiocholanolone)
and 5β-androstan-3α-ol-11,17-dione (11K-etiocholanolone) in diag-
nostic assessments of adrenal disorders would result in more accurate
diagnosis with fewer false positives and negative results.
While some of the aforementioned steroids are currently analysed in
vitro and in vivo by LC-MS/MS, using UPC2-MS/MS for their quantiﬁ-
cation is not routine practice. The analyses of C19, C11-oxy C19 and C21
steroids have been identiﬁed in vitro by Schloms et al. [19], using UPLC-
MS/MS, followed by Storbeck et al. [10], and Swart et al. [11], re-
porting on the quantiﬁcation of these steroids in vitro using UPLC-MS/
MS. The analysis completed by Schloms et al. [19] separated 21 steroids
within 10min, including T, cortisol, DHEA, A4, cortisone, 11OHA4,
17OHPROG, DHT, 16OHPROG and PROG. Swart et al. [11], separated
17 steroids in 5min, including cortisol, cortisone, DHEA, A4, T,
11OHA4, 11KA4, 11OHT, 11KT and DHT, while Storbeck et al. [10]
separated 11OHA4, 11KA4, 11OHT, 11KT and their 5α-reduced meta-
bolites in 5min using UPLC-MS/MS. In vivo analysis of the C11-oxy C19
steroids by LC-MS/MS in plasma was reported by Rege et al. [14], with
their method including 11OHA4, 11KA4, 11OHT and 11KT, and by
Turcu et al. [18], which included 11OHA4, 11KA4, 11OHT, 11KT,
DHEA, A4 and T. In 2015, Turcu et al. [20] reported on the analysis of
10 C21 steroids, including 21-dF and 11OHPROG, in serum, and in
2017, the same authors reported a method which separated 23 steroids,
which included the C11-oxy C19 steroids, using LC-MS/MS [21]. All the
above-mentioned methods included some of the C19, C11-oxy C19 and
C21 steroids, however, the C11-oxy C21 steroids have not been in-
vestigated and UPC2-MS/MS has not been used to quantify the steroids.
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Fig. 1. Adrenal steroid biosynthesis and peripheral metabolism in the classical, alternative and backdoor pathways. Steroids included in the method are indicated by black text. Boxed
steroid, potent androgen. CYP11A1, cytochrome P450 side-chain cleavage; CYP17A1, cytochrome P450 17α-hydroxylase; 3βHSD2, 3β-hydroxysteroid dehydrogenase type 2; CYP11B1,
cytochrome P450 11β-hydroxylase; CYP11B2, aldosterone synthase; 17βHSD, 17β-hydroxysteroid dehydrogenase; 11βHSD2, 11β-hydroxysteroid dehydrogenase type 2; SRD5A1/2, 5α-
reductase type 1/type 2; 3αHSD, 3α-hydroxysteroid dehydrogenase; DHEA, dehydroepiandrosterone/5-androsten-3β-ol-17-one; A4, androstenedione/4-androsten-3,17-dione; T, tes-
tosterone/4-androsten-17β-ol-3-one; 5αDIONE, 5α androstanedione/5α-androstan-3,17-dione; DHT, dihydrotestosterone/5α-androstan-17β-ol-3-one; AST, androsterone/5α-androstan-
3α-ol-17-one; 3αDIOL, 5α-androstan-3α,17β-diol; PROG, progesterone/4-pregnen-3,20-dione; DHPROG, dihydroprogesterone/5α-pregnan-3,20-dione; 11KPROG, 11keto-progesterone/
4-pregnen-3,11,20-trione; 17OHPROG, 17α-hydroxyprogesterone/4-pregnen-17α-ol-3,20-dione; 16OHPROG, 16α-hydroxyprogesterone/4-pregnen-16α-ol-3,20-dione; 11KDHPROG,
11keto-dihydroprogesterone/5α-pregnan-3,11,20-trione; 11OHPROG, 11α-hydroxyprogesterone/4-pregnen-11α-ol-3,20-dione or 11β-hydroxyprogesterone/4-pregnen-11β-ol-3,20-
dione; Pdiol, 5α-pregnan-3α,17α-diol-20-one; Pdione, 5α-pregnan-17α-ol-3,20-dione; 21-dF, 21-deoxycortisol/11β,17α-dihydroxypregn-4-ene-3,20-dione.
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More recently, our group quantiﬁed C19 and C11-oxy C19 steroids in
vitro and in vivo using UPC2-MS/MS [22,23], and the C11-oxy C21
steroids which were quantiﬁed in a method reported by Barnard et al.
[15], while a UPC2-MS/MS analytical method separating 19 steroids,
which included C19 and C11-oxy C19 steroids, has also been reported
[4]. Not any UPC2-MS/MS method has, to date, been reported which
enables the separation and quantiﬁcation of C19, C21 as well as their
C11-oxy derivatives in a single chromatographic step without prior
derivatization.
The aim of this study was therefore to develop a high-throughput
UPC2-MS/MS method for the separation and quantiﬁcation of C19 and
C21 steroids, and their C11-hydroxy and C11-keto metabolites, to fa-
cilitate the accurate evaluation of steroid panels within the steroid
metabolic pathways relevant to adrenal-linked endocrine diseases.
2. Materials and methods
2.1. Materials
Steroids including A4, T, DHT, dihydroprogesterone (DHPROG),
dehydroepiandrosterone (DHEA), 17OHPROG, cortisone and cortisol
were purchased from Sigma-Aldrich (St. Louis, MO, USA). 11OHA4,
11OHT, 11KA4, 11KT, 11KDHT, 11OHAST, 11keto-androsterone
(11KAST), 5α-pregnan-17α-ol-3,20-dione (pdione), 5αDIONE, AST,
5α-androstane-3α,17β-diol (3αDIOL), epietiocholanolone, 5α-
pregnan-3α,17α-diol-20-one (pdiol), 11KDHPROG, 11KPROG,
11βOHPROG, 11αOHPROG, 21-dF, 11OH-epietiocholanolone, 11K-
etiocholanolone and pregnanetriol were purchased from Steraloids
(Wilton, USA). PROG was purchased from BDH Chemicals Ltd. (Poole,
England) and 16OHPROG from Toronto Research Chemicals (Toronto,
Canada). Deuterated steroid standards were purchased from
Cambridge isotopes (Andover, MA, USA): testosterone 1, 2-D2 (D2T);
4-androsten-11β-ol-3,17-dione 2,2,4,6,6,16,16-D7 (D7A4); 4-andros-
tene-3,17-dione 2,2,4,6,6,16,16-D7 (D711OHA4) and progesterone
2,2,4,6,6,17A,21,21,21-D9 (D9PROG). FOODFRESH CO2 was pur-
chased from Afrox (Cape Town, South Africa), formic acid and methyl
tert-butyl ether (MTBE) from Sigma-Aldrich (St. Louis, MO, USA),
methanol 215 SpS from ROMIL Ltd. (Cambridge, England) and fetal
bovine serum (FBS) from Biochrom GmbH (Berlin, Germany). The
ACQUITY UPC2® ethylene-bridged hybrid (BEH) column
(3.0× 100 mm, 1.7 μm particle size) and VanGuard™ pre-column
(2.1× 5mm, 3.5 μM) were purchased from Waters (Waters
Corporation, Milford, USA).
2.2. Preparation of standards
Steroids were prepared in absolute ethanol (2 mg/mL) and used to
prepare three standard master mixes, 20, 200 and 1000 ng/mL in 50%
methanol. These were subsequently used to prepare reference standards
ranging from 0.01 to 1000 ng/mL by the addition of the appropriate
volume to FBS (matrix). Additional samples, used for method valida-
tion, were prepared by spiking the matrix and 50% methanol (no ma-
trix) with the appropriate volumes.
2.3. Steroid extraction
Prior to extraction, D2T (1.5 ng), D7A4 (15 ng), D711OHA4 (15 ng)
and D9PROG (15 ng) in 100 μL deionized water were added to samples
(steroid standards in 500 μL FBS), followed by the addition of 5mL
MTBE. Samples were extracted, as previously described
[4,10,11,15,21,22], by vortexing for 26min, the aqueous phase frozen
at −80 °C, after which the organic phase was collected and dried. The
dried residue was dissolved in 0.15mL 50% methanol in water and the
samples stored at −20 °C prior to UPC2-MS/MS analysis. In order to
analyse endogenous steroids present in the matrix, FBS (500 μL) was
extracted in triplicate according to the protocol described above.
2.4. Separation and quantiﬁcation of steroid metabolites
The C19 and C21 steroids analysed by UPC2®–MS/MS (Waters
Corporation, Milford, USA) were separated with an elution gradient
described in Table 1. Steroids, injection volume 2 μL, were eluted at a
ﬂow rate of 2mL/min in a total run time of 6min per sample. The
column temperature was set to 60 °C and the automated back pressure
regulator (ABPR) to 2000 psi. A Xevo TQ-S triple quadrupole mass
spectrometer (Waters, Milford, USA) was used for quantitative mass
spectrometric detection and all steroids were analysed in multiple re-
action monitoring (MRM) mode, using the positive electrospray ioni-
zation (ESI+) mode, with MRM settings shown in Table 2. Table 3
depicts the chemical formulas and structures, molecular mass of each
analyte, and the internal reference standard used to quantify each
analyte. The internal reference standard chosen for quantiﬁcation of
each steroid metabolite was chosen based on the retention time –the
internal standard that eluted the closest to the retention time of the
steroid metabolite was chosen as the quantifying reference standard.
Preceding the MS line, a make-up pump mixed 1% formic acid in me-
thanol at a constant ﬂow rate of 0.2mL/min. The following settings
were used: capillary voltage of 3.8 kV, source temperature 120 °C,
desolvation temperature 500 °C, desolvation gas 1000 L/h and cone gas
150 L/h. Data was collected and analysed with the MassLynx 4.1
(Waters Corporation) software program.
2.5. Method validation
Standard curves were generated for each steroid using standards
prepared in FBS with the range spanning 0.01, 0.02, 0.1, 0.2, 1, 2, 10,
20, 100, 200 and 1000 ng/mL, and extracted as described in Section
2.3. The limit of detection (LOD) for each steroid was deﬁned as the
lowest concentration at which a signal-to-noise (S/N) ratio> 3 was
measured for the quantiﬁer ion. The limit of quantiﬁcation (LOQ) was
deﬁned as the lowest concentration for each steroid at which a S/N
ratio> 10 was measured for the quantiﬁer ion and a S/N ratio> 3 for
the qualiﬁer ion(s). Linearity of the standard curves was assessed using
the Runs test in Graphpad Prism. The presence of endogenous steroids
in FBS was analysed in parallel with the validation of our samples and
veriﬁed not to interfere with our analysis (Supplemental Fig. 1). Ac-
curacy is deﬁned as the percent relative standard deviation (%RSD)
from the average response following repeated injections of a single
sample and precision is deﬁned as the %RSD from the average response
following the injection of independent replicate samples, with the
precision repeated over three days to assess inter-day variability [4].
Accuracy and precision were determined for the following reference
standard concentrations: 2, 20, 100 and 200 ng/mL, by the addition of
the appropriate volumes to FBS (matrix), prior to extraction. Recovery,
matrix eﬀects and process eﬃciency were determined at
2, 20, 100 and 200 ng/mL, according to the protocols reported by
Taylor, 2005 [24]. Recovery was calculated by comparing the response
of the steroid standards prepared in FBS and extracted as described
above, to that of FBS extracts with the post-addition of the same volume
(and concentration) of steroids. Matrix eﬀect were determined by
comparing FBS extracts with the post-extraction addition of steroids, to
Table 1
Gradient speciﬁcations of the UPC2 separation of steroid metabolites (solvent A, CO2;
solvent B, methanol).
Step Time (minutes) Solvent A (%) Solvent B (%) Curve
1 0 98 2 Initial
2 2.7 90 10 7
3 3.8 88 12 6
4 4.9 75 25 6
5 5 98 2 1
6 6 98 2 1
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Table 2
UPC2-MS/MS detection and quantiﬁcation of C19 and C21 steroid standards. Retention time (RT); molecular ion species and MRM mass transitions; mass spectrometer settings: cone
voltages (CV), collision energy (CE); and internal deuterated standards: D2T, D7A4, D9PROG and D711OHA4.
Steroid metabolite RT (min) Mass transitions CV (V) CE (eV)
Quantiﬁer Qualiﬁer Qualiﬁer
A4 1.38 287.2 > 96.9 287.2 > 108.8 – 30 30 – 15 15 –
T 2.47 289.2 > 97.2 289.2 > 109.0 – 30 30 – 22 22 –
5αDIONE 0.87 289.2 > 253.1 289.2 > 97.2 – 22 30 – 16 22 –
DHT 1.80 291.2 > 255.0 291.2 > 273.0 – 25 25 – 15 20 –
AST 1.69 273.2 > 105.3 291.3 > 273.3 – 30 18 – 30 8 –
3αDIOL 2.83 275.2 > 257.0 275.2 > 175.0 – 15 15 – 15 15 –
11OHA4 2.69 303.2 > 267.2 303.2 > 121.0 – 30 30 – 30 15 –
11OHT 3.69 305.3 > 121.0 305.3 > 269.0 – 35 35 – 20 15 –
11KA4 1.99 301.2 > 257.0 301.2 > 265.2 – 35 35 – 25 25 –
11KT 3.14 303.2 > 121.0 303.2 > 267.0 – 30 30 – 20 20 –
11KDHT 2.77 305.2 > 243.0 305.2 > 269.0 – 30 30 – 20 20 –
11OHAST 3.00 289.0 > 271.0 289.0 > 213.0 – 15 15 – 15 15 –
11KAST 2.53 305.0 > 147.2 305.0 > 173.1 – 30 30 – 30 30 –
DHEA 1.88 271.2 > 253.2 271.2 > 243 – 30 – – 15 – –
Epietiocholanolone 1.69 273.0 > 105.1 291.2 > 255.0 – 15 15 – 30 15 –
11OH-epietiocholanolone 3.00 289.0 > 271.0 289.0 > 213.0 289.0 > 253.0 15 15 15 15 20 15
11K-etiocholanolone 2.53 305.1 > 147.0 305.1 > 287.0 – 15 15 – 30 20 –
Pregnanetriol 3.57 301.2 > 135.0 301.2 > 81.0 – 25 25 – 15 25 –
PROG 1.32 315.2 > 97.0 315.2 > 109.0 – 28 28 – 20 26 –
DHPROG 0.78 317.0 > 105.2 317.0 > 95.0 317.0 > 175.2 30 30 30 30 30 20
Pdiol 2.90 317.4 > 111.0 317.4 > 299.0 – 20 20 – 15 25 –
Pdione 1.61 333.4 > 159.0 333.4 > 137.0 – 20 20 – 25 25 –
11KPROG 2.00 329.2 > 121.0 329.2 > 84.8 329.2 > 285.0 15 15 15 20 20 20
17OHPROG 2.32 331.1 > 97.0 331.1 > 109.0 – 26 26 – 22 28 –
16OHPROG 3.00 331.2 > 97.0 331.2 > 108.9 – 30 30 – 15 15 –
11KDHPROG 1.45 331.2 > 105.0 331.2 > 147.0 – 25 25 – 30 30 –
11αOHPROG 3.11 331.2 > 295.2 331.2 > 121.0 – 30 30 – 15 30 –
11βOHPROG 2.85 331.2 > 121.0 331.1 > 295.0 – 30 30 – 20 20 –
21-dF 3.37 347.1 > 121.0 347.1 > 269.2 – 20 20 – 25 15 –
Cortisone 3.35 361.2 > 163.0 – – 30 – – 30 – –
Cortisol 3.82 363.0 > 121.0 – – 30 – – 20 – –
D2T 2.47 291.0 > 99.1 291.0 > 111.2 – 30 30 – 20 30 –
D7A4 1.39 294.3 > 100.0 294.3 > 113.0 – 25 25 – 25 25 –
D9PROG 1.32 324.2 > 100.0 324.2 > 113.0 – 30 30 – 20 25 –
D711OHA4 2.68 310.2 > 99.8 310.2 > 147.2 – 25 25 – 30 25 –
Table 3
Description of steroid analytes including their biochemical names, chemical formulas and structures, molecular mass and the internal reference standard used to quantify each analyte.
Steroid metabolite Biochemical name Chemical formula Chemical structure Molecular weight Internal reference standard
A4 4-androsten-3,17-dione C19H26O2 286.4 D7A4
T 4-androsten-17β-ol-3-one C19H28O2 288.4 D2T
5αDIONE 5α-androstan-3,17-dione C19H28O2 288.4 D9PROG
DHT 5α-androstan-17β-ol-3-one C19H30O2 290.4 D2T
AST 5α-androstan-3α-ol-17-one C19H30O2 290.4 D2T
(continued on next page)
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Table 3 (continued)
Steroid metabolite Biochemical name Chemical formula Chemical structure Molecular weight Internal reference standard
3αDIOL 5α-androstan-3α,17β-diol C19H32O2 292.5 D2T
11OHA4 4-androsten-11β-ol-3,17-dione C19H2603 302.4 D711OHA4
11OHT 4-androsten-11β,17β-diol-3-one C18H28O3 304.4 D2T
11KA4 4-androsten-3,11,17-trione C19H2403 300.4 D7A4
11KT 4-androsten-17β-ol-3,11-dione C19H26O3 302.4 D2T
11KDHT 5α-androstan-17β-ol-3, 11-dione C19H28O3 304.4 D2T
11OHAST 5α-androstan-3α,11β-diol-17-one C19H30O3 306.4 D2T
11KAST 5α-androstan-3α-ol-11,17-dione C19H28O3 304.4 D2T
DHEA 5-androsten-3β-ol-17-one C19H2802 288.4 D9PROG
Epietiocholanolone 5β-androstan-3β-ol-17-one C19H30O2 290.4 D2T
11OH-epietiocholanolone 5β-androstan-3β,11β-diol-17-one C19H30O3 306.4 D711OHA4
11K-etiocholanolone 5β-androstan-3α-ol-11,17-dione C19H28O3 304.4 D711OHA4
Pregnanetriol 5β-pregnan-3α,17,20α-triol C21H36O3 336.5 D2T
(continued on next page)
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Table 3 (continued)
Steroid metabolite Biochemical name Chemical formula Chemical structure Molecular weight Internal reference standard
PROG 4-pregnen-3,20-dione C21H30O2 314.5 D9PROG
DHPROG 5α-pregnan-3,20-dione C21H32O2 316.5 D9PROG
Pdiol 5α-pregnan-3α,17α-diol-20-one C21H34O3 334.5 D2T
Pdione 5α-pregnan-17α-ol-3,20-dione C21H32O3 332.5 D7A4
11KPROG 4-pregnen-3,11,20-trione C21H28O3 328.5 D7A4
17OHPROG 4-pregnen-17α-ol-3,20-dione C21H30O3 330.5 D2T
16OHPROG 4-pregnen-16α-ol-3,20-dione C21H30O3 330.5 D2T
11KDHPROG 5α-pregnan-3,11,20-trione C21H30O3 330.5 D7A4
11αOHPROG 4-pregnen-11α-ol-3,20-dione C21H30O3 330.5 D2T
11βOHPROG 4-pregnen-11β-ol-3,20-dione C21H30O3 330.5 D2T
21-dF 4-pregnen-11β,17-diol-3, 20-dione C21H30O4 346.5 D2T
Cortisone 4-pregnen-17,21-diol-3,11,20-trione C21H28O5 360.4 D2T
Cortisol 4-pregnen-11β,17,21-triol-3,20-dione C21H30O5 362.5 D2T
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a pure solution in 50% methanol (no matrix; no extraction) which
contained the same volume (and concentration) of steroids. The dif-
ference in response between these two samples was divided by the re-
sponse of the pure solution to calculate the matrix eﬀect. Visually
showing the diﬀerent responses due to the three aforementioned pro-
tocols followed, are the generated standard curves shown in Supple-
mental Fig. 2. Lastly, the process eﬃciency was calculated by com-
paring the response of standards prepared in FBS (pre-extraction
addition of steroids) to that of the pure solution. In addition, accuracy
(bias) is described for all the steroids in Supplemental Table 1, and was
calculated by comparing the response of the validation samples (the
addition of the appropriate volumes of steroids to FBS and extracted;
expected test result) to a reference response (reference value; set as
100%), which was generated using standard curves for each steroid
using standards prepared in FBS and extracted, at 20, 100 and 200 ng/
mL [25].
3. Results
3.1. UPC2 separation of steroid standards
The high-throughput UPC2-MS/MS method allowed the chromato-
graphic separation and quantiﬁcation of 28 C19 and C21 steroids, as well
as 4 deuterated reference standards in a single 6-min step (Fig. 2). Al-
though some steroids could not be resolved, unique MRMs were de-
termined for accurate quantiﬁcation. These steroids include 11KA4 and
11KPROG eluting at 2.0min, and 11OHAST and 16OHPROG eluting at
3.0 min. The stereoisomers (5α, 3α-reduced vs 5β, 3α/β-reduced me-
tabolites) AST and epietiocholanolone; 11OHAST and 11OH-epie-
tiocholanolone; and 11KAST and 11K-etiocholanolone could however
not be chromatically resolved, and due to their MRMs being similar, the
individual stereoisomers could thus not be quantiﬁed accurately.
The separation and quantiﬁcation of steroids which have similar
structures, such as the 11αOHPROG and 11βOHPROG stereoisomers,
are possible due to the sensitivity and selectivity of the UPC2-MS/MS
system (Fig. 3). Steroids such as 11KPROG and its reduced form,
11KDHPROG, can also be separated and quantiﬁed due to the diﬀer-
ence in their MRMs. In addition, although the regioisomers, 17OH-
PROG and 16OHPROG, have the same MRMs, they ionise diﬀerently
due to the position of the C17 and C16 hydroxyl group thus enabling
separation.
Furthermore, most of the steroid metabolites included in the
method have two qualiﬁers, however, some steroids have one or three
qualiﬁers (Table 2). The quantiﬁer/qualiﬁer used as MRMs for each
steroid metabolite was optimized for the best selectivity, in order to
minimize transition cross-talk and to optimize the total ion count (TIC)
of each steroid. This allowed an optimal ‘points per peak’ value for the
method, allowing high peak resolution.
3.2. Performance and validation of the method
3.2.1. Calibration range
The calibration range allowed for the accurate determination of
LODs and LOQs of each steroid, with LODs and LOQs ranging from 0.01
to 10 ng/mL and from 0.01 to 20 ng/mL, respectively. A linear ﬁt with
acceptable r2-values (> 0.9947) was also obtained for all standard
curves (Table 4).
3.2.2. Accuracy and precision
Acceptable %RSDs (< 20%) were obtained for all the steroids for
both the accuracy and precision parameters (Table 5). Accuracy was
determined to be<15% for all steroids at 100 and 200 ng/mL, with
only epietiocholanolone (17.4%) lying mid concentration, and DHEA
(17.9%) and DHPROG (20.0%) in the lower concentration range
showing %RSD values> 15%. Accuracy therefore ranged from 1.5% to
20.0% in the lower concentration range, from 1.6% to 17.4% in the
middle concentration ranges and from 2.2% to 10.8% in the higher
concentration range. Furthermore, intra-day precision and inter-day
precision was tested to fully validate the method. Precision ranged from
2.4% to 19.9% for low concentrations, 1.7% to 19.3% for middle
concentrations and 1.6% to 14.4% for high concentrations tested during
the three-day period.
3.2.3. Recovery, matrix eﬀect and process eﬃciency
In Table 6, the recovery, matrix eﬀect and process eﬃciency are
described for all the steroids included in the method. Recovery ranged
from 63.6% to 100.9% at the lower concentrations, from 45.9% to
110.6% at the middle concentrations, and from 71.5% to 116.3% at the
high concentrations. Matrix eﬀect ranged from ionization enhancement
of 20.8% for 5αDIONE at the lower concentrations, to ionization sup-
pression of 37.3% and 14.6% for epietiocholanolone at the middle and
high concentrations, and ionization enhancement of 23.2% for preg-
nanetriol at the higher concentrations. Matrix eﬀect therefore ranged
from −50.7% to 28.1% over the concentration ranges tested, with
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Fig. 2. UPC2-MS/MS separation of 31 reference standards. C19
and C21 steroid standards, 100 ng/mL, are depicted in the elution
order (1) DHPROG, 0.78min; (2) 5αDIONE, 0.87min; (3) PROG,
1.32min; (4) A4, 1.38min; (5) 11KDHPROG, 1.45min; (6)
pdione, 1.61min; (7, 8) epietiocholanolone and AST, 1.69min;
(9) DHT, 1.80min; (10) DHEA, 1.88min; (11, 12) 11KA4 and
11KPROG, 2.00min; (13) 17OHPROG, 2.32min; (14) T,
2.47min; (15, 16) 11K-etiocholanolone and 11KAST, 2.53min;
(17) 11OHA4, 2.69min; (18) 11KDHT, 2.77min; (19) 3αDIOL,
2.83min; (20, 21) 11βOHPROG, 2.85min and pdiol, 2.90 min;
(22, 23, 24) 11OH-epietiocholanolone, 11OHAST and
16OHPROG, 3.00min; (25, 26) 11αOHPROG, 3.11min and
11KT, 3.14min; (27) cortisone, 3.35min; (28) 21-dF, 3.37min;
(29) pregnanetriol, 3.57min; (30) 11OHT, 3.69min; and (31)
cortisol, 3.82 min.
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ionization suppression of all the steroids determined at 100 ng/mL only.
Process eﬃciency, taking into account the extraction protocol and the
matrix, showed values ranging from 39.2% to 109.2% at the lower
concentrations, from 36.0% to 100.5% at the middle concentrations
and from 87.0% to 118.7% at the higher concentrations. Supplemental
Fig. 3 indicates the matrix eﬀect causing ionization suppression, in
addition to the recovery and process eﬃciency percentages obtained for
11OHA4, A4 and DHT at 100 ng/mL.
4. Discussion
This study describes a high-throughput UPC2-MS/MS method for
the separation and quantiﬁcation of C19 and C21 steroids, subsequent to
organic solvent extraction, without prior derivatization being required,
showing good recovery together with the MS system used showing good
accuracy, repeatability and reproducibility. Of note, the values ob-
tained for accuracy and precision at 100 ng/mL for the C19 and C11-oxy
C19 steroids were comparable to those reported also using a UPC2-MS/
MS method [4], ranging 2.4–9.5 vs 2.6–11.5 and 1.94–17.69 vs
2.2–10.2 for accuracy and precision, respectively. The sensitivity of our
method, reﬂected in the low LOD and LOQ values of each steroid,
shows that this method can be used to study steroid panels in clinical
samples, enabling the detection of steroids in the nmol/L range and at
physiological concentrations. Furthermore, the UPC2-MS/MS showed
superior selectivity by separating structurally closely related steroids,
including stereoisomers and regioisomers. A limitation of this method,
however, is the small number of deuterated reference standards used, as
many of the steroids included in our method do not yet have com-
mercially available deuterated forms. In addition, this method was
unable to chromatographically separate the C19 5α, 3α-reduced deri-
vatives (AST, 11OHAST and 11KAST) from the C19 5β, 3α/β-reduced
derivatives (epietiocholanolone, 11OH-epietiocholanolone and 11K-
etiocholanolone). The quantiﬁcation of steroids present in a complex
matrix may often be confounded by matrix eﬀects causing ion sup-
pression or enhancement. In order to circumvent these eﬀects and
possible loss of steroids during the extraction process, standards used to
quantify steroids present in a matrix such as plasma, should always
include the same amount of deuterated internal standards as in the
samples being processed, and steroid extraction should also be from a
medium which mimic the matrix eﬀect. Therefore, although matrix
eﬀects are observed in the current method, it does not signiﬁcantly
limit the analytical method. In addition, the level of endogenous ster-
oids present in FBS was assessed following extraction and conﬁrmed not
to interfere with the quantiﬁcation of the spiked matrix samples.
As the steroid metabolites included in this method are involved in
the classical-, alternative-, backdoor- and 11OHA4-pathway of adrenal
and peripheral steroid metabolism, the importance of this method is
highlighted in terms of their biosynthesis, activation and inactivation
by steroidogenic enzymes (Fig. 1). Cytochrome P450 17α-hydroxylase
(CYP17A1) activity, for example, may be assessed by quantifying
17OHPROG and 16OHPROG and their precursor metabolite, PROG, in
plasma, serum and tissue with the 3-4:1 ratio (17OHPROG: 16OH-
PROG) accepted as a normal ratio [20,26], with deviations reﬂecting
CYP17A1 over or under activity characteristic of diseases and adrenal
disorders in clinical conditions. CYP11B1 and CYP11B2 activity may
also be assessed, together with deﬁcient CYP21A2 activity, occurring in
21OHD and CAH, with increased levels of 17OHPROG and 21-dF de-
termined in vivo [8,9], with more comprehensive proﬁles contributing
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Fig. 3. UPC2-MS/MS separation of progesterone metabolites. Reference C21 steroid standards, 100 ng/mL, are depicted in the elution order (1) 11KDHPROG, 1.45min; (2) 11KPROG,
2.00min; (3) 17OHPROG, 2.32min; (4) 11βOHPROG, 2.85min; (5) 16OHPROG, 3.00min and (6) 11αOHPROG, 3.11min.
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to the elimination of false positives and negative diagnosis. In addition,
CYP11B1 activity is also important in the production of 11OHA4 from
A4, as well as 11OHT from T. Subsequent conversion of 11OHA4 and
11OHT by 11β-hydroxysteroid dehydrogenase type 2 (11βHSD2) to
11KA4 and 11KT, respectively, yields 11KT and 11KDHT in the
11OHA4-pathway, potent androgens which, to date, are not routinely
assessed in PCa and CRPC patients. 11βHSD2 is also essential in the
inactivation of adrenal cortisol to cortisone, with this method able to
separate and quantify cortisol and cortisone, together with 11OHPROG
and 11KPROG. Both 11OHPROG and 11KPROG have been identiﬁed in
urinary neonatal samples and levels shown to be age and sex speciﬁc
[27], further emphasising the application of our method enabling the
assessment of comprehensive in vivo steroid panels. In addition, while
quantifying cortisol levels in disease conditions such as Cushing's syn-
drome, Addison's disease, PCOS and CAH, the analyses of additional
steroid metabolites may further aid diagnosis and the identiﬁcation of
new disease markers. The backdoor pathway could also be analysed in
patients, as the current method quantiﬁes 17OHPROG, pdione (SRD5A
activity), pdiol (3αHSD activity), AST (CYP17A1 activity), 3αDIOL
(17βHSD activity) and DHT (3αHSD activity) (Fig. 1). 21-dF levels to-
gether with 11OHAST and 11KDHT, downstream metabolites in the
C11-oxy C21 backdoor pathway utilizing 21-dF [15], can also be de-
termined in patients. Clearly, this high-throughput UPC2-MS/MS
method facilitates improved diagnosis and prognosis determination in
patients suﬀering from steroid dependent diseases. Although this study
reports on the measurement of steroids present in a serum matrix, the
extraction protocol and MS method has the potential to be applied in
measuring steroids present in complex matrices such as urine, tissue,
follicular ﬂuid, saliva and hair.
5. Conclusions
We have developed and validated a method which separates and
quantiﬁes key steroids produced in adrenal and peripheral steroid
metabolism, and this is, to our knowledge, the ﬁrst method describing
the separation of 17 C19 and 14 C21 steroids in one chromatographic
Table 5
Method validation data: accuracy (n=8) and precision with inter-day variability (n=7).
Steroid metabolite Accuracy (%RSD) Precision (%RSD)
Day 1 Day 2 Day 3
ng/mL ng/mL
2 20 100 200 2 20 100 200 2 20 100 200 2 20 100 200
A4 3.2 2.6 4.8 3.7 4.7 5.6 1.9 5.7 7.9 2.2 2.2 8.0 13.4 14.7 8.8 4.9
T 3.9 5.2 3.0 3.9 2.4 4.1 2.8 2.6 5.9 6.5 5.5 5.5 10.0 8.7 8.6 3.7
5αDIONE 7.2 6.6 3.5 7.5 7.1 4.5 2.0 9.1 9.5 8.9 9.7 8.0 10.6 10.9 12.7 3.3
DHT 10.0 8.0 9.5 6.3 8.5 6.4 3.0 5.8 4.5 4.5 11.8 8.1 9.1 8.8 4.5 3.6
AST < LOQ 10.0 7.8 6.6 < LOQ 9.3 11.8 2.8 < LOQ 15.6 14.1 6.8 < LOQ 8.8 4.4 6.3
3αDIOL < LOQ 9.5 6.5 8.7 < LOQ 6.5 7.3 6.6 < LOQ 8.7 8.8 3.9 < LOQ 10.6 12.9 5.7
11OHA4 5.0 3.9 4.1 3.0 3.3 4.6 2.3 3.1 7.9 6.7 3.0 7.5 4.5 11.1 3.2 4.1
11OHT 8.7 3.1 5.1 9.0 11.8 5.4 3.0 6.0 11.2 9.2 10.7 7.0 9.7 9.5 7.9 6.1
11KA4 10.4 8.2 8.2 3.0 12.3 3.0 7.1 7.8 12.7 9.3 14.7 12.0 14.4 7.3 9.1 6.9
11KT 2.7 4.3 2.4 3.9 4.6 3.9 2.2 2.7 10.0 11.1 8.5 4.9 5.6 6.6 8.1 4.4
11KDHT <LOQ 3.4 7.0 7.1 < LOQ 5.9 3.4 1.7 < LOQ 10.9 13.5 5.6 < LOQ 10.1 8.9 4.8
11OHAST < LOQ 10.4 6.0 4.0 < LOQ 8.1 4.0 2.7 < LOQ 5.6 11.1 1.6 < LOQ 13.7 11.9 5.4
11KAST < LOQ 9.5 6.0 4.5 < LOQ 8.2 4.8 2.8 < LOQ 16.5 17.7 5.7 < LOQ 11.9 9.6 3.8
DHEA 17.9 6.3 10.8 5.3 15.1 10.7 2.3 2.0 15.3 10.5 11.0 8.6 18.1 12.5 11.5 5.3
Epietiocholanolone < LOQ 17.4 7.2 7.2 < LOQ 13.0 9.9 5.5 < LOQ 7.9 12.6 6.6 < LOQ 19.3 13.3 8.3
11OH-epietiocholanolone 8.7 8.7 8.0 4.0 8.2 5.5 4.1 1.9 12.6 1.7 4.2 3.4 19.9 3.3 2.7 5.3
11K-etiocholanolone < LOQ 6.9 8.8 4.6 < LOQ 6.2 6.7 5.0 < LOQ 9.1 13.4 5.8 < LOQ 14.5 7.6 6.1
Pregnanetriol < LOQ 6.4 7.6 10.8 < LOQ 6.0 8.1 14.4 < LOQ 7.3 8.0 10.3 < LOQ 15.1 6.4 7.2
PROG 1.5 3.1 1.6 2.2 4.8 4.3 3.0 4.7 7.4 3.6 3.6 7.5 11.1 17.9 8.7 3.3
DHPROG 20.0 4.8 8.3 5.8 12.4 11.5 6.3 4.1 6.9 10.0 12.4 8.9 19.4 12.8 9.7 8.9
Pdiol < LOQ 6.6 9.7 4.4 < LOQ 7.7 6.9 4.4 < LOQ 10.4 7.8 5.1 < LOQ 18.4 9.8 4.5
Pdione < LOQ 7.2 8.0 4.4 < LOQ 4.9 9.3 4.5 < LOQ 13.6 10.7 9.3 < LOQ 13.4 12.1 10.2
(continued on next page)
Table 4
Method validation data: LOD and LOQ of steroids and the calibration range in ng/mL;
linearity (r2).
Steroid metabolite LOD (pg on
column)
LOQ (pg on
column)
Calibration
range
r2
A4 <0.01
(< 0.07)
0.01 (0.07) 0.01–200 0.9991
T <0.01
(< 0.07)
0.01 (0.07) 0.01–200 0.9966
5αDIONE 0.2 (1.33) 1 (6.67) 0.2–1000 0.9999
DHT 1 (6.67) 1 (6.67) 1–200 0.9996
AST 10 (66.67) 20 (133.33) 10–200 0.9977
3αDIOL 0.2 (1.33) 10 (66.67) 0.2–200 0.9974
11OHA4 0.2 (1.33) 1 (6.67) 0.2–1000 0.9999
11OHT 0.1 (0.67) 0.2 (1.33) 0.1–1000 0.9998
11KA4 0.1 (0.67) 0.1 (0.67) 0.1–1000 0.9999
11KT 0.1 (0.67) 0.2 (1.33) 0.1–1000 0.9992
11KDHT 1 (6.67) 10 (66.67) 1–1000 0.9997
11OHAST 2 (13.33) 10 (66.67) 2–1000 0.9949
11KAST 0.2 (1.33) 10 (66.67) 0.2–1000 0.9993
DHEA 1 (6.67) 2 (13.33) 1–1000 0.9969
Epietiocholanolone 10 (66.67) 20 (133.33) 10–200 0.9988
11OH-epietiocholanolone 1 (6.67) 2 (13.33) 1–1000 0.9947
11K-etiocholanolone 0.2 (1.33) 10 (66.67) 0.2–1000 0.9992
Pregnanetriol 0.02 (0.13) 10 (66.67) 0.02–1000 0.9971
PROG <0.01
(< 0.07)
0.02 (0.13) 0.01–200 0.9990
DHPROG 1 (6.67) 2 (13.33) 1–1000 0.9987
Pdiol 2 (13.33) 10 (66.67) 2–1000 0.9963
Pdione 10 (66.67) 10 (66.67) 10–1000 0.9977
11KPROG 0.2 (1.33) 0.2 (1.33) 0.2–1000 0.9999
17OHPROG 0.1 (0.67) 0.1 (0.67) 0.1–200 0.9994
16OHPROG 0.1 (0.67) 0.1 (0.67) 0.1–1000 0.9989
11KDHPROG 0.2 (1.33) 1 (6.67) 0.2–1000 0.9995
11αOHPROG 0.2 (1.33) 1 (6.67) 0.2–1000 0.9997
11βOHPROG 0.2 (1.33) 1 (6.67) 0.2–1000 0.9995
21-dF 0.02 (0.13) 1 (6.67) 0.02–1000 0.9979
Cortisone <0.01
(< 0.07)
0.01 (0.07) 0.01–1000 0.9997
Cortisol < 0.01
(< 0.07)
0.01 (0.07) 0.01–1000 0.9984
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step utilizing UPC2-MS/MS. The current method has the analytical
power to measure multiple steroids in a run time of under 6min,
thereby eﬀectively condensing sample turnover rate, applicable in both
clinical and research ﬁelds. Ultimately, this method is able to determine
steroid proﬁles in vivo –relating androgen excess or deﬁciency observed
in patients to abnormal enzyme activity. Optimized and validated, our
method allows for the accurate quantiﬁcation of a comprehensive panel
of steroids and as such has diverse applications: proﬁling C11-oxy C19
and C11-oxy C21 steroids in patients may lead to establishing new
biomarkers improving the diagnosis of adrenal disorders with regards
to androgen excess or deﬁciency and while the method may be utilized
in prognostic scoring, it can also be applied in determining treatment
outcomes in patients. The UPC2-MS/MS analytical method clearly has
applications in the ﬁeld of steroid research as well as in the diagnosis of
clinical conditions, dependent on eﬀective and eﬃcient steroid analyses
and quantiﬁcation in which multiple steroid proﬁling produce in-
formative steroid panels.
Table 5 (continued)
Steroid metabolite Accuracy (%RSD) Precision (%RSD)
Day 1 Day 2 Day 3
ng/mL ng/mL
2 20 100 200 2 20 100 200 2 20 100 200 2 20 100 200
11KPROG 7.1 9.9 7.6 3.0 9.6 5.1 7.3 3.4 4.2 5.5 12.8 8.9 11.3 10.2 7.0 9.6
17OHPROG 10.2 5.9 8.3 4.4 7.7 8.0 4.4 7.4 12.8 11.4 8.5 7.9 12.5 7.0 11.8 3.7
16OHPROG 8.6 7.1 6.9 5.0 5.8 4.0 5.4 5.3 13.0 12.0 8.5 2.8 14.9 5.2 9.9 6.4
11KDHPROG 10.1 6.7 6.0 5.7 13.6 3.5 4.8 4.2 13.5 5.0 12.4 8.1 18.1 5.9 8.7 10.7
11αOHPROG 5.9 4.7 3.4 3.2 6.3 5.8 2.8 3.5 7.9 6.3 7.7 3.8 9.2 7.4 6.8 5.2
11βOHPROG 13.6 11.6 6.8 6.3 8.9 6.9 4.1 2.4 9.9 9.0 6.1 3.0 8.3 9.6 10.6 2.6
21-dF 9.5 7.1 8.7 10.9 9.7 4.5 6.3 7.9 10.0 5.0 9.1 7.0 6.4 5.4 5.9 6.6
Cortisone 11.9 8.6 7.3 11.6 12.9 6.5 6.4 13.5 6.3 7.6 12.0 10.0 6.6 8.6 7.1 10.6
Cortisol 6.3 6.1 6.9 3.7 16.3 7.7 8.4 7.5 5.6 7.8 8.8 5.9 7.7 6.4 8.1 4.4
Table 6
UPC2-MS/MS method validation for the extraction of steroid from FBS. Recovery (n=3); matrix eﬀect (n=3) and process eﬃciency (n=3).
Steroid metabolite Recovery (%) Matrix eﬀect (%) Process eﬃciency (%)
ng/mL ng/mL ng/mL
2 20 100 200 2 20 100 200 2 20 100 200
A4 63.6 47.8 69.0 99.3 −10.7 −17.6 −26.3 2.6 56.8 39.4 50.8 101.8
T 87.1 61.3 66.4 102.2 −38.8 −11.4 −39.8 −1.0 53.3 54.3 40.0 101.1
5αDIONE 90.4 69.1 74.4 101.4 20.8 −4.7 −22.2 10.1 109.2 65.9 57.9 111.6
DHT 81.3 89.8 102.0 105.7 −30.3 −28.8 −46.9 −4.6 56.7 63.9 54.1 100.8
AST < LOQ 71.3 103.3 98.6 < LOQ −17.8 −23.4 −0.3 < LOQ 58.6 79.1 98.3
3αDIOL < LOQ 77.1 99.3 82.8 < LOQ 28.1 −42.3 11.5 < LOQ 98.8 57.3 92.4
11OHA4 91.6 63.9 69.1 108.8 −36.1 −4.0 −42.2 −4.7 58.5 61.4 40.0 103.7
11OHT 74.3 68.8 67.0 80.7 −45.7 −31.0 −38.2 22.2 40.4 47.5 41.4 98.6
11KA4 86.4 54.7 60.7 107.7 −43.0 −24.4 −26.5 6.4 44.6 41.4 44.6 114.5
11KT 73.0 48.7 61.7 99.8 −46.3 −7.9 −41.6 5.5 39.2 44.9 36.0 105.3
11KDHT <LOQ 87.4 105.2 99.5 < LOQ 15.1 −46.7 3.0 < LOQ 100.5 56.1 102.4
11OHAST < LOQ 65.2 84.0 103.1 < LOQ 1.9 −46.0 4.8 < LOQ 66.5 45.4 108.0
11KAST < LOQ 78.4 110.6 107.2 < LOQ 24.8 −33.8 4.1 < LOQ 97.6 73.3 111.6
DHEA 94.1 97.5 84.5 100.4 5.6 1.5 −49.7 −0.3 99.4 99.0 42.5 100.1
Epietiocholanolone < LOQ 85.1 84.7 116.3 < LOQ −37.3 −42.3 −14.6 < LOQ 53.4 48.9 99.3
11OH-epietiocholanolone 100.9 83.3 80.7 101.7 −2.6 4.3 −42.7 7.0 98.3 86.9 46.3 108.8
11K-etiocholanolone < LOQ 83.4 94.4 108.0 < LOQ −21.8 −45.2 9.9 < LOQ 65.2 51.7 118.7
Pregnanetriol < LOQ 85.3 98.9 79.0 < LOQ 5.7 −27.7 23.2 < LOQ 90.1 71.5 97.3
PROG 81.5 64.6 62.4 96.8 −27.6 −31.7 −34.9 8.8 59.1 44.1 40.7 105.3
DHPROG 95.8 106.3 81.7 87.1 3.6 −33.4 −47.9 3.4 99.2 70.9 42.5 90.1
Pdiol < LOQ 76.9 75.7 91.7 < LOQ −26.2 −33.5 7.9 < LOQ 56.7 50.3 99.0
Pdione < LOQ 90.4 62.0 101.7 < LOQ −26.2 −25.1 2.4 < LOQ 56.7 46.5 104.1
11KPROG 87.5 58.3 62.8 104.8 −36.6 −30.4 −21.4 3.5 55.5 40.6 49.3 108.5
17OHPROG 73.8 67.2 68.0 99.0 −25.1 −11.1 −33.6 8.0 55.2 59.7 45.1 107.0
16OHPROG 72.4 55.0 91.1 98.4 −43.5 −24.4 −48.0 7.0 40.9 41.6 47.3 105.3
11KDHPROG 98.2 63.6 78.7 109.0 −45.3 −33.2 −36.7 −6.6 53.7 42.5 49.8 101.9
11αOHPROG 70.2 45.9 66.6 102.7 −41.1 −10.5 −44.9 6.4 41.1 41.1 36.7 109.3
11βOHPROG 98.9 62.5 83.7 99.8 −48.8 1.5 −50.7 4.1 50.6 63.5 41.3 103.9
21-dF 93.3 67.9 82.8 87.7 −49.7 −15.4 −45.9 15.4 47.0 57.4 44.8 101.2
Cortisone 65.0 51.1 71.4 71.5 −27.8 4.0 −48.8 21.7 47.0 53.1 41.5 87.0
Cortisol 76.6 72.5 81.1 92.1 −32.2 −22.8 −34.1 12.0 51.9 56.0 53.5 103.1
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6.2 Summary 
The novel method described in the manuscript enabled the separation and quantification of 31 steroid 
metabolites biosynthesised in adrenal and peripheral steroidogenic pathways using a single 
chromatographic step, permitting separation without prior derivatization. This method has since proved 
suitable for the quantification of steroid metabolites in vivo. Utilizing this method C11-oxy C19 and  
C11-oxy C21 steroid levels were determined in healthy neonates in the first 2 days of life, with 11OHA4 
and 11KPROG levels detected in plasma of girls and boys (manuscript in preparation), thus emphasizing 
the value of comprehensive LC-MS/MS analysis in second tier screening in neonates, which may aid in 
the early diagnosis of steroid-related diseases. This method has also been used to assess androgen 
excess in a cohort of 35 PCOS patients and 19 healthy controls (manuscript in preparation) –analyses of 
steroid panels in these patients allowed insight into the activity of adrenal steroidogenic enzymes, 
together with identifying and quantifying C11-oxy C19 and C11-oxy C21 steroids which have, to date, not 
been assessed clinically in PCOS patients. Furthermore, this method was also used to investigate steroid 
panels in follicular fluid of female patients (unpublished data). Steroid profiles in follicular fluid are 
currently not widely reported since the research has been limited by analytical methods lacking the 
sensitivity to measure multiple steroids in small volumes of fluid, hurdles which UPC2-MS/MS clearly 
overcomes. Finally, this method was also employed to determine levels of the C11-oxy C21 steroids in 
plasma and tissue of BPH and PCa patients (unpublished data) –further highlighting metabolites not 
currently considered in the clinical setting. 
Taken together, utilizing UPC2-MS/MS, in vivo steroids can be accurately quantified, novel metabolites 
can be identified and altered steroid metabolic pathways can be linked to defective enzymatic activities. 
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Furthermore, effective diagnosis of clinical conditions marked by androgen excess can be facilitated by 
steroid profiling, potentially identifying new steroid markers, using state-of-the-art UPC2-MS/MS. 
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Chapter 7 
General discussion and conclusion 
It is well documented that adrenal C19 steroids contribute to the biosynthesis of intratumoral active 
androgens (Stanbrough et al. 2006; Luu-The et al. 2008; Montgomery et al. 2008), and while 11OHA4 
has been shown to be a major contributor to the peripheral biosynthesis of active androgens in the 
prostate, the monitoring of 11OHA4 and its downstream metabolites has not, to date, been considered 
in the diagnosis or treatment of BPH, PCa and CRPC, in the clinical setting. The objective of this PhD study 
was therefore to evaluate the levels of the C11-oxy C19 steroids in plasma and in prostate tissue and to 
study their downstream metabolism, including inactivation and conjugation, in prostate cells, to further 
ascertain the relevance of these androgens in prostate diseases. 
Pre-receptor regulation of C11-oxy C19 steroid action is mediated by 11βHSD2, 17βHSDs and SRD5As. 
Endogenous 11βHSD2 activity was shown in all our cell model assays, while 17βHSD activities were 
preferred over the SRD5A catalysed reactions. In addition, the 11βHSD2 catalysed biosynthesis of 11KA4 
from 11OHA4 was preferred over the SRD5A conversion of 11OHA4 to 11OH-5αDIONE. This highlights 
the preferred conversion of 11OHA4 to 11KA4, with reductive 17βHSDs subsequently producing 11KT 
(Fig. 2.4), which was evident in the cell models assayed. 
Post-receptor regulation of C11-oxy C19 steroid action is mediated by 3αHSD, RL-HSD, UGT2Bs and SULTs. 
All our cell models displayed endogenous 3αHSD activity and produced inactive 3α-reduced metabolites, 
and analyses provided steroid profiles including the 3β-reduced C11-oxy metabolites, which were 
determined in PNT2 cells. 3αHSD activity was most prominent in C4-2B cells when 11KDHT was assayed, 
followed by VCaP, LNCaP and lastly BPH-1 cells. In contrast, RL-HSD activity was negligible towards  
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11K-3αDIOL in all the cell models assayed, while RL-HSD readily reactivated DHT in C4-2B and VCaP cells, 
suggesting the C11 keto moiety hampers RL-HSD activity. UGT2B activity towards C19 and C11-oxy C19 
steroids was the highest in LNCaP cells, and while no C11-oxy C19 steroid was glucuronidated in C4-2B 
and VCaP cells, UGT2B activity was also not detected in PNT2 and BPH-1 cells. Interestingly, the  
C19 steroids were readily glucuronidated in LNCaP and VCaP cells, while only DHT was glucuronidated in 
C4-2B cells. These data highlight that the presence of the C11-oxy moieties interferes with the 
glucuronidation of the C3 and C17 hydroxyl group of the C11-oxy C19 steroids, as well as impeding the 
inactivation and reactivation of the 5α-reduced C11-oxy C19 steroids compared to the C19 steroids, as 
demonstrated in BPH-1 cells. In LNCaP, VCaP and C4-2B cells, however, the inactivation of 11KDHT was 
more efficient than DHT, while its reactivation was negligible. The C11-oxy C19 steroids were shown not 
to be sulfated in LNCaP cells, and total conjugated levels of 11KT, 11OHT, 11KDHT and 11OHDHT were 
significantly less compared to T and DHT. Interestingly, A4 was shown to be sulfated in LNCaP cells, and 
as this steroid is not androgenic, sulfation of A4 may be a mechanism of pre-receptor steroid regulation, 
thereby hindering the subsequent production of T and DHT. Conversely, 11OHA4 was not sulfated and 
instead was metabolised to downstream metabolites in these cells. Clearly, in vitro steroid action is 
regulated by the pre-receptor androgen activation and post-receptor inactivation of androgens, which 
is dependent on the expression of steroidogenic enzymes, which in turn is specific to cell types. 
In the present study, it was shown that 11OHA4, 11OHT, 11KA4 and 11KT remained within the top tier 
of the 11OHA4-pathway in all the cell models when assayed. This shows the necessity for the expression 
of SRD5As, which would metabolise the top tier C11-oxy steroids, ultimately leading to the production 
of middle tier metabolites and, in particular, 11KDHT (Fig. 2.4). Since both SRD5A1 and SRD5A2 catalyse 
the production of 5α-reduced C11 metabolites (Storbeck et al. 2013; Swart et al. 2013), and are 
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expressed in prostate tissue (Russell and Wilson 1994; Uemura et al. 2008; Chang et al. 2011), this 
suggests that the 11OHA4-pathway would be active in vivo. Moreover, even though SRD5A activity is 
required to produce 11KDHT, which is equipotent to DHT, the top tier steroid that was preferentially 
produced in all our cell models, 11KT, is equipotent to T at 1 nM, and equipotent to DHT and 11KDHT at 
10 nM. 11KT binds and activates the AR and induces the expression of AR-mediated genes (Pretorius et 
al. 2016), suggesting even with minimal SRD5A activity, the 11OHA4-pathway still contributes an active 
steroid to the androgen pool. While this study demonstrated that 11KT is readily produced in vitro, this 
study also showed that 11KT is not readily glucuronidated in PCa cells, with unconjugated levels 
determined in plasma and tissue further contributing to the potency of this steroid.  
Our in vivo data show low circulatory T levels and negligible DHT levels under castrated conditions (both 
physical and chemical), while substantial 11OHA4, 11KT and 11KDHT levels were detected in PCa 
patients, suggesting an increased adrenal output of 11OHA4, together with a greater metabolic shunt in 
the 11OHA4-pathway in these patients. Furthermore, C11-oxy glucuronide levels were low in plasma of 
PCa patients, clearly showing impeded glucuronidation contributing to unconjugated steroid levels in 
circulation. Quantification of C11-oxy sulfates in plasma showed increased 11KDHT-S levels in the 
healthy subject while in the PCa patient, 11KDHT-S levels were low, and 11KDHT was also not sulfated 
in the analysis of the female plasma, suggesting impeded sulfation of this C11-keto steroid. However, 
the limited sample number restricts conclusive analyses. Furthermore, in the analysis of plasma from 
PCa patients, high circulatory levels of the downstream inactive metabolite, 11OHAST, was detected. 
This highlights that the steroid shunt in the 11OHA4-pathway is increased in PCa, and while the same 
shunt in the production of 11OHAST and 11KAST was shown in BPH tissue, as well as in CRPC tissue, high 
levels of 11OHA4, 11KT, 11OHT and 11KDHT were, however, detected in PCa tissue. 
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As this study focused on the C11-oxy C19 steroids with regards to PCa, it should be noted that the  
C11-oxy steroids have also been reported to be important in 21OHD and PCOS (Turcu et al. 2016;  
O’Reilly et al. 2017), while the potential role of the C11-oxy C21 steroids in these adrenal-linked endocrine 
diseases has not been characterized. In this regard the UPC2-MS/MS analytical method described in this 
thesis, which quantifies both C11-oxy C19 and C11-oxy C21 steroids, may have application in shedding 
light on the levels of these steroids in patients, while also modelling augmented metabolic pathways. It 
is possible that abnormally high levels of 17OHPROG and 21-dF identified in patients may be identified 
together with downstream metabolites, linking the backdoor pathway with defective CYP21A2 activity. 
If, however, high 11OHPROG and 11KPROG levels are detected, adrenal PROG will be identified as a 
precursor steroid feeding into the backdoor pathway and as such, the activity of CYP11B1, CYP11B2 and 
11βHSD2 will be highlighted. In this regard, comprehensive steroid profiles would enable analyses of 
metabolic pathways and subsequently patient specific clinical aspects, as our analyses clearly shows 
considerable variations in individual steroid levels detected in tissue and in plasma in PCa patients. 
Furthermore, our UPC2-MS/MS method has applications in aiding diagnosis and prognostic scoring in the 
clinical setting providing critical information on C11-oxy C19 and C21 steroids in adrenal-linked endocrine 
diseases. Moreover, the role of C11-oxy C19 and C21 steroids is as of yet undetermined in diseases and 
disorders other than 21OHD, PCOS and PCa, with the utilization of the UPC2-MS/MS potentially providing 
informative steroid panels in currently undefined physiological events, such as in adrenarche, 
premature- and delayed adrenarche, menopause, CAH and DSD.  
The ‘rediscovery’ of adrenal 11OHA4 since 2012 and recent reports showing that the adrenals produce 
high levels of 11OHA4, that it is biosynthesised from A4 by CYP11B1 and B2 catalysed reactions, and that 
11OHA4 and its metabolites are metabolised by 11βHSD2, 17βHSDs and SRD5As, producing 11KT and 
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11KDHT, which are AR agonists, have certainly placed this adrenal steroid under the spotlight and will 
for many years to come. The present investigation contributes to these findings and describes the 
metabolism of 11OHA4 and its metabolites in normal, BPH and PCa cell models. This PhD study shows 
for the first time the presence of 11OHA4 and its downstream metabolites in plasma of PCa patients and 
in BPH, PCa and CRPC tissue. The glucuronidation of the C11-oxy C19 steroid metabolites in vitro, and 
circulatory glucuronide and sulfate C11-oxy C19 steroid levels have been identified for the first time. Our 
analyses provide a comprehensive comparison between the metabolism of the C11-oxy C19 steroids and 
the C19 steroids by steroidogenic enzymes –comparing their activation, inactivation, reactivation, 
glucuronidation and sulfation. Our in vivo evidence provides a comparison between the C11-oxy C19 and 
C19 steroid levels in plasma and tissue, while also comparing their glucuronide and sulfate levels. In 
addition, this current study includes the development and validation of three UPC2-MS/MS methods for 
the detection and quantification of C19 and C21 steroid metabolites, which include the C11-oxy C19 and 
C11-oxy C21 steroids. 
Taken together, this study has shown the presence of the C11-oxy C19 steroids in plasma, in the castrated 
(physical and chemical) PCa scenario, as well as in plasma of healthy subjects, in addition to determining 
C11-oxy C19 steroid conjugates in circulation. Our analyses have also identified C11-oxy C19 steroids in 
tissue, in the castrated CRPC scenario, in PCa undergoing different treatment regimes, as well as in BPH. 
Furthermore, this study has established the metabolism of the C11-oxy C19 steroids in normal and BPH 
cell models, as well as in PCa cell models, with these representing different stages of PCa progression 
and CRPC. Clearly, the data in this thesis indicate that the C11-oxy C19 steroids are involved in PCa, with 
adrenal 11OHA4 and its downstream metabolites, 11KT and 11KDHT, now firmly established in the 
steroid arena. 
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Five key unanswered questions remain: 
1. How does the presence of the C11-hydroxy or C11-keto moiety hamper the binding of the steroid 
substrate to the UGT protein? In this regard, structure modelling and structure/function analyses would 
allow the examination of substrate binding in the active pocket with the C11 moiety potentially 
facilitating/hampering substrate/enzyme interaction; 
2. Which UGT isoform(s) are able to conjugate the C11-oxy C19 steroids? In this regard, intraprostatic and 
hepatic conjugation could contribute to circulatory glucuronide levels, and organs primarily involved 
would need to be clarified; 
3. What are the quantitative contributions of adrenal 11OHA4 and its metabolites in vivo, in circulation 
in normal, BPH, PCa (castrated and uncastrated) and CRPC patients?; 
4. Would profiling C11-oxy C19 steroids in PCa patients aid clinicians in the diagnosis and prognostic 
scoring of the disease, together with determining treatment outcomes?; would C11-oxy C21 steroids also 
need to be considered?; 
5. Are there viable targeted treatment options which can be employed to limit the C11-oxy C19 steroids 
in PCa, without adverse effects on normal adrenal steroidogenesis? 
Future recommendations 
Utilizing UPC2-MS/MS to profile C11-oxy steroids in adrenal-linked endocrine diseases may identify 
customized biomarkers, while also modelling steroid metabolic pathways. In this regard, analysis of large 
cohorts will aid in identifying the role of these C11-oxy steroids in adrenal-related diseases and in PCa. 
It should be noted that although this study has certainly highlighted the importance of the C11-oxy C19 
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steroids and the in vitro studies conducted were comprehensive, with the in vivo data highlighting similar 
findings, corroborating in vitro data, these studies were, however, limited and restricted to small sample 
numbers. Furthermore, C11-oxy C19 steroid glucuronide levels have not yet been established in tissue, 
while in vivo evidence of C11-oxy C19 steroid sulfate levels are also lacking. It is worth mentioning that 
the presence of CYP11B1 and B2 expression in peripheral tissue other than the adrenals, such as the 
prostate, also require further investigation. As A4 and T are readily produced in peripheral tissue, only 
the presence of CYP11B1 and B2 will catalyse the biosynthesis of 11OHA4 and 11OHT from A4 and T, 
respectively. Combined expression of CYP11B1, CYP11B2, 11βHSD2, 17βHSD and SRD5A in peripheral 
tissue will most certainly contribute to the production of C11-oxy C19 steroids, while C11-oxy C21 steroids 
will also be produced from PROG and 17OHPROG precursor steroids, thereby initiating the backdoor 
pathway. UPC2-MS/MS can potentially profile all of the previously mentioned metabolic pathways, while 
intratumoral steroid shunting due to treatment regimens such as enzyme inhibitors, could also be 
analysed and elucidated. Furthermore, while we show here that the C11-oxy C19 steroids are not 
efficiently glucuronidated, the regiospecific binding of the C11-oxy C19 steroids to UGT enzymes or 
inability to bind, together with compartmentalization and expression levels of the UGT2B isoforms within 
prostate cells, are still unclear.  
This thesis has discussed the C11-oxy C19 steroids in the context of disease in PCa –the question arises 
as to the contribution of these steroids to normal physiological development. Normal circulatory 
reference ranges throughout the lifespan of males and females are lacking, and while the current study 
identified circulatory C11-oxy C19 steroids in healthy subjects, in males and females, the sample number 
was limited. Furthermore, our unpublished data has shown the presence of 11OHA4 and 11KPROG in 
neonates following birth, and while these steroids could also potentially be maternally derived or from 
Stellenbosch University  https://scholar.sun.ac.za
180 
 
placental origin, the findings suggest these steroids may be involved in embryonic development. Another 
question arises, as to the contribution of these steroids to puberty. Indeed, this topic has been discussed 
by Turcu and Auchus (2017), who suggested that these steroids may contribute to adrenarche, a 
precondition to puberty. Clearly, these C11-oxy C19 steroids may be involved in normal development, in 
which adrenal steroids contribute to steroidogenesis in target tissue as secondary pathways, with 
11OHA4 not being an inactive metabolite of A4, as originally speculated (Goldzieher et al. 1978; Bélanger 
et al. 1993), but rather presenting a new perspective on adrenal precursor steroids and their 
downstream metabolism. 
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